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“Nature creates nothing
without a purpose”
Aristotle
1
Introduction
In this chapter, our interest in natural products is explained. Also the target of
choice, (+)-peloruside A is introduced as well as its interaction with biological
systems.
2
1.1 The importance of natural products
Nature has been a source of medicinal products since time immemorial.1–4 The
first records of sophisticated traditional medicine systems were carved on clay
tablets in Mesopotamia and date back to about 2600 B.C. They described, among
other things, the use of oils from different species (e.g. opium poppy, Papaver som-
niferum) to treat a variety of disorders, ranging from coughs to parasitic infections
and inflammation. Many of these are still used today. Also in ancient Egypt, proof
of early medicine was found. The best known pharmaceutical record is the Ebers
Papyrus, from 1500 B.C., which describes more than 700 ‘drugs’, mainly plants,
but also animals and minerals, and how to administer them: at that time, beer,
milk, wine and honey were commonly used vehicles. The first records of Chinese
and Indian civilizations describing the use of a wide variety of active (plant) in-
gredients (drugs) date both from about 1100 B.C. Oral tradition probably dates
back way longer.2
In the ancient Western world, the Greeks and Romans contributed substantially
to the rational development of the use of herbal drugs. Theophrastus, a disciple of
Aristotle (around 300 B.C.), dealt with the medicinal use of plants in his ‘Enquiry
into plants’ (Peri phyton historia). Later, the Greek physician Dioscorides (100
A.D.) travelled with the Roman armies in search of medicinal substances from
all over the Roman Empire. His work resulted in ‘On Medicinal Material’ (De
Materia Medica), an encyclopedia of about 600 plants, and a description of which
medicines can be obtained from them, when to use them, and in which quantities.
The Greek physician Galen (129-216 A.D.) published over 30 books on pharmacy
and medicine, and is well known for his complex prescriptions and formulas used
in compounding drugs, sometimes containing dozens of ingredients.1
Besides the monasteries in Western countries, it were especially the Arabs who
1.1. The importance of natural products
were responsible for the preservation of the Greco-Roman expertise, during the
Middle Ages. Even more, they expanded this knowledge to include the use of
their own resources, together with those of Chinese and Indian culture, which
were unknown to the West until then.3
During the Renaissance, interest in medicinal properties of natural products
revived in the West. Paracelsus, a German-Swiss physician and alchemist, was the
first to declare a link between pure chemical compounds in substances and their
effect as drug.2
“Quas enim oculis herbas cernimus, id non est Medicina. Item quas
gemmas, quasve arbores videmus, non est id Medicina recta ac perfecta.
Oculi enim saltem partem immundiorem ac rudem materiam vident,
quae a recta Medicina nondum segregata est, et in qua impurior pars
adhuc occultatur. Quid igitur? Impurior pars prius purganda est et
abicienda, et postea Medicina apparebit.”
Paracelsus, Labyrinthus medicorum errantium
“The herbs, minerals and trees we see, are not the medicine. We only
see a crude product, where the impurities are not yet separated from
the actual active medicine. What do we have to do then? We must
first purify this crude product; get rid of the impurities and then, the
medicine will appear.”
It was only until the beginning of the 19th century, that these active substances
were isolated in pure form. The use of poppy juice as a painkiller was described
already in the first Mesopotamian records, but the active substance, morphine
(1.1), was isolated only in 1804. Also the use of the bark of the cinchona tree in
treating malaria is a historic example of medical treatment from natural sources.
It was readily used by the Indians in the Andes and in the 17th century introduced
in Europe. Because of the bitterness of the cinchona powder, the British mixed
it with sugar and water, and thus protected themselves from malaria during the
4
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occupation of India, by drinking tonic (and gin).2 The active component, quinine
(1.2), was first isolated in 1820. Besides the use of the bark of the (Peruvian)
cinchona tree, it was discovered early on (1758) that the extract from the bark of
the willow tree also had a positive effect in the treatment of malaria. Rather than
targeting the cause of malaria, it relieved the symptoms. The willow tree had been
used in ancient civilizations, in the treatment of fever, pain and inflammation. Its
active ingredient, salicin (1.3), was obtained in a pure form in 1829, and seemed
to be comprised of a sugar (D-glucose) and salicyl alcohol.5,6 At this point, only
the chemical composition was known, not the structural formula, as concepts like
aromaticity or covalent bonds were only introduced later (respectively, by Kekule
and by Pauling). Oxidation of salicyl alcohol yielded salicylic acid 1.4, which was
found before in the leaves of wintergreen plants, and which was also used as pain
reliever. The German Hermann Kolbe came up with a process of synthesizing this
salicylic acid from sodium phenolate and carbon dioxide in 1859 (scheme 1.1). To
avoid side effects of the use of this drug, particularly gastric irritation, the acidity
of salicylic acid was lowered by acetylating it, resulting in aspirin, synthesized on
an industrial scale in 1899 by Bayer and still one of the most popular drugs.
HO
HO
O H
N
OH
O
N
N
HO
O O
OH
OH
OH
HO
1.1 1.2 1.3
Figure 1.1
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NaOH
CO2
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Scheme 1.1: Kolbe’s synthesis of salicylic acid 1.4
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Not only plants, but also microorganisms (bacteria and fungi) and marine
organisms are conventional sources for natural products. Microorganisms have
always been part of human life. Be it as food (yoghourt), for the preparation of
alcoholic beverages (yeasts), but also as medication. The discovery of penicillin
from the fungus Penicillium notatum by Fleming in 1929 and especially the use of
this as a therapeutic in the 1940’s were important milestones. They preluded the
‘Golden Age of Antibiotics’ and resulted in extensive investigation of Nature as a
source of novel bioactive agents.
Marine organisms on the other hand, do not have a significant history of use
in traditional medicine. This changed with the development of diving equipment,
some 50 years ago. Given the fact that 70% of earth‘s surface is covered by
water, pharmaceutical companies realized that the oceans possess a vast amount
of novel, structurally diverse, compounds. Therefore, the marine environment has
been increasingly explored as a source of bioactive compounds.7
Technological advances in instrumentation and structure elucidation techniques
improved the identification process of novel bioactive natural products. However,
in spite of these technological advances along the years, the screening of extracts
and isolation of the active component were still time-consuming. Therefore, in
the beginning of the nineties, the focus shifted somewhat away from natural prod-
ucts. The advent of automated high-throughput screening (HTS) had caused an
acceleration in biological testing, and as traditional extract-based screening could
not keep up with this speed, combinatorial chemistry was promoted as a better
approach to create “drug-like” compounds for HTS.
From 1997 on, Newman and Cragg reviewed the sources of new chemical en-
tities (NCEs), approved by the US Food and Drug Administration (FDA), the
European Medicine Agence (EMA) and similar institutions.8–10 It has been up-
dated regularly and is currently in its 4th edition, covering a time period from 1981
to 2010.11 They classified the NCE’s in different categories, based on their origin:
natural products as such (N), substances which are derived from natural products,
usually a semi-synthetic modification (ND), synthetic compounds without natural
product conception (S), synthetic compounds of which the pharmacophore is de-
6
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rived from a natural product (S*), and natural product botanicals, a class which
covers “defined mixtures” of botanicals (NB). They also use the subclass /NM to
indicate if a synthetic compound competes for a natural product target. To clar-
ify this classification, an example from each class belonging to the field of cancer
treatment will be given (figure 1.2).
Perhaps the most known natural product (N) in cancer treatment is pacli-
taxel (1.5) (Taxol R© by Bristol-Meyers Squibb), which is isolated from the bark of
Taxus Brevifolia, the (rare) Pacific yew tree.12 In an effort to cope with the lim-
ited bioavailability of paclitaxel, researchers developed the semi-synthetic analog
(ND) docetaxel (1.6) (Taxotere R©, Sanofi-Aventis), which is made starting from a
readily available precursor, 10-deacetyl baccatin III (1.7), from the more common
European yew tree. Carboplatin (1.8) is a totally synthetic molecule (S) which
causes DNA crosslinking, which inhibits in turn DNA repair and/or synthesis in
cancer cells. The non-steroidal bicalutamide (1.9) on the other hand is also a
purely synthetic molecule, but is appointed the subclass ‘natural product mimic’
(S/NM) as it competes with the natural ligand testosterone (1.10) for binding onto
the androgen receptor.13 Decitabine (1.11) is a synthetic cytidine (1.12) analog
(S*), which is incorporated in DNA strands upon which this is not recognized
anymore, and therefore, DNA methyltransferase is inhibited.14 Bexarotene (1.13)
is a formally synthetic compound, but chemically related to vitamin A.15 It also
competes with the natural 9-cis-retinoic acid (1.14) for binding on the retinoid X
receptor, thus it belongs to the subclass of the natural product mimics (S*/NM).
Compounds from biological sources, such as proteins or monoclonal antibodies
(B) and vaccines (V) are also discussed in the reviews, but are not considered here.
From the analysis, a few conclusions can be drawn (figure 1.3). First, while
66% of the 1073 approved small molecule NCE’s are formally synthetic (containing
S or S* in their nomenclature), only 36% of them is truly synthetic. The other
30% either corresponds to compounds containing a natural product-derived phar-
macophore (S*) or to compounds which are modeled on, or compete for a natural
product inhibitor of the molecular target (NM subclass). When looking at the
class of anticancer drugs, the numbers drop even lower to only 20% of the small
7
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molecule drugs being purely synthetic (S). Even more, out of the seven in 2010
approved antitumor agents, six of them were small molecules, of which one was
a natural product as such (N), and four are derived from natural products (ND).
This really shows the importance of exploring nature as source of new drugs.
ND, 299, 28% 
S, 378, 36% 
S/NM, 146, 14% 
S*, 55, 5% 
S*/NM, 122, 11% 
N, 59, 6% NB, 5, 0% 
ND S S/NM S* S*/NM N NB 
Figure 1.3: Source of small molecule approved drugs from 1980 to 2010. Reprinted
with permission from11 Copyright 2012, American Chemical Society.
Secondly, as reflected from the numbers and figures in the reviews, it is clear
there is a decline in output of R&D programs from pharmaceutical companies,
from the late eighties on (figure 1.4). A number of factors can be attributed for
this downward trend: the mounting costs of drug discovery, FDA‘s over-caution
in the drug approval process, and the disruption of laboratory activities because
of the merging of several companies.16 According to several researchers however,
it is significant that the downward trend in output has occurred during a period
of declining interest in natural products, in favor of reliance on new chemical
techniques such as combinatorial chemistry, because of the compatibility of these
with HTS approaches.
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Figure 1.4: Source of small molecule approved drugs from 1980 to 2010, by year.
Reprinted with permission from11 Copyright 2012, American Chemical Society.
Indeed, as the emphasis was mainly on the synthesis of large libraries of small
compounds, lacking molecular complexity and possessing a lot of flexibility, the
expected output in new chemical entitities was not realised.17,18 In fact, only one
de novo NCE resulting from combinatorial chemistry has been approved by the
FDA so far, which is the kinase inhibitor sorafenib (Nexavar R©, by Bayer) (1.15).
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Figure 1.5: Sorafenib
Because apparently combinatorial chemistry did not live up to the expectations,
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there was an evolution at the end of the nineties. The size of the libraries was
scaled down from tens of thousands or even millions of compounds towards tens
to hundreds of compounds. At the same time, the molecular complexity of the
compounds was increased, introducing bicyclic structures and chirality, resembling
more and more natural products. The introduction of these more complex, three-
dimensional natural product-like structures are thought to create better chances of
interacting with biological targets. This concept is also known as diversity-oriented
synthesis (DOS), formally introduced by Schreiber in 1998.19–22
A variant of this approach, is biology-oriented synthesis (BIOS), introduced
by Waldmann, where libraries are created by combining structural features of the
basic carbon skeleton of natural products and tested against clustered proteins
with a similar three-dimensional space around the binding pocket.23,24
As evidenced by this shift in combinatorial chemistry research, natural products
have continued to play a crucial role in the drug discovery process as they provide
a very valuable and vast pool for the discovery of templates and drug candidates.
Furthermore they are suitable for further optimization by synthetic means because
the chemical complexity of natural products is higher than structures from any
other source. In that respect, the discovery of natural products has been a driver
in the evolution of organic chemistry. As E. J. Corey put it: “natural products
are engines of the development of organic chemistry and links to the domain of
biology.”25
The complexity and molecular diversity indeed have boosted the development
of organic chemistry. In the 1940’s to 1960’s, R. B. Woodward succeeded in synthe-
sizing dozens of diverse structures of unprecedented complexity, among them qui-
nine26,26 (1.2), reserpine27 (1.16) and prostaglandin F2α
28(1.17). These achieve-
ments are particularly admirable as many of the now available purification or
spectroscopic techniques did not exist yet at that time.
With the advent of new analytical techniques, there was a surge in the identi-
fication of new natural products, which demanded for a more systematic approach
in designing a synthetic strategy. An answer to this demand was provided by E.
11
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Figure 1.6: Selected examples from natural products, synthesized by Woodward
J. Corey with the introduction of retrosynthetic analysis in 1961, for the synthesis
of longifolene29 (1.18, figure 1.7). In the following 30 years, Corey managed to
synthesize hundreds of natural products, including biotin30(1.19), ginkgolide B31
(1.20), picrotoxinin32 (1.21), ... This resulted in the development of new synthetic
methods, mechanistic proposals and asymmetric syntheses and led to important
contributions to the field of biology and medicine.
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Figure 1.7: Selected examples from natural products, synthesized by Corey
The importance of total synthesis of natural products is evidenced as a Nobel
Prize in Chemistry was awarded to both Woodward (1965) ‘for his outstanding
12
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achievements in the art of organic synthesis ’ and to Corey (1990) ‘for his devel-
opment of the theory and methodology of organic synthesis ’. The efforts and ac-
complishments of these two brilliant chemists have inspired and stimulated many
others to focus on the art and science of total synthesis.33,34
Total synthesis of natural products in many cases is appealed to for the elucida-
tion, confirmation or revision of a complex structure, especially when the absolute
configuration is unknown. On the other hand, total synthesis is often used as a
link to drug development programs, to deal with the supply of natural products.
When these are difficult to isolate in sufficient amounts, total synthesis is called
upon to deliver the necessary amounts to do (pre)clinical testing and later to bring
the drug to the market. A beautiful example of the above described use of nat-
ural products is the story of discodermolide (1.22, figure 1.8). Discodermolide
is a natural product which showed great potency as antitumor compound, but it
was isolated only in small amounts out of a sea sponge which is very rare. First,
the absolute configuration of the product was established through the synthesis of
both enantiomers by Schreiber.35 Since then, different research groups were able
to improve yields, efficiency and economy.36–38 These methodologies were used
by Novartis to produce multigram amounts of the compound and bring it to the
clinic.39–43 Unfortunately, the results of the clinical trials showed a lack of response
and an increased toxicity, so the program was stopped.
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Figure 1.8: Discodermolide
The story of discodermolide also proved something else: while natural products
often exhibit highly potent and selective bioactivity through interaction with a
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certain target, they are originally produced in their ecosystem for uses other than
we seek or need. Thus, natural products as such are not optimized to possess the
characteristics which are desired in a clinically useful drug. Also, the structural
diversity of natural products is limited by the available biosynthetic pathways of
the host organisms. Hence, it can be advantageous to synthesize analogs of the
natural product. In that way, the accessible structural diversity becomes immense.
When the natural product is easily accessible, diversification is probably the
simplest approach: functional group transformations can easily provide a lot of
analogs. However, one should keep in mind, that some desired transformations
cannot be performed as there can be incompatibilities with other functional groups
that are present in the molecule. Sometimes, as is the case for paclitaxel, there is
a readily available precursor, which can then be modified to gain access to a new
variety of analogs through semi-synthesis.
Another option is to focus on the pharmacophore of the natural product: the
substructural part of the molecule that bears the essential features necessary for
activity. Synthesizing an advanced intermediate that lacks the unnecessary com-
plexity, results in simplified analogs with a similar or even better activity than
the original natural product. This strategy is named diverted total synthesis by
Danishefsky, and is often a consequence of target oriented total synthesis.44,45 A
notable example is that of halichondrin B (1.23, figure 1.9), where total synthesis
studies revealed that the right hand half of the molecule is responsible for almost
all of the activity. This resulted in the synthesis of the simplified analog eribulin
(Halaven R©, 1.24), which was approved by the FDA in 2010, and is now produced
in a totally synthetic way.46–48
Closely related to this is the concept of function oriented synthesis (FOS), in-
troduced by Wender. The central principle of FOS is: “that the function of a
biologically active lead structure can be emulated, tuned or even improved by re-
placement with simpler scaffolds designed to incorporate the activity-determining
structural features (or their equivalent) of the lead compound.”49,50 By defining the
minimum set of features needed for a desired activity, it is possible to incorpo-
rate, through design, the required functionalities into more accessible and effective
14
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Figure 1.9: Halichondrin 1.23 and the simplified analog Eribulin1.24
agents. In this context, the series of bryostatin analogs Wender came up with,
is noteworthy. Bryostatin (1.25, figure 1.10) is a natural product that binds to
protein kinase C (PKC), which is responsible for a whole array of downstream
signaling events. Therefore, bryostatin is now in clinical trials for the treatment
of cancer and Alzheimer’s disease. Through computer-guided comparison of the
known PKC ligands, Wender proposed that the southern half of bryostatin is re-
sponsible for binding, whereas the northern half is responsible for keeping the
southern half in the correct conformation. This resulted in a first generation of
a simplified, but still very potent analog with a simplified northern half (spacer
domain) (1.26). Recently, based on further in silico studies, they came up with
a second generation analog, where the spacer domain is replaced by a salicylate
15
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(1.27).51 A simplification which resulted in a decreased number of steps, at the
expense of only a modest decrease in binding affinity (18 nM for salicylate vs. 1.1
nM for bryostatin).
This dissertation is also situated in the field of function oriented synthesis, the
natural product of interest being (+)-peloruside A.
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Figure 1.10: Different generations of Bryostatin analogs
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1.2 (+)-Peloruside A
1.2.1 Discovery
(+)-Peloruside A (1.28, figure 1.11) was discovered in 1999 by Northcote, West
and Battershill.52 They isolated the natural product from the sea sponge Mycale
hentscheli, together with three other compounds: (+)- mycalamide A (1.29) and
pateamine A (1.30) and B (1.31). These are all secondary metabolites that show
cytotoxic activity: the sponge produces these toxins to prevent growth of organisms
that compete for food and space. In this context, secondary metabolites do not
have a primary function directly involved in the normal growth, development or
reproduction of a species, but indirectly assist in survival during evolution.
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Figure 1.11: Secondary metabolites of the sea sponge Mycale hentscheli
Sponge specimens of Mycale hentscheli were collected at a depth of 7 to 15 me-
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ters in a specific place in New Zealand: the Pelorus sound. Because the structures
of the pateamines and mycalamide were already known from specimens collected at
other places, Northcote, West and Battershill named the new compound peloruside
A, after the original location of presence. It was observed that only specimens col-
lected at the deeper range of the sponge population contained detectable amounts
of peloruside A.
The original process to obtain pure compound starting from wet sponge is very
laborious and described in figure 1.12. The prevalence of peloruside in the sea
sponge is minimal as only 3 mg was isolated out of 170 g of wet sponge.
a)	  Wash	  with	  H2O	  
b)	  Elute	  with:	  	  
	  i)	  20%	  Me2CO/H2O	  
	  
	  ii)	  55%	  Me2CO/H2O	  
	  
	  iii)	  55%	  Me2CO/0.2M	  NH4OH	  
	  
	  iv)	  55%	  Me2CO/0.2M	  NH4OH,	  	  
	   	  adjusted	  to	  pH	  4	  with	  AcOH	  
Sponge	  specimen	  	  
(170	  g	  wet	  weight)	  
Methanolic	  	  
extracMon	  (24h)	   Combined	  
extracts	  	  
AdsorpMon	  
on	  Diaion	  HP20	   Packed	  poly(styrene-­‐	  
divinylbenzene)	  column	  	  
ConcentraMon	  
Brown	  viscous	  oil	  
(79mg)	  
a)	  DissoluMon	  in	  MeOH	  
b)	  AdsorpMon	  on	  Amberchrom	  resin	  
Packed	  poly(styrene-­‐	  
divinylbenzene)	  column	  	  
FracMonaMon	   32-­‐34%	  Me2CO	  in	  H2O	  	  
38-­‐40%	  Me2CO	  in	  H2O	  	  
Peloruside	  A	  (3.0	  mg)	  
Mycalamide	  A	  (10.6	  mg)	  
Packed	  poly(styrene-­‐	  
divinylbenzene)	  column	  	  
AdsorpMon	  
on	  Diaion	  HP20	  
a)	  Wash	  with	  H2O	  
b)	  Elute	  with	  acetone	   Pateamine	  (11.7	  mg)	  
Figure 1.12: The isolation process of peloruside A as described by Northcote et al.
Initially, Northcote et al. proposed the strucure of peloruside to be a 16-
membered, polyoxygenated macrolide, containing a pyranose ring, a trisubstituted
olefin possessing the Z-geometry and ten stereogenic centers. The connectivity of
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the basic skeleton was established via NMR, using COSY, TOCSY and HMBC
experiments, whereas the relative configuration of the stereocenters was proven us-
ing NOE correlations and vicinal couplings. However, because peloruside appears
as a colorless oil, it was not possible to obtain a crystal structure, and thus only
the relative configuration of these stereocenters could be determined. Upon mea-
surement of a positive sign of optical rotation (measured as solution in CH2Cl2),
the compound was named in full (+)-peloruside A.
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1.2.2 Synthesis
In 2003, De Brabander et al. published the first total synthesis of peloruside.53
This synthesis was of paramount importance for the determination of the absolute
configuration, as it was not yet known at that time. The originally synthesized
compound turned out to be the enantiomer (-)-peloruside A (1.32) (scheme 1.2),
possessing a negative sign of optical rotation and showing no effect on the growth of
tumor cells in vitro. Later, in a patent, De Brabander also described the synthesis
of the natural product (+)-peloruside A.54 In the synthesis of (-)-peloruside A,
methyl ketone 1.33a is coupled in an aldol reaction with aldehyde 1.33b, followed
by oxidation, to form diketone 1.33c, which forms dihydropyranone 1.33d after
deprotection. This fragment is further elaborated towards the advanced aldehyde
1.33e, which is coupled with methyl ketone 1.33f in another aldol reaction to
form 1.33g. After the enantioselective reduction and deprotection steps, seco
acid 1.33h is formed, which undergoes Mitsunobu-type macrolactonization (69%
yield), resulting in (-)-ent-peloruside A (1.32) after final deprotection.
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Scheme 1.2: Synthesis of (-)-ent-peloruside A by De Brabander et al. (2003) (LLS:
31 steps)
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In 2005, Taylor et al. published a new synthesis of (+)-peloruside A, rely-
ing on alternative aldol couplings (scheme 1.3).55 Homoallylic alcohol 1.34a is
Boc-protected, and consecutively transformed to iodocarbonate 1.34b. This is
converted to epoxide 1.34c, which undergoes nucleophilic attack by the anion of
1,3-dithiane to form aldehyde 1.34d. The carbon skeleton of this fragment is
elongated by Mukaiyama-type aldol reaction with silyl ether 1.34e, to form ad-
vanced methyl ketone 1.34f. This is coupled with aldehyde 1.34g, which was
obtained, making use of an oxazolidinone as chiral auxiliary (Xc). Consecutive
oxidation delivers diketone 1.34h, which is transformed into dihydropyranone-
containing macrolactone 1.34i by applying the necessary deprotections and Yam-
aguchi macrolactonisation (51% yield). After ring closure, the dihydropyranone
ring is converted to the pyranose ring using the same conditions De Brabander
used in his synthesis.
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Scheme 1.3: Synthesis of (+)-peloruside A by Taylor et al. (2005) (LLS: 30 steps)
In the total synthesis of Ghosh et al.56 (2008) chain elongations of 1.35a are
achieved using Brown’s allylation and Horner-Wadsworth-Emmons olefination to
form 1.35b (scheme 1.4). This is further transformed to aldehyde 1.35c by em-
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Scheme 1.4: Synthesis of (+)-peloruside A by Ghosh et al. (2008) (LLS: 29 steps)
ploying Sharpless’s asymmetric dihydroxylation. Grignard attack and oxidation
deliver enone 1.35d. A novel reductive enolization followed by a stereoselective
aldol reaction with aldehyde 1.35e results in 1.35f. After macrolactonization to
1.35g (64% yield), the pyranose ring of peloruside 1.28 is formed in the final
deprotection step.
The group of Evans published a total syntheses of peloruside in 2009 (scheme
1.5).57 Methyl ketone 1.36a, itself obtained by chiral auxiliary-mediated aldol
chemistry, was coupled with aldehyde 1.36b. After the necessary transformations,
keto-aldehyde 1.36c was formed. The hydroxyketone, resulting from the coupling
between 1.36c and methyl ketone 1.36d was converted to silane 1.36e. At this
point, the stage was set for one of the key steps of this synthesis: the highly selec-
tive tin-mediated intramolecular silane reduction, to deliver 1.36f. Further depro-
tection and selective methylation resulted in 1.36g, which could be transformed
to the natural product 1.28 in a straightforward fashion, via macrolactonisation
(68% yield).
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Scheme 1.5: Synthesis of (+)-peloruside A by Evans et al. (2009) (LLS: 22 steps)
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Scheme 1.6: Synthesis of (+)-peloruside A by Jacobsen et al. (2010) (LLS: 20
steps)
The year 2010 proved to be fruitful for the completion of total syntheses of
peloruside: both the group of Jacobsen and Hoye published their work. The
synthesis by Jacobsen58 is characterized by highly selective catalytic reactions
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involving epoxides for the synthesis of the building blocks. The most peculiar
step in this synthesis, however, is a diastereoselective hetero-Diels-Alder reaction
between diene 1.37a and aldehyde 1.37b, catalyzed by 1.37c to build up a part of
the pyranose precursor 1.37d (scheme 1.6). This fragment is further transformed
towards enone 1.37e, which is coupled with aldehyde 1.37f in a protocol which is
similar to the one used in Ghosh’s synthesis. The resulting hydroxyketone 1.37g is
conveniently transformed into peloruside 1.28, again through macrolactonisation
(52% yield).
The synthesis of Hoye is somewhat less elegant, as it requires more steps than
any other peloruside synthesis. However, some ingenious strategies and technolo-
gies that were developed in his lab are implemented.59
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Scheme 1.7: Synthesis of (+)-peloruside A by Hoye et al. (2010) (LLS: 36 steps)
To install the trisubstituted olefin, precursor 1.38a is transformed to lactone
1.38b in a relay ring closing metathesis (scheme 1.7).60 This is further elabo-
rated towards 1.38c, which undergoes a Blaise reaction and subsequent hydrolysis
to form 1.38d. A decarboxylation under neutral conditions provides methylke-
tone 1.38e. Another strategy that is implemented is the kinetic lactonization of
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pseudosymmetrical 1.38f to form 1.38g.61 This is further transformed to form
aldehyde 1.38h, which is coupled with methyl ketone 1.38e, resulting in hydrox-
yketone 1.38i. The macrolactone was formed with a yield of 54%.
Total synthesis efforts of Smith III et al. and Trost et al., resulted in the
synthesis of epimers of peloruside.
The synthesis by the group of Smith III62 was used to showcase the synthetic
utility of type I anion relay chemistry.63 The reaction product of the lithium anion
of dithiane 1.39a with epoxide 1.39b undergoes Brook rearrangement and then
attacks epoxide 1.39c to form dithiane 1.39d in one pot (scheme 1.8). This is
further converted to aldehyde 1.39e. On the other hand, aldehyde 1.39f is reacted
with silyl enol ether 1.39g in a Mukaiyama aldol reaction. The fragment is then
further transformed to dithiane 1.39h, of which the anion reacts with the previ-
ously synthesis aldehyde 1.39e. The coupled fragment is further converted to seco
acid 1.39i. During the macrolactonization of this fragment though, under Yam-
aguchi conditions at 90◦C (70% yield), the stereocenter at C2 was inverted, which
went unnoticed until final deprotection, resulting in (-)-2-epi -peloruside 1.40.
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Scheme 1.8: Synthesis of (-)-2-epi -peloruside by Smith III et al. (2008) (LLS: 27
steps)
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In the synthesis by Trost, desymmetrization of diol 1.41a is achieved by em-
ploying catalyst 1.41b, resulting in alcohol 1.41c (scheme 1.9).64 This was further
converted to methyl ketone 1.41d which is coupled in an aldol reaction with alde-
hyde 1.41e. The anion of alkyne 1.41f reacts with advanced aldehyde 1.41g, to
deliver ynone 1.41h after oxidation. A gold-catalyzed cyclization delivers dihy-
dropyranone 1.41i. Trost employs thus an alkyne as a linchpin for assembling
the carbon framework of peloruside, and takes advantage of the reactivity of this
triple bond to construct the pyranose ring. Macrolactonization towards 1.41j (57%
yield) and subsequent conversion of the dihydropyranone to the pyranose ring are
necessary to complete the synthesis. In the end, it was observed that the wrong
(enantiomeric) catalyst in the synthesis of the side chain was used, resulting in the
C18-epimer 1.42.
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Scheme 1.9: Synthesis of (-)-18-epi -peloruside by Trost et al. (2013) (LLS: 22
steps)
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1.2.3 Biological activity
Peloruside exerts its biological activity through binding to microtubuli. A focus on
some physiological and pathological concepts is thus necessary to discuss this.65–72
The structure, dynamics and function of microtubuli
Microtubuli are key components of the cytoskeleton, consisting of highly dynamic
fibres. These cylindrical fibres are formed by the association of heterodimers con-
sisting of alpha- and beta-tubulin, which are tightly bound together (figure 1.13a).
Each type of tubulin subunit has a binding site for GTP: a non-hydrolyzable site
on alpha-tubulin and a hydrolyzable site on beta-tubulin. They assemble in a
head-to-tail arrangement, leading to linear protofilaments with a distinct struc-
tural polarity. Sets of thirteen protofilaments are kept together by forming lateral
contacts, and further polymerize, resulting in the hollow microtubule cylinder with
beta-tubulin exposed at the so-called (+)-end and alpha-tubulin at the so-called
(-)-end.
The annotation ‘(+)-end’ emanates from the fact that the highly dynamic be-
haviour of microtubules (growing as well as shrinking) manifests itself mainly at
this end. In order to polymerize, microtubules use energy provided by the hydrol-
ysis of GTP. Thus, the free beta-tubulin subunit must be bound to GTP at its
hydrolysable site before assembly into microtubules can occur. Shortly after the
addition, GTP is irreversibly hydrolyzed to GDP. The majority of beta-tubulin
in the microtubule is thus in the GDP-bound state and capped with GTP-bound
tubuline at its (+)-end. It is generally considered that, upon hydrolysis, the con-
formation of GTP-bound tubulin changes from a straight to a more curved form,
inducing conformational strain.
When the GTP on a beta-tubulin is hydrolyzed to GDP before another GTP-
bound beta-tubulin is added (loss of the protective GTP-cap), the conformational
change of the exposed GDP-bound beta-tubulin results in rapid depolymerization,
known as a ‘catastrophe’ (figure 1.13b). When the addition of free tubulin-dimers
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Figure 1.13: Schematic representation of the dynamics of a microtubule. Reprinted
by permission from Macmillan Publishers Ltd:73 Copyright 2009.
at the GTP-cap is faster than hydrolysis to GDP, the microtubule is growing, also
known as a ‘rescue’. The process in which the individual microtubule ends switch
between phases of growth and shrinkage is called dynamic instability. In contrast,
a more subtle dynamic behaviour, consisting of net growth at one microtubule
end and balanced net shortening at the opposite end is called ‘treadmilling’. It is
the combination of these dynamic phenomena that determines and regulates the
biological functions of microtubules in all cells.
The highly organized arrangement and the dynamics of microtubules are crucial
in maintaining the cell shape, in the transport of different cell components, in cell
signalling and in cell division and mitosis in particular.
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Microtubules as target for the treatment of cancer
The eukaryotic cell cycle is tightly controlled by a number of cyclin dependent
protein kinase complexes (CDK complexes), through a series of phosporylation/
dephosphorylation events. Cells transverse the cell-cycle in two main phases: in-
terphase, consisting out of the G1, S and G2 phase, and mitosis. These processes
are depicted in figure 1.14.
Figure 1.14: Schematic representation of the cell cycle. Adapted by permission
from Macmillan Publishers Ltd:74 Copyright 2014.
In the G1 phase, cells commit to enter the cell cycle and prepare to replicate
their DNA and duplicate their centrosomes.
The actual replication and duplication occurs in the S phase. S phase CDK
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complexes phosphorylate prereplication complexes, inducing one round of repli-
cation initiation. Each chromosome is replicated, forming two sister chromatids,
connected by cohesin molecules. Mitotic CDK complexes are made during S phase
en G2, but their activities are inhibited until correct DNA synthesis is complete.
Any defect in DNA replication might be repaired during G2 phase. Activation of
mitotic CDK complexes causes initiation of mitosis.
At the onset of mitosis the chromosomes and centrosomes of the cell have been
replicated. During early prophase, the chromosomes condense. Later in prophase,
the centrosomes begin to move toward opposite poles. At each centrosome, micro-
tubules are nucleated and elongate. At prometaphase, the nuclear envelope breaks
down and microtubules attach to the kinetochores, specialized sites at each chro-
mosome centromer. This is achieved by a stochastic process in which kinetochores
of the chromosomes are captured by randomly elongating and contracting micro-
tubules emanating from the two spindle poles. Eventually, sister centromers are
attached to the microtubules from opposite poles. During metaphase, kinetochore
microtubules guide the alignment of sister chromatids at the equatorial plane of
the cell, a process called ‘congression’.
Next, the anaphase promoting complex (APC) is activated. APC targets co-
hesin regulators for degradation, allowing segregation of sister chromatids. During
anaphase, sister chromatids are separated as the kinetochore connected micro-
tubules pull them toward opposite poles. Subsequently, APC also degrades mi-
totic CDK complexes, resulting in the final mitotic events: the cell elongates and
cytokinesis (ring contraction) begins. In telophase, a nuclear membrane reforms
around each daughter nucleus and the chromosomes decondense. Mitosis results in
two identical daughter cells, each are containing two copies of every chromosome.
Cell cycle progression is monitored by checkpoint mechanisms that ensure faith-
ful duplication, and accurate chromosome segregation and distribution during mi-
tosis. The mitotic spindle assembly checkpoint monitors that all chromosomes
have achieved bivalent attachment to microtubules and that a tension is generated
through microtubule-mediated pulling of kinetochores to opposite directions.
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It is clear that well controlled dynamics of microtubules are indispensable for
correct cell division: for the reorganization of the existing network during the
transition from interphase to mitosis, and at different stages during mitosis. Any
disruption of the microtubule dynamics will lead to cell-cycle arrest and will even-
tually result in cell death.
As many cancer cells divide more frequently than normal cells, they pass
through mitosis more often and they become particularly susceptible to agents
that disrupt the microtubule dynamics. These agents are therefore called micro-
tubule inhibitors, antimitotic drugs or spindle poisons and belong to the most used
treatments of cancer.
The microtubule inhibitors are usually classified in two main groups. One
group, the microtubule-destabilizing agents, inhibits microtubule polymerization
at high concentrations. An example of this is vinflunine (Javlor R©) (1.43, figure
1.15), which is in clinical use for the treatment of different types of cancer.
The second group are the microtubule-stabilizing agents. These agents pro-
mote microtubule polymerization at high concentrations. Paclitaxel (Taxol R©) was
the first agent to be identified in this class. Other examples include docetaxel
(Taxotere R©) and ixabepilone (Ixempra R©) (1.44), which are also commonly used
in the clinic. Also (+)-peloruside A, the subject of this dissertation, is classified
as a microtubule-stabilizing agent.i Peloruside was reported to show cytotoxic
activity at nanomolar concentrations in different cancer cell lines.75,76
Microtubules as target for the treatment of neurodegenerative diseases77–79
Another therapeutic area where microtubule stabilizing agents can be employed,
is the area of neurodegenerative diseases.
iThe classification of anti-cancer drugs as microtubule ‘stabilizers’ or ‘destabilizers’ is actually
simplistic. Polymerization, and inhibition of polymerization respectively, have only an effect on
the mass of the microtubule-polymer at high concentrations. At clinically relevant concentra-
tions, the effect of the drugs in suppressing the microtubule dynamics is far more powerful than
the effects on polymer mass.67
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Figure 1.15: Vinflunine (1.43) and Ixabepilone (1.44)
Neurons are nerve cells that transmit nerve signals to and from the brain. The
neuron consists of a cell body with branching dendrites, and a projection, called
axon, which conducts the nerve signal (figure 1.16). At the other end of the axon,
the axon terminal transmits the electro-chemical signal across a synapse. This is
the gap between the axon terminal and the receiving cell.
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Figure 1.16: The structure of a neuron80
In the axons of neurons, microtubules form polarized linear arrays with the
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plus ends directed toward the synapses and the minus ends toward the cell body.
In this way, the microtubules provide both structural support and directional-
ity for the intracellular transport of proteins and vesicles between cell body and
synapse. This cytoskeletal structure, together with molecular motor proteins such
as kinesins and actins, comprise the axonal transport machinery. This machinery
is critical for the viability of a neural cell, and defects in axonal transport are
observed in several neurodegenerative diseases. Particularly in the axons of neu-
rons, microtubules are stabilized by the microtubule associated protein tau. When
tau is hyperphosphorylated, the binding affinity of this protein for microtubules is
reduced, and it becomes disengaged. An abnormal detachment of tau from the mi-
crotubules, alters the dynamics and organization of the axonal microtubules, which
causes axonal transport defects. Furthermore, free and hyperphosphorylated tau
is more prone to misfolding and aggregation, which can recruit functional tau
into an aggregation cascade, and thereby worsening the destabilization of axonal
microtubules.
Figure 1.17: Axonal transport defects caused by tau phosphorylation. Reprinted
with permission from79 Copyright 2012 American Chemical Society
By employing exogenous microtubule-stabilizing agents, the loss of tau could be
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compensated, thereby maintaining the appropriate organization and dynamics of
the microtubuli. The MSA epothilone D (1.45) proved to be efficient in doing this,
both in vitro and in vivo, and moved on to phase I clinical trials. Unfortunately,
it was discontinued due to side effects.
O
O OH O
OH
N
S
H
1.45
Figure 1.18: Epothilone D
In an in vitro assay, peloruside is effective in protecting the neurons against
phosphorylation of tau, however, it remains unclear whether it will penetrate the
blood-brain-barrier, which is of utmost importance in the treatment of CNS dis-
eases.78
The potential of (+)-Peloruside A as treatment for cancer, neurodegenerative
diseases or even autoimmune diseases has been recently reviewed by Miller et al..81
Binding pocket of (+)-peloruside A
In 2004, the group of Miller investigated the cytotoxicity of peloruside in paclitaxel-
resistant cell lines.82 This resistance can be a result of overactivation of active
transport mechanisms, like the permeability glycoprotein (Pgp), or because of mu-
tations of the β-tubuline gene, which encodes for the binding pocket of paclitaxel
(taxoid binding site). It was observed that peloruside retains its activity in these
resistant cell lines, suggesting it binds to a distinct location. Also the microtubule-
stabilizing agent laulimalide retained its activity, which meant both peloruside and
laulimalide bind to the same (or at least overlapping) binding pocket.
Further experiments showed that peloruside shows synergism with other (tax-
oid binding) MSA’s. No evidence of synergism between laulimalide and peloruside
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was observed, which supports the earlier stated hypothesis of a common bind-
ing pocket between these. Furthermore, this was supported by peloruside being
replaced by laulimalide, but not by other (taxoid binding) agents.
There has been a lot of discussion on the exact binding pocket of peloruside on
tubuline, and a lot of research has been done by different groups. Initial molecular
modelling experiments by Vilarrasa in 2004 suggested a pocket on α-tubulin.83
Jime´nez-Barbero and Dı´az also suggested a binding pocket on α-tubulin, based on
advanced NMR studies and molecular mechanics calculations.84 The same study
also provided the bioactive conformation of peloruside, both in the free state and
bound to tubulin.
Another study combined advanced MS experiments, using the exchange of
hydrogen and deuterium to map the binding interactions (HDX-MS), together with
computational simulations and came up with a binding pocket on β-tubulin.85
Both above suggestions were, as it seems, combined in a new proposal, by
the groups of Barasoain and Dı´az.86 This suggestion comprised the binding of
peloruside in a two-step mechanism (as is the case for paclitxel), of which the
initial event is the binding to β-tubulin, upon which the ligand is transported to
the inside of the α-tubulin. The same research indicated that the primary free
alcohol at C24 is essential for binding.
Hamel et al. used the docking site of Huzil (originating from the HDX-MS
experiments), but reoriented peloruside in this site, thereby enabling the intro-
duction of new hydrogen bonds and hydrophobic interactions.87 This resulted in
an updated binding interactions profile between peloruside and β-tubulin (figure
1.19)
In 2011, the isolation of a series of peloruside-resistant cell lines was achieved.
From experiments on these cell lines, in combination with HDX-MS, it was shown
that the mutations result in a conformational change in a cleft where the side
chain is predicted to dock. This illustrates the importance of the side chain in the
binding process.88
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Figure 1.19: Important binding interactions between (+)- peloruside A and β-
tubulin, according to Hamel et al. Reprinted with permission from87 Copyright
2010 American Chemical Society.
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Figure 1.20: Important binding interactions between (+)- peloruside A and β-
tubulin, identified by means of X-ray crystallography. Reprinted by permission of
John Wiley and sons from89 Copyright 2014.
Proof of the actual binding site of peloruside was delivered in 2014 by Stein-
metz’s group by means of X-ray crystallography.89 They were able to determine the
tubulin-bound peloruside structure and suggested that peloruside is able to bridge
two adjacent tubulin dimers. Together with the important binding interactions
(figure 1.20), they came up with a rationale for the observed synergistic interac-
tions between peloruside and e.g. paclitaxel: by means of an allosteric interaction,
induced by peloruside, the binding pocket of the taxanes becomes stabilized.
Analogs of (+)-peloruside A and their activity
Besides (+)-peloruside A, three other natural congeners of peloruside exist, peloru-
side B (1.46), C (1.47) and D (1.48) (figure 1.21).90,91 Peloruside B only differs
from A by the absence of an O-methyl group linked to the C3 alcohol, and has a
similar biological activity. In the case of peloruside C, which differs in degree of
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oxidation at the pyran, the cytotoxicity is reduced, but still present. In the case
of Peloruside D on the other hand, where the pyran ring has shifted, cytotoxicity
is only observed at far higher concentrations (millimolar range).
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Figure 1.21: Natural occuring congeners of (+)-peloruside A
Besides the earlier described C2- and C18-epimers, of which no biological data
are available, also the C11-epimer (1.49) was described in a patent by Ghosh (fig-
ure 1.22).92 Intriguingly, this epimer had a comparable bioactivity as the original
peloruside A. In this same patent, Ghosh also described the experimental and bio-
logical data for 2 analogs lacking the oxygen at C2: one with the original methoxy
at C7 (1.50) and one with the free alcohol at this position (1.51). A drop in
activity was observed, suggesting the alcohol at C2 is important for binding.
A bunch of deoxygenated analogs were synthesized. Both E and Z C12 –C13
unsatured analogs (1.52 and 1.53) were synthesized by Zhao and Taylor,93 lacking
oxygens at C11 and C13 (figure 1.22). The rationale behind this was the prediction
of NMR and computational studies that the C9 –C15 region of the original natural
product is flexible compared to the rigid C2 –C3 and C5 –C9 region. Unfortunately,
the analogs were too unstable to perform biological experiments.
The group of Altmann synthesized a THP analog (1.54), lacking the sub-
stituents at C7, C8 and C9,
94 and two monocyclic analogs (1.55 and 1.56), where
the embedded ring is missing (figure 1.23).95,96 Of the latter two, one (the R-
analog, 1.55) has a hydroxyl in an equivalent position as the hemiacetal group in
peloruside A. The activity of the THP analog 1.54 is only 10 fold lower, compared
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Figure 1.22: Synthetic analogs of peloruside (1)
to the natural product. For the (7S ) monocyclic analog, the biological activity
was non existing, whereas the (7R) analog still showed a modest activity in the
micromolar range. The strongly simplified analog 1.57 did only show very modest
activity.97
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Figure 1.23: Synthetic analogs of peloruside (2)
The NaBH4 reduction product of natural peloruside (1.58)
75 and the 2-deoxy
analog (1.59)92 were also reported (figure 1.24). The former showed a ten-fold
decrease in activity, whereas the latter was completely inactive.
The importance of the free alcohol at C24 was shown by derivatizing natural
peloruside. Upon acetylation of the primary alcohol (1.60), the activity was ten
times lower, whereas chloroacetylation of the primary alcohol resulted in an analog
(1.61) with comparable activity as the natural product.86 This is probably due to
hydrolysis of the ester in vitro, resulting in the in situ formation of peloruside A.
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Figure 1.24: (Semi)-synthetic analogs of peloruside (3)
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Figure 1.25: Semi-synthetic analogs of peloruside (4)
The treatment of natural peloruside with acid delivered different analogs, de-
pending on the acid (figure 1.25). When catalytic TFA was employed, a furanose
analog (1.62) was formed, whereas, upon the use of trifluoromethanesulfonic acid,
a pyranone analog was obtained (1.63).91 The activity of these analogs is in the
micromolar range.
All the aforementioned analogs are discussed in detail in a recently published
review98 and their activity is summarized in table 1.1.
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Compound HL-60 P388 A2780 HCT116
1.28 7-35 18 19
1.46 33
1.47 221
1.48 2000
1.49 10
1.50 120
1.51 320
1.54 163
1.55 1170
1.56 >20000
1.57 15000
1.58 221
1.59 >5000
1.60 257
1.61 27
1.62 15000
1.63 7000
Table 1.1: IC50-values of peloruside analogs in specified cell lines (nM) (HL-60:
human leukaemia cells, P388: murine leukaemia cells, A2780: ovarian carcinoma cells, HCT116:
colon carcinoma cells).
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Tetrahydropyran analogs
In this chapter, the synthesis towards a first set of analogs is described. The main
challenge was the implementation of a fairly unexplored reaction to introduce
chemical complexity, while opening up possibilities for diversification, and analog
development.
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2.1 Introduction
In order to investigate the importance of the hemi-acetal function in peloruside
and the substituents on the pyranose ring, a set of analogs was designed where
this pyranose ring is replaced by a tetrahydropyran (THP) ring, whether or not
with a substituent at the C7 position (2.1).
Our design is based on the aldol coupling of two advanced intermediates: a
methyl ketone 2.2, containing two stereocenters and the trisubstituted double bond
of the side chain, and an aldehyde 2.3, containing the (substituted) THP ring and
two additional stereocenters (Scheme 2.1). The synthesis of the latter fragment
was based on the Mukaiyama-aldol Prins (MAP) cyclization,99 a cascade/domino
reaction between an aldehyde 2.4 and a bisnucleophile 2.5, in the presence of a
Lewis acid.
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Scheme 2.1: Retrosynthetic analysis of the envisaged THP analogs
During the course of this PhD, in 2013, the synthesis of the 7,8,9-trideoxy
analog 1.54 (thus with an unsubstituted THP-ring) was published by the group
of Altmann (scheme 2.2).94 Key steps include glycolate aldol addition of boron-
enolate 1.54a to aldehyde 1.54b, a vinyllithium addition of the corresponding
lithiate of 1.54c to 1.54d. The THP ring of the latter compound is constructed
from 1.54e via a Prins cylization with CeCl3 and LiI. Hydroxyester 1.54e is the
result of an Evans-Tishchenko reduction (vide infra) of hydroxyketone 1.54f with
aldehyde 1.54g.
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Scheme 2.2: Retrosynthetic analysis of the 7,8,9-trideoxy-analog 1.54 by Altmann
2.2 Synthesis of the C12-C20 methyl ketone 2.2
The synthesis of the C12-C20 fragment was developed earlier in our lab as part of
a Master thesis and is represented in figure 2.3.100 In literature, the installation of
the stereocenter at C18 is usually accomplished using a chiral auxiliary, or making
use of asymmetric transition metal catalysis. Here, the catalytic approach for the
formation of 2.8 is preferred, as it is shorter and more elegant. Also, this procedure
was reported in literature.101,102 The zirconium-catalyzed asymmetric carbomag-
nesation was developed in the lab of Hoveyda and encompasses the enantioselective
addition of a Grignard reagent to an ‘activated’ Z -alkene.
The chiral catalyst used is (S,S )-ethylene-1,2-bis(η5-4,5,6,7-tetrahydro-1-inde-
nyl)zirconium (R)-1,1’-bi-2-naphtolate ((S,S )-(EBTHI)ZrBINOL) (2.16). The
corresponding proposed catalytic cycle is depicted in scheme 2.4 and starts with
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Scheme 2.3: Synthesis of the C12-C20 fragment (2.2)
the complexation of ethylene (2.16a) upon addition of EtMgCl to the catalyst.
Next, enantioselective cycloinsertion of dihydrofuran (2.6), via 2.16b leads to the
formation of zirconacyclopentane intermediate 2.16c.
The enantioselectivity of this insertion arises from the specific addition mode,
avoiding any unfavorable interactions (2.16b favored), whereas approach via the
alternative enantioface is blocked by the cyclohexyl unit of the tetrahydroindenyl
ligand (2.16b unfavored). In this respect, the cis- geometry of the alkene, is very
important to obtain high levels of stereoinduction. After insertion, upon attack of
ethylmagnesiumchloride, the zirconacyclopentane 2.16c is regioselectively cleaved,
affording the less sterically hindered intermediate 2.16d, which can irreversibly
eliminate towards alkene 2.16e. Subsequent β-hydride transfer from the ethyl
(2.16f), followed by reductive elimination affords the magnesium alkoxide 2.9a,
47
2.2. Synthesis of the C12-C20 methyl ketone 2.2
regenerating the catalytic species 2.16a.
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Scheme 2.4: Proposed catalytic cycle of the enantioselective zirconium-catalyzed
carbomagnesation of 2.6101
Homoallylic alcohol 2.8 was isolated after distillation at atmospheric pressure,
at which stage the enantiomeric excess could be determined using chiral GC (enan-
tiomeric ratio >98:2), which is in agreement with the values that are reported in
literature.101 The alcohol 2.8 was protected as MEM ether 2.9, with a yield of 40%
over two steps. This lower yield is explained as the amount of expensive catalyst
is optimized in terms of turnover numbers more than in terms of absolute total
yield.103
The resulting alkene 2.9 is then oxidatively cleaved using ozone (scheme 2.3),
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and the resulting aldehyde 2.10 is subjected to the Still-Gennari variant of the
Horner-Wadsworth-Emmons (HWE) olefination to form the α-β-unsaturated ester
2.11.104
R1
O
H
P
CF3CH2O
CF3CH2O
O O
OMe
Me
COOMe
O
HR1
P
RO
RO
O
Me
COOMe
O
R1H
P
RO
RO
O
R1
CO2Me
Me
CO2Me
Me
R1
O P(OR)2
CO2Me
MeH
R1
O
O P(OR)2
CO2Me
MeR1
H
O
fast
O
P(OR)2
CO2Me
MeH
R1
O
slow
2.17
2.18
2.19a
2.20a 2.21a
2.19b 2.20b
2.21b
2.22
Scheme 2.5: Selectivity of the Still-Gennari reaction
The latter modification makes use of an α-branched phosphonoacetate under
salt-free conditions to introduce the Z -olefin in 77% yield over 2 steps as a single
diastereomer. In general, the phosphoryl-stabilized carbanion (2.17) attacks alde-
hyde 2.18 in a stepwise manner (scheme 2.5).105 This leads to the oxyanion inter-
mediates 2.19a and 2.19b, which can decompose to the olefin via a four-membered
ring intermediate 2.20a and 2.20b. The erythro transition state 2.19b, which pre-
cedes the formation of Z -olefin 2.21b, is less sterically hindered, compared to the
threo transition state 2.19b, thus, under kinetic control, the former will prevail.
However, the stereochemical outcome in the HWE-reaction is not only determined
by the stereochemistry in the initial C-C bond forming step, but also by the pos-
sibility of the intermediates to do the reverse reaction. If the dissociation of the
oxaphosphetane is slow, under thermodynamic conditions, an equilibrium can set
in, and through rotation (2.22), the most stable isomer will be formed. This is
prevented by the use of an electrophilic phosphonate (caused by the presence of
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the trifluoroethyl groups), and strongly dissociating conditions (the K+ counter
ion of the base is trapped by a cryptand, so the anion is not stabilized), causing
a rapid breakdown of the oxaphosphetane 2.20b, resulting in the formation of
Z -olefin.
The required α-branched phosphonoacetate is synthesized in two steps, starting
by reacting ethylphosphonic dichloride (2.23) with trifluoroethanol. The anion
of the resulting phosphonate 2.24 is then reacted with methylchloroformate to
produce phosphonate 2.25 in variable yields.106,107
O
P
O
O
O
OMe
Cl
P
O
Cl
a b
a) CF3CH2OH, NEt3, THF, RT; b) i) BuLi, HMDS, THF, -78°C; ii) Cl(CO)OMe
89% 50%
CF3
F3C
O
P
O
O
CF3
F3C
2.23 2.24 2.25
Scheme 2.6: Preparation of the α-branched phosphonoacetate
The geometry of the α,β-unsaturated ester 2.11 is proven using nuclear Over-
hauser effect spectroscopy (NOESY). This makes use of the dipolar interaction
between nuclear spins to prove correlation between protons. The intensity of this
nuclear Overhauser effect is approximately proportional to 1/r6, where r is the
distance between two protons. Hence, only protons which are in close enough
proximity (i.e. closer than 5A˚) will show a signal in the NOESY spectrum. In this
spectrum (figure 2.1) a crosspeak is visibile between vinylic proton 2 and the allylic
methyl protons at position 1, whereas a crosspeak between protons at position 1
and 3 (in case of the E -geometry) is lacking.
The unsaturated ester is transformed to the aldehyde by DIBAH reduction to
2.12, followed by Dess-Martin periodinane oxidation to 2.13, in 95% yield over
two steps. The resulting aldehyde is then subjected to a stereoselective Brown
allylation,108–113 to yield homoallylic alcohol 2.14 in 79% isolated yield.
The chiral allylating reagent (-)-B-allyl-diisopinocampheylborane 2.28 is pre-
pared by hydroboration of (+)-α-pinene (2.26), followed by methanolysis, leading
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3
3
4a 4b
4a
4b
5
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MEMO
O
12
3
4
5 O
Figure 2.1: NOESY spectrum of 2.11
to the corresponding dialkyl methoxyborane 2.27. Upon treatment of the latter
with allylmagnesium bromide, the requested allylborane is formed in high enan-
tiomeric purity (figure 2.7). The boron atom acts as a Lewis acid in activating the
aldehyde, while, at the same time, the aldehyde functions as a Lewis base, thereby
increasing the nucleophilicity of the allylborane.
BOMei) BH3.SMe2, Et2O
ii) MeOH
74%
2
B
2
MgBr
Et2O
2.26 2.27 2.28
Scheme 2.7: Synthesis of (-)-B-allyldiisopinocampheylborane
The origin of stereoselectivity can be explained by a difference in transition
state, where, in the unfavored mode of addition to the aldehyde, a steric interaction
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H H
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2.29a 2.29b
Figure 2.2: Origin of stereoselectivity in Brown’s asymmetric allylation
between a methyl of one pinene group and the methylene of the allyl group causes
an increase in energy (2.29b). This interaction is absent when the aldehyde is
attacked from its other enantioface (2.29a) (figure 2.2).114
Verification of absolute stereochemistry via Mosher ester
analysis
In order to determine the absolute configuration of the stereocenter formed during
allylation, the Mosher method is applied. Mosher derived an empirical correlation
between the configuration of a stereocenter and NMR chemical shifts of diastere-
omeric α-methoxy-α-trifluoromethylphenylacetate (MTPA) esters, and developed
a model to rationalize this.115,116
First, the chiral, secondary alcohol must be converted into both diastereomeric
MTPA derivatives. The 1H-NMR spectra of the diastereomers with known config-
uration at the acid moiety, but unknown configuration at the carbinyl centre are
then recorded and compared. The difference in chemical shift of the two diastere-
omers can be used to assign the absolute configuration of the carbinol. Based on
experiments on molecules with known absolute configuration, Mosher developed
a model which could account for this difference in chemical shift (Figure 2.3). To
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rationalize this model, one should look at the conformation of each diastereomer
in which the ester adopts the transo¨ıd conformation around its O-(CO) bond, and
in which both the α-trifluoromethyl substituent of the MTPA ester and the me-
thine proton of the secondary alcohol are syn-coplanar. This should not be the
ground-state conformations, but they are the most important conformation to ex-
plain the different spectroscopic behavior of the diastereomers. The phenyl group
of the MTPA ester imposes an anisotropic magnetic shielding effect on protons
that reside above or below the plane of this phenyl ring. This shielding results
in a more upfield (lower ppm value) shift for the affected protons in the NMR
spectrum. Consequently, the difference in chemical shift between the R-MTPA
ester and the S -MTPA ester (δRS = δR-δS ) will be negative for R1 and positive
for R2.
O
O
CF3
H
OMePhR1
R2O
O
CF3
H
MeOR1
R2
Ph
O CF3
PhMeO
R1 R2
O CF3
OMePh
R1 R2
(S)(R)
Figure 2.3: The Mosher model
Thus, by calculating the difference in chemical shift between corresponding
pairs of protons in R1, respectively R2 for both diastereomeric MTPA-esters, the
configuration of an unknown stereocenter can be assigned. i
iAs the Mosher model is based on empirical results, it is not definitive proof of the absolute
stereochemistry. However, it is a common tool in total synthesis to assign this.
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Therefore, both R- and S - MTPA esters (2.30 and 2.31) were synthesized,
using the corresponding (S )- and (R)- MTPA-chlorides (Scheme 2.8).
OH O
O
CF3
R' R
''
R' = Ph, R'' = OMe : (R)-MTPA ester 90%
R' = OMe, R'' = Ph : (S)-MTPA ester 92%
(S)-MTPA-Cl or 
(R)-MTPA-Cl, 
Et3N, DMAP
CH2Cl2, RT
OMEM OMEM
2.14
2.30
2.31
Scheme 2.8: Synthesis of the Mosher esters 2.30 and 2.31
The difference in chemical shift between the (R)- and (S )- diastereomeric esters
2.30 and 2.31 (2.32 in figure 2.4) most likely indicated the absolute configuration
of 2.14 to be S.
O
MTPA
+0.0428
+0.0203
+0.0001
+0.0146
-0.1803
OH
-0.0211
OMEM
OMEM
∂R-∂S < 0 : R1
∂R-∂S > 0 : R2
O CF3
PhMeO
R1 R2
O CF3
OMePh
R1 R2
(R)-ester (S)-ester
2.32
2.14
Figure 2.4: The Mosher model applied to 2.14
The new homoallylic alcohol 2.14 was protected as MPM ether. This protect-
ing group can be selectively cleaved, which is necessary to close the macrocycle
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later on in the synthesis. Standard conditions including deprotonation with NaH
and reaction with MPM chloride in the presence of TBAI afforded 2.15 in 96%
yield. In a final step, the terminal alkene in 2.15 was converted to the corre-
sponding methyl ketone. This was achieved using Wacker-Tsuji conditions: a
Pd(II)-catalyzed process in which the reacted Pd(0) is reoxidized by addition of
an external oxidant, in this case Cu(OAc)2.
117 In the catalytic process (scheme
2.9), complexation of the alkene to Pd(II) makes it susceptible for nucleophilic
attack. The attack mainly happens at the more substituted position, as the de-
veloping positive charge is better tolerated at the secondary position compared
to the primary. This results in the formation of a σ-alkyl Pd-complex, which can
rapidly undergo β-hydride elimination to enol 2.2a, which tautomerizes to the cor-
responding ketone 2.2. The remaining Pd-complex 2.33a will undergo a reductive
elimination, resulting in a Pd(0)-species 2.33b, which needs to be reoxidized. This
is achieved by the external oxidant, Cu(OAc)2, which in turn is reduced to a Cu(I)
species (Cu(OAc)). By performing the reaction under an oxygen atmosphere, the
Cu(I) species can be reoxidized to Cu(II) with formation of water, so in principle,
catalytic amounts of Cu(OAc)2 are sufficient.
118
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Pd(OAc)2
[Pd]AcO
AcO
R
R
HO
H
AcO[Pd]
OH
HR
H
OAc
[Pd]AcO H
[Pd]
2 Cu(OAc)2
2 Cu(OAc)
H2O
2 HOAc
1/2 O2
R
OH
R
O
2.33
2.33c
2.33d
2.33a
2.33b
2.2a 2.2
2.15
Scheme 2.9: Catalytic cycle of the Wacker-Tsuji oxidation
2.3 Synthesis of the C1-C3 fragment 2.4
The synthesis of aldehyde 2.4 is based on the chiral pool approach, starting from
D-mannitol (2.34). First, the regioselective protection of the 1,3- and 4,6-diols
as benzylidene acetals (2.35) was achieved under sulphuric acid catalysis. The
modest yield (30%) is explained by the formation of different regioisomers, as
shown by LC-MS analysis.119 From here on, the synthesis was mainly described
by Reetz et al..120 However, this procedure proved to be not reproducible, and thus,
optimization was necessary. Benzylation of the resulting secondary alcohols in 2.35
was achieved by combining benzyl bromide with a KOH-solution in DMSO.121 The
advantages of this procedure are that it can be performed at room temperature
and that special precautions against ingress of moist, such as using dry DMSO or
performing the reaction under inert atmosphere are not necessary.
The subsequent cleavage of the benzylidene acetals in 2.36 was accomplished
by acid catalyzed methanolysis in a biphasic mixture of methanol and hexane,122
rendering tetrol 2.37. Next, the primary alcohols had to be selectively protected.
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OH OH OH
OH OH OH
O O OH
OH O O
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OBn O O
Ph
Ph
TBSO OH OBn
OBn OH OTBS
TBSO O
OBn
a b c
a) PhCHO, H2SO4, DMF, RT; b) KOH, DMSO, BnBr, RT c) HCl, MeOH/C6H14 5/3, RT; d) TBSCl, 
imidazole, CH2Cl2, RT; e) NaIO4, THF/H2O 4/1, RT
30% 93% 73%
e
95%
OH OH OBn
OBn OH OH
d
99%
2.34 2.35 2.36
2.37 2.38 2.4
Scheme 2.10: Synthesis of the C1-C3 aldehyde
The reported procedure (NEt3, DMAP)
120 did not prove effective enough as the
reaction did not proceed to completion, even after prolonged reaction times. Per-
forming the reaction in CH2Cl2 with imidazole as a base, however proved very
effective, as the reaction was finished within one hour, providing the bis-TBDMS
ether 2.38 in 99% yield.
The final step to obtain the first building block, the oxidative cleavage of the
resulting diol 2.38 with sodium periodate, proceeded smoothly in 95% yield, re-
sulting in two molecules of aldehyde 2.4, with the correct stereochemistry at C2.
2.4 Synthesis of the C4-C11 bisnucleophile 2.5
As 2,2-dimethyl-1,3-propanediol (neopentylglycol, (2.39), scheme 2.11) already
contains the gem-dimethyl unit present in the bisnucleophile, it is an ideal start-
ing point for the synthesis of 2.40. Protection and oxidation then sets the stage
for stereoselective allyl addition, and subsequent vinylation of the resulting ho-
moallylic alcohol.
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OH OH MPMO OH MPMO O
MPMO OH MPMO O
a c
e
f
a) 4-MeO-PhCH(OMe)2, CSA, CH2Cl2, RT; b) LiAlH4, AlCl3, Et2O, -10°C; c) i) (COCl)2, DMSO, -78°C 
ii) Et3N, CH2Cl2, -78°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, 
THF, allylOAc, 120°C; e) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, 
THF, allylOAc, 2-PrOH, 120°C;  f) Hg(CF3COO)2, EtOCHCH2, RT
92% 98%
96%
96% e.e.
80%
95% e.e.
73%
d
O O
b
99%
PMP
2.39 2.41 2.42 2.43
2.44 2.40
Scheme 2.11: Synthesis of the MPM protected C4-C11 enol ether
As there was already a benzyl protecting group present in the aldehyde build-
ing block 2.4, the choice fell on the use of a p-methoxy benzyl protecting group,
which could be orthogonally removed later in the synthesis. It was opted to mono-
protect the original diol in a two-step procedure, as experience in the lab for the
monobenzylation of this diol had shown that this could be achieved in high yields
and without intermediate purification.123
Herefore, the diol was protected as acetal (2.41), making use of p-methoxy
benzyl dimethyl acetal and CSA. In a first attempt, it was used for the next reac-
tion without further purification. For the reduction, a combination of LiAlH4 and
equimolar portions of AlCl3 was used. In this case, AlH2Cl is formed, according
to the equation AlCl3 + LiAlH4 −−⇀↽− 2 AlH2Cl + LiCl, which was shown to be the
active species in the reduction of the acetal.124
In a third, consecutive step, Swern conditions were applied to oxidize the alco-
hol 2.42 to aldehyde 2.43. After purification, minor amounts of p-methoxy ben-
zaldehyde were isolated, originating from the excess of p-methoxy benzyl dimethyl
acetal which was used in the first step, and which was respectively reduced and
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oxidized again. As this impurity was complicating the separation after the oxida-
tion, it was decided to repeat the synthesis with purification after every step. In
this way, the yields (91% over 3 steps) and the ease of separation were improved.
Having aldehyde 2.43 in hand, the stereoselective allylation was the next step.
Several conditions were tested (table 2.1) and the best one was selected, based on
the highest enantiomeric excess. This was determined by chiral LC. A first method
(entry 1) made use of stoichiometric amounts of the chiral allylating reagent (−)-
B-allyldiisopinocampheylborane 2.28, as described before (scheme 2.7). The se-
lectivity of the reaction with this chiral reagent was however lower than expected
(table 2.1, entry 1). Moreover, purification of the reaction was laborious, because
of the abundant side products. Therefore, our attention turned to catalytic sys-
tems, making use of a Lewis acid in combination with a chiral ligand.
Entry catalyst ligand allyl donor T e.e. yield
1 none none (– )-(ipc)2Ballyl -78
◦C 30% n.d.
2 Ti(iPrO)4 (S )-BINOL allylSnBu3 -20
◦C 41% n.d.
3 TiF4 (S )-BINOL allylSiMe3 0
◦C 84% n.d.
4 [Ir(cod)Cl]2
(S )-MeO,Cl-
BIPHEP
allylOAc 120◦C 96% 96%
Table 2.1: Allylation conditions (n.d.: not determined)
In this respect, the catalytic asymmetric allylation reaction, designed by G.E.
Keck in 1993, is a useful method.125 According to Corey, by combining two equiv-
alents of the chiral (R)- or (S )- BINOL ligand with one equivalent of Ti(iOPr)4,
a bis-BINOL titanate ester ((BINOL)2Ti) is generated, which makes up the cat-
alytic species.126,127 On the basis of this two ligand model (figure 2.5), Corey
proposed that a transmetallation occurs, when the allylstannane reacts with the
(BINOL)2Ti complex, resulting in an allyl-Ti(IV) complex where the trialkyltin
group is attached to one of the BINOL oxygens, upon which this oxygen dissociates
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from titanium. Coordination of the aldehyde then occurs, according to Corey’s
model, in such a way that a hydrogen bonding interaction can emerge between the
formyl hydrogen and one of the oxygens of the BINOL ligand, thereby forming a
trigonal bipyramidal structure (2.45, figure 2.5). In this arrangement, the non-
bonding steric repulsions are minimized and the allyl group is placed in a basal
position, whereas the formyl O is based in an apical position, which is ideal for
the allylation to occur. Thus, according to the proposed model, based on a formyl
hydrogen bond, the (S ) configuration of the homoallylic alcohol stems from (S )-
BINOL and vice versa. It should be noted that this is only a working model, which
provides a rationale for the observed enantioselectivity, but too little is known to
provide the real origin of asymmetric induction.
O
SnR3
O
O
O
O
Ti
R H
2.45
Figure 2.5: Corey’s proposal for a transition-state structure in the Keck allylation.
As the optical purity using the Keck method was also disappointing (table 2.1,
entry 2), another catalytic system, developed by Carreira was tested (entry 3, ta-
ble 2.1). This method is known to be particularly effective for the enantioselective
allylation of hindered, aliphatic, non-enolizable aldehydes.128,129 The catalytic sys-
tem makes use of TiF4 as catalyst in combination with the chiral BINOL ligands,
and non toxic allylsilanes as allyl donor. In general, Ti(IV)/BINOL catalysts are
too weak Lewis acids for the allylation with less nucleophilic allylsilanes. However,
due to the increased electronegativity of fluorine, TiF4 is an exception. Further-
more, the fact that a Ti-F bond is stronger than a Si-F bond may assist in catalyst
turnover.
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1H-NMR experiments showed formation of propene and Me3SiF upon mixing
of the TiF4-BINOL complex with allyltrimethylsilane, suggesting that the latter
originally acts as a base to neutralize the formed HF during the catalyst prepara-
tion. Moreover, the formation of an allyltitanium species was not visible, indicating
that a transmetalation as suggested by the Corey model in the Keck allylation,
is not occuring. In terms of stereochemical outcome, however the model is still
valid, as the (S )-BINOL ligand produces the (S )-enantiomer. Duthaler proposed
a transition state where the electrophilic Ti center activates the aldehyde, and
simultaneously, the fluoride complexes the silicium of the allylsilane, hereby in-
creasing the reactivity of the latter.130,131 This could then directly produce the
silylated homoallylic alcohol, with regeneration of the catalyst.
Ti
F
F
Ti
F
F
O
O O
O
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O
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Me3
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Ti
F
O
R
SIMe3
OSiMe3
R
2.46 2.47
2.482.49
Scheme 2.12: Catalytic cycle for the enantioselective allylation using TiF4, as
proposed by Duthaler130
The outcome of this test reaction in terms of enantioselectivity was better
than the previous ones (table 2.1, entry 3), however, as there was still room for
improvement, another method was tested.
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In 2008, Krische et al. reported on a novel enantioselective, iridium-catalyzed
allylation method, via transfer hydrogenative coupling of allyl acetate.132,133 The
optimized catalytic system employs [Ir(cod)Cl]2 as iridium source, together with a
chelating phosphine ligand and cesium m-nitrobenzoate as an additive. Different
test reactions suggested that m-nitrobenzoate and the iridium center must be
closely associated during the enantioselective addition. Therefore, the group of
Krische was able to isolate a catalytically relevant complex, using (R)-BINAP as
a ligand. A single-crystal x-ray diffraction experiment revealed the presence of
an ortho-cyclometalated iridium(III) - pi allyl complex (Figure 2.6). Despite its
stability, this complex is considered to be the active catalyst, based on the use of
the isolated complex, instead of its in situ generation, which gives better results.
O
NO2
O
P
Ir
P
Figure 2.6: Catalytically active ortho-cyclometalated iridium(III) - pi-allyl com-
plex, as determined by single X-ray diffraction analysis.133
Very remarkable is that this method promotes carbonyl allylation both from
the aldehyde as from the alcohol oxidation level. In the former case, isopropanol
is added as hydrogen donor, in the latter case, the alcohol acts both as aldehyde
precursor and reducing agent.
Based on the observations, Krische proposed two possible catalytic cycles.133
In a first one (scheme 2.13, upper half), the iridium carboxylate 2.51a, which
is in equilibrium with ortho-cyclometalated complex 2.50, undergoes oxidative
addition and then can undergo acetate-assisted ortho-metalation through the six-
membered transition structure 2.52b. This results, after loss of acetic acid, in the
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formation of σ-allyl C,O-benzoate complex 2.53, which can rapidly equilibrate
with the corresponding pi-allyl haptomer 2.54, of which the X-ray structure was
confirmed. Extra evidence for this equilibrium was provided by performing the
allylation with isotopically labeled allyl acetate (CH2CHCD2OAc), which resulted
in equimolar amounts of the deuterio and isodeuterio homoallylic alcohols. The
allyl group is then transferred to the aldehyde, resulting in the homoallyl irid-
ium alkoxide 2.55. In this step, β-hydride elimination is probably prevented by
coordination of the olefin of the formed alcohol. On the other hand, when the
homoallylic alcohol is exchanged for a reactant alcohol or for isopropanol (in the
case where the aldehyde is used as the allylation substrate), β-hydride elimination
can occur, forming complex 2.57. The starting complex 2.50 is then regenerated
by dissociation of the resulting aldehyde, upon which the cycle is complete.
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Scheme 2.13: Proposed catalytic cycles for the iridium catalyzed allylation. (Ln
= Cl,MeO-BIPHEP)133
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Also the second possible pathway is in agreement with the observations (scheme
2.13, lower half). Here, the cyclometalated system stays intact during the complete
cycle. Proton loss from the originally cyclometalated complex 2.50 is assisted by
the stabilization of the new anion (iridium (I) benzoate 2.51b) by the carboxylate
and the electron withdrawing groups thereon. Oxidative addition of allyl acetate
results in the anionic Ir(III) σ-allyl complex 2.52b, which can loose the acetate
to form the same active species as in the first proposal. The rest of the catalytic
cycle is consequently identical.
Based on the coordination mode which was revealed in the X-ray structure
of 2.54, a stereochemical model which accounts for the observed induction was
proposed (figure 2.7). In complex 2.53, the aldehyde is positioned in such a way,
that it occupies the biggest open space. The allyl group however is placed between
the bisaryl and the phenyl moieties of the ligand. This creates a favored mode of
addition, in which the aldehyde’s formyl hydrogen is projected into the pi-face of a
phenyl moiety of the ligand. This causes a weakly attractive C-H – pi interaction,
an interaction which is also sometimes observed in peptide folding.134,135 On the
other hand, in the disfavored mode of addition, the R group of the aldehyde
projects in the pi-face of a phenyl moiety of the ligand, giving rise to a strong
steric interaction.
R' P
Ir
O
O
NO2
P
R'
Ph
H
R O
Cl
MeO R' P
Ir
O
O
NO2
P
R'
Ph
R
H O
R
Cl
MeO
favored disfavored2.532.53
Figure 2.7: Proposed stereochemical model accounting for the observed stereoin-
duction in the iridium catalyzed allylation. Part of the Cl,MeO-BIPHEP ligand
(R’-R’) is omitted for clarity.133
Using this method, starting from the alcohol as a substrate, the yield of 2.44
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was 80% and the e.e. 94%, whereas, starting from the aldehyde, both yield and
e.e. were 96%.
The final step in the synthesis of the C4-C11 fragment, the vinylation of the
homoallylic alcohol 2.44, was accomplished under mercury catalysis (scheme 2.11).
In 1956, Watanabe and Conlon reported on the preparation of vinyl ethers via
transetherification of commercially available alkylvinyl ethers.136 Their research
revealed that mercury salts are highly specific catalysts in doing this, whereas other
metals were mainly inactive. The proposed reaction mechanism with Hg(OAc)2
is in essence a reversible alkoxymercuration, where the equilibrium is shifted by
using a large excess of the alkylvinyl ether.
Hg(OAc)2 AcOHg+ + AcO-
AcOHg+ + O + ROH
OR
HgOAc
O + H+
O + ROH+
OR
Hg
O
OR
HgOAc
O
2
+ HOAc
OR
HgOAc
O + EtOH + RO
2.58a
2.58a
2.58b
2.58b
2.58b
2.58c
Scheme 2.14: Proposed reaction mechanism for the mercury catalyzed vinyla-
tion136
After dissociation of the mercuric salt (scheme 2.14), the vinyl group is acti-
vated by the formed cation 2.58a, upon which the reactant alcohol can attack and
intermediate 2.58b is formed. Further dissociation of the salt opens the possibility
for an identical addition of the reactant alcohol, resulting in diacetal 2.58c. This
hypothesis originated from the ability of the original authors to synthesize and
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isolate intermediates like 2.58b, R being methyl or ethyl. These isolated species,
in the absence of acid, proved to be also catalytically active. Later, the actual
formation of intermediate 2.58b during the reaction itself was shown.137 There is
however no direct evidence for the formation of an intermediate like 2.58c in the
reaction mixture, however, when adding a base to the mixture, the acetic acid is
precipitated as salt, shifting the equilibrium to the formation of 2.58c (as proven
by NMR), and the catalyst is inactivated.137This means a proton from the formed
acetic acid is necessary to decompose intermediate 2.58c and get the desired vinyl
ether.
For the vinylation of 2.44 to 2.40 (scheme 2.11), when using Hg(OAc)2 in
ethylvinyl ether, the reaction did not run to completion. However, when chang-
ing the catalyst to Hg(CF3COO)2, 2.40 was formed in 73%, after 3 days. This
vinylation occurred without loss of optical purity, as verified by chiral LC.
Once again, the absolute stereochemistry of this center was assigned using
Mosher ester analysis. After synthesizing the (R)- and (S )-MTPA esters of the
homoallylic alcohol 2.44, the 1H NMR spectra were recorded. The difference in
chemical shift between corresponding signals of the (R)- and (S )-ester (2.59) is
depicted in figure 2.8. From the analysis of Mosher’s model, it appeared that
the wrong enantiomer was obtained (2.60). This was caused by a mistake of the
chemical supplier who had sold the (R)-Cl,MeO-BIPHEP ligand under the name
of its enantiomer. Pursuing the synthesis with the correct (S )-ligand delivered the
opposite (envisaged) enantiomer, as confirmed by chiral LC.
MPMO OH MPMO O
O
CF3
R' R
''
R' = Ph, R'' = OMe : (R)-MTPA ester 89%
R' = OMe, R'' = Ph : (S)-MTPA ester 81%
(S)-MTPA-Cl or 
(R)-MTPA-Cl, 
Et3N, DMAP
CH2Cl2, RT
2.44
2.61
2.62
Scheme 2.15: Synthesis of the Mosher esters 2.61 and 2.62
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O
MTPA
∂R-∂S < 0 : R1
∂R-∂S > 0 : R2
O
OMe
-0.0455
-0.0640
-0.0599
-0.0456
-0.0550+0.0369
+0.0345
+0.0446
+0.0229
+0.0295
OHMPMO
O CF3
PhMeO
R1 R2
O CF3
OMePh
R1 R2
(R)-ester (S)-ester
2.59
2.60
Figure 2.8: The Mosher model applied to 2.44
2.5 The Mukaiyama aldol - Prins cyclization (I)
The Mukaiyama aldol - Prins cyclization is a cascade or domino reaction between
an aldehyde and a bisnucleophile. According to Tietze, a cascade reaction is
defined as follows: “A cascade reaction is a process in which two or more bond-
forming transformations occur based on functionalities formed in the previous step.
Furthermore, no additional reagents, catalysts, or additives can be added to the
reaction vessel, nor can reaction conditions be changed.” 138 In this case, the two
bond forming transformations are a Mukaiyama aldol reaction and a Prins reaction.
The Mukaiyama aldol reaction in general is a Lewis acid catalyzed nucleophilic
addition of an enol silyl ether 2.63 to a carbonyl compound 2.64, thereby gener-
ating one C-C bond, resulting in a β-hydroxy carbonyl compound (2.65) (scheme
2.16). The aldol reaction is one of the most important C-C bond forming reactions
in organic synthesis.
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O
R1 H
OSiMe3
R3
R2 R1
OH
R2
O
R3
Lewis Acid
2.64 2.63 2.65
Scheme 2.16: The Mukaiyama aldol reaction
The Prins reaction in general is a nucleophilic addition of an alkene 2.66 to
an activated carbonyl compound 2.64 (scheme 2.17). Starting from the resulting
carbocation 2.67 and dependent on the reaction conditions and the nature of the
alkene, different products can be formed.
O
R1 H
R4
R5
R2
R1
OH
R5
Lewis Acid
R3
R4
R2 R3
2.64 2.66 2.67
Scheme 2.17: The Prins reaction
The Mukaiyama aldol - Prins cascade reaction was first reported in 2001 by
Rychnovsky, for the formal total synthesis of Leucascandrolide A (2.68, scheme
2.18).139 It was known that electrophilic additions of alkyl enol ethers could be
problematic because the intermediate oxocarbenium ion 2.69 (scheme 2.19) is very
reactive and can produce oligomers by reacting with the starting enol ether. In or-
der to avoid this, they came up with the idea of introducing a second nucleophilic
group into the enol ether that is reactive enough to trap the oxocarbenium ion
and by consequence to produce a new ring. When this second nucleophile is an
alkene (2.70), the trapping reaction becomes a Prins cyclization. The remaining
carbocation in 2.71 can then be trapped by an external nucleophile. At first, the
only so-called bisnucleophile, which was reactive enough to prevent oligomeriza-
tion, was the allylsilane 2.72 (figure 2.9). Using this allylsilane, MAP reactions
with a variety of aldehydes were performed in good yield, but without significant
facial selectivity in aldehyde addition.139
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O
H
O
OBn
O
OTIPS
TMSH
H
O OH
OBn
H
H
O
OTIPS
H
H
O OMe
O
H
H
O
O
H
H
OH
i) BF3.OEt2, 2,6-DTBP, 
CH2Cl2, -78°C
ii) NaBH4, EtOH
78%, 5.5:1 dr
2.68
Scheme 2.18: First application of the Mukaiyama aldol - Prins cyclization, for the
synthesis of Leucascandrolide A 2.68139
O
TMS
Ph
2.72
Figure 2.9: Allylsilane 2.72
Later, Rychnovsky proved that it was possible to perform the MAP reaction us-
ing simple, easier-to-synthesize, alkenes, by choice of an appropriate Lewis acid.99
The use of TiBr4 proved the most effective, and led to the 3-bromo-2,6-cis sub-
stituted tetrahydropyran 2.73a as a 1:1 mixture of diastereomers at the alcohol
epimeric centre, but with a selectivity for the equatorial bromide (>95:5) (table
2.2, entry 1). Testing the scope of the reaction, Rychnovsky came up with some
interesting results concerning the stereochemistry, when using the aldehydes with
protected alcohols. A first observation was that, when using a TBDPS-protecting
group at the β-position of the aldehyde, the behavior is identical to an aliphatic
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O
R1
O
LA
R1
O
LA
R1
O
LA
R2
O
R1
O
LA
R2
O
R1
O
LA
R2
O
R1
OH
R2
O
Nu
Nu
a
b
cd
2.69
2.702.71
Scheme 2.19: General mechanism for the Mukaiyama aldol - Prins cyclization
aldehyde, with a strong selectivity for the equatorial bromide (entry 2). A benzy-
loxy group at this position, however, showed an increase in the formation of axial
bromide (entry 3). Also, when this benzyloxy group was present at the α-position
of an enantiomerically pure aldehyde, there was an increase in formation of axial
bromide (entries 4-5). At the same time, however there was a strong selectivity
for the alcohol stereogenic centre, in favor of the syn-product (>95:5), regardless
of the absolute stereochemistry of the α-chiral center of the aldehyde. On the
other hand, in case of a silyl-protecting group at this α-position of the aldehyde,
the stereoselectivity for the alcohol center dropped again (entry 6). The origin
of selectivity at the carbinol was thought to be chelation-controlled, where there
has been no conclusive explanation for the origin of the selectivity at the bromide
center.
Also this new approach, using a simple homoallylic alkyl enol ether 2.78
and TiBr4, proved successfully for the synthesis of Leucascandrolide A (scheme
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O
R
O O
R
OH
H
H
TiBr4
2,6-DTBP
CH2Cl2
 -78°C
Br
2.74 2.75 2.73
Entry enol ether aldehyde product dr(OH) eq/ax
1 2.74
O
2.75a
O
OH
H
H
Br
2.73a 1.1:1 >95:5
2 2.74
O
TBDPSO
2.75b
O
OH
H
H
Br
TBDPSO
2.73b 1.2:1 >95:5
3 2.74
O
BnO
2.75c
O
OH
H
H
Br
BnO
2.73c 1:1 68:32
4 2.74
O
OBn
2.75d
O
OH
H
H
Br
OBn
2.73d >95:5 68:32
5 2.74
O
OBn
2.75e
O
OH
H
H
Br
OBn
2.73e >95:5 66:34
6 2.74
O
OTBS
2.75f
O
OH
H
H
OTBS
Br
2.73f 68:32 >95:5
Table 2.2: Selected literature examples of MAP cyclizations
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2.20).140 In this case, using a β-alkoxy aldehyde (2.76, a 1,3-anti -relationship was
observed between the β-alkoxy group and the new alcohol (2.77), probably orig-
inating from chelation-controlled addition (7.8:1 anti:syn for the axial bromide
(53% yield), 4.5:1 anti:syn for the equatorial bromide (44% yield)).
O OMe
O
H
H
O
O
H
H
OH
O
H
O
OTIPS
H
H
iPr
O
OTBDPS
O OH
OTIPS
H
H
O
OTBDPS
Br
H
H
iPr
TiBr4:Ti(iOPr)4 9:1,
2,6-DBMP, CH2Cl2, 
-78°C
97%
2.76 2.78 2.77
2.68
Scheme 2.20: TiBr4-catalyzed Mukaiyama aldol - Prins cyclization, for the syn-
thesis of Leucascandrolide A 2.68140
Based on these literature results, we reasoned to have the perfect aldehyde
coupling partner in hand, where an α-substituent is available for chelation and
a bulky group at the β-position prevents chelation, thereby inducing the correct
stereochemistry at C3.
In a first attempt to synthesize the tetrahydropyran ring, we combined enol
ether 2.40 with aldehyde 2.4 in the presence of 2 equivalents of TiBr4 and 2,6-
di-tertbutyl-4-Me-pyridine (DBMP) as bulky base. Unfortunately, the expected
cyclization did not occur. On the contrary, acetal 2.79 was formed, in 80% yield as
73
2.6. Synthesis of the C5-C11 bisnucleophile 2.85
a diastereomeric mixture at the alcohol center (ratio 1.5:1). A possible explanation
for the formation of this structure is that the Mukaiyama aldol is effective, thereby
forming the required oxocarbenium ion, but instead of this cation being caught by
the alkene, the MPM protected alcohol interferes (2.79a in figure 2.10). Cleavage
of this protecting group is then triggered by complexation of the benzylic oxygen
with the oxocarbenium ion as a Lewis acid.
MPMO O TBSO O
OBn
O O
OH
OBn
TBSO
TiBr4
2,6-DBMP
CH2Cl2
-78°C
2.40 2.4 2.79
Scheme 2.21: First attempt on the Mukaiyama aldol - Prins cyclization
O
O
O
OBn
TiBr3
TBSO
MeO
O O
OH
OBn
TBSO
MeO
Br
2.79a 2.79
Figure 2.10: Presumed mechanism for the formation of acetal 2.79
Encouraged by these first results, it was decided to change the nature of the
protecting group of the alcohol at C11. Using an ester protecting group would
reduce the electron density, thereby lowering the chance of this oxygen to trap the
oxocarbenium ion during Prins cyclization.
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OH OH O OH O O
O OH O O
b
d
e
a) DMAP, NEt3, CH2Cl2, RT; b)  i) (COCl)2, DMSO, -78°C ii) Et3N, CH2Cl2, -78°C; c) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-
BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, THF, allylOAc, 120°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-
Cl-3-NO2-benzoic acid, THF, allylOAc, 2-PrOH, 120°C;  e) Hg(CF3COO)2, EtOCHCH2, RT
99%
68%
98% e.e.
44%
96% e.e.
82%
c
a
90%
OO
O
O
Cl
O
OH O O
2.39 2.80 2.81 2.82
2.832.84 2.85
Scheme 2.22: Synthesis of the ester protected C4-C11 enol ether
2.6 Synthesis of the C5-C11 bisnucleophile 2.85
As a napthoyl ester had already proven to be compatible with the required MAP
conditions,141 it was implemented in our synthesis (scheme 2.22). In a first step,
2,2-dimethyl-1,3-propanediol (2.39) was monoprotected using the stable and com-
mercially available 2-napthoyl chloride (2.80). To prevent protection of both al-
cohol functionalities, the starting diol was used in excess and thus the protecting
group served as limiting reagent. In this way, and under nucleophilic catalysis,
ester 2.81 was formed in 90% yield. The resulting alcohol could be directly al-
lylated, using Krische’s method, however the yield was only 44%. Therefore, an
extra oxidation step was included to provide aldehyde 2.82. The use of Swern con-
ditions proved to be superior over other methods like Dess-Martin periodinane or
TPAP-NMO in terms of yield (99% vs. 82% and 73%, respectively). Ir-catalyzed
allylation from this oxidation level resulted in 68% of homoallylic alcohol 2.83,
which was 99% enantiomerically pure (e.e. 98%). Also, 25% of 2.84 could be iso-
lated, emerging from migration of the protecting group to the secondary alcohol
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and accounting for the lower yield. The absolute stereochemistry of the newly ob-
tained alcohol was assigned by synthesizing the corresponding MTPA esters (2.86
and 2.87), measuring the 1H-NMR spectra, subtracting the corresponding ppm
values of both the (R)- and (S )-MTPA esters and applying the Mosher model
(scheme 2.23 and figure 2.11). Vinylation of the homoallylic alcohol, using the
Hg-catalyzed method, resulted in enol ether 2.85 in 82% yield.
O OH O O
O
CF3
R' R
''
R' = Ph, R'' = OMe : (R)-MTPA ester 89%
R' = OMe, R'' = Ph : (S)-MTPA ester 81%
(S)-MTPA-Cl or 
(R)-MTPA-Cl,  
DMAP
CH2Cl2, RT
O O
2.83
2.86
2.87
Scheme 2.23: Synthesis of the Mosher esters 2.86 and 2.87
O
MTPA
O
+0.0410
+0.0572
+0.0544
+0.0450
+0.0611
-0.0380
-0.0266
OHO
O
O
-0.0533
-0.0788
∂R-∂S < 0 : R1
∂R-∂S > 0 : R2
O CF3
PhMeO
R1 R2
O CF3
OMePh
R1 R2
(R)-ester (S)-ester
2.88
2.83
Figure 2.11: The Mosher model applied to 2.83
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2.7 The Mukaiyama aldol - Prins cyclization (II)
In a second attempt to form the THP ring, using the modified bisnucleophile
2.85, the oxocarbenium ion indeed was trapped by the allyl group, resulting in
the formation of THP ether 2.89 in 60%, be it as a mixture of four diastereomers
(scheme 2.24). Also, the formation of a minor amount (7%) of 2.90 was observed,
emerging from the 2-oxonia Cope rearrangement, which is a known side reaction
during Prins cyclizations. The relative stereochemistry of this product was all-cis,
however, the absolute stereochemistry was not determined.
O O TBSO O
OBn
TiBr4
2,6-DBMP
CH2Cl2
-78°C
O
O O
O
Br
H
H
OHTBSO
OBn
2.85 2.4 2.89
Scheme 2.24: Second attempt on the Mukaiyama aldol - Prins cyclization
O O
O
O
OTBS
OBn
2.90
Figure 2.12: The 2-oxonia cope rearrangement product
These products, together with the excess of aldehyde, the bulky, non nucle-
ophilic base and some side products, coming from deprotection of the TBS-ethers,
resulted in a complex mixture, which was difficult to analyze. Several attempts
to separate the diastereomers on normal or reversed phase LC failed (different
gradients and different columns were tried). Moreover, only three peaks with the
correct mass could be identified on reversed phase LC-MS. Therefore, what we
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thought that was the mixture of diastereomers, was isolated (as a mixture) by
flash column chromatography and submitted to chemical derivatization, in order
to verify if it contained four diastereomers (Scheme 2.25).
TPAP, NMO
4Â MS, 
CH2Cl2, RT
O O
O
Naph
Br
H
H
OTBSO
OBn
O O
O
Br
H
H
OHTBSO
OBn
O O
O
Naph
Br
H
H
OTBSO
OBn
83%
O O
O
Naph
H
H
OHTBSO
OBn
O O
O
Naph
H
H
OHTBSO
OBn
81%
Bu3SnH
AIBN
PhMe,110°C
2.89
2.91 2.92
2.93 2.94
Scheme 2.25: Chemical derivatization of the MAP diastereomers
A first part of the mixture was oxidized using the catalytic system of TPAP in
combination with NMO. This resulted in a mixture of two diastereomers (together
81% yield), which could be separated by flash chromatography and -after NMR
analysis- could be identified as the equatorial (2.91) and axial (2.92) bromide (1:1
ratio).
In a second part of the mixture, the bromine was radically reduced using
Bu3SnH and AIBN as initiator. This resulted also in a mixture of two diastere-
omers 2.93 and 2.94, which now proved to be the epimeric alcohols (1:1). These
results confirm that the original conditions for the MAP reaction indeed result in
a mixture of 4 diastereomers.
In an attempt to improve the diastereomeric ratio, different conditions were
tested (table 2.3).
In a standard experiment (entry 1, table 2.3), the Lewis acid is added to a
mixture of enol ether and aldehyde at -78◦C. Four diastereomers are formed in a
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Entry Lewis acid remarks observations
1 TiBr4 fast addition 60% yield
2 TiBr4 slow addition 78% yield
3 TiBr4 precooled at -78◦C precipitation of TiBr4
4 TiBr4 change addition mode TBS deprotection
5 TiBr4:Ti(iOPr)4 9:1 - ratio 1:1:1:1
6 TiBr4:Ti(iOPr)4 1:1 - more formation of 2.90
7 TiCl4 - ratio 1:1:1:1
8 TMSBr - formation of 2.95
9 TMSBr 2.5 eq. DBMP formation of 2.95
10 Ti(iOPr)4 - no reaction
11 Ti(iOPr)4 quench with TMSBr no reaction
Table 2.3: MAP test reactions
1:1:1:1 ratio, with a yield of 60%. A first observation (entry 2) was an improve-
ment of the yield when adding the Lewis acid slowly. Unfortunately, the d.e. was
unaffected. This improvement is mainly due to loss of the TBS group upon fast
addition. As the catalyst is added as a solution in CH2Cl2, an attempt was made
to precool this solution in order to gain better control of the temperature. Un-
fortunately, TiBr4 precipitated at -78
◦C (entry 3). In order to gain better control
of the stereoselectivity, the mode of addition was changed: first, the Lewis acid
and aldehyde were combined, hence enabling chelation of the benzyl group, and
afterwards the enol ether was added. This resulted mainly in deprotection of the
TBS ether (entry 4). Different Lewis acids (blends) were used (entries 5-8), to
investigate the steric and/or electronic effects thereof. Where the TiBr4:Ti(iOPr)4
9:1 blend and TiCl4 did not show an improvement in d.e., the TiBr4:Ti(iOPr)4
1:1 blend showed a big increase in formation of the 2-oxonia Cope rearrangement
product.
In all the above cases, and also in literature, the trapping nucleophile originated
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from the Lewis acid. Therefore, using a Lewis acid in catalytic amounts is not an
option. Using a chiral BINOLTiBr2 compound in stoichiometric amounts would
be far too expensive. In order to develop a catalytic system, a bromide source
should be added to the reaction mixture to trap the carbocation after Prins cycli-
sation. Therefore, first, the use of TMSBr as Lewis acid was tested. This resulted
in formation of product 2.95 (figure 2.13), probably coming from enolization of
the silyl activated aldehyde, hence producing HBr. In order to prevent this, the
experiment was repeated with an excess of base, compared to the aldehyde (2.5
eq. base, 2 eq. aldehyde) (entry 9), unfortunately without improvement. Finally,
pure Ti(iOPr)4 was tested (entry 10), but did give no reaction, as judged from
TLC. Also, after quenching with TMSBr (entry 11), no cyclization product was
formed, and the starting enol ether was recuperated in 90% yield.
O O
O
Br
2.95
Figure 2.13: Reaction product when performing the reaction with TMSBr
The use of a more bulky silyl protecting group could possibly improve the
stereoselectivity by increasing the sterical hindrance at the S i face, upon chelation
with titanium. Therefore, a TBDPS ether was installed on the aldehyde (2.96),
which was straightforward, starting from 2.37 (scheme 2.26)
TBDPSO OH OBn
OBn OH OTBDPS
TBDPSO O
OBn
a) TBDPSCl, imidazole, CH2Cl2, RT; e) NaIO4, THF/H2O 4/1, RT
e
85%
OH OH OBn
OBn OH OH
d
99%
2.37 2.97 2.96
Scheme 2.26: Synthesis of the TBDPS protected aldehyde 2.96
Subjecting this aldehyde to the MAP cyclization conditions with enol ether
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2.85 (scheme 2.27) resulted in 84% of the envisaged target material, unfortunately,
again as a mixture of diastereomers in a 1:1 ratio. Also, 8% of the 2-oxonia Cope
rearrangement product was isolated. No traces of silyl deprotected product were
observed, which makes sense as a TBDPS ether is less acid sensitive than a TBS
ether.
O O TBDPSO O
OBn
TiBr4
2,6-DBMP
CH2Cl2, -78°C
84%
O
O O
O
Br
H
H
OHTBDPSO
OBn
2.85 2.96 2.98
Scheme 2.27: MAP reaction with the TBDPS protected aldehyde 2.96
2.8 Installing the correct stereochemistry
Earlier on, when analysing the diastereomeric mixture, it was shown that ketones
2.91 and 2.92 could be separated by column chromatography (scheme 2.25).
Asymmetric reduction of these ketones would give access to the correct stereo-
chemistry at C3, thereby creating two sets of analogs: one with the axial bromide,
and another one with the equatorial bromide. The results of the reduction are
summarized in table 2.4.
First, the Corey-Itsuno reduction was tested. In this reaction, the ketone is
reduced by borane in the presence of a chiral catalyst.142,143 The catalyst, an
oxazaborolidine, contains a methyl group on the endocyclic boron, and is derived
from proline. Both enantiomers of this so-called CBS catalyst (named after Corey,
Bakshi and Shibata) are commercially available as they are very air and moisture
stable. The catalytic cycle, which also accounts for the stereoinduction, has been
proposed to contain four important steps (scheme 2.28). First, the rapid and
reversible coordination of BH3 to the nitrogen of the catalyst (2.100a) activates
the borane as a hydride donor and increases the Lewis acidity of the endocyclic
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O O
O
Br
H
H
OHTBSO
OBn
O O
O
Br
H
H
OTBSO
OBn
3 3
2.91 2.99
Entry Reagent Temperature (◦C) d.e. (%)
1 (S )-(-)-2-Me-CBS-oxazaborolidine -30 54
2 (S )-(-)-2-Me-CBS-oxazaborolidine -78 72
3 (R)-(+)-2-Me-CBS-oxazaborolidine -78 60
4 L -selectride -78 74
4 N -selectride -78 74
Table 2.4: Asymmetric reduction of ketone 2.91
boron atom of the catalyst (2.100b). 11B-NMR and X-ray diffraction experiments
proved the formation of this complex and also confirmed the structure to be cis-
fused. Next, because of the rigid [3.3.0] ring system, the strongly Lewis acidic
complex can only bind to the ketone, so that this ketone and the vicinal BH3
group have a cis-exo-orientation and in such a way that the sterical interactions
are minimized (2.100c). Therefore, the bigger the difference in size between the
two R groups on the carbonyl, the better the stereoinduction. Moreover, binding
in this way positions the electron deficient carbonyl carbon atom in alignment with
the coordinated borane so it can undergo a face-selective intramolecular hydride
transfer via a six-membered transition state. The regeneration of the catalyst and
concomitant dissociation of the reduction product can occur in two ways. Either,
the alkoxide ligand attached to the endocyclic boron of the complex reacts with
the borane which is attached to the nitrogen via a cyclo-elimination (2.100d) or
it reacts by addition of another molecule of borane to form a six-membered BH3-
bridged species (2.100e), which can in turn decompose to the catalyst and the
borinate (2.100f).
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Scheme 2.28: Catalytic cylce for the CBS reduction
Assigning the methylene group next to the carbonyl in 2.91 (table 2.4) as the
small group and the benzyloxy-methine as the large one, the use of the (S )-CBS
catalyst should yield the correct stereochemistry. It can be seen clearly that a lower
temperature is advantageous in terms of selectivity, going from a diastereomeric
excess of 54% at -30◦C (entry 1) to 72% at -78◦C (entry 2). Unexpectedly, the
use of the enantiomeric catalyst did not provide the opposite diastereomer as the
major compound. Instead, there was a preference for the same diastereomer, with
still an acceptable ratio of 80:20 at -78◦C.
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Another option was the use of stoichiometric amounts of steric organoboro-
hydrides, especially tri-sec-butylborohydrides (selectrides). Both lithium (L) and
sodium (N) selectride gave identical selectivity results (74% d.e.) as judged from
LC-MS. After column chromatography, the diastereomeric ratio using L-selectride
was increased to 93:7 (86% d.e.) with a total yield of 85%.
To prove the configuration at C3 in 2.99, we chose to make use of the stereocenter
of the benzyloxy substituent at C2, which is known, as it originates from the chiral
pool. Therefore, the free rotation around the C2-C3 bond should be prevented.
To do this, the TBS ether at C1 was removed (2.101), and an acetal was formed
between the resulting primary alcohol and the previously formed alcohol at C3,
thereby locking the conformation in a six-membered ring (scheme 2.29).
TBAF could deprotect the alcohol in a straightforward way, where the use of
dimethoxymethane and P2O5 provided acetal 2.102 in a moderate yield of 45%
(scheme 2.29).
O O
O
Br
H
H
OHTBSO
OBn
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71%
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O
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H
H
OHOH
OBn CH2(OMe)2,
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O O
O
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H
H
OTBSO
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85%
O O
O
Br
H
H
OO
OBn
H
2.91 2.99
2.101 2.102
Scheme 2.29: Synthesis of 2.102 to prove the absolute stereochemistry.
The approximate correlation between the dihedral angle formed by two coupled
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protons and the observed vicinal coupling constant (3J) in the NMR spectrum
is described by the Karplus equation.144–146 In the original equation, 3J(φ) =
Acos2φ + Bcosφ + C, φ is the dihedral angle, and A, B, and C are empirically
derived parameters. However, there are other structural parameters that influence
the scalar coupling, for instance the electronegativity of attached substituents or
the relative disposition between them. Therefore, Altona et al. came up with a
a more complex equation, taken into account these effects. The actual equation
is rather complex and requires the electronegativities of all substituents to be
entered.147
Using the program Mspin,148 we could come up with a Karplus curve for 2.102,
as depicted in figure 2.14.
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Figure 2.14: The Karplus curve for vicinal protons at C2-C3 in 2.102
Assuming the 1,3-dioxane 2.102 adopts a chair conformation, and the C3 center
possesses the correct (R)-stereochemistry, there are two possible conformers: one
where the benzyloxy group occupies an equatorial postion and the methylene-
linked tetrahydropyran the axial position, or vice versa (figure 2.15, left). In both
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cases, there will be a small dihedral angle between the vicinal protons at C2 and
C3, hence a small scalar coupling is expected.
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Figure 2.15: Possible conformers for 2.102 (left) or its unwanted diasteromer
2.103 (right)
In the other case, when the C3 center possesses the unwanted (S )-stereochemistry,
only one conformer will prevail, where both substituents of the dioxane ring adopt
an equatorial position (figure 2.15, right). In this case, the dihedral angle between
vicinal protons on C2 and C3 will be approximately 180
◦, corresponding to a big
scalar coupling.
When looking at the 1H NMR spectrum of 2.102, proton H3 has three different
coupling partners, resulting in a ddd signal with coupling constants 9.9, 5.1 and 1.7
Hz. The largest of these couplings constants (9.9 and 5.1 Hz) originate from the
adjacent methylene protons H4a and H4b. The smallest one should then evidently
originate from coupling with H2. It is however hard to isolate this coupling constant
when looking at this proton H2 in the spectrum due to some overlap.
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Figure 2.16: 1H NMR spectrum of 2.102 in CDCl3 (500 MHz)
The coupling constant of 1.7 Hz for JH2,H3correlates in the Karplus curve with
a small dihedral angle, which corresponds with conformers 2.102a or 2.102b.
This is a first clue that the obtained stereochemistry is the desired one. To be
completely sure, however, the undesired diastereomer should be synthesized, and
the NMR spectrum should be compared with that of the desired one.
Unfortunately, at this point in time, the priorities of our research group shifted
towards other analogs. Therefore, I could not pursue the completion of the THP
analog. Overall, the Mukaiyama aldol - Prins approach proved powerful for the
generation of the tetrahydropyranyl ring, be it without the desired control of stere-
ochemistry. To avoid the encountered problems to introduce the stereochemistry,
it might be better to pursue an alternative synthesis (see future perspectives).
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Phenyl analogs
During the second year of my PhD, a simplified peloruside analog that was syn-
thesized before, was biologically tested in vitro and showed promising activity.
Therefore, I was assigned to re-evaluate the synthesis route of this phenyl analog
and design (a route towards) new analogs, based on the simplified ring system. In
this chapter, the results concerning these topics are discussed.
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3.1 Introduction
3.1.1 Pelofen B
During a previous PhD, pelofen B (3.1) was synthesized: an analog of peloruside
B where the pyranose ring has been replaced by a phenyl ring.149 The total number
of stereocenters was thus reduced from 10 to 6, thereby diminishing the synthetic
complexity. As in peloruside B, the alcohols at C2 and C3 are not differentiated
and the activity stays the same, 3.1 is an analog of peloruside B, thereby further
reducing the molecular complexity. The compound was tested for its biological
activity in collaboration with prof. Bracke (laboratorium for experimental cancer
research), which led to some promising results (table 3.1).
On a weight per volume basis, pelofen showed, in a qualitative test, an equal po-
tency as paclitaxel in its ability to disturb the cytoplasmatic microtubule complex
in PTK-2 cells. This should be considered with care, as pelofen has a molecular
weight of 464 g/mol, whereas paclitaxel weighs almost twice as much (854 g/mol).
However, the lower molecular weight could also be advantageous, as it is asso-
ciated with better cell penetration through the membrane and reduced aspecifc
cytotoxicity.
Treatment Concentration State of cytoplasmatic MT-complex after
(µg/ml) 1h 5h 24h
DMSO - normal normal normal
paclitaxel 0.1 normal disturbed disturbed
1.0 disturbed disturbed disturbed
pelofen 0.1 disturbed disturbed disturbed
1.0 disturbed disturbed disturbed
Table 3.1: Results of the first experiments on the in vitro activity of pelofen,
compared to paclitaxel.
Therefore, it was decided to further investigate the potential of this molecule.
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In order to do this, the amount of pelofen had to be scaled up, and new analogs
had to be developed in order to investigate the SAR of pelofen and, indirectly of
peloruside. Most of the results of this thesis are part of a patent, which was filed
in 2015.150
In the original synthesis route (scheme 3.1), the key coupling steps are an asym-
metric aldol reaction between aldehyde 2.13 and methyl ketone 3.2, and a Stille
reaction for the introduction of the C1-C3-unit. Whereas for the introduction of
the stereochemistry, an asymmetric reduction and a Sharpless asymmetric dihy-
droxylation were used. After installation of the correct stereochemistry, a standard
ring-closing macrolactonization resulted in formation of the 16-membered macro-
lactone, which, after deprotection, yielded the simplified peloruside B analog 3.1.
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Scheme 3.1: Original synthesis route towards pelofen B (3.1)
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The original synthesis however, contained some flaws. Firstly, the aldol reaction
between fragment 2.13 and methyl ketone 3.2 induced the inverse stereochemistry
at C15 (3.3). Secondly, this was only discovered later, so the asymmetric 1,3-syn
reduction originally also installed the inverse stereochemistry at C13 (3.4). The
wrong stereocenters could be corrected in three extra steps: the correct stereo-
chemistry at C13 was inverted under Mitsunobu conditions (3.4 to 3.5), whereas
the stereochemistry at C15 could be inverted using an oxidation - CBS reduc-
tion protocol (3.7 to 3.1). Thirdly, the final steps in the synthesis of 3.1, the
macrolactonization and the final deprotection, were low yielding (36% and 40%,
respectively), causing a significant drop in overall yield. Therefore, a new synthesis
was developed, avoiding the previously observed obstacles (scheme 3.2).
3.1.2 New synthesis of pelofen B
The newly developed retrosynthetic analysis (scheme 3.2) starts with the discon-
nection at the lactone moiety, in the forward route corresponding again to a macro-
lactonization. The second disconnection is also identical to the original route, were
a Stille reaction between phenyl fragment 3.9 and γ-bromocrotonate 3.6 should
assure the coupling. The biggest difference in the new synthesis route lies in the
construction of fragment 3.9. Whereas in the original route, the stereochemistry
at C11 is already established before, and the stereochemistry at C15 is the result
of the aldol coupling, in the new route, it is the other way around. Thus, in the
new synthesis of 3.1, fragment 3.9 is constructed via aldol product 3.10, which
is the result of the coupling between a methyl ketone 2.2, where the stereochem-
istry at C15 is already established, and a prochiral aldehyde 3.11. In this way,
the correct stereochemistry at C11 is directly installed, and the synthesis becomes
shorter. Next, an Evans-Tishchenko reduction would directly install the correct
stereochemistry at C13, and also differentiate between the alcohols at C11 and C13
by protecting the former as an ester. We envisaged the simultaneous deprotection
of this ester with the methyl ester when setting free the hydroxy acid needed for
macrolactonization. In this way, the final deprotection would also become easier,
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as it was especially the sterically hindered MEM ether at C11 which required the
harsh conditions in the original synthesis. Aldehyde 3.11 can be constructed in
only two steps, starting from 2-bromophenyl acetonitrile (3.12), which is commer-
cially available. The synthesis of methyl ketone 2.2 starts from 2,3-dihydrofuran
(2.6) and ethylmagnesium bromide (2.7) and was described in chapter 2 (scheme
2.3).
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Scheme 3.2: New retrosynthetic analysis of pelofen B (3.1)
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3.2 Results and discussion
3.2.1 Construction of the C5–C20 fragment 3.9
Aldehyde 3.11 is prepared, according to a known procedure, starting from the com-
mercial 2-bromophenyl acetonitrile 3.12 in two steps.149,151 First, double methy-
lation of the benzylic postition delivers the gem-disubstituted nitrile 3.13 in 99%
yield. Subsequent reduction of this nitrile and acidic workup yields aldehyde 3.11
in 90% (scheme 3.3).
Br
O
Br
NC
Br
NC99% 90%
a) KOtBu, MeI, THF, -40°C; b) i) DIBAH, PhMe, -78°C, ii) 6M aq. HCl, RT
a b
3.12 3.13 3.11
Scheme 3.3: Construction of the C5 –C11 aldehyde 3.11
The key steps for the completion of the C5 –C20 fragment include a 1,5-anti al-
dol addition, an Evans-Tishchenko reduction and a Stille Coupling to the stannane
(vide infra).
The 1,5-anti aldol addition
R
OP OBL2
H R'
O
R
OP O
R'
OH
R
OP O
R'
OH
1,5-anti 1,5-syn
3.14 3.15a 3.16a
Scheme 3.4: Remote asymmetric induction in the boron aldol reaction of a β-
alkoxy methyl ketone
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The first observation of remote 1,5-anti induction in the aldol reaction of methyl
ketone-derived enolborinates was done by Masamune and coworkers in 1989 in
their work towards the synthesis of the C1 –C16 fragment of bryostatin 1.
152 Al-
though the selectivity was low (1,5-anti vs 1,5-syn 2:1), this represented evidence
for remote induction to stimulate further research. Paterson153 and Evans154 si-
multaneously came up with empirical examples of remote 1,5-anti induction with
very good selectivity. They both concluded that the nature of the protecting
group on the β-oxygen (3.14 in scheme 3.4) is critical in determining the level of
stereoinduction: benzylic ethers and acetals gave good 1,5-anti -induction (3.15a),
whereas the use of a silyl ether gave an alteration in diastereoselection (3.15b).
The applicability of this type of aldol reaction was demonstrated in the synthe-
sis of a variety of natural products possessing 1,3-polyol motifs,155 among which
peloruside.156
The origin of the selectivity was first thought to arise from a pi-stacking in-
teraction between benzylic protecting groups and the boron enolate in the cyclic
transition state. However, this could not explain the obtained high levels of induc-
tion with β-alkoxy substituents like OMe, or cyclic ethers like tetrahydropyranyl
rings.157
Early computational studies by Houk158,159 and Bernardi160 had shown that
chair-like and boat-like transition states in boron-mediated aldol reactions of methyl
ketones are relatively close in energy. Further studies by Paton and Goodman161,162
confirmed this and proposed four possible transition states, dependent on the ori-
entation of the extra-annular β-alkoxy substituent (figure 3.1). This substituent
can be oriented away from the cyclic transition structure (boat-out 3.17b, chair-
out 3.18b) or can be oriented back toward the cyclic core (boat-in 3.17a, chair-in
3.18a).
The first simulations on a simple, non-chiral boron-enolate (figure 3.1) revealed
that the boat conformation where the alkoxy side chain is folded toward the ap-
proaching aldehyde and the forming C-C bond (boat-in, 3.17a) is preferred. On
steric grounds, this is counter-intuitive, but it appeared that the distance be-
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Figure 3.1: Competing transition structures for the boron aldol reaction of an
achiral β-methoxy methyl ketone with ethanal according to Goodman161
tween the β-oxygen and the formyl hydrogen is rather short, suggesting a favor-
able formyl-hydrogen bond. In the corresponding chair conformation (chair-in),
the C-H–O distance is somewhat bigger, therefore resulting in less stabilization.
Moreover, when achieving a close C-H–O contact, the β-carbon eclipses the enolate
double bond, resulting in 1,3-allylic strain.
As the boat-like transition structures are the most favorable ones, for the calcu-
lations on more advanced structures, where the β-center is chiral, only these were
considered. Also for these systems, because of the formyl hydrogen bond, a boat-
shaped structure where the alkoxy group is folded back inside is favored. However,
because of the chirality of the β-center, discrimination between two different tran-
sition states is now possible (figure 3.2): 1,5-anti 3.19 and 1,5-syn 3.20. Here,
the 1,5-anti transition structure 3.19 is favored, because it lacks any steric inter-
actions between the β-alkyl group and one of the ligands on boron, an interaction
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which is notably present in the 1,5-syn transition structure 3.20.
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Figure 3.2: Diastereomeric 1,5-anti and 1,5-syn transition structures according to
Goodman161
These postulations resulted in a model transition state where the formyl hy-
drogen is part of a seven-membered ring with the enolate and the forming C-C
bond. This model is in agreement with the experimental results: methyl ethers,
benzyl ethers and acetals are capable of forming the hydrogen bond and result
in 1,5-anti induction. Silyl ethers on the other hand have no preference for an
internal hydrogen bond because of the lower electron density of the oxygen and
the bigger steric impediment, so there will be less selectivity. Also the fact that
the selectivity is lower in more polar solvents, is in agreement with this model as
more polar solvents will attenuate the electrostatic interactions between the formyl
hydrogen and the alkoxy oxygen.
Dias and coworkers expanded the model proposed by Goodman, as they ob-
served that this model is not in agreement with some experimental results (figure
3.3).163 Thus, they assumed the Goodman-model is only applicable for methyl
ketones with small and medium β-alkyl substituents and they proposed a com-
plementary model of induction that includes both the volume effect of the β-
substituent as that of the protecting group at the β-oxygen. According to the
improved model, in case of a bulky β-alkyl group (t-Bu, Ph3C-) and a protecting
group of intermediate size (P=Bn, MPM, TBS), the transition structures were
the β-alkoxy substituent is pointing towards the cyclic core and thus capable of
forming a hydrogen bond, now are energetically unfavorable, because of the in-
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creased steric repulsions (3.21 for the 1,5-anti transition structure, 3.22 for the
1,5-syn transition state). Therefore, in this particular case, the out-transition
states should be considered, where the bulky β-substituent points away from the
ring and the ligands on boron as far as possible. Discrimination between 1,5-anti
and 1,5-syn is now a consequence of the position of the -OP group. In the 1,5-out
anti transition structure (3.23) the oxygen of this -OP is in close proximity with
the oxygen of the enolate (electronic repulsion) and the protecting group clashes
with a ligand on boron (steric repulsion). Therefore it is higher in energy. The
1,5-out syn transition structure (3.24) on the other hand, positions the -OP bond
opposite of the C-O enolate bond, therefore lowering both electronic and steric
repulsions. According to Dias’ proposed model, in case of a large alkyl group
and an intermediate protecting group, the 1,5-syn adduct will thus prevail. This
selectivity will be lost again when a larger protecting group is used, thereby intro-
ducing new repulsive interactions. This is in perfect agreement with the observed
experimental results.163,164
The previously described model(s) explain why in the original synthesis of
pelofen, the 1,5-syn aldol product was obtained. The methyl ketone contained
a protecting group with an intermediate size (MEM-ether), and a bulky β-alkyl
substituent. Therefore, the model of Dias should be applied (3.24), which accounts
for the observed syn-selectivity. Anticipating this problem, we chose to make use
of achiral aldehyde 3.11 and couple it with methyl ketone 2.2 (scheme 3.5), which
possesses a relatively small sp2-hybridized β-alkyl substituent and an intermediate-
sized protecting MPM-group. Application of the Goodman-model, results in the
prevalence of the 1,5-in-anti transition structure (3.19) and thus the envisaged
selectivity.
Generation of the boron enolate is achieved by adding chlorodicyclohexylborane
and triethylamine to methyl ketone 2.2. Addition of aldehyde 3.11 at -78◦C results
in the formation of 3.10 as a single diastereomer in 88% yield. At this stage, the
absolute stereochemistry was indicated by Mosher ester analysis.
Both (R)- and (S )- MTPA esters were prepared in a modest yield (54% and
38%, respectively) and had to be purified using preparative HPLC (scheme 3.6).
99
3.2. Results and discussion
O
B
O
H
O
R'
R
H
L
O
B
O
H
O
R'
H
R
L
LL
P P
O
B
O
H
R'
L
L
H
R
O
HH
P
O
B
O
H
R'
L
L
O
R
H
H H
P
1,5-in-anti 1,5-in-syn
1,5-out-anti 1,5-out-syn
3.21 3.22
3.23 3.24
Figure 3.3: Diastereomeric 1,5-anti and 1,5-syn transition structures according to
Dias163
Not all protons could be assigned in the 1H-NMR spectrum, as there were overlap-
ping signals, especially in the aromatic region. Therefore, only one proton signal
of the phenyl ring was available to apply the model (figure 3.4). The difference in
chemical shift between the (R)- and (S )- ester is in agreement with the proposed
stereochemistry at C11. However, as the available set of data points on the right
hand side of the molecule was limited, the stereochemistry was also verified, rela-
tive to the stereochemistry at C15. This could only be achieved after reduction of
the ketone.
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Scheme 3.5: Construction of the C5 –C20 fragment 3.27
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Scheme 3.6: Synthesis of the Mosher esters 3.28 and 3.29
Thus, the resulting β-hydroxy ketone was stereoselectively reduced by means of
101
3.2. Results and discussion
O
∂R-∂S < 0 : R1
∂R-∂S > 0 : R2
O
BrOMEM
OMPM
MTPA
OHO
BrOMEM
OMPM
1:
2:
3:
4:
5a:
5b:
6:
- 0.0605
- 0.0908
- 0.0791
+ 0.0087
+ 0.0148
+ 0.0237
+ 0.0051
1
2
3
45a
5b
6
O CF3
PhMeO
R1 R2
O CF3
OMePh
R1 R2
(R)-ester (S)-ester
3.30
3.10
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a SmI2-catalyzed intramolecular Evans-Tishchenko reduction (scheme 3.5).
165,166
The Tishchenko reduction is the Lewis acid mediated condensation of two equiv-
alents of an aldehyde to form an ester. The variant, reported by Evans in 1990
entails the Lewis acid catalyzed condensation of a β-hydroxy ketone with an alde-
hyde to form a 1,3-anti diol monoester (scheme 3.7). It has been suggested that
the catalytic species is samarium(III) pinacolate 3.31, generated from SmI2 and
the aldehyde (scheme 3.8) through a pinacol reduction. This explains the change
of colour from deep blue to yellow upon addition of this aldehyde.
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Scheme 3.7: The Evans-Tishchenko reduction
The proposed mechanism for this reaction involves Lewis acid catalyzed hemi-
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Scheme 3.8: Generation of a catalytically active samarium(III) pinacolate
acetal formation, followed by intramolecular hydride transfer to the newly formed
carbinol center, via a 6,6-chair type transition state (3.32 in scheme 3.7). The
stereoselectivity itself may be attributed to the coordination of Sm to both car-
bonyl and hemiacetal oxygens.
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Scheme 3.9: Proof of the relative stereochemistry (I)
To prove the anti - relationship between the alcohol at C11 and the one on C13,
the propionate ester was removed, and an acetonide (3.34) was installed (scheme
3.9). From inspection of the 13C chemical shifts of this acetonide, the relative con-
figuration can be assigned.167,168 This is based on the difference in conformation
between a cis-1,3- and an trans-1,3-diol acetonide. Most 1,3-dioxanes, including
cis-1,3-acetonides exist in a chair conformation, as depicted in figure 3.5. Trans-
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Figure 3.5: Proof of the relative stereochemistry (II)
1,3-acetonides are the exception, resulting from a severe 1,3-syn-diaxial interaction
between an R group and one of the methyl groups of the acetonide in the chair
conformation. Therefore, the trans-1,3-acetonide will adopt a twist-boat confor-
mation, where the dioxane is nearly C2-symmetrical (not taking into account the
difference between R1 and R2). As a result, the chemical shift of the methyls of the
acetonide will be nearly identical. On the other hand, when a 1,3-dioxane adopts
a chair conformation, as in the case of a cis-1,3-acetonide, the methyl groups
are diastereotopic, and therefore have a different chemical shift. From extensive
literature search by Rychnovsky169 the chemical shift of the methyls of a trans-
1,3-acetonide in the 13C spectrum on average is 24.6 ppm, whereas in case of a
cis-1,3-acetonide, one methyl group has a chemical shift of around 30.0 ppm, and
the other around 19.6 ppm. Evans had also pointed out earlier that the chemical
shift of the central acetal carbon correlates well with the cis and trans conforma-
tion, the former having an average chemical shift of 98.5 ppm, while the latter has
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an average shift of 100.6 ppm.170
In our case, the 13C chemical shift of the two methyls are 25.0 and 24.4 ppm,
respectively. Also, the central quaternary carbon has a chemical shift of 100.5
ppm. All these results confirm the anti conformation between the two hydroxyls.
To have a solid proof of the 1,5-anti induction during the aldol reaction, the
relation between the stereocenter at C13 and the previously determined one at C15
should be established. Therefore, the p-methoxyphenyl acetal 3.35 was formed
(scheme 3.9). This could be achieved under anhydrous, oxidative conditions, us-
ing DDQ. NOESY-analysis of the formed, chair-like 1,3-dioxane shows crosspeaks
between the axial protons of acetal 3.35, thus confirming the 1,3-cis-relationship
(figures 3.5 and 3.6).
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Figure 3.6: NOESY spectrum of 3.35 in CDCl3
Since the efforts to prove the correct chemistry all pointed in the good direction,
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the synthesis of the C5 –C20 fragment (3.9) was continued (scheme 3.5). First, a
methyl ether at C13 was installed using the methyl version of Meerwein’s reagent,
Me3OBF4 to yield 3.26, then the aromatic bromide was converted to the corre-
sponding trimethylstannane 3.9 in a Stille reaction with hexamethylditin. The
same conditions as in the original synthesis were used: 10 mol% Pd(PPh3)4 as
catalyst and Ph3P as additive to improve the stability of the catalyst in solution,
resulted in a yield of 89%. The use of Ph3As as additive, instead of Ph3P, did
not have a significant effect on reaction rate or yield. The general mechanism of
the Stille coupling is depicted in scheme 3.10.171 The first step is the oxidative
addition of the halide 3.42 to the catalyst (Pd(0), 3.43). Next, the Pd(II) com-
plex 3.43a can undergo a transmetalation, where the halogen is exchanged for a
ligand on the stannyl moiety 3.44, with formation of a trialkyltin halide 3.45 and
3.43b. Consequent trans-cis isomerization (3.43c), sets the stage for reductive
elimination to occur, forming again a Pd(0) complex 3.43 and the cross-coupled
product 3.46.
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Scheme 3.10: Catalytic cycle of the Stille reaction
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3.2.2 Completion of the phenyl analog: macrolactoniza-
tion approach
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Scheme 3.11: Further elaboration towards pelofen via macrolactonization
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In a first approach towards the previously synthesized phenyl analog of peloruside
A, it was decided to make use of the previously established chemistry.149 Therefore,
the next key steps include again a Stille coupling, an asymmetric dihydroxylation
and a macrolactonization (scheme 3.11).
The cross coupling between stannane 3.9 and allylic bromide 3.6, using Pd2
(dba)3 ·CHCl3 as catalyst, delivered the unsaturated methyl ester 3.47 in 92%
yield, together with a minor amount of an isomer where the alkene possesses the
Z -configuration. This was verified by comparing the coupling constant of the
corresponding vicinal alkene protons in the 1H-NMR spectrum: 15.6 Hz for the
E -isomer, 11.5 Hz for the Z -isomer.
The disubstituted olefin in 3.47 was then regioselectively oxidized to diol 3.48
using Sharpless’s asymmetric dihydroxylation protocol.172 As E -1,2-disubstituted
olefins are regarded as the standard substrate for this protocol, the use of a com-
mercially available premix of all the reagents, the so-called AD-mix, was ade-
quate. This premix contains K2OsO2(OH)4 as a non-volatile OsO4 source, a chi-
ral ligand, i.e. bis(dihydroquinidine)phtalazine (DHQD)2PHAL for AD-mix β or
bis(dihydroquinine)phtalazine (DHQ)2PHAL for AD-mix α, K2CO3 to create a
basic environment and K3Fe(CN)6 as co-oxidant. These reagents combined with a
biphasic mixture make sure the OsO2(OH)4
2– species (3.52a, scheme 3.12) is oxi-
dized to Os(VIII) (3.52b) in the aqueous phase, so there is no oxidant other than
OsO4 (3.52c) present in the organic layer. Therefore, after osmylation (3.52d),
the resulting osmium(VI) monoglycolate ester 3.52e undergoes hydrolysis with
formation of the diol and again, an Os(VI) species (3.52a). The former stays in
the organic phase, while the latter goes directly into the aqueous phase, where the
cycle can be repeated.
The formation of the osmium(VI) monoglycolate ester 3.52e is thought to pro-
ceed in a stepwise manner. The first step would then be a [2 + 2]-like cycloaddition
of the olefin across an Os = O bond, forming 3.52d, upon which, in a second step,
rearrangement occurs to form the glycolate ester product 3.52e. Both empirical
results and ab initio calculations support this mechanism.173,174 The stereochemi-
cal selectivity is evidently determined by choice of the dimeric ligand, which creates
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Scheme 3.12: General mechanism of the Sharpless asymmetric dihydroxylation
an enzyme-like binding pocket. The interplay between an attractive stabilization
interaction and a repulsive steric interaction creates the bias for facial selectivity.
Based on empirical results, Sharpless developed a mnemomic device to predict
the stereoselectivity (figure 3.7). According to this model, the use of AD-mix β
induces the correct stereochemistry.
The reaction was performed in the presence of MeSO2NH2 and NaHCO3. The
former is known to speed up the reaction, the latter is added to create a buffered
system, thereby avoiding hydrolysis of the methyl ester. Diol 3.48 was formed in
88% (isolated yield), with a diastereomeric excess of 97%. The resulting alcohols
were protected as MOM- ethers (3.8) in 97% yield. Next, the MPM ether at C15
was selectively deprotected using DDQ in a biphasic mixture of CH2Cl2 and a
phosphate buffer at pH 7, resulting in formation of 3.49 in 95% yield.
To obtain the ω-hydroxy acid necessary for macrolactonization, the methyl
109
3.2. Results and discussion
RM
H
RS
RL
AD-mix β
AD-mix α
Figure 3.7: Mnemomic device for the prediction of the stereochemical outcome of
the SAD
ester must be hydrolyzed. However, also the propionate ester should be removed at
this point, as it would be very difficult to remove the latter later on in the synthesis
without affecting the macrocyle. Standard, mild conditions (LiOH) did remove
the methyl ester easily, but removal of the propionate ester at C11 required much
longer reaction times. After 7 days, the reaction was not yet finished but 83% of
seco acid 3.50 could be isolated after flash column chromatography. TLC-analysis
showed almost complete conversion after 13 days, without notable formation of
epimers. The use of LiOOH, formed in situ by combining LiOH and H2O2, had an
accelerating effect on the hydrolysis of the methyl ester but not on the hydrolysis
of the propionate ester. Also the use of potassium hydroxide did not speed up the
reaction. A mild procedure, published by Nicolaou employing MeSnOH at elevated
temperatures175 proved to be very slow, even for the hydrolysis of the methyl ester.
Another possibility was the transesterification of the propionate ester with MeOH
and K2CO3, and in a second step, the methyl ester could then be hydrolyzed.
However, the transesterification did not work under the tested conditions as the
propionate ester was unaffected.
In another approach, which requires two more steps but circumvents the long
reaction times, both esters are first reduced, and then, selective oxidation of the
primary alcohol provides the required seco acid (scheme 3.13). In order to get
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a good selectivity, it was decided to postpone the removal of the MPM ether,
until after the oxidation of the primary alcohol to the carboxylic acid. In this
way, the oxidation procedure only had to distinguish between a sterically hindered
secondary alcohol and a primary alcohol, as the secondary allylic alcohol was still
protected.
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Scheme 3.13: Reduction - oxidation procedure to obtain the seco acid 3.50
Di-ester 3.8 was reduced using LiAlH4 in 89% yield. Next, selective oxidation
of the primary alcohol of 3.53 was achieved with catalytic amounts of TEMPO
(3.56) and bisacetoxy iodobenzene (BAIB) (3.57) as terminal oxidant (scheme
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Scheme 3.14: Catalytic cycle for the TEMPO oxidation of alcohols
First, ligand exchange of the alcohol with BAIB generates acetic acid, which
is necessary to form the active species. Under the influence of AcOH, TEMPO
(3.56) disproportionates (dismutation) into an oxoammonium salt 3.56a and hy-
droxylamine 3.56b (scheme 3.14). The former is the primary oxidant, capable of
oxidizing the alcohol to the aldehyde, and itself being reduced to hydroxylamine.
This is reoxidized by the hypervalent iodine reagent BAIB 3.57, resulting in the
formation of iodobenzene 3.58, acetic acid and TEMPO.
The product is put crude in the next reaction: a Pinnick-Lindgren oxidation
of the aldehyde 3.54 to the carboxylic acid 3.55 (scheme 3.13). Here, by combin-
ing NaClO2 with NaH2PO4, HClO2 is generated, which can add to the aldehyde
(3.59, scheme 3.15). Pericyclic fragmentation of the formed adduct 3.60 results
in the carboxylic acid and HOCl. The latter product is capable of destroying the
NaClO2 reagent, with formation of ClO2. Therefore, 2-methyl-2-butene is added
as a scavenger for trapping the HOCl formed, generating a halohydrin 3.61.
Several TEMPO-mediated methods exist to oxidize a primary alcohol directly
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Scheme 3.15: Mechanism for the Pinnick-Lindgren oxidation of aldehydes to car-
boxylic acids, with scavenging of HOCl
to the carboxylic acid.177–179 However, as they all employ an excess of oxidant,
they were not tested, out of fear for non-selective oxidation of the alcohol at C11.
Deprotecting the alcohol at C15 in 3.55 at the stage of the carboxylic acid
occurred without problems, under identical conditions as before, resulting in 3.50
with a yield of 90% over three steps.
Macrolactonization
A crucial step in the synthesis of pelofen (3.1) is the formation of the macrocyclic
lactone. Numerous methods exist to accomplish this, and there is no generally
applicable method which is always successful. On the one hand, the size of the
macrocycle is important for ring closure: 4-, 5- and 6-membered lactones are
formed rather easily. The medium reactivity of 7-membered lactones is compara-
ble to that of 13- or highered membered macrolactones, whereas the formation of
8- to 11-membered macrolactones is considered to be rather difficult.180 On the
other hand, the possibility to adopt the reactive conformation should be consid-
ered: conformationally constrained macrocycles can or cannot possess a preorgan-
isation which leads to smooth, respectively difficult ring closure. Several factors
can attribute to these considerations: the mode of activation of the seco acid, the
presence of protecting groups, sterical hindrance, ... Several examples of macrocy-
clizations in the total synthesis of natural products are reported in literature.181,182
In general, all macrolactonizations can be divided into two categories: addi-
tion of the alcohol to an activated carboxylic acid, or nucleophilic attack of the
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carboxylate to an activated alcohol (in which the hydroxyl group is converted to
a good leaving group). The latter (e.g. Mitsunobu macrolactonization) usually
occurs with inversion of the stereochemistry, and thus, is not preferable in our
synthesis, as the stereochemistry at C15 is already the correct one. Therefore, only
methods were tested were the carboxylic acid is activated, as summarized in table
3.2.
Entry Activating reagent Remarks Results
1
2,4,6-trichlorobenzoyl
chloride
DMAP 36% yield
2
2,4,6-trichlorobenzoyl
chloride
activation diluted,
DMAP
31% yield
3
2,4,6-trichlorobenzoyl
chloride
DMAP, one pot 16% yield*
4
2,4,6-trichlorobenzoyl
chloride
4-pyrrolidino-pyridine,
one pot
9% yield*
5
2-methyl-6-nitrobenzoic
anhydride
DMAP
no full conversion,
5% yield*
6 2,2’-dipyridylsulfide, PPh3 80
◦C
no product
observed
7 2,2’-dipyridylsulfide, PPh3 AgOTf, RT
no product
observed
8 2,2’-dipyridylsulfide, PPh3 AgOTf, 80
◦C
no product
observed
9
1-methyl-2-chloro-
pyridiniumiodide
NaHCO3
33% unknown
product
Table 3.2: Some tested conditions for macrolactonization of 3.50. All experiments
were carried out at a dilution of 0.66 mM. (*: based on LC)
In a first series of experiments (table 3.2, entry 1), the Yamaguchi procedure
was tested at room temperature (scheme 3.16).183 Here, the seco acid is pre-
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activated with 2,4,6-trichlorobenzoyl chloride (3.62) to form the mixed anhydride
3.63a, which then, over a duration of 12h is added via syringe pump to a dilute
solution (0.66 mM) of DMAP in toluene. In this way, an acylpyridinium species
3.63b is prone to undergo intramolecular attack of the ω-alcohol. The ring closure
does occur, along with formation of some epimers and a lot of dimer, resulting in
a modest yield of 36%. MS analysis during the anhydride formation showed that
dimer formation already took place during this stage of the cyclization, even in
the absence of DMAP. Anticipating this, the activation itself was attempted un-
der dilute conditions (1.3 mM). Unfortunately, did this not result in a decrease of
dimer formation (entry 2), nor in a better yield.
Also the use of a one-pot procedure, also known as the Yonemitsu conditions
of the Yamaguchi macrolactonization, where both 2,4,6-trichlorobenzoyl chloride,
DIPEA and DMAP are combined in one flask and to which a dilute solution of
the seco acid is added via syringe pump,184 did not show an improvement (table
3.2, entries 3-4). Both the use of DMAP and 4-pyrrolidino-pyridine proved ineffec-
tive, as they resulted in more dimer formation. The influence of the temperature
using Yamaguchi conditions was not investigated. Although the mechanism is
comparable, the use of an alternative benzoic anhydride (2-methyl-6-nitrobenzoic
anhydride) can improve the yield of the envisaged cyclized monomer.185,186 In our
case however, no improvement was observed (entry 5). The carboxylic acid was
not fully converted, even after prolonged reaction times, resulting in a poor yield
of 6%, based on LCMS.
In nature, ester bonds are formed via thioesters.187 This inspired Corey and
Nicolaou for the chemical synthesis of macrolactones. First, a thioester 3.64
(scheme 3.17) is synthesized by combining dipyridyl disulfide and PPh3, which is in
essence an oxidation-reduction condensation reaction, reported by Mukaiyama.188,189
Initial attack of triphenylphosphine on the bipyridyl disulfide will form a phospho-
nium salt 3.65a, of which the phosphorus can be attacked by the carboxylic acid
with substitution of pyridylthiol and formation of a second phosphonium species
3.65b. Attack of the pyridyl thiolate anion on the activated carbonyl then gen-
erates thioester 3.64 and triphenylphosphine oxide. Once the thioester is formed,
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Scheme 3.16: Reaction mechanism of the Yamaguchi macrolactonization
internal proton transfer from the alcohol to the pyridine affords an intermediate
3.64a in which both the carbonyl and the hydroxyl group are activated, resulting
in the macrocyclization and formation of thiopyridone. Therefore, this method
is also known as the double activation method, and it is essentially electrostati-
cally driven. The proton transfer itself can be achieved by thermal activation or
by metal catalysis. This metal possibly chelates to the sulfur, thereby accelerat-
ing the macrolactonization. Gerlach’s modification employs silver salts and allows
some reactions to be carried out at room temperature.190
The use of this method for the cyclization of 3.50 however was not a success
(entries 6-8).The formation of the thioester was observed in LC-MS, but no macro-
lactone was detected. Also, it must be said, that the analysis of the mixtures was
hampered due to the presence of both triphenylphosphine oxide and thiopyridone.
Another method, employing Mukaiyama’s salt (1-methyl-2-chloropyridinium
iodide, 3.67, scheme 3.18) and NaHCO3, was efficient in reducing the amount
of dimer.191 However, LC-MS analysis showed the formation of epimers (different
retention time, same mass). The major isomer was isolated (33%) but could not
be identified using NMR spectroscopy (table 3.2, entry 9).
The mechanism of this reaction involves chloride substitution by the carboxy-
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Scheme 3.18: Macrolactonization using Mukaiyama’s salt
late anion to give a highly activated acyloxypyridinium species 3.67a, which then
undergoes macrolactonization with formation of N-methyl-2-pyridone 3.67b.
3.2.3 The synthesis of 2,3-dideoxy pelofen (3.74)
While attempting to find an efficient macrolactonization en route to pelofen (3.1),
an analog lacking the substituents at positon C2 and C3 (3.74) was synthesized
(scheme 3.19). Bearing in mind the earlier encountered problems of ester depro-
tection, it was decided to first reduce the propionate ester in 3.9, resulting in
stannane 3.68. Stille reaction employing the same conditions as before delivered
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Scheme 3.19: Synthesis of the 2,3-dideoxy analog (3.74) of pelofen
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unsaturated ester 3.69 nearly quantitatively, without observation of the Z isomer.
Next, the conjugated double bond was regioselectively saturated to ester 3.70
using NaBH4 and catalytic amounts of NiCl2.6H2O in MeOH.
192,193 The exact
mechanism of this reaction is unknown: both the in situ formation of Ni2B and
H2 or the generation of a nickel hydride could account for the active species.
194
The MPM ether in 3.70 was removed with DDQ (96% yield) and the remain-
ing methyl ester was hydrolysed to obtain the ω-hydroxy acid necessary for ring
closure. The first attempt to close the macrocycle, by applying Yamaguchi’s con-
ditions, via preparation of the mixed anhydride in toluene and then addition to a
diluted solution of DMAP in toluene (0.66 mM) delivered 3.73 in 88% over two
steps, without dimer formation or epimerization. The final deprotection of the
primary alcohol proceeded smoothly in 96% yield, making use of ZnBr2 as Lewis
acid and a thiol as scavenger.
Compound 3.74 was tested for its biological activity by professor Bracke (lab-
oratorium for experimental cancer research) in two different assays on MO4 cells.
These cells are murine, virally transformed fibrosarcoma-like cells, which are highly
invasive, tumorigenic in a specific mouse, and sensitive to microtubule inhibitors.
Because of these features, they are an ideal model for cancer in vitro. The MTT as-
say is a measure for the viability of the cell, correlated with the metabolic events
that lead to apoptosis or necrosis of the cell.195 Sulforhodamine B (SRB) is an
anionic dye that binds to proteins electrostatically. The fixed dye, measured pho-
tometrically after solubilization, correlates with total protein synthesis rate and
therefore with cell proliferation.196
Unfortunately, no statistically significant results could be obtained so far.
Therefor, no conclusions about the importance of the substituents at the C2 and
C3 position could be drawn.
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3.2.4 New route to pelofen and analogs at the C2–C3-
position
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Scheme 3.20
Although the 2,3-dideoxy-analog was not active, its synthesis opened possibilities
for the synthesis of pelofen (3.1) and other analogs with modifications in the
C2 –C3-region. As the macrolactonization of seco acid 3.72 without substituents
at C2 and C3 proceeded without difficulties, it was considered to ring close the
unsaturated ω-hydroxy acid 3.76 (scheme 3.20). Late stage dihydroxylation of the
conjugated olefin would then install the alcohols at C2 and C3, and deprotection
of the primary alcohol at C24 would immediately result in 3.1.
The removal of the MPM proceeded as planned (scheme 3.20). However, upon
hydrolysis of the methyl ester, using LiOH, the olefin partly migrated towards the
phenyl ring to form a mixture of the envisaged conjugated carboxylic acid 3.76
and styrene-like derivatives 3.78 (scheme 3.21). Upon use of the earlier reported,
milder hydrolysing agent Me3SnOH, the reaction was complete in 24h, but the
migration was not prevented, and a similar mixture was obtained.
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Scheme 3.21: Isomerization of the conjugated ester to the styrene derivative 3.78
As the double bond migration occured only at the time of hydrolysis, and not
during the preceding Stille coupling, we considered to directly install the carboxylic
acid via Stille reaction (scheme 3.22). Therefore, the MPM ether of stannane 3.79
was removed easily, and the resulting stannane 3.80 was coupled with E -4-bromo
crotonic acid under Pd(0)-catalysis. In this way, the amount of migration was
restricted to a minimum. However, this time, destannylation occurred as a side
reaction. The addition of an excess of DIPEA to neutralize the acid resulted in a
complex mixture, which unfortunately still contained the destannylated product.
The isolated yield of carboxylic acid 3.76 was therefore limited to 53%. Neverthe-
less, with pure 3.76 in hand, the macrolactonization was attempted, under exactly
the same conditions as with the dideoxy analog. In this case, not only a significant
amount of dimer was formed, but also migration of the double bond was observed,
probably caused by the basic conditions during the Yamaguchi macrolactoniza-
tion. The yield was not determined, but the main product was identified to be the
styrene derivative possessing the Z configuration (3.78a) (scheme 3.22).
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Scheme 3.22
3.2.5 Diversification of phenyl analogs: Ring-Closing Metathe-
sis approach
As the envisaged target could not be obtained in an acceptable yield via macro-
lactonization, another approach was attempted: the ring-closing metathesis. A
retrosynthetic analysis is represented in scheme 3.23.
Two reactions are essential in synthesizing the diene precursor for the ring-
closing metathesis: the allylation through Stille coupling of 3.80 to afford 3.82
and the acryloylation of 3.80 to acryloyl ester 3.83 (scheme 3.24). Initially, these
two reactions were optimized simultaneously.
A first test for the Stille coupling, employing allyl bromide in THF and Pd2dba3.
CHCl3 as catalyst, again resulted in partial migration of the olefin to obtain con-
jugation with the aromatic ring. Therefore, efforts were made to suppress the
isomerization, summarized in table 3.3. Judged by TLC and LC analysis, the
122
CHAPTER 3. PHENYL ANALOGS
O
O
O
OHHO
OH
OHH
O
O
O
OHMEMO
H
OMEM
O OMe OH
O
RCM
OMEM
OH OMe
SnMe3
OH
3.1 3.77
3.81 3.80
Scheme 3.23: Retrosynthetic analysis of 3.1 via ring-closing metathesis
reaction in pure allylbromide (entry 4) was the cleanest, minimizing isomerization
and formation of by-products.
Entry catalyst # eq. catalyst solvent T (◦C) time %isomer
1 Pd2dba3.CHCl3 0.05 THF 60 90 min 23
2 Pd2dba3 0.05 THF 60 90 min 15
3 [allylPdCl]2 0.15 THF 60 30 min 5
4 Pd2dba3.CHCl3 0.05 neat 60 30 min 4
5 Pd2dba3.CHCl3 0.05 THF 21 12 h 9
Table 3.3: Cross coupling conditions for the aryl allylation with allyl bromide
The introduction of the acryloyl group in 3.68 was thought to be straightfor-
ward, even in the presence of two free hydroxyl groups, as there is a big difference
in sterical environment between both. However, the reaction turned out to be
unselective, as reaction with acryloyl chloride resulted in double esterification (in
a 1:1 ratio). Yamaguchi esterification (acrylic acid, 2,4,6-trichlorobenzoyl chlo-
ride, Et3N, DMAP) was selective, but inefficient, as the reaction did not run to
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Scheme 3.24: Key steps in the synthesis of diene 3.81
completion. Steglich esterification, employing acrylic acid, EDCI.HCl and DMAP,
required long reaction times (several days), but gave a clean, spot-to-spot reaction
on TLC, in favor of the required mono-ester 3.83. After isolation however, the
yield proved to be only 10%.
To avoid the problems associated with the double esterification, we decided to
oxidize the alcohol at C11 to the ketone. This way of ‘protecting’ the alcohol opened
up the additional possibility to gain access to analogs with variations on this
C11. For instance, stereoselective reduction or reductive amination could introduce
both epimeric alcohols, respectively amines, whereas Wolff-Kishner reduction could
remove the substituent at C11.
Ley-Griffith oxidation of 3.79 (scheme 3.25) using catalytic perruthenate and
NMO proved to be superior over Swern oxidation, giving 3.84 in 95% yield. The
subsequent deprotection of the C15 allylic alcohol to 3.85 proceeded in a compara-
ble yield. The acrylation however, again, caused some difficulties. Performing the
reaction with pure acryloyl chloride and DMAP as base (entry 1, table 3.4) did
only give trace amounts of 3.86, but the starting material could be recuperated.
Making use of Et3N as base and DMAP as nucleophilic catalyst and a large excess
of the acid chloride gave full conversion. However, after column chromatography,
only 30% could be isolated (entry 2). Omitting DMAP from the reaction mixture
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Scheme 3.25: Synthesis of diene 3.87, the precursor for ring-closing metathesis
and adding the acid chloride as a 0.1M solution in CH2Cl2, resulted in a good
crude yield (entry 3), which was not purified and put into the next reaction. How-
ever, the yield after the next step was lower than expected, probably because the
isolated yield of 3.86 was much lower than the crude yield. Next, DIPEA was used
as base, and the reaction was started with 5 equivalents of acid chloride (again as
a solution in CH2Cl2). As the starting material 3.85 was not fully converted (as
evaluated by TLC analysis), another 2.5 equivalents were added after 3h. Still,
this gave no full conversion, but the starting and target material were separated
by means of column chromatography, resulting in 86% of ester 3.86, and 9% of
recovered alcohol 3.85. In order to get full conversion, the reacion was performed
with 10 equivalents of acid chloride from the start (as in entries 2 and 3). This
time however, the starting material was again not fully converted, and the yield
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was even lower than in case of portion-wise addition (entry 5). Introduction of
the arylic allyl group was achieved by applying the previously optimized method
(Pd2dba3.CHCl3 in neat allyl bromide), yielding diene 3.87 in 95%, without no-
table migration of the olefin to form the styrene-derivative.
Entry base CH2CHCOCl eq. RCOCl observations yield
1 DMAP neat 2
trace amounts
of 3.86
<1%
2
Et3N,
DMAP
neat 10 full conversion 30%
3 Et3N 0.1M in CH2Cl2 10 full conversion 99% crude
4 DIPEA 0.1M in CH2Cl2 5 + 2.5
no full
conversion
86% (95%
brsm)
5 DIPEA 0.1M in CH2Cl2 10
no full
conversion
71% (84%
brsm)
Table 3.4: Tested conditions for the acryloylation of 3.85 (brsm: based on recov-
ered starting material)
Efforts were also undertaken to develop an alternative synthesis of diene 3.87,
where the original arylic bromide is maintained throughout the synthesis (scheme
3.26). Thus, the bromide does not have to be converted to the stannane, which
reduces the number of steps, as the bromide can be directly coupled with an allyl
group in a Suzuki or Stille reaction. This last step still has to be optimized, as
only trace amounts were detected in preliminary experiments, employing either
allyl-pinacolboronate, CsF and PdCl2(dppf).CH2Cl2 for the Suzuki coupling, or
allyl-tributyltin and Pd(PPh3)4 for the Stille reaction.
With diene 3.87 in hand, the ring-closing metathesis reaction could be tested.
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Scheme 3.26: Alternative synthesis of diene 3.87
Ring-closing metathesis
Olefin metathesis is the net transposition of fragments of alkenes, by the scission
and regeneration of carbon-carbon double bonds.197 Ring-closing metathesis is
a specific type, where two alkenes react with a catalyst, in order to generate a
(macro)cyclic olefin.198–200 The reaction is driven to completion because volatile
products are formed and removed.
Transition metal-catalyzed metathesis was originally observed in industry in
the 1950’s, mainly in polymerization reactions. The reaction mechanism, however,
remained a mystery until Chauvin in the 70’s published his proposal, based on the
previously observed findings and supported by new experiments.201
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Scheme 3.27: Chauvin’s reaction mechanism for the ring-closing olefin metathesis
The catalytic cycle consists of an initiation phase (scheme 3.27, top), where the
active complex is generated, and a propagation phase (scheme 3.27, bottom), which
is repeated until the starting diene is consumed, or an equilibrium is reached. In
the initiation step, an olefin of the substrate 3.91 reacts with the metal alkylidene
3.92 in a [2+2] cycloaddition, to generate a metallocyclobutane 3.92a. Next, a
[2+2] cycloreversion creates a new (substrate-loaded) metal alkylidene 3.92b, with
expulsion of an olefin, of which one alkylidene is coming from the catalyst (C) and
one is coming from the starting material (C2). The newly formed metal alkylidene
3.92b again can undergo a cycloaddition to the other olefin of the diene to form
a new metallocyclobutane 3.92c, which can in turn disintegrate in the forward
direction to form the cyclized product 3.93 and a new, metal alkylidene 3.92d.
The latter acts as the active catalyst in the catalytic cycle, where another series
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of cycloaddition/cycloreversion events leads to the cyclization product 3.93 and
the active species 3.92d.
From this mechanism, which relies on a metal alkylidene initiating the metathe-
sis, Chauvin suggested that catalysis by -on purpose- synthesized metal-alkylidene
complexes could efficiently induce metathesis reactions. Synthesis of these types
of catalyst was mainly done by Schrock and Grubbs, who, together with Chauvin,
received the Noble Prize in 2005 ‘for the development of the metathesis method in
organic synthesis ’.202
While the catalysts developed by Schrock are based on molybdenum or tung-
sten, those developed by Grubbs are based on ruthenium. In general, the Ru-based
catalyst are more compatible with functional groups and more stable to air and
moisture. Several of them are commercially available, two of which were tested:
Grubbs 2nd generation catalyst (3.94) and Hoveyda Grubbs 2nd generation cata-
lyst (3.95), which are depicted in figure 3.8.
Ru
Cl
Cl
N N
Ru
Cl
Cl
N N
P O
3.94 3.95
Figure 3.8: Structure of the Grubbs (3.94) and Hoveyda-Grubbs’s (3.96) 2nd
generation catalysts
The reaction was optimized in function of conversion and in function of cyclic
monomer formation, compared to the formation of oligomers (diolide, or even tri-
olide). As also cross metathesis can occur, in which an olefin from the diene is
coupled to an olefin of another diene molecule, different types of dimer can be
formed: head-to-head coupling as well as head-to-tail coupling is possible. More-
over, the dimers can exist in an open form as well as in their closed form.
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The reactions were tested on a 0.5-1 mg scale of diene 3.87, and executed un-
der high dilution to avoid oligomer formation. From TLC- and LC analysis, a few
conclusions could be drawn (table 3.5) First, toluene proved to be a better solvent
than CH2Cl2 as it gave a cleaner reaction (entries 1-3). Next, it seemed that the
Hoveyda-Grubbs catalyst 3.96 was too reactive, as significantly more oligomers
were formed, while the amount of desired monomer was moderate to low (entries
3-5). Using the Grubbs catalyst 3.94, the influence of the temperature was investi-
gated (entries 6- 7). The best result was obtained when performing the reaction at
higher temperature (110◦C) in PhMe (entry 7). Applying the same conditions for
a shorter reaction time (entry 8) resulted in less monomer formation, although the
starting material was almost fully converted. This suggested an equilibrium be-
tween oligo- and monomer can set in in function of time. Therefore the conditions
were repeated in an even more dilute system, but again with different reaction
times. (entries 9-10). However, no clear relationship between reaction time and
monomer formation could be observed. The use of a lower amount of catalyst
(entry 11) did not give significant differences.
OMEM
O OMe O
O
O
O
O
OMEMO
H
18% (E):
O
O
O
OMEMO
H
Grubbs II
PhMe, 110°C
28% (Z):
22%
3.87
3.97
3.98
3.99
Scheme 3.28: Result of the ring-closure metathesis on a 17 mg scale
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The reaction was then performed on a slightly bigger scale (17 mg) using 10
mol% Grubbs 2nd generation catalyst, 1mM solution in toluene, 15 min reac-
tion time (scheme 3.28). LC indicated good conversion (98%) and around 70%
monomer yield. After multiple column chromatographic purifications however, 3
compounds were isolated: 18% of the E -isomer 3.98, 28% of the Z -isomer 3.99
and 22% of the styrene-derivative 3.97. The migration of the double bond towards
this styrene-derivative was not observed in the test reactions, at least not to this
extent, as the peaks in the chromatogram overlap. The configuration of the double
bond in 3.97 was established to be Z, based on the coupling constants between
the vicinal protons (3J = 11.5 Hz).
These results indicate this route can be used to generate quickly several analogs,
with modifications in the C2-C4 region. However, in order to set a straightforward
route towards pelofen 3.1, the final ring-closing metathesis step needs further
optimization. Also, the transformation of the double bond into other functional
groups needs further research.
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4.1 Aims
Peloruside (4.1, figure 4.1) is a natural product which shows cytotoxic activity at
nanomolar concentrations. More importantly, it acts as a microtubule stabilizer
in a similar way as paclitaxel, a well established chemotherapeutic. Because of its
low natural abundancy and complexity, peloruside cannot be used as such in the
clinic. To explore the potential of this natural product, SAR analysis can be of use
to come up with more simplified analogs that retain their activity. Therefore, in
this thesis, attempts were made to investigate the importance of the substituents
on the pyranose ring of peloruside by making simplified analogs 4.2. Our aim was
to construct the THP-ring through application of the Mukaiyama aldol - Prins
reaction. (Chapter 2)
On the other hand, the synthesis of a simplified analog, pelofen B (4.3), in
which the full pyranose ring has been replaced by a phenyl ring, developed in our
lab, was re-evaluated to come up with a more straightforward synthesis, which
would allow access to analogs with varied functional groups. (Chapter 3)
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Figure 4.1
4.2 Tetrahydropyran analogs
4.2.1 Results
Our design for the synthesis of THP-analogs 4.2 (scheme 4.1) was based on the
aldol coupling of two advanced intermediates: a methyl ketone 4.4, containing two
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stereocenters and the trisubstituted olefin of the side chain, and an aldehyde 4.5,
containing the THP ring and two additional stereocenters. The synthesis of the
latter fragment was based on the Mukaiyama aldol - Prins (MAP) cyclization, a
cascade reaction between an aldehyde 4.6 and a bisnucleophile 4.7, in the presence
of a Lewis acid.
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Scheme 4.1: Retrosynthetic analysis of the envisaged THP analogs
The synthesis of the C12 –C20 fragment 4.4 (scheme 4.2) started with the
carbomagnesation of dihydrofuran (4.8) with ethylmagnesium chloride (4.9), in
a zirconium-catalysed reaction, which proceeded with excellent enantioselectivty
(>98:2). The resulting homoallylic alcohol was protected as an acetal, and the
olefin was oxidatively cleaved by ozone, delivering aldehyde 4.11. The Z -double
bond was constructed using phosphonate 4.17 in a modification of the Horner-
Wadsworth-Emmons reaction, developed by Still and Gennari. The geometry
of the double bond was confirmed by NOE spectroscopy. A reduction-oxidation
procedure delivered aldehyde 4.14 which could be stereoselectively allylated in a
Brown allylation reaction. Both isolated yield (79%) and diastereomeric excess
(90%) of this reaction were satisfying. The stereochemistry of the carbinol in
4.15 was assigned using Mosher-ester analysis. After protection of the resulting
homoallylic alcohol 4.15 as MPM-ether, the terminal olefin was selectively oxi-
dized to the methyl ketone 4.4 in a Pd-catalyzed Wacker oxidation. Overall, this
building block was synthesized in a linear sequence of 9 steps with a total yield
of 21%. This somewhat lower yield is basically due to the first step (40%), which
was optimized in terms of catalyst turnover number.
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Scheme 4.2: Synthesis of the C12-C20 fragment 4.4
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Scheme 4.3: Synthesis of aldehyde 4.6
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The second fragment 4.5 is comprised of two building blocks itself. The
first one, aldehyde 4.6, is obtained from D-mannitol, of which 4 hydroxyls were
protected with benzaldehyde as 1,3-4,6 bis-benzylidene acetal 4.19 in 30% yield
(scheme 4.3). The remaining alcohols were benzylated, after which the benzyli-
dene acetals were removed again, to provide tetrol 4.21. The primary alcohols
were selectively protected as silyl ether, to form bis-silyl ether 4.22. Oxidative
cleavage of the remaining diol was achieved with sodium periodate and afforded
aldehyde 4.6 in 19% yield over 5 steps.
OH OH MPMO OH MPMO O
MPMO OH MPMO O
a c d
e
a) 4-MeO-PhCH(OMe)2, CSA, CH2Cl2, RT; b) LiAlH4, AlCl3, Et2O, -10°C; c) i) (COCl)2, DMSO, -78°C 
ii) Et3N, CH2Cl2, -78°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, 
THF, allylOAc, 2-PrOH, 120°C;  e) Hg(CF3COO)2, EtOCHCH2, RT
92% 98% 96%
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Scheme 4.4: Synthesis of enol ether 4.28
The other building block (4.28), necessary for the synthesis of fragment 4.5,
started with the acetalisation of 2,2-dimethyl-1,3-propanediol with 4-methoxybenzyl
dimethylacetal, followed by reductive opening to alcohol 4.25 (scheme 4.4). This
was oxidized under Swern conditions, delivering aldehyde 4.26, which was stere-
oselectively allylated with a chiral iridium catalyst, at elevated temperatures. The
resulting homoallylic alcohol 4.27 was vinylated using mercury catalysis to form
bisnucleophile 4.28. The overall yield for this building block was 62% over 5 steps
and the enantiomeric excess 96%.
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Scheme 4.5: First attempt on the Mukaiyama aldol - Prins cyclization
In a first attempt to perform the Mukaiyama aldol - Prins cyclization between
aldehyde 4.6 and diene 4.28, the p-methoxybenzyl ether proved not to be compat-
ible with the Lewis acidic conditions required for the cyclization (scheme 4.5). As a
consequence, only acetal 4.29 was formed. Therefore, the diene was resynthesized
using a less sensitive ester as protecting group.
OH OH O OH O O
O OH O O
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e
a) DMAP, NEt3, CH2Cl2, RT; b)  i) (COCl)2, DMSO, -78°C ii) Et3N, CH2Cl2, -78°C; c) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-
BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, THF, allylOAc, 120°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-
Cl-3-NO2-benzoic acid, THF, allylOAc, 2-PrOH, 120°C;  e) Hg(CF3COO)2, EtOCHCH2, RT
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Scheme 4.6: Synthesis of the ester protected C4-C11 enol ether 4.34
The synthesis of the naphtoyl-protected enol ether started with the monopro-
tection of diol 4.23 with naphtoylchloride (scheme 4.6). Swern oxidation of the
remaining alcohol in 4.31 yielded aldehyde 4.32 which could be allylated under
Krische conditions, affording homoallylic alcohol 4.33 in an isolated yield of 68%
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with an enantiomeric excess of 98%. The final mercury-catalyzed vinylation oc-
curred with a yield of 82%. Overall, this 2nd generation enol ether was synthesized
in 4 steps with a total yield of 50% with an excellent enantiopurity.
The second attempt on the Mukaiyama aldol - Prins cyclization, was successful
in terms of carbon-skeleton formation, but not in terms of stereoselectivty: the
envisaged bromo-THP ether 4.35 was formed in 78% yield, be it as a mixture of
diastereomers at the bromine center and the C3 alcohol (scheme 4.7). Attempts to
improve the diastereoselectivity by changing the Lewis acid, the order of addition
or control of the temperature all failed. Increasing the bulk of the aldehyde by
replacement of the TBS ether by a less acid sensitive TBDPS ether improved
the yield of the cascade reaction to 84%, without improving the diastereomeric
outcome.
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Scheme 4.7: Mukaiyama aldol - Prins cyclization with enol ether 4.36
The complex mixture was analyzed by means of chemical derivatization (scheme
4.8): reductive removal of bromine gave the two diastereomeric alcohols at C3
(4.38 and 4.39), whereas oxidation of this C3 alcohol to the ketone, gave both
equatorial 4.40 and equatorial bromide 4.41. The stereocenter at C5 was always
cis compared to the substituent at C9, the latter which was established previously
in the allylation reaction.
After separation, ketone 4.40 was stereoselectively reduced with L-selectride to
alcohol 4.42 in 85% yield, now enriched in one diastereomer. The configuration of
this alcohol was established by deprotecting the TBS ether and forming acetal 4.43
between the alcohols at C1 and C3. From the Karplus relation, it could be derived
that the newly formed hydroxyl is in syn position compared to the benzyloxy
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Scheme 4.8: Derivatization and further elaboration of the MAP-product 4.35
group, originating from the chiral pool. Thus, the correct stereochemistry was
installed.
4.2.2 Future perspectives
Important steps in the further elaboration of the C1 –C11 fragment (scheme 4.9)
include methylation of the C3-alcohol of 4.44, and transformation of the resulting
bromide 4.45 to , for instance, methyl ether 4.46. After deprotection of the naph-
toyl ester, the primary alcohol should be oxidized to aldehyde 4.47, which can
then be coupled with the C12 –C20 fragment 4.4 in an aldol coupling, resulting in
4.48. After this, one more stereoselective (reductive) step is needed to complete
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the full carbon skeleton with the correct stereochemistry. Deprotection and oxi-
dation are then key to form the ω-hydroxy acid, necessary for macrolactonization.
Final deprotection would then give the 8,9-dehydroxy analog 4.49 of peloruside.
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Scheme 4.9: Future steps for the completion of the synthesis of the 8,9-dehydroxy
analog of (+)-Peloruside A.
In light of the difficulties encountered with the installation of the correct stere-
ochemistry in 4.44, using the Mukaiyama aldol-Prins approach, an alternative
approach might be more successful. As described in scheme 4.10, the tetrahydropy-
ranyl group in 4.50 could be constructed from reaction of homoallylic alcohol 4.51
with aldehyde 4.52 in a classic Prins reaction.203 The aldehyde itself can be con-
structed from D-(-)-tartaric acid (4.53), a chiral compound which already posseses
the desired stereochemistry. This synthesis is described in literature.204,205
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Scheme 4.10: Alternative build-up for the tetrahydropyranyl ring.
4.3 Phenyl analogs
4.3.1 Improved synthesis of pelofen B via macrolactoniza-
tion
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MeOH, pH 7 buffer, H2O2, RT; d) EtCHO, SmI2, THF, -20°C; e) Me3OBF4, 1,8-bis(dimethylamino)naphtalene, 
CH2Cl2, RT; f) Me3SnSnMe3, Pd(PPh3)4, PPh3, PhMe, 70°C
a b OMPM
OMEM
O
88%
d.r.>95:5
c
OMEM
OMPM O
Br
OH
98%
d.r.>95:5
d
OMEM
OMPM OH
Br
O O
86%
e,f
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OMPM OMe
SnMe3
O O
4.54 4.55 4.56 4.4
4.57 4.58
4.59
Scheme 4.11: Synthesis of the C5 –C20 fragment 4.59 for the synthesis of pelofen
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An improved synthesis was developed for pelofen B (4.3), starting from the com-
mercially available 3-bromophenyl acetonitrile 4.54, which was first alkylated to
4.55 (scheme 4.11). This was reduced to the imine, which, after acid hydrolysis,
afforded aldehyde 4.56, in 89% yield over 2 steps. This was coupled with the
earlier synthesized C12 –C20 methyl ketone 4.4 in a stereoselective aldol coupling
making use of chlorodicyclohexylborane, delivering β-hydroxyketone 4.57 in 88%
yield, as a single diastereomer.
At this stage, the stereochemistry was assigned by the synthesis of the cor-
responding Mosher esters. Next, Evans-Tishchenko reduction using propionalde-
hyde and diiodosamarium resulted in the differentiated anti -1,3-monoester 4.58.
At this stage, the relative stereochemistry between the alcohol generated in the
aldol addition (C11) and the alcohol generated in the Evans-Tishchenko reduction
(C13) was established by the synthesis of acetonide 4.60 (figure 4.2), followed by
NMR-analysis.
Also, the relative stereochemistry between the MPM protected alcohol (C15)
and the alcohol originating from the reduction (C13) was established by synthesis
of the corresponding PMP acetal 4.61 (figure 4.2) and NMR analysis. After
methylation of the newly formed alcohol in 4.58, the bromide was converted to
trimethyltin-derivative 4.59 in a Pd(0)-catalyzed Stille coupling.
OMEM
O O
Br
O O
OMEM
OMPM O
Br
O
PMP
H H
H
4.60 4.61
Figure 4.2
Completion of the carbon skeleton of the phenyl analog 4.3 was achieved by
coupling of the advanced stannane 4.59 with commercially available methyl 4-
bromocrotonate in a second Stille coupling (scheme 4.12). Dihydroxylation of the
resulting double bond was achieved using Sharpless’s AD mix β, a combination of a
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catalytic amount of K2OsO4 · 2 H2O, a chiral ligand (bis(dihydroquinidine)phtalazine,
(DHQD)2PHAL) , a base (K2CO3) and a co-oxidant. This afforded diol 4.62 in
88% with a d.e. of 97%. Both alcohols were protected as MOM ethers in 97%
yield. The MPM ether was deprotected with DDQ (95% yield), after which both
esters were hydrolyzed under basic conditions. LiOH gave the cleanest reaction,
but complete conversion took quite long (multiple days). In the end, the ω-hydroxy
acid necessary for macrolactonization 4.63 was obtained in 83% after 7 days.
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OMPM OMe
SnMe3
O O
OMEM
OMPM OMe
MeO
O
a
92%
OMEM
OMPM OMe
MeO
O OMOM
OMOM
b
88%
97% d.e.
76%
c-e
g
O
O
Et
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O
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O
O
O
OHHO
OH
OHH
O
O
O
OHMEMO
OMOM
OMOMH
77%
a) (E)-4-Br-CH2CHCHCOOMe, Pd2dba3.CHCl3, THF, 70°C; b) AD-mix β, MeSO2NH2, NaHCO3, tBuOH:H2O 
1:1, RT; c) MOM-Cl, DIPEA, CH2Cl2, reflux; d) DDQ, pH7 buffer, CH2Cl2, RT; e) LiOH.H2O, THF:H2O 3:1, 
RT; f) i) 2,4,6-trichlorobenzoylchloride, DIPEA, THF, RT; ii) DMAP, PhMe, RT; g) 4M HCl, THF:H2O 1:1, RT
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OH OMe
HO
O OMOM
OMOM
36%
f
OH
4.59 4.64
4.62 4.63
4.65 4.3
Scheme 4.12: Completion of the synthesis of pelofen 4.3
To circumvent these longer reaction times, another approach was implemented,
where both esters were reduced using LiALH4, with the MPM ether still intact
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(scheme 4.13). The resulting primary alcohol 4.66 was then selectively oxidized to
the carboxylic acid in two steps. Finally, the MPM ether was successfully cleaved
in the presence of the carboxylic acid, affording 4.63 with a combined yield of 80%
over four steps.
Different attempts on the macrolactonization were made, but the original yield
of 36%, achieved using Yamaguchi conditions could not be improved. Both varying
the conditions using 2,4,6-trichlorobenzoylchloride or trying a number of different
activating agents were insufficient in improving the yield. The final deprotection
under acidic conditions, resulted in the desired phenyl analog 4.3 in 77% yield.
Overall, the synthesis was completed in a longest linear sequence of 20 steps,
starting from ethylmagnesium chloride, the total number of steps being 22, result-
ing in an overall yield of 2.7%. This represents an improvement of the original
route by 1 step in longest linear sequence, 4 steps in the total number of steps and
an improved yield by almost 400% (0.7% overall yield in the original route).
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OMPM OMe
MeO
O OMOM
OMOM
O
O
Et
OMEM
OMPM OMe
OH OMOM
OMOM
OH
OMEM
OH OMe
O OMOM
OMOM
OH
a b,c,d
a) LiAlH4, Et2O, 0°C; b) TEMPO, PhI(OAc)2, CH2Cl2,RT; c) NaH2PO4, NaClO2, 2-Me-2-butene, tBuOH:H2O 
1:1, RT; d) DDQ, pH 7 buffer, CH2Cl2, RT
89% 90%
3 steps
HO
4.67 4.66
4.63
Scheme 4.13: Alternative synthesis of the seco acid 4.63.
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4.3.2 Synthesis of 2,3-dideoxy pelofen (3.74)
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OMPM OMe
SnMe3
O O a
100%
OMEM
OMPM OMe
SnMe3
OH b
100%
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OMPM OMe OH c
96%
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OMPM OMe OH d-f
84%
3steps
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O
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96%
a) LiAlH4, Et2O, 0°C; b) (E)-4-Br-CH2CHCHCOOMe, Pd2dba3.CHCl3, THF, 70°C; c) NiCl2.6H2O, 
NaBH4, MeOH, 0°C; d) DDQ, pH7 buffer, CH2Cl2, RT; e) LiOH.H2O THF:H2O 1:1 RT; f) i) 2,4,6-
trichlorobenzoylchloride, DIPEA, PhMe, RT; ii) DMAP, PhMe, RT; g) n-BuSH, ZnBr2, CH2Cl2, RT
4.59 4.68
4.69 4.70
4.71 4.72
Scheme 4.14: Synthesis of the 2,3-dideoxy analog of pelofen (4.72).
An analog of pelofen B, lacking the C2 and C3 substituents, could give insight
in the importance of these hydroxyl groups for the activity. This analog was easily
accessible through the previously developed route (scheme 4.14).
Starting from stannane 4.59 we anticipated the difficult deprotection of the
propionate ester, so it was reduced first. The resulting alcohol 4.68 could be used
without protecting group in the following steps. Stille coupling with the earlier
used methyl 4-bromocrotonate resulted in unsaturated ester 4.69. The double
bond of this conjugated ester was reduced with NaBH4 under nickel catalysis,
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without affecting the double bond present in the side chain, delivering ester 4.70
in 96% yield over three steps. The seco-acid necessary for macrolactonization was
generated by deprotection of the MPM-ether and consecutive basic hydrolysis of
the methyl ester. The macrolactonization, applying Yamaguchi conditions, this
time delivered the macrolactone 4.71 in a high yield (84% over three steps). The
final deprotection using a Lewis acid in combination with a thiol as a scavenger,
proceeded extremely well, affording the 2,3-dideoxy analog of pelofen 4.72 in 96%
yield.
Overall, the synthesis of this analog was accomplished in 20 steps, starting
from ethylmagnesium chloride, with a total number of 22 steps and a total yield
of 12%. So far, no statistically significant results for the activity of this analog are
available.
4.3.3 New route to pelofen B and analogs at the C2–C3-
position
OMEM
OH OMe OH
O
O
O
HO
O
HO
4.73 4.74 4.75
Scheme 4.15: Observed isomerization in the saponification of 4.73
As the macrolactonization of the unsubstituted analog proceeded very smoothly,
attempts were made to perform the ring closure while the double bond at C2 –C3
was still present. This approach would have provided rapid access to analogs in
this region, as substituents could be introduced at a very late stage in the syn-
thesis, after macrocyclization and maybe even after final deprotection. Unfortu-
nately, upon saponification of the conjugated methyl ester 4.73, a minor amount
of the envisaged carboxylic acid 4.74 was formed, and isomerization of the double
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bond towards the styrene derivatives (4.75) was observed (scheme 4.15). Direct
Stille coupling of 4-bromocrotonic acid, appeared to be a solution to this problem.
However, the same isomerization occurred under the basic conditions used for the
macrolactonization. Because of the complexity of the formed reaction mixtures,
this route was abandoned.
4.3.4 Pelofen B via ring-closing metathesis
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OMPM OMe
SnMe3
OH a
95%
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OMPM OMe
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94%
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a) TPAP, NMO, 4Â molecular sieves, CH2Cl2,RT; b) DDQ, pH7 buffer, CH2Cl2, 0°C; c) CH2CHCOCl, DIPEA, 
CH2Cl2, RT, 0°C; d) CH2CHCH2Br, Pd2dba3.CHCl3, 60°C; e) Grubbs II, PhMe, 110°C
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O
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O
OMEMO
H
c
18%
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O
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28% (Z):
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4.77 4.78
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Scheme 4.16: Synthesis of unsaturated macrolactone 4.80 through ring-closing
metathesis
Finally, a last approach to get to pelofen B was tested, based on the ring-closing
metathesis reaction (scheme 4.16), which is, besides the macrolactonization, a
frequently used reaction in the total synthesis of macrocycles.
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It was decided to oxidize the alcohol at the C11 position in 4.68 (scheme 4.16),
before liberating the allylic alcohol, as selective acrylation proved problematic.
This way of ’protecting’ the alcohol at C11 could later on give access to the envis-
aged alcohol as well as the inverted one, and also introduction of other substituents
were thought to be possible. The oxidation was achieved using ruthenium catal-
ysis and delivered ketone 4.76 in 95% yield. Next, the MPM ether was removed,
liberating allylic alcohol 4.77. The optimized conditions for the acryloylation,
employing a 0.1M solution of acryloyl chloride in CH2Cl2 and DIPEA resulted in
acryloyl ester 4.78 in 71%, with still some 10% starting alcohol left. The final
step in the formation of the precursor diene 4.79 was the allylation reaction of the
aromatic ring under Stille conditions, which occurred in neat allyl bromide, with
a yield of 95%, without notable isomerization of the double bond. The metathesis
reaction itself was optimized in terms of monomer versus oligomer formation in
function of dilution, solvent, catalyst, reaction time, and temperature. Employing
Grubbs’ 2 nd generation catalyst at 110◦C in toluene for short reaction times, the
reaction reached an optimal ratio of 70:30, in favor of the monomer. It was ex-
pected that a mixture of the E and Z double bond would be formed. During the
scale up of this reaction, however, it was observed that the 66% isolated ring closed
product was comprised of a mixture of the Z and E isomer 4.80 of the ring-closed
conjugated ester (28% vs. 18%, respectively) as well as of the Z -styrene derivative
(22%).
4.3.5 Future perspectives
During this work, the synthesis of pelofen B itself was optimized for all but one
steps, being the macrolactonization. A parameter that was not investigated during
this macrolactonization is the influence of the temperature. In light of the good
results of the ring closing metathesis at higher temperatures, this could be a viable
option for the further optimization of this reaction.
For the fast introduction of modifications at a later stage in the synthesis
(scheme 4.17), the ring closing metathesis approach seems the better choice. Start-
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Scheme 4.17: Rapid access to pelofen analogs through diversification of 4.83
ing from the unsaturated macrocycle 4.83, different analogs can be accessed in a
simple way (scheme 4.17). At the C2 –C3 position, dihydroxylation of the E -
double bond should result in the syn alcohols, whereas dihydroxylation of the Z -
olefin should result in the anti diols (step A). Reduction of the ketone at C11 will
give both epimeric alcohols, whereas reductive amination would give the epimeric
amines (step B). The primary alcohol at C24 can be easily deprotected under acidic
conditions, so it will be prone to substitution reactions (step C).
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5.1 General info
All reactions were carried out under an argon atmosphere in oven-dried glassware,
and solvents were freshly distilled prior to use, except if otherwise indicated. Di-
ethyl ether and tetrahydrofuran were distilled from sodium/benzophenone, toluene
and benzene from sodium. Dichloromethane, 2,6-lutidine, pyridine and triety-
lamine were distilled from calcium hydride.
Reactions were monitored by thin layer chromatography (TLC) on 0.25mm
Macherey-Nagel SIL G-25 UV254 silica gel plates. Visualization occurred by UV-
light (254 nm) and by staining in a molybdate solution (0.4 g Ce(SO4)2, 10 g
(NH4)6Mo7O24.4H2O, 200 ml H2O and 10 ml conc. H2SO4) or in a permanganate
solution (3 g KMnO4, 20 g K2CO3, 5 ml 5% aqueous NaOH and 300 ml H2O).
Flash chromatography was carried out with silica gel supplied from Davisil (30-200
µm) or Rocc (40-63 µm) for more difficult separations using solvents of technical
quality. All other reagents were purchased from Aldrich, Acros or TCI and used
without purification, unless noted otherwise.
1H NMR- and 13C NMR-spectra were recorded on a Bruker Avance 300 or a
Bruker AM 500 spectrometer as indicated, with chemical shifts (δ) reported in
ppm relative to the residual solvent signal of the deuterated solvent. Multiplicities
are reported as singlet (s), doublet (d), triplet (t) and quartet (q) or combina-
tions thereof, while coupling constants (J) are reported in Hz. When necessary,
multiplets were analyzed using Gaussian fitting parameters, instead of the stan-
dard exponential parameters. 13C NMR-spectra were recorded using the attached
proton test (APT).
IR-spectra were recorded on a Perkin-Elmer SPECTRUM 1000 FT-IR spec-
trometer with a Pike Miracle HATR module unless otherwise indicated. Optical
rotation was recorded with a Perkin-Elmer 241 polarimeter at 589 nm and/or 365
nm. Melting points were recorded with an Electrothermal IA 9100 series.
EI-MS were recorded on a Hewlett-Packard 5989A mass spectrometer or a
Hewlett-Packard G1800B GCD system. LCMS and MS analysis were performed
on an Agilent 1100 series HPLC system with a diode array detector and single quad
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MS detector (G1946C) with an electrospray ionization source (ESI-MS), using a
Phenomenex Luna C18(2) column (250 x 4.6 mm; 5 µm) or Phenomenex Kinetex
C18 column (150 x 4.6 mm; 5 µm). HRMS spectra were recorded with an Agilent
6220A time-of-flight MS detector with a multimode ionization source. Analytical
chiral LC separation was performed with an Agilent 1100 series HPLC system
with a diode array detector, using a Chiralcel (OD-H, OJ-H, OB-H) or Chiralpak
(AD-H, AS-H, IA) column.
5.2 Synthesis of the C12 –C20 fragment 2.2
5.2.1 Synthesis of MEM-protected homoallylic alcohol 2.9
O
MgCl
OMEM
THF, RT, 40h
40%
OH
MEMCl, DIPEA, 
CH2Cl2, 40°C, 17h
2.6 2.7
2.8 2.9
2.16
To a solution of 2,5-dihydrofuran (2.6) (3.92 ml, 51.8 mmol, 1.33 eq.) in THF
(16 ml) at 0◦C was added ethylmagnesium chloride (2.7) (19.5 ml of 2.0M solution
in THF, 38.9 mmol, 1 eq.) dropwise. The mixture was warmed to RT and stirred
for an additional 15 min. The contents of an unopened flask of (S,S )-ethylene-
1,2-bis(η5-4,5,6,7-tetrahydro-1-indenyl)zirconium (R)-1,1’-bi-2-naphtholate (2.16,
133 mg, 0.156 mmol, 0.5 mol%) were added entirely and the reaction flask was
shielded from light. After stirring for 40h, the reaction was quenched by pouring
in a saturated aqueous solution of NH4Cl (100 ml), extracted with Et2O (3 x 100
ml). The combined organic fractions were dried over MgSO4 and concentrated
through atmospheric destillation (vigreux). The crude product (2.8) was dissolved
in CH2Cl2 (11.7 ml) and DIPEA (8.14 ml, 64.7 mmol, 1.2 eq.) was added. Upon
dropwise addition of MEM-Cl (4.45 ml, 38.9 mmol, 1 eq.) formation of a white
fume was observed. The solution was refluxed for 17 h and afterwards poured in a
saturated aqueous solution of NaHCO3 (20 ml). The phases were separated and the
aqueous phase was extracted with CH2Cl2 (3 x 20 ml). After drying over MgSO4
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the solvent was removed by careful evaporation in vacuo. Flash chromatography
(CH2Cl2/Et2O 98/2) provided 2.9 (2.94 g, 40% yield) as a pale yellow, clear oil.
Name: (R)-3-(((2’-methoxyethoxy)methoxy)methyl) pent-1-ene
Formula: C10H20O3
Molecular weight: 188.3 g/mol
Rf: 0.38 (pentane/ Et2O 7/3)
[α]D = -15.9 (c = 0.97 in CHCl3)
[α]365 = -52.2 (c = 0.97 in CHCl3)
1H-NMR (300 MHz; C6D6): δ (ppm) = 5.71-5.59 (1H, m), 5.08-5.02 (2H, m (app.
d)), 4.59 (2H, s), 3.62-3.59 (2H, m (app. t)), 3.49-3.37 (2H, m), 3.34 (2H,
t, J = 4.7 Hz), 3.12 (3H, s), 2.24-2.13 (1H, m), 1.62-1.48 (1H, m), 1.34-1.19
(1H, m), 0.87 (3H, app. t, J = 7.4 Hz)
APT (75 MHz; C6D6): δ (ppm) = 140,88 (CH); 115,91 (CH2); 96,11 (CH2); 72,52
(CH2); 71,50 (CH2); 67,50 (CH2); 59,20 (CH3); 46,15 (CH); 24,69 (CH2);
11,94 (CH3)
IR (HATR): 3733 (w), 3080 (w), 2960, 2926, 2875, 2815, 2355, 2337, 2210 (w),
2057 (w), 1640, 1457, 1420, 1380, 1365, 1284, 1242, 1200, 1178, 1157, 1113,
1098, 1047 (s), 1023, 994, 950, 913, 849, 768, 678 cm-1
EI-MS (m/z; (%)): 119 (2), 113 (6), 105 (1), 95 (3), 90 (5), 89 (100), 84 (2), 83
(8), 82 (15), 77 (1), 73 (2), 71 (3), 69 (3), 68 (1), 67 (4), 60 (3), 59 (59), 57
(2), 56 (1), 55 (15), 54 (2), 53 (2), 45 (6), 44 (3), 43 (4), 42 (1), 41 (8)
5.2.2 Synthesis of aldehyde 2.10
OMEM
O
OMEM
i) O3, CH2Cl2, -78°C
ii) PPh3
2.9 2.10
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Through a solution of 2.9 (7.53 g, 40 mmol, 1 eq.) in CH2Cl2 (40 ml) at -78
◦C
was bubbled ozone until the reaction mixture colored blue. After an additional 20
min of bubbling ozone, the excess O3 was removed by bubbling Ar through the
solution until the blue color disappeared. A solution of PPh3 (12.59 g, 48 mmol,
1.2 eq.) in CH2Cl2 (8 ml) was added via a double-ended needle and the flask was
rinsed with CH2Cl2 (4 ml) after which the temperature was raised slowly to RT and
concentrated carefully in vacuo. Purification by means of flash chromatography
(pentane/Et2O 6/4) provided pure 2.10 (7.16 g), which was not completely dried
due to its volatility, and used as such in the next reaction.
Name: (S )-2-(2’-methoxyethoxymethyl)-butanal
Formula: C9H18O4
Molecular weight: 190.2 g/mol
Rf: 0.16 (pentane/ Et2O 6/4)
5.2.3 Synthesis of phosphonate 2.25
O
P
O
O
O
OMeCl
P
O
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CF3CH2OH, NEt3, 
THF, RT
i) BuLi, HMDS, THF, -78°C;
 ii) Cl(CO)OMe
89% 50%
CF3
F3C
O
P
O
O
CF3
F3C
2.23 2.24 2.25
Synthesis of phosphonate ester 2.24
To a solution of CF3CH2CH2OH (29.3 ml, 408 mmol, 2 eq.) in THF (610 ml)
at 0◦C, was added NEt3 (62.6 ml, 449 mmol, 2.2 eq.), followed by a solution of
ethylphosphonic dichloride (2.23) (21.8 ml, 204 mmol, 1 eq.) in THF (80 ml) with
formation of white fume and white precipitate. The addition funnel was rinsed
with THF (22 ml) and the reaction mixture was warmed to RT and stirred for
2h. The slightly brown solution with white precipitate was filtered over celite and
rinsed with dry THF. The solvent was removed through atmospheric destillation
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(vigreux). Purification by destillation in vacuo provided 2.24 (47.33 g, 84% yield,
bp 84◦C at 16mm Hg) as a colorless, clear oil.
Name: Ethylphosphonic acid bis-(2’,2’,2’-trifluoroethyl) ester
Formula: C6H9F6O3P
Molecular weight: 274.1 g/mol
Rf: 0.23 ((hexane/ acetone 8/2))
ESI-MS (m/z): 275.0 (M + H+)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 4.47-4.26 (4H, m), 1.98-1.84 (2H, m),
1.20 (3H, dt, J = 21.6 Hz (31P-1H), 7.7 Hz)
APT (75 MHz;C6D6): δ (ppm) = 122,77 (C, dq, J = 275.8 Hz (
19F-13C), 7.6 Hz
(31P-13C)), 62.03 (CH2, dq, J = 37.6 Hz (
19F-13C), 6.1 Hz (31P-13C)), 19.11
(CH2, d, J = 142.6 Hz (
31P-13C)), 6.02 (CH3, d, J = 7.1 Hz (
31P-13C))
IR (HATR): 1418 (w), 1284, 1252, 1231, 1162 (s), 1106, 1073 (s), 1035, 1015, 961,
841, 731 cm-1
Synthesis of phosphonate 2.25
To n-BuLi (200 ml, 1.6M in hexane, 2.1 eq.) at -20◦C was added dropwise a
solution of HMDS (76.7 ml, 350 mmol, 2.3 eq.) in THF (175 ml). The addition
funnel was rinsed with THF (52 ml) and the reaction mixture was stirred for 15’
at -20◦C. Afterwards, the reaction mixture was further cooled to -78◦C, and a
solution of 2.24 (41.8 g, 152 mmol, 1eq.) and methyl chloroformate (12.4 ml, 160
mmol, 1.05 eq.) in THF (500 ml) was added dropwise and the addition funnel
rinsed with THF (33 ml). The mixture was warmed to 0◦C over 45’ and diluted
aqueous HCl was added, until acidic (control by pH indicator). After separating
the organic phase, the aqueous phase was extracted with CH2Cl2 (3 x 250 ml) and
the combined organic phases were dried over MgSO4 and evaporated in vacuo.
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Purification by in vacuo destillation provided 2.25 (9.09 g, 50% yield, bp 125◦C
at 16mm Hg) as a colorless, clear oil that solidified on refrigeration.
Name: methyl 2-(bis(2’,2’,2’-trifluoroethoxy)phosphoryl)propanoate
Formula: C8H11F6O5P
Molecular weight: 332.1 g/mol
Rf: 0.31 (hexaan/ethylacetaat 6/4)
ESI-MS (m/z): 333.0 (M + H+)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 4.50-4.36 (4H, m), 3.78 (3H, s), 3.28-
3.13 (1H, m), 1.52 (3H, dd, J = 22.2 Hz (31P-1H), 7.4 Hz)
APT (75 MHz;C6D6): δ (ppm) = 169.07 (C, d, J = 3.0 Hz (
31P-13C)), 122.60
(C, dq, J = 274.5 Hz (19F-13C), 8.0 Hz (31P-13C)), 62.77 (CH2, dq, J = 37.8
Hz (19F-13C), 5.9 Hz (31P-13C)), 53.14 (CH3), 39.50 (CH, d, J = 140.3 Hz
(31P-13C)), 11,73 (CH3, d, J = 6.6 Hz (
31P-13C))
IR (HATR): 1740, 1458 (w), 1438 (w), 1420 (w), 1289, 1259, 1162 (s), 1068 (s),
960, 867, 840 cm-1
5.2.4 Synthesis of ester 2.11
OMEMOMEM
O
O
O
18-crown-6, KHMDS,
THF, -78°C
77%
2 steps
2.10 2.11
2.25
To a solution of 2.25 (15.01 g, 45 mmol, 1.2 eq.), and 18-crown-6 ether (59.72
g, 226 mmol, 6 eq.), in THF (843 ml) at -78◦C was added KHMDS (90 ml, 0.5M
in toluene, 1.2 eq.) dropwise. After stirring for 20 min at that temperature, a
cooled solution of 2.10 (7.16 g) in THF (57 ml) was added. After stirring for
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1.5 h, the reaction mixture was poured in a saturated aqueous NH4Cl solution
(700 ml). After separating the organic phase, the water phase was extracted with
EtOAc (3 x 700 ml) and the combined organic phases were dried over MgSO4.
After evaporation in vacuo the mixture was filtered (P4). Purification by flash
chromatography (pentane/Et2O 6/4) provided 2.11 (8.09 g, 77% yield over 2 steps)
as a pale yellow, clear oil.
Name: (2Z, 4R)-Methyl 4-(2’-methoxyethoxymethoxymethyl)-2-methylhex-2-eno-
ate
Formula: C13H24O5
Molecular weight: 260.3 g/mol
Rf: 0.30 (pentane/ Et2O 6/4)
[α]D = -32.7 (c = 1.25 in CHCl3)
[α]365 = -1.51 (c = 1.25 in CHCl3)
1H-NMR (300 MHz; C6D6): δ (ppm) = 5.71 (1H, d, J = 9.8 Hz); 4.60 (2H, s);
3.64-3.58 (3H, m), 3.51 (2H, d, J = 5.6 Hz), 3.37-3.34 (5H, m), 3.13 (3H, s),
1.89 (3H, s), 1.71-1.57 (1H, m), 1.40-1.26 (1H, m), 0;92 (3H, app. t, J = 7.4
Hz)
APT (75 MHz; C6D6): δ (ppm) = 167.74 (C), 144.91 (CH), 128.46 (C), 95.54
(CH2), 72.07 (CH2), 70.78 (CH2), 67.06 (CH2), 58.50 (CH3), 50.67 (CH3),
40.86 (CH), 25.11 ((CH2), 20.95 (CH3), 11.70 (CH3)
IR (HATR): 2953, 2929, 2874, 1716 (m), 1647 (w), 1455, 1435, 1366 (w), 1260,
1219 (m), 1192, 1176, 1156, 1132, 1113, 1093 (s), 1045 (s), 1020, 989, 946
(w), 934 (w), 890 (w), 847, 826 (w), 770 cm-1
EI-MS (m/z; (%)): 149 (6), 95 (8), 90 (5), 89 (66), 88 (4), 86 (18), 85 (5), 84
(30), 67 (6), 59 (78), 55 (7), 53 (4), 51 (17), 49 (55), 48 (6), 47 (14), 46 (39),
45 (100), 44 (9), 43 (24), 42 (11), 41 (18)
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5.2.5 Synthesis of allylic alcohol 2.12
OMEMOMEM
DIBAL-H, 
CH2Cl2, -78°C
100%
O
O
OH
2.11 2.12
To a solution of 2.11 (8.09 g, 31.09 mmol, 1 eq.) in CH2Cl2 (311 ml) at -
78◦C was added DIBAL-H (77.7 ml, 1.0M in hexane, 2.5 eq.)) dropwise. After
stirring for 1 h at -78◦C, a saturated solution of Rochelle’s salt in water (414
ml) was added and the reaction mixture was warmed to RT. After stirring for
3h at RT, the mixture was transferred to a separation funnel, the organic phase
was separated and the aqueous phase was extracted with EtOAc (3 x 414 ml).
The combined organic phases were dried over MgSO4 and evaporated in vacuo.
Purification by flash column chromatography (CH2Cl2/ acetone 85/15) provided
2.12 (7.20 g, 100% yield) as a pale yellow, clear oil.
Name: ((2Z,4R)-4-(2’-Methoxyethoxymethoxymethyl)-2-methylhex-2-en-1-ol
Formula: C12H24O4
Molecular weight: 232.3 g/mol
Rf: 0.24 (CH2Cl2/ acetone 85/15)
[α]D = +11.4 (c = 1,25 in CHCl3)
[α]365 = +49.7 (c = 1,25 in CHCl3)
ESI-MS (m/z): 255.1 (M + Na+)
1H-NMR (300 MHz; C6D6): δ (ppm) = 4.94 (1H, d, J = 9.9 Hz), 4.49 (2H,
s), 4.26 (1H, d, J = 11.6 Hz), 3.87-3.81 (1H, m), 3.54 (2H, t, J = 5.4 Hz),
3.38-3.29 (3H, m), 3.17 (1H, t, J = 9.0 Hz), 3.11 (3H, s), 2.58-2.46 (1H, m),
2.27 (1H, d, J = 5.4 Hz), 1.83 (3H, s), 1.37-1.24 (1H, m), 1.12-0.97 (1H, m),
0.78 (3H, app. t, J = 7.32 Hz)
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APT (75 MHz; C6D6): δ (ppm) = 138.47 (Cq), 130.24 (CH), 95.57 (CH2), 72.17
(CH2), 71.33 (CH2), 67.33 (CH2), 61.92 (CH2), 58.63 (CH3), 40.26 (CH),
25.25 (CH2), 22.52 (CH3), 11.87 (CH3)
IR (HATR): 3428 (b), 2958, 2923, 2874, 1453, 1412 (w), 1377 (w), 1242 (w), 1199
(w), 1172, 1108 (m), 1043 (s), 1013 (s), 945, 900 (w), 849 cm-1
EI-MS (m/z; (%)): 149 (11), 141 (5), 126 (10), 105 (6), 97 (19), 96 (61), 95 (11),
89 (56), 86 (18), 84 (34), 83 (14), 82 (8), 81 (50), 79 (7), 73 (8), 72 (8), 71
(8), 69 (14), 67 (9), 59 (100), 57 (14); 56 (5); 55 (24); 51 (17); 49 (57); 47
(12); 46 (10); 45 (52); 44 (5); 43 (57); 42 (6); 41 (29)
5.2.6 Synthesis of aldehyde 2.13
OMEMOMEM
Dess-Martin periodinane, 
pyridine, CH2Cl2, RT
95%
OH O
2.12 2.13
To a solution of 2.12 (4.50 g, 19.4 mmol, 1 eq.) in CH2Cl2 (193 ml) at 0
◦C
was added pyridine (7.8 ml, 96.9 mmol, 5 eq.) and fresh Dess-Martin periodinane
(12.3 g, 29.1 mmol, 1.5 eq.). The reaction mixture was warmed to RT and stirred
for 1h before adding a premixed solution of saturated aqueous Na2S2O3 (200 ml)
and NaHCO3 (200 ml). After 15’ of stirring, the mixture was transferred to a
separation funnel, the organic phase was separated and the remaining aqueous
phase was extracted with EtOAc (3 x 400 ml), dried over MgSO4 and carefully
evaporated in vacuo. Purification by means of flash chromatography (CH2Cl2/
acetone 92/8) provided 2.13 (4.24 g, 95%) as a yellow, clear oil.
Name: ((2Z,4R)-4-(2’-Methoxyethoxymethoxymethyl)-2-methylhex-2-enal
Formula: C12H22O4
Molecular weight: 230.3 g/mol
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Rf: 0.47 (CH2Cl2/ acetone 93/7)
5.2.7 Synthesis of homoallylic alcohol 2.14
Synthesis of (-)-diisopinocampheylmethoxyborane (2.27)
BOMe2
i) BH3.SMe2, THF, RT
ii) MeOH, Et2O, 0°C
89%
2.26 2.27
To a stirring solution of (+)-α-pinene (2.26), freshly distilled over CaH2, (17.7
ml, 112 mmol, 2.5 eq.) in THF (13.4 ml) was added BH3 · SMe2 (4.2 ml, 45 mmol,
1 eq.) over 30’ at a constant temperature of 23◦C. After the addition, the stirring
was stopped and the solution was left untouched overnight, during which white
crystals were formed. The solution was then cooled to 0◦C for 2h, after which the
supernatans was removed using a double-ended needle. The white chrystals were
washed with pre-cooled, dry Et2O (3 x 8 ml) at 0
◦C, and dried, first by blowing Ar,
then overnight in vacuo, yielding (-)-diisopinocampheylborane (11.4 g, 40 mmol,
89%)
(-)-diiospinocampheylborane (11.4 g, 40 mmol, 1 eq.) was suspended in Et2O
(40 ml) and cooled to 0◦C. MeOH (1.6 ml, 40 mmol, 1 eq.) was then added
dropwise and the solution was stirred at RT until everything was dissolved to form
2.27.
Allylation
OMEMOMEM
i) (-)Ipc2BOMe, allylMgBr, 
Et2O, -78°C
ii) NaOOH, RT
79%
O OH
2.13 2.14
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The solution of (-)-diisopinocampheylmethoxyborane (2.27) (12.6 g, 40 mmol,
2.4 eq) in Et2O (40 ml) was diluted with Et2O (143 ml) and cooled to -78
◦C.
Allylmagnesiumbromide (40 ml, 40 mmol, 1M in Et2O, 2.4 eq.) was added drop-
wise, upon which the reaction mixture became turbid and a black aggregate was
formed. The reaction mixture was first stirred for 15’ at -78◦C, followed by 1h of
stirring at RT, resulting in a white solution. The reaction mixture was then cooled
back to -78◦C, and a solution of the starting material (3.8 g, 17 mmol, 1 eq.) in
Et2O (26 ml) at -78
◦C was added via a double-ended needle. The reaction mixture
was stirred overnight during which the temperature was allowed to rise from-78◦C
to -30◦C. TLC-analysis after 13h (CH2Cl2/acetone 9/1) showed complete conver-
sion of the starting material. The reaction was quenched by adding a solution of
NaOOH in water. This solution was prepared beforehand by adding H2O2 (10.5
ml, 119 mmol, 7.2 eq.) to a solution of NaOH (3.2 g, 80 mmol, 4.8 eq.) in H2O (26
ml) at 0◦C in a separate flask. The NaOOH-solution was transferred to the reac-
tion mixture at 0◦C, after which it was stirred at RT for 4h. The reaction mixture
was then poured in a saturated aqueous NH4Cl solution (100 ml), the phases were
separated and the aqueous phase was extracted with EtOAc (3 x 200 ml). The
combined organic phases were dried over MgSO4 and concentrated. Purification
was accomplished by consecutive flash column chromatography (CH2Cl2/acetone
95/5; Hexane/acetone 8/2; CH2Cl2/acetone 88/12), yielding the target material
(3.6 g, 79%) as a clear, colorless oil.
Name: (5Z,4S,7R)-7-(((2’-methoxyethoxy)methoxy)methyl)-5-methylnona-1,5-di-
ene-4-ol
Formula: C15H28O4
Molecular weight: 272.4 g/mol
Rf: 0.15 (CH2Cl2/ acetone 9/1)
[α]D: -6.6 (c = 0.84 in CHCl3)
ESI-MS (m/z): 255.2 (M - H2O + H
+); 295.2 (M + Na+)
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HR-MS: calculated for (M+NH4
+) 290.2326, found 290.2323 (∆ 1.0 ppm)
1H-NMR (300 MHz; C6D6): δ (ppm) = 5.91 (app. dt, J = 17.2, 10.3, 6.9 Hz,
1H), 5.10 (app. ddt, J = 17.2, 3.6, 1.8 Hz, 1H), 5.03 (app. ddt, J = 10.2,
2.3, 1.1 Hz, 1H), 4.94 (app. dd, J = 9.9, 1.8 Hz, 1H), 4.64 (app. t, J = 7.2
Hz, 1H), 4.48 (app. s, 2H), 3.59-3.46 (m, 2H), 3.36 (dd, J = 9.1, 4.9 Hz, 1H),
3.33-3.26 (m, 2H), 3.14 (dd, J = 17.9, 9.0 Hz, 1H), 3.11 (s, 3H), 2.65-2.50
(m, 1H), 2.39-2.28 (m, 1H), 1.89 (d, J = 1.5 Hz, 3H), 1.36-1.21 (m, 1H),
1.14-0.97 (m, 1H), 0.78 (app. t, J = 7.3 Hz, 3H)
APT (75 MHz; C6D6): δ (ppm) = 140.46 (C), 136.31 (CH), 131,13 (CH), 116.87
(CH2), 95.86 (CH2), 72.55 (CH2), 71.76 (CH2), 69.25 (CH), 67.62 (CH2),
58.97 (CH3), 39.84 (CH), 39.37 (CH2), 25.60 (CH2), 18.60 (CH3), 12.29
(CH3)
IR (HATR): 3435 (b), 2929, 2876, 2186 (w), 2009 (w), 1982 (w), 1451, 1408, 1376,
1292, 1242, 1199, 1174, 1111 (m), 1095, 1044 (s), 1019 (s), 989 (m), 938, 911,
852 cm-1
EI-MS (m/z; (%)): 155 (8), 149 (9), 127 (3), 126 (9), 125 (96), 121 (4), 111 (3),
109 (9), 108 (7), 107 (25), 105 (5), 97 (14), 96 (3), 95 (11), 94 (3), 93 (11),
91 (5), 90 (3), 89 (51), 86 (4), 84 (8), 83 (15), 81 (14), 80 (3), 79 (13), 77
(5), 71 (8), 69 (19), 67 (9), 65 (3), 60 (3), 59 (100), 57 (13), 56 (4), 55 (31),
53 (7), 51 (5), 49 (11), 46 (4), 45 (29), 44 (6), 43 (51), 42 (5), 41 (45)
5.2.8 Synthesis of (R)-MTPA ester 2.30
OH O
O
CF3
Ph OMe
(S)-MTPA-Cl, Et3N, 
DMAP, CH2Cl2, RT
OMEM OMEM
90%
2.14 2.30
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To a solution of 2.14 (50 mg, 0.18 mmol, 1 eq.) and 4-(N,N -dimethylamino)py-
ridine (DMAP) (2 mg, 0.02 mmol, 0.1 eq.) in pyridine (370 µl) was added (S )-
(-)-α-methoxy-α-trifluoromethylphenylacetylchloride ((S )-MTPA-Cl) (52 µl; 0.28
mmol, 1.5 eq.) at RT. After 22h of stirring at RT, TLC-analysis (CH2Cl2/acetone
9/1)indicated complete consumption of the starting material, and the reaction
mixture was poured in H2O (10 ml) and extracted with CH2Cl2 (4 x 10 ml). The
organic phases were combined, dried over MgSO4 and concentrated in vacuo. Flash
column chromatography (pentane/ EtOAc 8/2) delivered 2.30 (81 mg, 90%) as a
clear oil.
Name: (4S,5Z,7R)-7-(((2’-methoxyethoxy)methoxy)methyl)-5-methylnona-1,5-di-
en-4-yl (R)-3”,3”,3”-trifluoro-2”-methoxy-2”-phenylpropanoate
Formula: C25H35F3O6
Molecular weight: 488.5 g/mol
Rf: 0.76 (CH2Cl2/acetone 9/1)
1H-NMR (300 MHz; C6D6): δ (ppm) = 7.74 (2H, d, J = 7.7 Hz), 7.14-7.04 (3H,
m), 6.05 (1H, dd, J = 8.4, 5.9 Hz), 5.65-5.51 (1H, m), 5.12 (1H, dd, J = 10.3,
1.0 Hz), 5.01-4.93 (2H, m), 4.67 (2H, dd , J = 7.3, 6.7 Hz), 3.75-3.64 (2H,
m), 6.63-3.48 (5H, m), 3.42 (2H, app. t, J = 5.2 Hz), 3.15 (3H, s), 2.89-2.77
(1H, m), 2.49-2.39 (1H, m), 2.22-2.14 (1H, m), 1.72-1.58 (1H, m), 1.46 (3H,
d, J = 1.3 Hz), 1.27-1.13 (1H, m), 0.80 (3H, app. t, J = 7.5 Hz)
APT (75 MHz; C6D6): δ (ppm) = 166.05 (C), 133.91 (CH), 133.67 (CH), 133.13
(C), 129.99 (3 x CH), 128.98 (C); 128.22 (2 x CH), 126.60 (C), 122.78 (C),
118.55 (CH2), 96.23 (CH2), 74.90 (CH), 72.61 (CH2), 71.52 (CH2), 67.61
(CH2), 59.00 (CH3), 55.97 (CH3), 40.43 (CH), 37.65 (CH2), 25.71 (CH2),
18.14 (CH3), 12.40 (CH3)
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5.2.9 Synthesis of (S)-MTPA ester 2.31
OH O
O
CF3
MeO Ph
(R)-MTPA-Cl, Et3N, 
DMAP, CH2Cl2, RT
OMEM OMEM
92%
2.14 2.31
To a solution of 2.14 (50 mg, 0.18 mmol, 1 eq.) and 4-(N,N -dimethylamino)py-
ridine (DMAP) (2 mg, 0.02 mmol, 0.1 eq) in pyridine (370 µl) was added (R)-
(-)-α-methoxy-α-trifluoromethylphenylacetylchloride ((R)-MTPA-Cl) (52 µl; 0.28
mmol, 1.5 eq.) at RT. After 22h of stirring at RT, TLC-analysis (CH2Cl2/acetone
9/1)indicated complete consumption of the starting material, and the reaction
mixture was poured in H2O (10 ml) and extracted with CH2Cl2 (4 x 10 ml). The
organic phases were combined, dried over MgSO4 and concentrated in vacuo. Flash
column chromatography (pentane/EtOAc 8/2 delivered 2.31 (83 mg, 92%) as a
clear oil.
Name: (4S,5Z,7R)-7-(((2’-methoxyethoxy)methoxy)methyl)-5-methylnona-1,5-di-
en-4-yl (S )-3”,3”,3”-trifluoro-2”-methoxy-2”-phenylpropanoate
Formula: C25H35F3O6
Molecular weight: 488.5 g/mol
Rf: 0.76 (CH2Cl2/acetone 9/1)
1H-NMR (300 MHz; C6D6): δ (ppm) = 7.71 (2H, d, J = 7.6 Hz), 7.13-7.03 (3H,
m), 6.16 (1H, app. t, J = 6.6 Hz), 5.63-5.49 (1H, m), 5.14 (1H, d, J = 10.3
Hz), 4.97-4.89 (2H, m), 4.61 (2H, dd, J = 7.7, 6.7 Hz), 3.65-3.62 (2H, m),
3.48-3.43 (5H, m), 3.41-3.37 (2H, m), 3.13 (3H, s), 2.86-2.74 (1H, m), 2.49-
2.39 (1H, m), 2.21-2.12 (1H, m), 1.64 (3H, d, J = 1.3 Hz), 1.60-1.49 (1H, m),
1.24-1.09 (1H, m), 0.78 (3H, app. t, J = 7.5 Hz)
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APT (75 MHz; C6D6): δ (ppm) = 166,22 (C); 134.14 (CH), 133.72 (C), 133.51
(CH), 133.27 (C), 130.02 (3 x CH), 128.89 (2 x CH), 126.64 (C), 122.83 (C),
118.59 (CH2), 96.12 (CH2), 74.56 (CH), 72.58 (CH2), 71.55 (CH2), 67.56
(CH2), 58.99 (CH3), 55.67 (CH3), 40.41 (CH), 37.63 (CH2), 25.65 (CH2),
18.45 (CH3), 12.37 (CH3)
5.2.10 Synthesis of methoxyphenyl methyl ether 2.15
OMEMOMEM
i) NaH, THF, 0°C
ii) MPMCl, TBAI, DMF RT
99%
OH OMPM
2.14 2.15
To a flask containing NaH (1.05 g, 26 mmol, 2 eq., 60m% dispersion in mineral
oil) was added a solution of 2.14 (3.58 g, 13 mmol, 1 eq.) in THF (40 ml) at 0◦C.
The reaction mixture was stirred for 30’ at RT, after which methoxyphenylmethyl-
chloride (3,6 ml, 26 mmol, 2 eq.) was added dropwise via syringe, followed by a
suspension of tetrabutylammoniumiodide (9.7 g, 26 mmol, 2 eq) in DMF (13 ml).
The reaction was stirred at RT for 5h, after which TLC-analysis (CH2Cl2/acetone
9/1) showed complete conversion of the starting material. The reaction mixture
was then gently poured in a separation funnel containing water (200 ml), and ex-
tracted with Et2O (4 x 200 ml). The combined organic fractions were dried over
MgSO4, and concentrated. The product was purified by flash column chromatog-
raphy (pentane/Et2O 8/2), yielding the desired product 2.15 as a clear yellow oil
(5.10 g, 13 mmol, 99%).
Name: (5Z,4S,7R)-4-((4”-methoxybenzyl)oxy)-7-(((2’-methoxyethoxy)methoxy)-
methyl)-5-methylnona-1,5-diene
Formula: C23H36O5
Molecular weight: 392.5 g/mol
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Rf: 0.31 (pentane/Et2O 6/4)
[α]D: -66.9 (c = 7.6 mg/ml in CHCl3)
ESI-MS (m/z): 410.2 (M + NH4
+)
HR-MS: calculated for (M+?) ?, found ? (∆ ? ppm)
1H-NMR (300 MHz; C6D6): δ (ppm) = 7.39 (app. d, J = 8.6 Hz, 2H), 6.86 (app.
d, J = 8.9 Hz, 2H), 5.96 (dddd, J = 17.1, 10.2, 7.4, 6.8 Hz, 1H), 5.20 (dd, J
= 10.3, 2.0 Hz, 1H), 5.10 (app. ddd, J = 17.1, 3.6, 1.4 Hz, 1H), 5.04 (app.
ddt, J = 10.1, 2.2, 1.1 Hz, 1H), 4.61 (app. s, 2H), 4.60 (d, J = 11.7 Hz, 1H),
3.39 (dd, J = 8.1, 5.8 Hz, 1H), 4.36 (d, J = 11.7 Hz, 1H), 3.64-3.60 (m, 2H),
3.42 (app. dd, J = 6.4, 3.1 Hz, 2H), 3.39-3.34 (m, 2H), 3.32 (s, 3H), 3.12 (s,
3H), 2.71-2.52 (m, 2H), 3.42 (app. dddt, J = 14.1, 7.3, 5.9, 1.3 Hz, 1H), 1.80
(d, J = 1.3 Hz, 3H), 1.61-1.46 (m, 1H), 1.27-1.11 (m, 1H), 0.83 (app. t, J =
7.4 Hz, 3H)
APT (75 MHz; C6D6): δ (ppm) = 160.98 (C), 136.84 (C), 136.34 (CH), 132.35
(CH + C), 129.67 (2 x CH), 116.81 (CH2), 114.42 (2 x CH), 96.12 (CH2),
77.12 (CH), 72.61 (CH2), 72.07 (CH2), 70.18 (CH2), 67.59 (CH2), 59.03
(CH3), 55.12 (CH3), 39.79 (CH), 39.54 (CH2), 25.92 (CH2), 18.47 (CH3),
12.33 (CH3)
IR (HATR): 3008 (w), 2933 (w), 2876 (w), 1613 (w), 1513, 1462 (w), 1455 (w),
1300 (w), 1247, 1214, 1172, 1110, 1095, 1075, 1049 (m), 991 (w), 916 (w),
847 (w), 823 (w), 751 (s), 666 cm-1
5.2.11 Synthesis of methylketone 2.2
OMEMOMEM
PdCl2, Cu(OAc)2, O2
DMF/H2O 10/1, RT
91%
OMPM OMPM O
2.15 2.2
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To a solution of the diene 2.15 (5.10 g, 13 mmol, 1 eq.) in a mixture of DMF
(240 ml) and water (24 ml) was added Cu(OAc)2 (3.94 g, 20 mmol, 1.5 eq.) in
one portion and PdCl2 (582 mg, 3.3 mmol, 0.25 eq.) in different portions. The
reaction mixture was bubbled using O2 and stirred at room temperature until
TLC-analysis showed complete conversion of the starting material. The reaction
mixture was then poured in water (500 ml) and extracted with Et2O (3 x 800
ml). The combined organic phases were dried over MgSO4 and concentrated.
After concentration, the crude product was filtered over a patch of celite, rinsed
with Et2O (200 ml), and transferred to a separation funnel containing water (300
ml) using Et2O (100ml). The phases were separated and the aqueous phase was
extracted with Et2O (2 x 300 ml). Again, the combined organic phases were
dried over MgSO4 and concentrated. Purification via flash column chromatography
(pentane/ Et2O 6/4) delivered methyl ketone 2.2 as a clear yellow oil (4.88 g, 12
mmol, 91%).
Name: (5Z,4S,7R)-4-((4”-methoxybenzyl)oxy)-7-(((2’-methoxyethoxy)methoxy)-
methyl)-5-methylnon-5-en-2-one
Formula: C23H36O6
Molecular weight: 408.5 g/mol
Rf: 0.16 (pentane/Et2O 6/4)
[α]D: -43.8
◦ (c = 8.0 mg/ml in CHCl3)
ESI-MS (m/z): 426.2 (M+NH4
+); 431.2 (M+Na+)
HR-MS: calculated for (M+NH4
+) 426.2850, found 426.2850 (∆ 0 ppm)
1H-NMR (300 MHz; C6D6): δ (ppm) = 7.33 (app. d, J = 8.3 Hz, 2H), 6.82 (app.
d, J = 8.4 Hz, 2H), 5.18 (app. d, J = 10.2 Hz, 1H), 5.01 (dd, J = 9.4, 2.9
Hz, 1H), 4.60 (app. s, 2H), 4.55 (d, J = 11.4 Hz, 1H), 4.38 (d, J = 11.4 Hz,
1H), 3.66-3.58 (m, 2H), 3.48-3.34 (m, 4H), 3.30 (s, 3H), 3.13 (s, 3H), 2.78
(dd, J = 15.4, 9.4 Hz, 1H), 2.78-2.65 (m, 1H), 2.12 (dd, J = 15.4, 3.0 Hz,
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1H), 1.80 (s, 3H), 1.75 (d, J = 1.0 Hz, 3H), 1.59-1.43 (m, 1H), 1.24-1.07 (m,
1H), 0.81 (app. t, J = 7.4 Hz, 3H)
APT (75 MHz; C6D6): δ (ppm) = 205.02 (C), 160.04 (C), 136.12 (C), 132.60
(CH), 131.90 (C), 129.89 (2 x CH), 114.42 (2 x CH), 96.11 (CH2), 73.90 (CH),
72.62 (CH2), 72.02 (CH2), 70.60 (CH2), 67.60 (CH2), 59.03 (CH3), 55.11
(CH3), 48.30 (CH2), 39.98 (CH), 31.17 (CH3), 25.76 (CH2), 18.54 (CH3),
12.27 (CH3)
IR (HATR): 3013 (w), 2957 (w), 2933 (w), 2871 (w), 1714, 1611 (w), 1514, 1462
(w), 1454 (w), 1358 (w), 1300 (w), 1248, 1216, 1173, 1092, 1049, 850 (w),
822 (w), 752 (s), 666 (w) cm-1
5.3 Synthesis of the C1-C3 aldehyde
5.3.1 Synthesis of 1,3-4,6 dibenzylidene mannitol 2.35
30%
PhCHO, DMF, 
H2SO4, RT
OH
OH
OHOH
OH OH O
O
O
O
OH
HO
H
H
2.34 2.35
To a solution of D-mannitol (2.34) (50 g, 275 mmol, 1 eq.) in DMF (150 ml)
was added benzaldehyde (60 ml, 591 mmol, 2.15 eq.). Then, concentrated H2SO4
(10 ml, 183 mmol, 0.66 eq.) was added dropwise and the resulting suspension was
stirred for 3 days at room temperature. After 3 days, the reaction mixture was
poured in a mixture of K2CO3 (15 g) in ice water (1.5 L). Next, petroleum ether
(250 ml) was added and the resulting mixture was stirred until all the ice was
melted. A white precipitate was formed, which was filtered off and washed with
petroleum ether (3 x 100 ml). The resulting white solid was first triturated from
CHCl3, then recrystallised from MeOH to deliver 2.35 as white needles (29.5 g,
82.3 mmol, 30%).
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Name: (4R,5R)-4-[(4’R,5’R)-5’-hydroxy-2’-phenyl-1’,3’-dioxan-4’-yl]-2-phenyl-1,3-
dioxan-5-ol
Formula: C20H22O6
Molecular weight: 358.4 g/mol
Rf: 0.32 (hexane/EtOAc 3/7)
Melting point: 198◦C
[α]D: -8.2 (c = 1.0 mg/ml in acetone)
ESI-MS (m/z): 359.2 (M+H+)
HR-MS: calculated for (M+H+) 359.1489, found 359.1492 (∆ 0.8 ppm)
1H-NMR (500 MHz; aceton–d6): δ (ppm) = 7.52-7.48 (m, 4H), 7.37-7.30 (m,
6H), 5.55 (s, 2H), 4.59 (bd, J = 5.3 Hz, 2H), 4.28-4.24 (m, 2H), 4.12-4.05
(m, 4H), 3.69-3.61 (m, 2H)
APT (125 MHz; aceton–d6): δ (ppm) = 139.65 (2 x C), 129.22 (4 x CH), 128.66
(4 x CH), 127.10 (4 x CH), 101.64 (2 x CH), 79.71 (2 x CH), 72.17 (2 x CH2),
60.36 (2 x CH)
IR (HATR): 3473, 2977, 2863, 2506 (w) 2155, 2021, 1990, 1977, 1447, 1411, 1396,
1377, 1364, 1223, 1101, 1070, 1047 (s), 1026 (s), 1003, 968, 925, 778, 747,
736, 698, 630 cm-1
5.3.2 Synthesis of 2.36
93%
KOH, DMSO, 
BnBr, RT
O
O
O
O
OBn
BnO
H
H
O
O
O
O
OH
HO
H
H
2.35 2.36
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To a suspension of KOH (8.98 g, 160 mmol, 8 eq.) in DMSO (40 ml) were
added 2.35 (7.16 g, 20 mmol, 1 eq.) and benzylbromide (7.14 ml, 60 mmol, 3 eq.)
at room temperature. The reaction mixture was stirred for 4h at RT, after which
TLC-analysis (CH2Cl2/MeOH 96/4; micro-extraction from Et2O:water) indicated
full conversion of the starting material. The reaction mixture was poured in water
(400 ml) and extracted with CH2Cl2 (4 x 400 ml). The combined organic layers
were washed with a saturated aqueous solution of NaCl (400 ml), then dried over
MgSO4, and concentrated. Flash column chromatography (pentane/Et2O 8/2)
and recrystallisation from CHCl3:hexane 6:1 delivered 2.36 as white crystals (10.0
g, 18.6 mmol, 93%).
Name: (4R,5R)-4-[(4’R,5’R)-5’-hydroxymethylphenyl-2’-phenyl-1’,3’-dioxan-4’-yl]-
2-phenyl-5-hydroxymethylphenyl-1,3-dioxan
Formula: C34H34O6
Molecular weight: 538.6 g/mol
Rf: 0.18 (pentane/Et2O 8/2)
Melting point: 110◦C
ESI-MS (m/z): 539.2 (M+H+)
HR-MS: calculated for (M+H+) 539.2428, found 539.2432 (∆ 0.7 ppm)
1H-NMR (500 MHz; aceton–d6): δ (ppm) = 7.46-7.23 (m, 20H), 5.56 (s, 2H),
4.70 (d, J = 11.9, 2H, A part of AB-spinsystem), 4.67 (d, J = 12.0, 2H, B
part of AB-spinsystem), 4.42 (dd, J = 10.6, 5.2 Hz, 2H), 4.14 (dd, J = 10.5,
1.4 Hz, 2H), 3.95 (app. tdd, 10.3, 5.2, 1.3 Hz, 2H), 3.69 (app. t, J = 10.4
Hz, 2H)
APT (125 MHz; aceton–d6): δ (ppm) = 139.48 (2 x C), 139.28 (2 x C), 129.35
(2 x CH), 129.17 (4 x CH), 128.97 (2 x CH), 128.80 (2 x CH), 128.72 (2 x
CH), 128.57 (2 x CH), 128.41 (2 x CH), 127.13 (4 x CH), 101.63 (2 x CH),
78.23 (2 x CH), 72.84 (2 x CH2), 70.03 (2 x CH2), 67.55 (2 x CH)
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IR (HATR): 2868, 2852, 2171, 2026, 1977, 1456, 1372, 1220, 1091 (s), 1024 (s),
1012 (s), 964, 743 (s), 696 (s) cm-1
5.3.3 Synthesis of tetrol 2.37
73%
HCl, MeOH: 
hexane 5:3, RT
HO
HO
OH
OH
OBn
BnO
H
H
O
O
O
O
OBn
BnO
H
H
2.36 2.37
Compound 2.36 (6 g, 11.1 mmol, 1 eq.) was dissolved in a mixture of MeOH
(560 ml) and hexane (337 ml). Concentrated HCl (2.7 ml, 12 M, 2.9 eq.) was
added, upon which a clear reaction mixture was formed. After stirring for 15h,
water (45 ml) was added, the biphasic mixture was transferred to a separation
funnel, and the layers were separated. The aqueous layer was basified with a
saturated aqueous solution of Na2CO3 (21 ml) and further with solid Na2CO3
until the pH reached 8-9. The salts were filtered, the filtrate was concentrated
and taken up again in boiling EtOAc. The solids were filtered out, and the filtrate
was concentrated again. The residu was subjected to column chromatography (4%
MeOH in EtOAc), which, after drying overnight in vacuo, delivered tetrol 2.37
(2.93 g, 8.1 mmol, 73%) as white, fluffy solids.
Name: (2R,3S,4S,5R)-2,5-bis(benzyloxy)hexane-1,3,4,6-tetraol
Formula: C20H26O6
Molecular weight: 362.4 g/mol
Rf: 0.23 (4% MeOH in EtOAc)
Melting point: 121◦C
ESI-MS (m/z): 363.2 (M+H+)
HR-MS: calculated for (M+H+) 363.1802, found 363.1805 (∆ 0.8 ppm)
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1H-NMR (500 MHz; DMSO): δ (ppm) = 7.36-7.29 (m, 8H), 7.27-7.22 (m, 2H),
4.70 (d, J = 11.6 Hz, 2H), 4.53 (d, J = 11.6 Hz, 2H), 4.47 (dd, J = 5.9, 5.1
Hz, 2H), 4.43 (d, J = 7.7 Hz, 2H), 3.82 (ddd, J = 11.7, 4.9, 3.2 Hz, 2H), 3.75
(app. t, J = 8.1 Hz, 2H), 3.57 (app. dt, J = 11.4, 5.7 Hz, 2H), 3.47 (ddd, J
= 8.2 Hz, 5.0, 3.1 Hz, 2H)
APT (125 MHz; DMSO): δ (ppm) = 139.31 (2 x C), 128.03 (4 x CH), 127.38 (4
x CH), 127.10 (2 x CH), 80.04 (2 x CH), 71.50 (2 x CH2), 68.46 (2 x CH),
61.04 (2 x CH2)
IR (HATR): 3468, 3370, 3258, 2946, 2920, 2873, 1463, 1452, 1408, 1370, 1095 (s),
1075 (s), 1034 (s), 1024 (s), 995, 850 (s), 750, 738 (s), 698 cm-1
5.3.4 Synthesis of diol 2.38
99%
TBS-Cl, imidazole, 
CH2Cl2, RT
TBSO
HO
OH
OTBS
OBn
BnO
H
H
HO
HO
OH
OH
OBn
BnO
H
H
2.37 2.38
To a solution of compound 2.37 (1g, 2.76 mmol, 1 eq.) in CH2Cl2 (28 ml) was
added imidazole (470 mg, 6.90 mmol, 2.5 eq.) and the mixture was stirred for 5’
at room temperature. Then, the solution was cooled down to 0C and a solution
of TBS-Cl in CH2Cl2 (6.35 ml, 1M solution, 6.35 mmol, 2.3 eq.) was added via a
cannula. The reaction mixture was stirred for 3h at room temperature, poured in
water (100 ml) and diluted with CH2Cl2 (50 ml). The layers were separated and
the aqueous one was extracted with CH2Cl2 (2 x 50 ml). The combined organic
layers were dried over MgSO4 and concentrated. The residu was subjected to flash
column chromatography (hexane/EtOAc 8/2) to deliver 2.38 (1.62 g, 2.74 mmol,
99%) as a colorless oil.
Name: (2R,3S,4S,5R)-2,5-bis(benzyloxy)hexane-1,6-bis(tert-butyl-dimethylsilyloxy)-
3,4-diol
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Formula: C32H54O6Si2
Molecular weight: 590.9 g/mol
Rf: 0.57 (Hexane/EtOAc 8/2)
ESI-MS (m/z): 591.3 (M+H+)
HR-MS: calculated for (M+H+) 591.3532, found 591.3527 (∆ 0.8 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.36-7.26 (m, 10H), 4.74 (d, J = 11.5
Hz, 2H), 4.63 (d, J = 11.5 Hz, 2H), 3.93 (app. t, J = 5.5 Hz, 2H), 3.87 (dd,
J = 10.8, 5.0 Hz, 2H), 3.78 (dd, J = 10.8, 5.3 Hz, 2H), 3.62 (app. dt, J =
6.7, 5.1 Hz, 2H), 3.22 (bd, J = 5.4 Hz, 2H), 0.89 (s, 18H), 0.06 (s, 12H)
APT (125 MHz; DMSO): δ (ppm) = 138.56 (2 x C), 128.52 (4 x CH), 128.08 (4
x CH), 127.83 (2 x CH), 80.52 (2 x CH), 73.43 (2 x CH2), 70.22 (2 x CH),
63.80 (2 x CH2) 26.03 (6 x CH3), 18.38 (2 x C), -5.31 (2 x CH3), -5.35 (2 x
CH3)
5.3.5 Synthesis of aldehyde 2.4
95%
NaIO4, THF:H2O
4:1, RT
TBSO O
OBnTBSO
HO
OH
OTBS
OBn
BnO
H
H
2.38 2.4
To a solution of diol 2.38 (500 mg, 0.85 mmol, 1 eq.) in a mixture of THF (14
ml) and water (3.4 ml) was added NaIO4 and the reaction mixture was stirred at
room temperature for 3h, after which TLC-analysis (hexane/EtOAc 9/1) indicated
full conversion of the starting material. The reaction mixture was diluted with
Et2O (35 ml) and washed with water (3 x 10 ml) and brine (10 ml). After drying
over MgSO4 and concentration, the crude aldehyde 2.4 was obtained (473 mg, 1.6
mmol, 95%) as a colorless oil, which was used as such in the next reaction
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5.4. Synthesis of the MPM protected C5 –C11 fragment
Name: (R)-2-benzyloxy-3-(tert-butyldimethylsilyloxy)propanal
Formula: C16H26O3Si
Molecular weight: 294.5 g/mol
Rf: 0.37 (Hexane/EtOAc 9/1)
5.4 Synthesis of the MPM protected C5 –C11 frag-
ment
5.4.1 Synthesis of acetal 2.41
92%
4-MeOPhCH(OMe)2,
CSA, CH2Cl2, RT
HO OH
O
O
O
2.39 2.41
To a solution of 2.39 (5g, 48.0 mmol, 1 eq.) in CH2Cl2 (130 ml) were added
anisaldehyde-dimethyl acetal (9 ml, 52.8 mmol, 1.1 eq.) and camphorsulfonic acid
(134 mg, 0.58 mmol, 0.012 eq.) and the resulting solution was stirred at room
temperature until TLC-analysis (pentane/ EtOAc 1/1) showed full conversion of
the starting material (2h). The mixture was transferred to a separation funnel,
diluted with CH2Cl2 (250 ml) and washed with an aqueous solution, saturated
in NaHCO3. The organic layer was dried over MgSO4 and concentrated. Flash
column chromatography (hexane/EtOAc 9/1) delivered 2.41 (9.8 g, 44.2 mmol,
92%) as white solid.
Name: 2-(4’-methoxyphenyl)-5,5-dimethyl-1,3-dioxane
Formula: C13H18O3
Molecular weight: 222.3 g/mol
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Rf: 0.24 (hexane/EtOAc 9/1)
ESI-MS (m/z): 223.1 (M+H+)
1H-NMR (300 MHz; DMSO–d6): δ (ppm) = 7.37-7.31 (m, 2H), 6.94-6.87 (m,
2H), 5.34 (s, 1H), 3.75 (s, 3H), 3.65 (d, J = 10.6 Hz, 2H, A part of AB-
spinsystem), 3.59 (d, J = 10.6 Hz, 2H, B part of AB spinsystem), 1.18 (s,
3H), 0.74 (s, 3H)
5.4.2 Synthesis of alcohol 2.42
99%
LiALH4,, AlCl3, CH2Cl2, 
Et2O, -10°C to RT
O OH
O
O
O
O
2.41 2.42
To a solution of acetal 2.41 (9.8 g, 44.1 mmol, 1 eq.) in a mixture of CH2Cl2
(88 ml) and Et2O (88 ml) at -10
◦C was added LiAlH4 (1.68 g, 44.1 mmol, 1 eq.)
in one portion. Then, a cooled (0◦C) solution of AlCl3 (5.9 g, 44.1 mmol, 1 eq.) in
Et2O (33 ml) was added and the RM was stirred for 10’ at -10
◦C, and 1h at room
temperature. Upon completion of the reaction (TLC analysis pentane/ Et2O) the
mixture was cooled to 0◦C, and quenched by the addition of first EtOAc (43 ml),
and then water (130 ml). The mixture was transferred to a separation funnel,
the layers were separated and the aq. one was extracted with CH2Cl2 (2 x 200
ml). The combined organic phases were washed with brine, dried over MgSO4
and concentrated. Flash column chromatography (pentane/EtOAc 8/2) delivered
alcohol 2.42 (9.76g, 43.9 mmol, 99%)
Name: 3-((4’-methoxybenzyl)oxy)-2,2-dimethylpropan-1-ol
Formula: C13H20O3
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Molecular weight: 224.3 g/mol
Rf: 0.19 (pentane/EtOAc 8/2)
ESI-MS (m/z): 247.1 (M+Na+)
1H-NMR (300 MHz; DMSO–d6): δ (ppm) = 7.26-7.20 (m, 2H), 6.93-6.86 (m,
2H), 4.42 (t, J = 5.4 Hz, 1H), 4.37 (s, 2H), 3.74 (s, 3H), 3.16 (d, J = 5.4 Hz,
2H), 3.13 (s, 3H), 0.80 (s, 6H)
APT (75 MHz; DMSO–d6): δ (ppm) = 158.56 (C), 130.80 (C), 128.79 (2 x CH),
113.59 (2 x CH), 75.75 (CH2), 72.06 (CH2), 67.31 (CH2), 55.02 (CH3), 36.61
(C), 21.82 (2 x CH3)
5.4.3 Synthesis of aldehyde 2.43
98%
i) (COCl)2, DMSO, 
CH2Cl2, -78°C
ii) NEt3
O O
O
O OH
O
2.42 2.43
To a solution of oxalylchloride (4.3 ml, 50.6 mmol, 2.2 eq.) in CH2Cl2 (125
ml) at -78◦C was added dimethylsulfoxide (7.8 ml, 110 mmol, 4.8 eq.) dropwise.
Then, alcohol 2.42 (5.15 g, 23 mmol, 1 eq.) was added dropwise as a solution
in CH2Cl2 (46 ml) and the resulting mixture was stirred for 15’ at -78
◦C. Next,
Et3N (16 ml, 115 mmol, 5 eq.) was added dropwise, the solution was stirred at
the same temperature for 10’, then allowed to warm to RT and stirred for 5h.
The reaction was quenched by addition of HCl (240 ml, 0.1M). The layers were
separated, and the aqueous one was extracted with CH2Cl2 (2 x 250 ml). The
combined organic phases were dried over MgSO4, concentrated and subjected to
flash column chromatography (pentane/ Et2O 75/25), delivering aldehyde 2.43 (5
g, 22.9 mmol, 98%)
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Name: 3-((4’-methoxybenzyl)oxy)-2,2-dimethylpropanal
Formula: C13H18O3
Molecular weight: 222.3 g/mol
Rf: 0.44 (pentane/Et2O 7/3)
1H-NMR (300 MHz; DMSO–d6): δ (ppm) = 9.47 (s, 1H), 7.24-7.17 (m, 2H),
6.93-6.87 (m, 2H), 4.38 (s, 2H), 3.74 (s, 3H), 3.43 (s, 2H), 0.98 (s, 6H)
APT (75 MHz; DMSO–d6): δ (ppm) = 205.45 (CH), 158.72 (C), 130.00 (C),
129.05 (2 xCH), 113.66 (2 x CH), 74.13 (CH2), 72.09 (CH2), 55.02 (CH3),
46.78 (C), 18.51 (2 x CH3)
5.4.4 Synthesis of homoallylic alcohol 2.44
96%
96% e.e.
allylOAc, [Ir(cod)Cl]2,
(S)-(-)-MeO-BIPHEP),
CsCO3, 4-Cl-3-NO2-PhCOOH,
2-PrOH, THF, 120°C
O
O
O O
O
OH
2.43 2.44
In a pressure tube, a mixture of [Ir(cod)Cl]2 (93 mg, 0.14 mmol, 0.025 eq.), (S )-
(-)-(6,6’-dimethoxybiphenyl-2,2’-diyl)bis(diphenylphosphine) (180 mg, 0.28 mmol,
0.05 eq.), Cs2CO3 (360 mg, 1.11 mmol, 0.2 eq.), 3-chloro-4-nitrobenzoic acid (111
mg, 0.55 mmol, 0.1 eq.) and aldehyde 2.43 (1.23 g, 5.53 mmol, 1 eq.) was
dissolved in THF (27 ml). Then, allyl acetate (5.95 ml, 55.3 mmol, 10 eq.) and
2-propanol (850 µl, 11.1 mmol, 2 eq.) were added, the tube was sealed, heated to
120◦C and stirred at that temperature for 66h, after which TLC-analysis (hexane/
EtOAc 8/2) indicated completion of the reaction. Then, the reaction mixture
was evaporated on silica. Flash column chromatography (solid loading; hexane to
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hexane/ EtOAc 9/1) delivered homoallylic alcohol 2.44 (1.4 g, 5.31 mmol, 96%)
as colorless oil.
The enantiomeric excess was measured on a Chiralpak IA column, using a 30’
isocratic gradient of n-hexane/EtOH 98:2.
Name: (S )-1-((4’-methoxybenzyl)oxy)-2,2-dimethylhex-5-en-3-ol
Formula: C16H24O3
Molecular weight: 264.4 g/mol
Rf: 0.31 (hexane/EtOAc 8/2)
ESI-MS (m/z): 287.1 (M+Na+)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 7.26-7.20 (m, 2H), 6.90-6.84 (m, 2H),
5.92 (dddd, J = 17.0, 10.2, 7.2, 6.7 Hz, 1H), 5.15-5.04 (m, 2H), 4.44 (app.
s, 2H), 3.81 (s, 3H), 3.51 (ddd, J = 10.3, 3.5, 2.6 Hz, 1H), 3.35 (d, J =
8.9 Hz, 1H, A part of AB-spinsystem), 3.26 (d, J = 8.9 Hz, 1H, B part of
AB-spinsystem), 3.10 (d, J = 3.8 Hz, 1H), 2.32-2.21 (m, 1H), 2.11-1.99 (m,
1H), 0.92 (s, 3H), 0.91 (s, 3H)
5.4.5 Synthesis of enol ether 2.40
73%
EtOCHCH2, 
Hg(CF3COO)2, RT
O
O
O
O
OOH
2.44 2.40
To a solution of alcohol 2.44 (730 mg, 2.77 mmol, 1 eq.) in ethyl vinylether
(41 ml) was added mercury(II)trifluoroacetate (236 mg, 0.55 mmol, 0.2 eq.) and
the reaction mixture was stirred for 5 days at room temperature. A saturated
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aqueous solution of NaHCO3 (50 ml)was added to the mixture, the phases were
separated and the aqueous one was extracted with Et2O (3 x 40 ml). The combined
organic phases were dried over MgSO4, concentrated and subjected to flash column
chromatography (hexane/ Et2O 95/5) to yield enol ether 2.40 (587 mg, 2.02 mmol,
73%) as a colorless oil.
Name: (3S )-1-(((2,2-dimethyl-3-(vinyloxy)hex-5-en-1-yl)oxy)methyl)-4-methoxybenzene
Formula: C18H26O3
Molecular weight: 290.4 g/mol
Rf: 0.52 (hexane/EtOAc 8/2)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 7.27-7.21 (m, 2H), 6.91-6.84 (m, 2H),
6.27 (dd, J = 13.9, 6.4 Hz, 1H), 5.85 (app. ddt, J = 17.1, 10.1, 7.0 Hz,
1H), 5.11-4.99 (m, 2H), 4.42 (d, J = 11.6 Hz, 1H, A part of AB-spinsystem),
4.35 (d, J = 11.6 Hz, 1H, B part of AB-spinsystem), 4.26 (dd, J = 13.9,
1.3 Hz, 1H), 3.84-3.79 (m, 4H), 3.75 (dd, J = 6.8, 5.9 Hz, 1H), 3.28 (d, J =
8.8 Hz, 1H, A part of AB-spinsystem), 3.09 (d, J = 8.8 Hz, 1H, B part of
AB-spinsystem), 2.30-2.22 (m, 2H), 0.93 (s, 3H), 0.91 (s, 3H)
APT (75 MHz; CDCl3): δ (ppm) = 159.19 (C), 154.50 (CH), 136.24 (CH), 130.94
(C), 129.24 (2 x CH), 116.79 (CH2), 113.82 (2 x CH), 86.73 (CH2), 85.22
(CH), 76.72 (CH2), 72.83 (CH2), 55.40 (CH3), 39.71 (CH), 34.89 (CH2),
21.99 (CH3), 20.44 (CH3)
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5.5 First attempt on the MAP reaction
5.5.1 Synthesis of acetal 5.1
2,6-DTMP, TiBr4,
CH2Cl2, -78°C
O
O
O
O TBSO O
OBn
O
H
OH
OBn
TBSO
H
2.40 2.4 5.1
To a solution of enol ether 2.40 (50 mg, 0.17 mmol, 1 eq.), aldehyde 2.4
(119 mg, 0.40 mmol, 2.3 eq.) and 2,6-di-t-butyl-4-methyl-pyridine (53 mg, 0.26
mmol, 1.5 eq.) in CH2Cl2 (1.7 ml), was added TiBr4 (1 ml, 0.34 mmol, 0.34 M,
2 eq.) at -78◦C. The reaction mixture was stirred for 15 minutes, after which
TLC-analysis (hexane/ EtOAc 9/1) showed full conversion of the enol ether. The
reaction was quenched by the careful addition of a saturated aqueous solution of
NaHCO3 (5 ml), and water (5 ml) and diluted with CH2Cl2 (10 ml). The layers
were separated, and the aqueous one was extracted with CH2Cl2 (3 x 10 ml). The
combined organic phases were dried over MgSO4, concentrated and subjected to
flash column chromatography (hexane/ EtOAc 8/2), resulting in isolation of one
pure diastereomer of acetal 5.1 (stereochemistry not assigned), while the other
one was contaminated with other compounds (not reported).
Formula: C34H53O6Si
Molecular weight: 665.8 g/mol
Rf: 0.10 (hexane/ EtOAc 9/1)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.37-7.27 (m, 5H), 5.85 (dddd, J =
17.2, 10.2, 7.1, 6.3 HZ, 1H), 5.06 (ddd, J = 17.2, 3.4, 1.6 Hz, 1H), 5.02
(app. ddt, J = 10.2, 2.1, 1.1 Hz, 1H), 4.75 (d, J = 11.6 Hz, 1H, A part of
AB-spinsystem), 4.74 (dd, J = 6.0, 3.8 Hz, 1H), 4.60 (d, J = 11.6 Hz, 1H, B
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part of AB-spinsystem), 4.03 (app. dt, J = 9.5, 3.1 Hz, 1H), 3.84 (dd, J =
10.6, 5.4 Hz, 1H), 3.77 (dd, J = 10.6, 5.8 Hz, 1H), 3.55 (d, J = 11.1 Hz, 1H),
3.43 (app. td, J = 5.6, 3.4 Hz, 1H), 3.38 (d, J = 11.1 Hz, 1H), 3.33 (dd, J
= 9.9, 2.7 Hz, 1H), 2.87 (bs, 1H), 2.22-2.16 (m, 1H), 2.15-2.07 (m, 1H), 1.91
(ddd, J = 14.1, 9.6, 3.9 Hz, 1H), 1.83 (ddd, J = 14.1, 6.0, 2.9 Hz, 1H), 1.05
(s, 3H), 0.90 (s, 9H), 0.72 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 138.69 (C), 135.83 (CH), 128.47 (2 x CH),
128.17 (2 x CH), 127.80 (CH), 116.48 (CH2), 101.11 (CH), 84.64 (CH), 81.73
(CH), 78.57 (CH2), 73.25 (CH2), 67.96 (CH), 63.25 (CH2), 38.62 (CH2),
34.02 (CH2), 32.94 (C), 26.05 (3 x CH3), 21.66 (CH3), 18.72 (CH3), 18.38
(C), -5.30 (CH3), -5.33 (CH3)
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5.6 Synthesis of the naphtoyl protected C5 –C11
fragment
5.6.1 Synthesis of ester 2.81
90%
Et3N, DMAP, 
CH2Cl2, RT
O
Cl
HO OH
O
O OH
2.39 2.80 2.81
To a solution of neopentylglycol 2.39 (8.2 g, 78.7 mmol, 3 eq.) in CH2Cl2 (47
ml) were added Et3N (7.3 ml, 52.5 mmol, 2 eq.) and DMAP (160 mg, 1.3 mmol,
0.05 eq.) To this mixture, a solution of naphtoylchloride 2.80 (5 g, 26.2 mmol, 1
eq.) in CH2Cl2 (26 ml) was added via cannula. The flask was rinsed with CH2Cl2
(2 x 2 ml), and the resulting mixture was stirred for 6 days at room temperature.
The reaction was quenched by addition of an aqueous saturated NaHCO3-solution.
The phases were separated and the aqueous one was extracted further with CH2Cl2
(3 x 20 ml). The combined organic phases were dried over MgSO4, concentrated
and subjected to flash column chromatography (hexane/EtOAc 65/35), delivering
alcohol 2.81 (6.16g, 23.6 mmol, 90%) as white solids.
Name: 3-hydroxy-2,2-dimethyl-2-naphtoate
Formula: C16H18O3
Molecular weight: 258.3 g/mol
Rf: 0.31 (hexane/EtOAc 65/35)
Melting point: 73◦C
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.67 (app. s, 1H), 8.13-8.05 (m, 2H),
8.00 (app. t, J = 9.0 Hz, 2H), 7.67-7.58 (m, 2H), 4.22 (s, 2H), 3.87 (bs, 1H),
3.51 (d, J = 5.34 Hz, 2H), 1.06 (s, 6H))
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APT (125 MHz; DMSO): δ (ppm) = 166.93 (C), 136.43 (C), 133.51 (C), 131.47
(CH), 130.18 (CH), 129.21 (CH), 129.14 (CH), 128.78 (C), 128.63 (CH),
127.69 (CH), 125.88 (CH), 70.75 (CH2), 68.47 (CH2), 37.13 (C), 21.97 (2 x
CH3)
IR (HATR): 3504, 3462, 2956, 2925, 1682 (s), 1630, 1470, 1372, 1295, 1274 (s),
1230 (s), 1197 (s), cm-1
5.6.2 Synthesis of aldehyde 2.82
99%
i) (COCl)2, DMSO, 
CH2Cl2, -78°C
ii) NEt3
O
O O
O
O OH
2.81 2.82
To a solution of oxalylchloride (360 µl, 4.26 mmol, 2.2 eq.) in CH2Cl2 (11
ml) at -78◦C was added dimethylsulfoxide (660 µl, 9.29 mmol, 4.8 eq.) dropwise.
Then, alcohol 2.42 (500 mg, 1.94 mmol, 1 eq.) was added dropwise as a solution
in CH2Cl2 (4 ml) and the resulting mixture was stirred for 15’ at -78
◦C. Next,
Et3N (1.35 ml, 9.68 mmol, 5 eq.) was added dropwise, the solution was stirred
at the same temperature for 10’, then allowed to warm to RT and stirred for 1h.
The reaction was poured into water (50 ml) and diluted with CH2Cl2 (40 ml). The
layers were separated, and the aqueous one was extracted with CH2Cl2 (2 x 50 ml).
The combined organic phases were dried over MgSO4, concentrated and subjected
to flash column chromatography (hexane/ EtOAc 9/1), delivering aldehyde 2.82
(490 mg, 1.90 mmol, 99%)
Name: 2,2-dimethyl-3-oxopropyl 2’-naphthoate
Formula: C16H16O3
Molecular weight: 256.3 g/mol
Rf: 0.29 (hexane/ EtOAc 9/1)
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Melting point: 49◦C
ESI-MS (m/z): 257.2 (M+H+)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 9.69 (s, 1H), 8.55 (dd, J = 1.6, 0.6 Hz,
1H), 8.00 (dd, 8.6, 1.7 Hz, 1H), 7.97-7.94 (m, 1H), 7.90-7.86 (m, 2H), 7.60
(ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.3 HZ, 1H), 4.44 (s,
2H), 1.25 (s, 6H)
APT (75 MHz; DMSO–d6): δ (ppm) = 203.63 (CH), 166.52 (C), 135.79 (C),
132.59 (C), 131.34 (CH), 129.55 (CH), 128.56 (CH), 128.43 (CH), 127.93
(CH), 127.02 (C), 126.89 (CH), 125.23 (CH), 68.61 (CH2), 46.79 (C), 19.17
(2 x CH3)
IR (HATR): 2974 (w), 1726, 1708 (s), 1469, 1368, 1352, 1282 (s), 1228, 1195 (s),
1129, 1093 (s), 971, 919, 879, 837, 780 (s), 763 (s) cm-1
5.6.3 Synthesis of homoallylic alcohol 2.83
68%
allylOAc, [Ir(cod)Cl]2,
(S)-(-)-MeO-BIPHEP),
CsCO3, 4-Cl-3-NO2-PhCOOH,
2-PrOH, THF, 120°C
O
O OH
O
O O
2.82 2.83
In a pressure tube, a mixture of [Ir(cod)Cl]2 (53 mg, 0.08 mmol, 0.025 eq.), (S )-
(-)-(6,6’-dimethoxybiphenyl-2,2’-diyl)bis(diphenylphosphine) (102 mg, 0.16 mmol,
0.05 eq.), Cs2CO3 (204 mg, 0.63 mmol, 0.2 eq.), 3-chloro-4-nitrobenzoic acid (63
mg, 0.31 mmol, 0.1 eq.) and aldehyde 2.82 (803 mg, 3.13 mmol, 1 eq.) was
dissolved in THF (15 ml). Then, allyl acetate (3.37 ml, 31.3 mmol, 10 eq.) and
2-propanol (480 µl, 6.3 mmol, 2 eq.) were added, the tube was sealed, heated to
120◦C and stirred at that temperature for 66h, after which TLC-analysis (hexane/
EtOAc 8/2) indicated completion of the reaction. Then, the reaction mixture
was evaporated on silica. Flash column chromatography (solid loading; hexane to
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hexane/ EtOAc 9/1) delivered homoallylic alcohol 2.83 (632 mg, 2.10 mmol, 68%)
as white solid.
The enantiomeric excess (98%) was measured on a Chiralcel OD-H column,
using a 30’ isocratic gradient of n-hexane/EtOH 98:2.
Name: (3S )-3-hydroxy-2,2-dimethylhex-5-en-1-yl 2’-naphthoate
Formula: C19H22O3
Molecular weight: 298.4 g/mol
Rf: 0.30 (hexane/EtOAc 8/2)
Melting point: 46◦C
ESI-MS (m/z): 299.2 (M+H+)
HR-MS: calculated for (M+H+) 299.1642, found 299.1640 (∆ 0.6 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.60 (d, J = 1.7 Hz, 1H), 8.06 (dd, J
= 8.6, 1.9 Hz, 1H), 7.97 (app. dd, J = 8.1, 0.8 Hz, 1H), 7.91-7.78 (m, 2H),
7.60 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.4 Hz, 1H),
5.90 (dddd, J = 17.1, 10.2, 8.2, 5.8 Hz, 1H), 5.20-4.13 (m, 2H), 4.48 (d, J
= 10.9 Hz, 1H), 4.13 (d, J = 11.0 Hz, 1H), 3.58 (dd, J = 10.6, 2.2 Hz, 1H),
2.42 (dddd, J = 14.0, 5.7, 3.8, 1.7 Hz, 1H), 2.19 (bs, 1H), 2.14 (app. dddt,
J = 14.0, 10.5, 8.3, 1.0 Hz, 1H), 1.10 (s, 3H), 1.07 (s, 3H)
APT (125 MHz; aceton–d6): δ (ppm) = 167.12 (C), 136.26 (CH), 135.71 (C),
132.63 (C), 131.23 (CH), 129.52 (CH), 128.45 (CH), 128.37 (CH), 127.92
(CH), 127.59 (C), 126.84 (CH), 125.32 (CH), 118.16 (CH2), 74.27 (CH),
71.28 (CH2), 38.87 (C), 36.30 (CH2), 21.96 (CH3), 19.54 (CH3)
IR (HATR): 3486, 2971, 1682 (s), 1631, 1372, 1274 (s), 1229, 1197, 1133, 1101,
1068, 993, 972, 904, 862, 774, 758 cm-1
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NMR-data of the migration product 2.84
OH
O
O
2.84
Name: (3S )-1-hydroxy-2,2-dimethylhex-5-en-3-yl 2’-naphthoate
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.61 (d, J = 1.6 Hz, 1H), 8.05 (dd, J
= 8.7, 1.8 Hz, 1H), 7.97 (app. dd, J = 8.2, 0.9 Hz, 1H), 7.91-7.87 (m, 2H),
7.61 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.56 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H),
5.81 (app. ddt, J = 17.0, 10.2, 6.9 Hz, 1H), 5.27 (dd, J = 8.5, 4.6 Hz, 1H),
5.13 (ddd, J = 17.0, 3.2, 1.5 Hz, 1H), 5.01-4.97 (m, 1H), 3.43 (d, J = 11.8
Hz, 1H), 3.20 (d, J = 11.6 Hz, 1H), 2.54-2.50 (m, 2H), 1.11 (s, 3H), 0.97 (s,
3H)
APT (125 MHz; aceton–d6): δ (ppm) = 167.78 (C), 135.83 (C), 134.80 (CH),
132.63 (C), 131.48 (CH), 129.55 (CH), 128.57 (CH), 128.41 (CH), 127.93
(CH), 127.18 (C), 126.88 (CH), 125.39 (CH), 117.81 (CH2), 77.21 (CH),
69.44 (CH2), 39.84 (C), 34.04 (CH2), 22.28 (CH3), 19.00 (CH3)
5.6.4 Synthesis of (R)-MTPA ester 2.86
99%
(R)-MTPA-Cl, DMAP,
CH2Cl2, RT
OOHO O
O O O
Ph
CF3
OMe
2.83 2.86
To a solution of 2.83 (10 mg, 33 µmol, 1 eq.) and 4-(N,N -dimethylamino)py-
ridine (DMAP) (16 mg, 134 µmol, 4 eq.) in CH2Cl2 (335 µl) was added (R)-(-)-α-
methoxy-α-trifluoromethylphenylacetylchloride ((R)-MTPA-Cl) (13 µl, 67 µmol,
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2 eq.) at RT. After 19h of stirring at RT, TLC-analysis (hexane/ EtOAc 8/2)
indicated complete consumption of the starting material, and the reaction mixture
was poured in an aqueous saturated NH4Cl solution (5 ml) and extracted with
CH2Cl2 (3 x 5 ml). The organic phases were combined, dried over MgSO4 and
concentrated in vacuo. Flash column chromatography (hexane/ EtOAc 95/5)
delivered 2.87 (17 mg, 32 µmol, 99%) as a clear oil.
Name: (3S )-2,2-dimethyl-3-(((2”S )-3”,3”,3”-trifluoro-2”-methoxy-2”-phenylpro-
panoyl)oxy)hex-5-en-1-yl 2’-naphthoate
Formula: C29H29F3O5
Molecular weight: 514.5 g/mol
Rf: 0.17 (hexane/ EtOAc 95/5)
ESI-MS (m/z): 532.2 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 532.2305, found 532.2300 (∆ 1.0 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.63 (app. d, J = 1.7 Hz, 1H), 8.07
(dd, J = 8.6, 1.7 Hz, 1H), 7.99 (app. dd, J = 8.1, 0.7 Hz, 1H), 7.92-7.87 (m,
2H), 7.60 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.58-7.51 (m, 3H), 7.40-7.31 (m,
3H), 5.78 (dddd, J = 17.0, 10.1, 8.3, 5.7 Hz, 1H), 5.42 (dd, J = 9.5, 3.1 Hz,
1H), 5.07 (ddd, J = 17.0, 3.0, 1.7 Hz, 1H), 5.02 (ddd, J = 10.1, 2.4, 1.6 Hz,
1H), 4.24 (d, J = 11.1 Hz, 1H), 3.97 (d, J = 11.1 Hz, 1H), 3.47 (s, 3H), 2.58
(app. dddt, J = 14.8, 5.8, 3.1, 1.6 Hz, 1H), 2.40 (app. dddt, J = 14.8, 9.5,
8.4, 1.0 Hz, 1H), 1.10 (s, 3H), 1.07 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.60 (C), 166.18 (C), 135.74 (C), 134.21
(CH), 132.66 (C), 131.79 (C), 131.37 (CH), 129.76 (CH), 129.66 (CH), 128.54
(3 x CH), 128.49 (CH), 128.46 (CH), 128.00 (CH), 127.90 (CH), 127.33 (C),
126.82 (CH), 125.28 (CH), 123.59 (q, 2 J(C-F3) = 289 Hz, C), 118.32 (CH2),
85.00 (q, J = 3 J(C-F3) = 27.6 Hz, C), 79.25 (CH), 70.10 (CH2), 55.31 (CH3),
38.57 (C), 34.88 (CH2), 21.81 (CH3), 20.77 (CH3)
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5.6.5 Synthesis of (R)-MTPA ester 2.87
99%
(S)-MTPA-Cl, DMAP,
CH2Cl2, RT
OOHO O
O O O
Ph
CF3
OMe
2.83 2.87
To a solution of 2.83 (10 mg, 33 µmol, 1 eq.) and 4-(N,N -dimethylamino)py-
ridine (DMAP) (16 mg, 134 µmol, 4 eq.) in CH2Cl2 (335 µl) was added (S )-(-)-α-
methoxy-α-trifluoromethylphenylacetylchloride ((S )-MTPA-Cl) (13 µl, 67 µmol,
2 eq.) at RT. After 19h of stirring at RT, TLC-analysis (hexane/ EtOAc 8/2)
indicated complete consumption of the starting material, and the reaction mixture
was poured in an aqueous saturated NH4Cl solution (5 ml) and extracted with
CH2Cl2 (3 x 5 ml). The organic phases were combined, dried over MgSO4 and
concentrated in vacuo. Flash column chromatography (hexane/ EtOAc 95/5)
delivered 2.87 (17 mg, 32 µmol, 99%) as a clear oil.
Name: (3S )-2,2-dimethyl-3-(((2”R)-3”,3”,3”-trifluoro-2”-methoxy-2”-phenylpro-
panoyl)oxy)hex-5-en-1-yl 2’-naphthoate
Formula: C29H29F3O5
Molecular weight: 514.5 g/mol
Rf: 0.17 (hexane/ EtOAc 95/5)
ESI-MS (m/z): 532.2 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 532.2305, found 532.2288 (∆ 3.4 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.64 (app. d, J = 1.8 Hz, 1H), 8.08
(dd, J = 8.6, 1.7 Hz, 1H), 8.00 (app. dd, J = 8.1, 0.8 Hz, 1H), 7.93-7.88 (m,
2H), 7.61 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.58-7.54 (m, 3H), 7.39-7.29 (m,
3H), 5.84 (dddd, J = 17.0, 10.1, 8.3, 5.4 Hz, 1H), 5.47 (dd, J = 9.7, 3.0 Hz,
192
CHAPTER 5. EXPERIMENTAL PROCEDURES
1H), 5.11 (app. ddd, J = 17.0, 3.0, 1.8 Hz, 1H), 5.08 (app. dtd, 10.2, 1.7,
0.9 Hz, 1H), 4.19 (d, 11.1 Hz, 1H), 3.89 (d, 11.1 Hz, 1H), 3.56 (s, 3H), 2.62
(app. dddt, J = 15.0, 5.4, 3.1, 1.7 Hz, 1H), 2.44 (app. dddt, J = 15.0, 9.6,
8.5, 1.1 Hz, 1H), 1.06 (s, 3H), 1.05 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.53 (C), 166.15 (C), 135.75 (C), 134.56
(CH) 132.66 (C), 132.22 (C), 131.36 (CH), 129.69 (CH), 129.64 (CH), 128.51
(CH), 128.47 (CH), 128.39 (3 x CH), 127.91 (CH), 127.57 (CH), 127.36 (C),
126.84 (CH), 125.28 (CH), 123.55 (q, 2 J(C-F3) = 289 Hz, C), 118.31 (CH2),
84.55 (q, J = 3 J(C-F3) = 27.6 Hz, C), 79.19 (CH), 69.96 (CH2), 55.67 (CH3),
38.64 (C), 34.97 (CH2), 21.83 (CH3), 20.60 (CH3)
5.6.6 Synthesis of enol ether 2.85
82%
EtOCHCH2, 
Hg(CF3COO)2, RT
OOHO O
O O
2.83 2.85
To a solution of alcohol 2.83 (668 mg, 2.24 mmol, 1 eq.) in ethyl vinylether
(34 ml) was added mercury(II)trifluoroacetate (191 mg, 0.45 mmol, 0.2 eq.) and
the reaction mixture was stirred for 3 days at room temperature. A saturated
aqueous solution of NaHCO3 (25 ml) was added to the mixture, the phases were
separated and the aqueous one was extracted with Et2O (3 x 30 ml). The combined
organic phases were dried over MgSO4, concentrated and subjected to flash column
chromatography (pentane/ Et2O 95/5) to yield enol ether 2.85 (596 mg, 1.83
mmol, 82%) as a yellowish oil.
Name: ((3S )-2,2-dimethyl-3-(vinyloxy)hex-5-en-1-yl 2’-naphthoate
Formula: C21H24O3
Molecular weight: 324.4 g/mol
193
5.6. Synthesis of the naphtoyl protected C5 –C11 fragment
Rf: 0.39 (pentane/ Et2O 95/5)
ESI-MS (m/z): 325.2 (M+H+)
HR-MS: calculated for (M+H+) 325.1798, found 325.1799 (∆ 0.3 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.60 (d, J = 1.6 Hz, 1H), 8.05 (dd, J
= 8.6, 1.8 Hz, 1H), 7.97 (app. dd, J = 8.0, 0.8 Hz, 1H), 7.92-7.87 (m, 2H),
7.60 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.56 ddd, J = 8.1, 6.8, 1.4 Hz, 1H),
6.30 (dd, J = 13.9, 6.4 Hz, 1H), 5.90 (app. ddt, J = 17.1, 10.1, 7.0 Hz, 1H),
5.13 (ddd, J = 17.1, 3.3, 1.6 Hz, 1H), 5.08 (app. ddt, J = 10.1, 2.1, 1.1 Hz,
1H), 4.31 (dd, J = 13.9, 1.6 Hz, 1H), 4.25 (d, J = 10.9 Hz, 1H), 4.20 (d, J =
10.9 Hz, 1H), 3.89 (dd, J = 6.4, 1.5 Hz, 1H), 3.78 (dd, J = 8.5, 4.0 Hz, 1H),
2.46-2.35 (m, 2H), 1.11 (s, 3H), 1.10 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.67 (C), 153.71 (CH), 135.69 (CH+C),
132.65 (C), 131.13 (CH), 129.51 (CH), 128.43 (CH), 128.39 (CH), 127.93
(CH), 127.72 (C), 126.94 (CH), 125.26 (CH), 117.33 (CH2), 87.74 (CH2),
85.27 (CH), 70.69 (CH2), 39.48 (C), 35.14 (CH2), 22.07 (CH3), 20.54 (CH3)
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5.7 Second attempt on the MAP reaction and
proof of stereochemistry
5.7.1 Synthesis of THP ether 2.89
2,6-DTMP, TiBr4,
CH2Cl2, -78°C
O
TBSO O
OBn
O
O
60%
O O
O
Br
H
H
OHTBSO
OBn
2.85 2.4 2.89
To a solution of enol ether 2.85 (274 mg, 0.84 mmol, 1 eq.), aldehyde 2.4 (528
mg, 1.79 mmol, 2.1 eq.) and 2,6-di-t-butyl-4-methyl-pyridine (289 mg, 1.41 mmol,
1.7 eq.) in CH2Cl2 (5 ml), was added TiBr4 (5.2 ml, 1.7 mmol, 0.34 M, 2 eq.) at
-78◦C. The reaction mixture was stirred for 2h, after which TLC-analysis (hexane/
EtOAc 8/2) showed full conversion of the enol ether. The reaction was quenched
by the careful addition of a saturated aqueous solution of NaHCO3 (25 ml), and
diluted with CH2Cl2 (20 ml). The layers were separated, and the aqueous one was
extracted with CH2Cl2 (3 x 25 ml). The combined organic phases were dried over
MgSO4, concentrated and subjected to flash column chromatography (hexane/
EtOAc 9/1), resulting isolation of THP-ether 2.89 (353 mg, 0.55 mmol, 60%) as
a mixture of diastereomers. Also, the oxonia-Cope rearrangement product could
be isolated (0.06 mmol, 7%).
Formula: C37H51BrO6Si
Molecular weight: 699.8 g/mol
Rf: 0.26-0.31 (hexane/ EtOAc 8/2)
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The 2-oxonia cope rearrangement product 2.90
O O
O
O
OTBS
OBn
2.90
Formula: C37H50O6Si
Molecular weight: 618.9 g/mol
Rf: 0.56 (hexane/ EtOAc 8/2)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.60 (app. bs, 1H), 8.07 (dd, J = 8.6,
1.6 Hz, 1H), 7.97 (app. d, J = 7.9 Hz, 1H), 7.91-7.85 (m, 2H), 7.62-7.52 (m,
2H), 7.38-7.24 (m, 5H), 5.81 (app. ddt, J = 17.1, 10.0, 7.0 Hz, 1H), 5.06
(ddd, J = 17.3, 2.1, 1.5 Hz, 1H), 5.03 (ddd, J = 10.2, 2.2, 1.1 Hz, 1H), 4.75
(d, J = 11.9 Hz, 1H, A part of AB-spinsystem), 4.69 (d, J = 11.9 Hz, 1H,
B part of AB-spinsystem), 4.48 (s, 1H), 4.32 (d, J = 10.7 Hz, 1H, A part of
AB-sinsytem), 4.25 (d, J = 10.7 Hz, 1H, B part of AB-spinsystem), 3.86-3.79
(m, 2H), 3.71 (dd, J = 10.8, 5.7 Hz, 1H), 3.64-3.58 (m, 1H), 3.50-3.45 (m,
1H), 2.37-2.28 (m, 1H), 2.24-2.16 (m, 1H), 1.49 (app. dt, J = 13.0, 2.5 Hz,
1H), 1.38 (app. dt, J = 13.0, 11.2 Hz, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.89
(s, 9H), 0.05 (s, 3H), 0.04 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.85 (C), 139.07 (C), 135.63 (C), 134.25
(CH), 132.68 (C), 131.06 (CH), 129.51 (CH), 128.38 (2 x CH), 128.28 (CH),
128.25 (CH), 128.07 (C), 127.93 (2 x CH), 127.92 (CH), 127.58 (CH), 126.73
(CH), 125.44 (CH), 117.21 (CH2), 104.11 (CH), 81.77 (CH), 77.16 (CH),
75.83 (CH), 73.38 (CH2), 70.29 (CH), 62.79 (CH2), 40.48 (CH2), 39.27 (C),
32.18 (CH2), 26.06 (3 x CH3), 20.44 (CH3), 20.01 (CH3), 18.39 (C), -5.26 (2
x CH3)
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5.7.2 Synthesis of debrominated THP ethers 2.93 and 2.94
Bu3SnH
AIBN
PhMe,110°C
83%
O O
O
Naph
H
H
OHTBSO
OBn
O O
O
Br
H
H
OHTBSO
OBn
O O
O
Naph
H
H
OHTBSO
OBn
2.89 2.93 2.94
To a solution of bromide 2.89 (10 mg, 14 µmol, 1 eq.) and tributyltin hydride
(21 µl, 21µ, 1M in cyclohexane, 1.5 eq.) in toluene (570 µl) was added AIBN
(spatula tip, 0.05 eq.). The pressure tube was sealed, heated to 110◦C, and stirred
for 2h. Then, the reaction mixture was poured in water (10 ml) and extracted
with CH2Cl2 (3 x 10 ml). The combined organic layers were dried over MgSO4 and
concentrated. The residu was purified by flash column chromatography (CH2Cl2/
Et2O 99/1), resulting in 2 diastereomers, a less polar one, (3.6 mg, 5.8 µmol, 41%)
and a more polar one (3.5 mg, 5.6 µmol, 40%). The absolute configuration of the
alcohol was not established.
Formula: C37H52O6Si
Molecular weight: 620.9 g/mol
More apolar isomer
Rf: 0.30 (CH2Cl2/ Et2O 98/2)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 8.60 (app. bs, 1H), 8.06 (app. dd, J =
8.6, 1.7 Hz, 1H), 7.99-7.94 (m, 1H), 8.72 (app. d, J = 8.7 Hz, 2H), 7.63-7.51
(m, 2H), 7.37-7.22 (m, 5H), 4.74 (d, J = 11.9, 1H, A part of AB-spinsystem),
4.63 (d, J = 11.7, 1H, B part of AB-spinsystem), 4.44 (d, J = 10.7 HZ, 1H),
4.12-4.03 (m, 2H), 3.86 (dd, J = 10.9, 4.3 Hz, 1H), 3.78 (dd, J = 10.8, 5.8
HZ, 1H), 3.60-3.50 (m, 1H), 3.43 (app. td, J = 5.6, 4.4 Hz, 1H), 3.27-3.19
(m, 2H), 1.92-1.82 (m, 1H), 1.71-1.22 (m, 7H), 1.04 (s, 3H), 1.03 (s, 3H),
0.89 (s, 9H), 0.06 (s, 6H)
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More polar isomer
Rf: 0.28 (CH2Cl2/ Et2O 98/2)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 8.59 (app. bs, 1H), 8.06 (app. dd,
J = 8.6, 1.7Hz, 1H), 8.00-7.95 (m, 1H), 7.89 (app. d, J = 8.5 Hz, 2H),
7.63-7.51 (m, 2H), 7.35-7.23 (m, 5H), 4.75 (d, J = 11.7 HZ, 1H, A part of
AB-spinsystem), 4.55 (d, J = 11.9 Hz, 1H, B part of AB-spinsystem), 4.22
(d, J = 10.9 Hz, 1H, A part of AB-spinsystem), 4.19 (d, J = 10.9 Hz, 1H, B
part of AB-spinsystem), 4-3.92 (m, 1H), 3.88 (dd, J = 10.8, 4.3 HZ, 1H), 3.77
(dd, J = 10.7, 5.8 Hz, 1H), 3.47-3/37 (m, 2H), 3.31-3.24 (m, 2H), 1.92-1.82
(m, 1H), 1.80-1.16 (m, 7H), 1.06 (s, 3H), 1.03 (s, 3H), 0.89 (s, 9H), 0.06 (s,
3H), 0.05 (s, 3H)
5.7.3 Synthesis of ketones 2.91 and 2.92
TPAP, NMO
4Â MS
CH2Cl2, RT
81%
O O
O
Naph
Br
H
H
OTBSO
OBn
O O
O
Br
H
H
OHTBSO
OBn
O O
O
Naph
Br
H
H
OTBSO
OBn
2.89 2.91 2.92
To a suspension of alcohol 2.89 (400 mg, 0.57 mmol, 1 eq.), N-methyl morpho-
line N-oxide (NMO) (200 mg, 1.71 mmol, 3 eq.), and molecular sieves (4 A˚) (375
mg) in CH2Cl2 (15 ml) was added tetrapropyl ammonium perruthenate (TPAP)
(10 mg, 0.03 mmol, 0.05 eq.) in one portion. The reaction mixture was stirred for
3h at room temperature, after which it was filtered over a P4 filter. The filtrate
was concentrated and purified by consecutive flash column chromatography (hex-
ane/ EtOAc 9/1) to yield 2.91 (159 mg, 0.23 mmol, 40%) and 2.92 (161 mg, 0.24
mmol, 41%).
Formula: C37H49BrO6Si
Molecular weight: 697.8 g/mol
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More apolar isomer (equatoral bromide, 2.91)
Name: 2-((2”S,4”R,6”S )-6”-((R)-3”’-(benzyloxy)-4”’-((tert-butyldimethylsilyl)-
oxy)-2”’-oxobutyl)-4”-bromotetrahydro-2H-pyran-2”-yl)-2-methylpropyl 2’-
naphthoate
Rf: 0.62 (hexane/ EtOAc 8/2)
ESI-MS (m/z): 714.3 (M+NH4
+)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 8.58 (app. d, J = 1.6 Hz, 1H), 8.04
(dd, J = 8.6, 1.7 Hz, 1H), 7.98 (app. dd, J = 8.0, 0.8 Hz, 1H), 7.90-7.87 (m,
2H), 7.60 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.3 Hz,
1H), 7.36-7.27 (m, 5H), 4.61 (d, J = 11.9 Hz, 1H, A part of AB-spinsystem),
4.57 (d, J = 11.9 Hz, 1H, B part of AB-spinsystem), 4.23-4.14 (m, 1H), 4.21
(d, J = 10.8 Hz, 1H, A part of AB-spinsystem), 4.16 (d, J = 10.8 Hz, 1H, B
part of AB-spinsystem), 3.91-3.79 (m, 4H), 3.30 (dd, J = 11.4, 1.7 Hz, 1H),
2.91 (dd, J = 17.5, 6.5 Hz, 1H), 2.62 (dd, J = 17.5, 6.0 Hz, 1H), 2.33-2.27
(m, 2H), 1.85 (app. dt, J = 12.8, 11.7 Hz, 1H), 1.65 (ddd, J = 12.8, 12.1,
11.0 Hz, 1H), 1.03 (s, 3H), 1.02 (s, 3H), 0.84 (s, 9H), 0.04 (s, 3H), 0.03 (s,
3H)
APT (75 MHz; CDCl3): δ (ppm) = 208.43 (C), 166.71 (C), 137.72 (C), 135.68
(C), 132.67 (C), 131.11 (CH), 129.55 (CH), 128.61 (2 x CH), 128.39 (CH),
128.37 (CH), 128.05 (CH), 127.98 (2 x CH), 127.92 (CH), 127.77 (C), 126.81
(CH), 125.33 (CH), 85.54 (CH), 81.76 (CH), 73.56 (CH), 72.71 (CH2), 70.38
(CH2), 63.98 (CH2), 47.11 (CH), 45.78 (CH2), 43.14 (CH2), 38.32 (C), 37.58
(CH2), 25.95 (3 x CH3), 21.71 (CH3), 20.45 (CH3), -5.34 (CH3), -5.36 (CH3)
More polar isomer (axial bromide, 2.92)
Name: 2-((2”S,4”S,6”S )-6”-((R)-3”’-(benzyloxy)-4”’-((tert-butyldimethylsilyl)-
oxy)-2”’-oxobutyl)-4”-bromotetrahydro-2H-pyran-2”-yl)-2-methylpropyl 2’-
naphthoate
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Rf: 0.52 (hexane/ EtOAc 8/2)
ESI-MS (m/z): 714.3 (M+NH4
+)
1H-NMR (300 MHz; CDCl3): δ (ppm) = 8.62 (app. d, J = 1.7 Hz, 1H), 8.07
(dd, J = 8.7, 1.9 Hz, 1H), 7.96 (app. dd, J = 8.1, 0.8 Hz, 1H), 7.90-7.86
(m, 2H), 7.59 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.54 (ddd, J = 8.1, 6.8, 1.3
Hz, 1H), 7.39-7.26 (m, 5H), 4.79 (app. quint. J = 3.0 Hz, 1H), 4.63 (d, J
= 11.9 Hz, 1H, A part of AB-spinsystem), 4.57 (d, J = 11.9 Hz, 1H, B part
of AB-spinsystem), 4.47-4.41 (m, 1H), 4.21 (d, J = 10.8 Hz, 1H, A part of
AB-spinsystem), 4.14 (d, J = 10.7 Hz, 1H, B part of AB-spinsystem), 3.96
(dd, J = 11.2, 1.6 Hz, 1H), 3.92 (dd, J = 5.3, 4.3 Hz, 1H), 3.86 (app. d, J
= 4.6 Hz, 2H), 2.88 (dd, J = 16.8, 7.5 Hz, 1H), 2.57 (dd, J = 16.8, 5.1 Hz,
1H), 2.07-2.00 (m, 2H), 1.87 (ddd, J = 14.4, 11.1, 3.3 Hz, 1H), 1.72 (ddd, J
= 14.5, 11.0, 3.5 Hz, 1H), 1.04 (s, 3H), 1.01 (s, 3H), 0.86 (s, 9H), 0.04 (s,
3H), 0.03 (s, 3H)
APT (75 MHz; CDCl3): δ (ppm) = 208.36 (C), 166.79 (C), 137.85 (C), 135.68
(C), 132.69 (C), 131.21 (CH), 129.58 (CH), 128.57 (2 x CH), 128.34 (2 x
CH), 127.95 (2 x CH), 127.90 (2 x CH), 127.82 (C), 126.77 (CH), 125.41
(CH), 85.78 (CH), 76.57 (CH), 72.73 (CH2), 70.45 (CH2), 69.15 (CH), 64.04
(CH2), 50.72 (CH), 45.60 (CH2), 39.48 (CH2), 37.81 (C), 33.62 (CH2), 25.97
(3 x CH3), 21.40 (CH3), 21.04 (CH3), -5.32 (2 x CH3)
5.7.4 Synthesis of alcohol 2.99
L-selectride,
THF, -78°C
85%
86% d.e.
O O
O
Br
H
H
OTBSO
OBn
O O
O
Br
H
H
OHTBSO
OBn
2.91 2.99
To a solution of ketone 2.91 (20 mg, 28 µmol, 1. eq.) in THF (0.4 ml) was
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added L-selectride (143 µl, 143 µmol, 1M in THF, 5 eq.) at -78◦C. After 2 hours of
stirring at that temperature, the reaction was quenched by the addition of water
(5 ml) and diluted with EtOAc (5 ml). The layers were separated and the aqueous
layer was extracted with EtOAc (2 x 5 ml). The combined organic phases were
dried over MgSO4, concentrated and subjected to flash column chromatography
(hexane/ EtOAc 8/2), delivering 2.99 (17 mg, 24 µmol, 85%) as a sticky oil.
Name: 2-((2”S,4”R,6”S )-6”-((2”’R,3”’R)-3”’-(benzyloxy)-4”’-((tert-butyldime-
thylsilyl)oxy)-2”’-hydroxybutyl)-4”-bromotetrahydro-2H-pyran-2-yl)-2-me-
thylpropyl 2’-naphthoate
Formula: C37H51BrO6Si
Molecular weight: 699.8 g/mol
Rf: 0.50 (hexane/ EtOAc 8/2)
ESI-MS (m/z): 699.3 (M+H+)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.58 (app. bs, 1H), 8.04 (dd, J = 8.6,
1.7 Hz, 1H), 7.98 (app. d, J = 8.0 Hz, 1H), 7.92-7.88 (m, 2H), 7.61 (ddd,
J = 8.2, 6.9, 1.3 Hz, 1H), 7.56 (ddd, J = 8.0, 6.9, 1.3 Hz, 1H), 7.35-7.25
(m, 5H), 4.73 (d, J = 11.8 Hz, 1H, A part of AB-spinsystem), 4.48 (d, J =
11.8 Hz, 1H, B part of AB-spinsystem), 4.26 (d, J = 10.8 Hz, 1H, A part of
AB-spinsystem), 4.14 (d, J = 10.7 Hz, 1H, B part of AB-spinsystem), 4.09
(app. tt, J = 12.0, 4.3 Hz, 1H), 3.93-3.88 (m, 1H), 3.85 (dd, J = 10.8, 4.6
Hz, 1H), 3.77 (dd, J = 10.8, 5.2 Hz, 1H), 3.36 (app. dd, J = 8.8, 4.7 Hz, 1H),
3.32-3.26 (m, 1H), 3.23 (dd, J = 11.3, 1.5 Hz, 1H), 2.96 (bs, 1H), 2.32-2.26
(m, 1H), 2.19-2.13 (m, 1H), 1.85 (dd, J = 24, 13 Hz, 1H), 1.79 (app.dt, J =
14.2, 8.2 Hz, 1H), 1.69 (dd, J = 23.8, 12.3 Hz, 1H), 1.62 (app. dt, J = 14.2,
4.7 Hz, 1H), 1.05 (s, 6H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.65 (C), 138.55 (C), 135.70 (C), 132.66
(C), 131.14 (CH), 129.52 (CH), 128.50 (2 x CH), 128.47 (CH), 128.40 (CH) ,
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128.34 (2 x CH), 127.94 (CH), 127.90 (CH), 127.68 (C), 126.89 (CH), 125.29
(CH), 81.71 (CH), 80.21 (CH), 76.18 (CH), 72.69 (CH2), 70.47 (CH2), 69.64
(CH), 63.13 (CH2), 47.34 (CH), 43.36 (CH2), 38.77 (CH2), 38.32 (CH2),
37.70 (CH2), 26.03 (3 x CH3), 21.81 (CH3), 20.59 (CH3), 18.38 (C), -5.33 (2
x CH3)
5.7.5 Synthesis of diol 2.101
TBAF, THF,
0°CO O
O
Br
H
H
OHTBSO
OBn
O O
O
Br
H
H
OHOH
OBn
71%
2.99 2.101
To a solution of alcohol 2.99 (17 mg, 24 µmol, 1 eq.) in THF (100 µl) was
added TBAF (36 µl, 36 µmol, 1.5 eq.) at 0C. The reaction was stirred at that
temperature for 1h. TLC-analysis (hexane/ EtOAc 6/4) after 25’ indicated full
conversion. The reaction was quenched by the addition of water (5ml) and diluted
with EtOAc (5 ml). The phases were separated and the aqueous one was extracted
with Et2O (3 x 5 ml). The combined organic extracts were dried over MgSO4 and
concentrated, delivering diol 2.101 (10 mg, 17 µmol, 71%) as a solid, which was
used as such in the next reaction.
Name: 2-((2”S,4”R,6”S )-6”-((2”’R,3”’R)-3”’-(benzyloxy)-2”’,4”’-dihydroxybutyl)-
4”-bromotetrahydro-2H-pyran-2”-yl)-2-methylpropyl 2’-naphthoate
Formula: C31H37BrO6
Molecular weight: 585.5 g/mol
Rf: 0.18 (hexane/ EtOAc 6/4)
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5.7.6 Synthesis of acetal 2.102
CH2(OMe)2, P2O5, 
CH2Cl2, 0°C
O O
O
Br
H
H
OHOH
OBn
O O
O
Br
H
H
OO
OBn
45%
2.101 2.102
To a solution of diol 2.101 (9 mg, 15 µmol, 1 eq.), and dimethoxymethane (320
µl, 3.61 mmol, 240 eq.) in CH2Cl2 (1.8 ml), was added phosphorous pentoxide (90
mg, 600 µmol, 40 eq.) at 0C. The reaction was quenched by the addition of a
saturated aqueous solution of NaHCO3 (1ml) and extracted with Et2O (3 x 3 ml).
The combined organic layers were dried over MgSO4, concentrated and subjected
to flash column chromatography (hexane/ EtOAc 8/2), delivering acetal 2.102 (4
mg, 7 µmol, 45%) as yellowish oil.
Name: 2-((2”S,4”R,6”S )-6”-(((4”’R,5”’R)-5”’-(benzyloxy)-1”’,3”’-dioxan-4”’-yl)-
methyl)-4”-bromotetrahydro-2H-pyran-2”-yl)-2-methylpropyl 2’-naphthoate
Formula: C32H37BrO6
Molecular weight: 597.6 g/mol
Rf: 0.26 (hexane/ EtOAc 8/2)
ESI-MS (m/z): 614.2 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 614.2112, found 614.2108 (∆ 0.6 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 8.58 (app. bs, 1H), 8.04 (dd, J = 8.6,
1.6 Hz, 1H), 8.02 (app. d, J = 8.0 Hz, 1H), 7.97-7.92 (m, 2H), 7.67-7.58 (m,
2H), 7.26-7.22 (m, 1H), 7.19-7.14 (m, 2H), 6.93-6.90 (m, 2H), 5.07 (d, J =
6.1 Hz, 1H), 5.76 (d, J = 6.1 Hz, 1H), 4.56 (d, J = 12.4 Hz, 1H, A part of
AB-spinstem 1), 4.47 (d, J = 10.5 Hz, 1H, A part of AB-spinsystem 2), 4.11
(app.d, J = 13.4 Hz, 1H), 3.91 (d, J = 12.5 Hz, 1H, B part of AB-spinsystem
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1), 3.83 (ddd, J = 9.9, 5.1, 1.7 Hz, 1H), 3.77 (d, J = 10.5 Hz, 1H, B part of
AB-spinsystem 2), 3.77-3.70, (m, 1H), 3.73 (dd, J = 12.5, 1.3 Hz, 1H), 2.87
(dd, J = 11.4, 1.8 Hz, 1H), 2.85 (app. td, J = 1.7, 0.5 Hz, 1H), 2.39-2.32
(m, 1H), 2.17-2.13 (m, 1H), 1.90-1.85 (m, 1H), 1.80 (ddd, J = 13.4, 10.0, 3.2
Hz, 1H), 1.72-1.64 (m, 2H), 1.58-1.52 (m, 1H), 1.07 (s, 3H), 0.96 (s, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 166.47 (C), 137.88 (C), 135.76 (C), 132.68
(C), 131.04 (CH), 129.45 (CH), 128.80 (2 x CH), 128.77 (CH), 128.61 (CH),
128.39 (2 x CH), 128.05 (CH), 127.99 (CH), 127.55 (C), 127.20 (CH), 125.08
(CH), 94.02 (CH2), 80.25 (CH), 75.20 (CH), 72.95 (CH), 70.64 (CH2), 70.46
(CH2), 69.52 (CH), 67.06 (CH2), 47.15 (CH), 43.33 (CH2), 38.05 (C), 37.23
(CH2), 36.12 (CH2), 29.85 (CH2), 22.35 (CH3), 19.23 (CH3)
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5.8 Synthesis of the C5 –C12 fragment of pelofen
5.8.1 Synthesis of nitrile 3.13
Br
NC
Br
NC99%
KOtBu, MeI, 
THF, -40°C
3.12 3.13
To a stirring solution of 3’-bromophenylacetonitrile (3.12) (22.15 g, 113 mmol)
in THF (330 ml) at -40◦C was added KOt-Bu (27.90 g, 249 mmol) and the mixture
was stirred for 10’. After dropwise addition of MeI (17.6 ml, 283mmol) the cooling
bath was removed and the resulting pink milk was stirred at RT. TLC-analysis
(micro-extraction 1M HCl/Et2O; pentane/Et2O 9/1) indicated completion of the
reaction after 2.5h. 1M HCl solution (50 ml) was added reaction mixture and the
resulting yellow mixture was poured in H2O (150 ml), followed by extraction (3 x
200 ml EtOAc). The combined organic fractions were washed with a mixture of
a saturated aqueous NaHCO3 solution and brine 2/1 (300 ml), dried over MgSO4
and concentrated in vacuo. The resulting brown oil was purified by flash column
chromatography (pentane/Et2O 9/1) to give 3.13 (25.05 g, 99% yield) as a clear,
yellow oil.
Name: 2-(3’-Bromophenyl)-2-methylpropanenitrile
Formula: C10H10BrN
Molecular weight: 224.1 g/mol
Rf: 0.42 (pentane/Et2O 8/2)
1H-NMR (300 MHz; aceton–d6): δ (ppm) = 7.71 (1H, s), 7.58-7.52 (2H, m (app.
t)), 7.41-7.36 (1H, m), 1.74 (6H, s)
APT (75 MHz; aceton–d6): δ (ppm) = 145.47 (C), 131.80 (CH), 131.74 (CH),
129.12 (CH), 125.21 (CH), 124.65 (C), 123.33 (C), 37.88 (C), 29.02 (2 x CH3)
205
5.8. Synthesis of the C5 –C12 fragment of pelofen
IR (HATR): 3066 (w), 2982, 2937, 2875 (w), 2237, 1594, 1566, 1476, 1418, 1392,
1369, 1274 (w), 1239, 1198, 1176 (w), 1114, 1091, 1074, 997, 934, 879, 847,
784 (s), 722, 692 (s), 657 cm-1
5.8.2 Synthesis of aldehyde 3.11
Br
O
Br
NC 90%
i) DIBAH, PhMe, -78°C
 ii) HCl, RT
3.13 3.11
To a stirring solution of 3.13 (1.50 g, 6.69 mmol, 1eq.) in toluene (10.7 ml)
at -50◦C was added DIBAL-H (6.75 ml, 10.04 mmol, 25 w% in PhMe, 1.5 eq.)
dropwise over an hour, using a syringe pump. After the addition, the mixture was
stirred for 2 h at the same temperature, upon which TLC-analysis (pentane/Et2O
9/1) showed complete conversion of the starting material. 6M HCl (20.1 ml) was
added, the cooling bath was removed and the mixture was stirred for 1h. The
mixture was poured in H2O (10 ml) and the phases were separated. The aqueous
phase was extracted with CH2Cl2 (5 x 30 ml) and the combined organic phases
were washed with a preformed mixture of a saturated aqueous NaHCO3 solution
(15 ml) and saturated aqueous NaCl solution (15 ml). After drying over MgSO4
and concentration, flash column chromatography (pentane
ceEt2O 9/1) provided 3.11 (1.36 g, 90% yield) as a clear yellow oil.
Name: 2-(3’-Bromophenyl)-2-methylpropanal
Formula: C10H11BrO
Molecular weight: 227.1 g/mol
Rf: 0.39 (pentane/Et2O 9/1)
1H-NMR (300 MHz; aceton–d6): δ (ppm) = 9.54 (1H, s), 7.50-7.47 (2H, m),
7.39-7.32 (2H, m), 1.46 (6H, s) ppm
206
CHAPTER 5. EXPERIMENTAL PROCEDURES
APT (75 MHz; aceton–d6): δ (ppm) = 202.26 (C), 145.51 (C), 131.53 (CH),
131.01 (CH), 130.62 (CH), 126.75 (CH), 123.38 (C), 50.96 (C), 22.82 (2 x
CH3)
IR (HATR): 3440 (w), 3065 (w), 2973, 2932, 2874 (w), 2807, 2705, 1723 (s), 1592,
1564, 1477, 1409, 1394, 1365, 1305 (w), 1240, 1175 (w), 1113 (w), 1092, 1074,
996, 947 (w), 911, 879, 845, 783, 760, 694 (s), 670 cm-1
5.9 Synthesis of the C5 –C20 fragment
5.9.1 Synthesis of hydroxyketone 3.10
Br
O
i) Cy2BCl, Et3N, Et2O, -78°C
ii) MeOH, HOOH, pH7-buffer, RT
88%
OMEM
OMPM O
OMEM
OMPM O
Br
OH
2.2 3.11 3.10
To a stirred solution of ketone (1.00 g, 2.45 mmol, 1 eq.) in Et2O (29 ml)
was added triethylamine (580 µl, 4.16 mmol, 1.7 eq.) at RT. The solution was
then cooled to 0◦C and chlorodicylcohexylborane (3.67 ml, 3.67 mmol, 1.5 eq.,
1 M in hexane) was added dropwise, upon which the reaction mixture became
turbid. After stirring for 30’ at 0◦C, the reaction mixture was further cooled to
-78◦C. A cooled solution of aldehyde (1.69 g, 7.34 mmol, 3eq.) in Et2O (7 ml)
(-20◦C) was then added via a double-ended needle and the flask containing the
aldehyde was rinsed with Et2O (3 x 1 ml). The reaction mixture was stirred for
15h upon which it was able to warm up to -40◦C, after which tlc-analysis showed
complete conversion of the starting material (hexane/acetone 8/2). The reaction
was quenched by consecutive addition of pH 7 phosphate buffer (26 ml), MeOH (26
ml) and H2O2 (4.1 ml, 36.7 mmol, 15 eq., 35 v% in H2O) and stirred for 3h at RT.
The reaction mixture was then poured into a separation funnel containing water
(150 ml), extracted with CH2Cl2 (4 x 150 ml), dried over MgSO4 and concentrated.
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Purification using gradient flash column chromatography (hexane/acetone 95/5 to
hexane/acetone 9/1) resulted in hydroxyketone 3.10 as a clear colorless oil (1.37
g, 2.16 mmol, 88%).
Name: (3S,7S,10R,8Z )-2-(3’-bromophenyl)-3-hydroxy-7-((4”-methoxybenzyl)oxy)-
10-(((2”’-methoxyethoxy)methoxy)methyl)-2,8-dimethyldodec-8-en-5-one
Formula: C33H47BrO7
Molecular weight: 635.6 g/mol
Rf: 0.32 (hexane/acetone 8/2)
[α]D: -11.6
◦ (c = 10 mg/ml in CHCl3)
ESI-MS (m/z): 654.2 (M+NH4
+)
HR-MS: calculated for (M+Na+) 657.2397, found 657.2401 (∆ 0.6 ppm)
1H-NMR (500 MHz; CD2Cl2): δ (ppm) = 7.52 (app. t, J = 1.9 Hz, 1H), 7.34
(ddd, J = 7.8, 2.1, 1.0 Hz, 1H), 7.31 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.20-7.14
(m, 3H), 6.85 (app. d, 8.7 Hz, 2H), 5.18 (dd, J = 10.5, 1.5 Hz, 1H), 4.72 (dd,
J = 10.1, 3.0 Hz, 1H), 4.64 (d, J = 6.6 Hz, 1H, A part of AB-spinsystem),
4.63 (d, J = 6.6 Hz, 1H, B part of AB-spinsystem), 4.31 (d, J = 11.1 Hz,
1H), 4.124 (d, J = 11.1 Hz, 1H), 4.118 (dd, J = 10.5, 1.8 Hz, 1H), 3.79 (s,
3H), 3.63-3.60 (m, 2H), 3.51-3.48 (m, 2H), 3.46 (dd, J = 9.4, 5.8 Hz, 1H),
3.37 (dd, J = 9.4, 7.0 Hz, 1H), 3.31 (s, 3H), 2.85 (dd, J = 15.3, 10.1 Hz, 1H),
2.62-2.53 (m, 1H), 2.43 (dd, J = 17.2, 1.8 Hz, 1H), 2.26 (dd, J = 17.2, 10.4
Hz, 1H), 2.20 (dd, J = 15.3, 3.0 Hz, 1H), 1.69 (d, J = 1.4 Hz, 3H), 1.55-1.45
(m, 1H), 1.28 (s, 3H), 1.26 (s, 3H), 1.20-1.10 (m, 1H), 0.78 (app. t, J = 7.5
Hz, 3H)
APT (125 MHz; CD2Cl2): δ (ppm) = 210.22 (C), 159.59 (C), 150.01 (C), 135.28
(C), 132.56 (CH), 131.10 (C), 130.30 (CH), 130.06 (CH), 129.73 (2 x CH),
129.49 (CH), 125.90 (CH), 122.73 (C), 113.99 (2 x CH), 95.84 (CH2), 74.65
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(CH), 73.51 (CH), 72.21 (CH2), 71.71 (CH2), 70.15 (CH2), 67.13 (CH2),
58.98 (CH3), 55.61 (CH3), 48.03 (CH2), 46.16 (CH2), 42.16 (C), 39.71 (CH),
25.35 (CH2), 25.12 (CH3), 23.66 (CH3), 17.97 (CH3), 11.92 (CH3)
IR (HATR): 3503, 2924, 2357, 1706, 1613, 1514, 1464, 1410, 1248, 1174 cm-1
5.9.2 Synthesis of (S)-Mosher ester 3.29
(R)-MTPA-Cl, 
pyridine, 
DMAP, RT
38%
OMEM
OMPM O
Br
OH
OMEM
OMPM O
Br
O O
CF3MeO
Ph
3.10 3.29
To a solution of the hydroxy ketone 3.10 (22 mg, 35 µmol, 1 eq.) in pyridine
(69 µl) were added (R)-MTPA-Cl (12.9 µl, 70 µmol, 2 eq.) and DMAP (0.4
mg, 3.5 µmol, 0.1 eq.) at RT. The reaction was stirred at RT for 20h, after
which the mixture was poured in water (10 ml). The mixture was extracted
with CH2Cl2 (4 x 10 ml), dried over MgSO4 and concentrated. The product was
purified by flash column chromatography (pentane/Et2O 1/1) and preparative
HPLC, yielding 3.29 as a colorless oil (11 mg, 13 µmol, 38%).
Name: (3’S,7’S,10’R,8’Z )-2-(3-bromophenyl)-7’-((4”-methoxybenzyl)oxy)-10’-
(((2”’-methoxyethoxy)methoxy)methyl)-2’,8’-dimethyl-5’-oxododec-8’-en-3’-
yl (S )-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate
Formula: C43H54BrF3O9
Molecular weight: 851.8 g/mol
Rf: 0.30 (pentane/Et2O 1/1)
ESI-MS (m/z): 868.2 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 868.3242, found 868.3235 (∆ 0.8 ppm)
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1H-NMR (500 MHz; CD2Cl2): δ (ppm) = 7.53 (app.t, J = 1.9 Hz, 1H), 7.42-7.29
(m, 7H), 7.18 (app. t, J = 7.8 Hz, 1H), 7.13 (app. d, J = 8.7 Hz, 2H), 6.84
(app. d, J = 8.7 Hz, 2H), 5.84 (dd, J = 6.0, 5.0 Hz, 1H), 5.18 (app. dd, J =
10.5, 1.5 Hz, 1H), 4.70 (dd, J = 10.3, 2.5 Hz, 1H), 4.64 (d, J = 6.6 Hz, 1H, A
part of AB-spinsystem), 4.63 (d, J = 6.6 Hz, 1H, B part of AB-spinsystem),
4.29 (d, J = 10.8 Hz, 1H), 4.11 (d, J = 10.8 Hz, 1H), 3.79 (s, 3H), 3.64-3.60
(m, 2H), 3.51-3.48 (m, 2H), 3.46 (dd, J = 9.5, 5.7 Hz, 1H), 3.39-3.35 (m,
4H), 3.31 (s, 3H), 2.80 (dd, J = 15.5, 10.3 Hz, 1H), 2.61-2.53 (m, 3H), 2.09
(dd, J = 15.5, 2.6 Hz, 1H), 1.66 (d, J = 1.4 Hz, 3H), 1.55-1.45 (m, 1H), 1.28
(s, 3H), 1.25 (s, 3H), 1.19-1.10 (m, 1H), 0.76 (app. t, J = 7.4 Hz, 3H)
APT (125 MHz; CD2Cl2): δ (ppm) = 204.93 (C), 165.83 (C), 159.57 (C),148.30
(C), 135.31 (C), 132.49 (CH), 132.09 (C), 131.18 (C), 130.37 (CH), 130.19
(CH), 130.13 (CH), 129.97 (CH), 129.75 (2 x CH), 128.76 (3? x CH), 128.13
(CH), 125.84 (CH), 123.82 (q, J(13C-19F) = 287.9 Hz, C), 122.97 (C), 113.97
(2 x CH), 95.84 (CH2), 85.01 (app. d, J(
13C-19F) = 57.2 Hz, C), 78.48
(CH), 73.56 (CH), 72.22 (CH2), 71.69 (CH2), 70.26 (CH2), 67.13 (CH2),
58.98 (CH3), 55.62 (CH3), 55.44 (CH3), 47.70 (CH2), 45.30 (CH2), 42.13
(CH2), 39.69 (CH), 30.11 (C), 25.33 (CH2), 24.80 (CH3), 24.50 (CH3), 17.97
(CH3), 11.83 (CH3)
5.9.3 Synthesis of (R)-Mosher ester 3.28
(S)-MTPA-Cl, 
 DMAP, 
pyridine, RT
54%
OMEM
OMPM O
Br
OH
OMEM
OMPM OH
Br
O O
CF3MeO
Ph
3.10 3.28
To a solution of the hydroxy ketone 3.10 (26 mg, 41 µmol, 1 eq.) in pyridine
(82 µl) were added (S )-MTPA-Cl (30 µl, 160 µmol, 4 eq.) and DMAP (0.5 mg, 4.1
µmol, 0.1 eq.) at RT. The reaction was stirred at RT for 20h, after which the mix-
ture was poured in water (10 ml). The mixture was extracted with CH2Cl2 (4 x 10
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ml), dried over MgSO4 and concentrated. The product was purified by flash col-
umn chromatography (pentane/Et2O 1/1) and preparative HPLC, yielding 3.28
as a colorless oil (19 mg, 22 µmol, 54%).
Name: (3’S,7’S,10’R,8’Z )-2-(3-bromophenyl)-7’-((4”-methoxybenzyl)oxy)-10’-
(((2”’-methoxyethoxy)methoxy)methyl)-2’,8’-dimethyl-5’-oxododec-8’-en-3’-
yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate
Formula: C43H54BrF3O9
Molecular weight: 851.8 g/mol
Rf: 0.30 (pentane/Et2O 1/1)
ESI-MS (m/z): 868.3 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 868.3242, found 868.3236 (∆ 0.7 ppm)
1H-NMR (500 MHz; CD2Cl2): δ (ppm) = 7.45 (app.t, J = 1.9 Hz, 1H), 7.44-7.35
(m, 5H), 7.34 (ddd, J = 7.9, 2.0, 1.0 Hz, 1H), 7.21 (ddd, J = 7.9, 1.9, 0.9
Hz, 1H), 7.20-7.17 (m, 1H), 7.13 (app. d, J = 8.4 Hz, 2H), 6.84 (app. d, J
= 8.5 Hz, 2H), 5.82 (dd, J = 7.2, 3.9 Hz, 1H), 5.19 (app.d, J = 10.4, 1.5 Hz,
1H), 4.70 (dd, J = 10.3, 2.6 Hz, 1H), 4.645 (d, J = 6.6 Hz, 1H, A part of
AB-spinsystem), 4.636 (d, J = 6.6 Hz, B part of AB-spinsystem), 4.30 (d, J
= 10.8 Hz, 1H), 4.11 (d, J = 10.8 Hz, 1H), 3.79 (s, 3H), 3.64-3.61 (m, 2H),
3.52-3.48 (m, 2H), 3.46 (dd, J = 9.5, 5.8 Hz, 1H), 3.39-3.35 (m, 4H), 3.32 (s,
3H), 2.82 (dd, J = 15.4, 10.3 Hz, 1H), 2.62-2.53 (m, 3H), 2.11 (dd, J = 15.4,
2.7 Hz, 1H), 1.67 (d, J = 1.4 Hz, 3H), 1.54-1.45 (m, 1H), 1.22 (s, 3H), 1.16
(s, 3H), 1.18-1.09 (m, 1H), 0.76 (app. t, J = 7.4 Hz, 3H)
APT (125 MHz; CD2Cl2): δ (ppm) = 205.31 (C), 165.77 (C), 159.58 (C), 154.63
(CH), 147.98 (C), 135.21 (C), 132.60 (CH), 132.50 (C), 131.11 (C), 130.29
(CH), 130.20 (CH), 130.11 (CH), 129.95 (CH),129.80 (3? x CH), 128.68 (2 x
CH), 127.91 (CH), 125.82 (CH), 123.82 (q, J(13C-19F) = 288.4 Hz, C), 122.92
(C), 113.99 (2 x CH), 95.84 (CH2), 78.02 (CH), 73.56 (CH), 72.21 (CH2),
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71.68 (CH2), 70.23 (CH2), 67.12 (CH2), 58.98 (CH3), 55.62 (2 x CH3), 47.71
(CH2), 45.31 (CH2), 42.30 (CH2), 39.70 (CH), 30.11 (C), 25.35 (CH3), 25.33
(CH2), 23.99 (CH3),17.96 (CH3), 11.86 (CH3) (One C not visible, in the
region between 95-80 ppm)
5.9.4 Synthesis of hydroxy ester 3.25
EtCHO, SmI2, 
THF, -20°C
98%
OMEM
OMPM O
Br
OH
OMEM
OMPM OH
Br
O O
3.10 3.25
To a solution of propionaldehyde (200µl, 2.79 mmol, 4 eq.) in THF (5 ml)
was added SmI2 (3.5 ml, 0.35 mmol, 0.5 eq., 0.1M solution in THF) at 0
◦C. The
solution colored blue, changed rapidly to green and in the end to yellow. The
solution was further cooled to -20◦C and a solution of hydroxyketone 3.10 (443
mg, 0.70 mmol, 1 eq.) in THF (2 ml) was added using a double-ended needle and
the flask containing the starting material was rinsed with THF (5 ml). The reaction
was stirred at -20◦C for 4 hours, after which TLC-analysis (hexane/acetone 8/2)
showed complete conversion.i The reaction was quenched by adding NaHCO3 (15
ml) and water (10 ml), extracted with EtOAc (3 x 25 ml), dried over MgSO4 and
concentrated. Purification using flash column chromatography (hexane/acetone
87.5/ 12.5) delivered alcohol 3.25 (478 mg, 98%).
Name: (3S,5R,7S,10R,8Z )-2-(3’-bromophenyl)-5-hydroxy-7-((4”-methoxybenzyl)-
oxy)-10-(((2”’-methoxyethoxy)methoxy)methyl)-2,8-dimethyldodec-8-en-3-yl
propionate
Formula: C36H53BrO8
iThere is only a very subtle difference in Rf -value, however, when looking at the back of
the tlc-plate after staining with the molybdate containing reagent, the starting material has a
red/pink glance, whereas the target material has a blue/green glance.
212
CHAPTER 5. EXPERIMENTAL PROCEDURES
Molecular weight: 693.7 g/mol
Rf: 0.25 (hexane/acetone 8/2)
[α]D: -47.2
◦ (c = 9.9 mg/ml in CHCl3)
HR-MS: calculated for (M+Na+) 715.2816, found 715.2797 (∆ 2.7 ppm)
1H-NMR (500 MHz; CD2Cl2): δ (ppm) = 7.49 (app. t, J = 1.9 Hz, 1H), 7.33
(ddd, J = 7.8, 2.0, 1.0 Hz, 1H), 7.31 (ddd, J = 7.9, 2.0, 1.0 Hz, 1H), 7.20-
7.14 (m, 3H), 6.84 (app. d, J = 8.7 Hz, 2H), 5.33 (dd, J = 10.8, 1.8 Hz,
1H), 5.18 (dd, J = 10.4, 1.6 Hz, 1H), 4.68 (d, J = 7.0 Hz, 1H, A part of
AB-spinsystem), 4.67 (d, J = 7.0 Hz, 1H, B part of AB-spinsystem), 4.43
(dd, J = 9.1, 4.7 Hz, 1H), 4.36 (d, J = 11.2 Hz, 1H), 4.15 (d, J =11.2 Hz,
1H), 3.79 (s, 3H), 3.67-3.64 (m, 2H), 3.55-3.52 (m, 2H), 3.52-3.46 (m, 1H),
3.47 (dd, J = 9.5, 5.9 Hz, 1H), 3.39 (dd, J = 9.4, 6.8 Hz, 1H), 3.36 (s, 3H),
2.57-2.48 (m, 1H), 2.27 (qd, J = 7.6, 3.8 Hz, 2H), 1.87 (app. dt, J = 14.3,
9.0 Hz, 1H), 1.67 (d, J = 1.4 Hz, 3H), 1.51-1.31 (m, 4H), 1.300 (s, 3H), 1.297
(s, 3H), 1.19-1.12 (m, 1H), 1.08 (app. t, J = 7.6 Hz, 3H), 0.79 (app. t, J =
7.5 Hz, 3H)
APT (125 MHz; CD2Cl2): δ (ppm) = 174.87 (C), 159.24 (C), 148.91 (C), 135.48
(C), 132.15 (CH), 130.79 (C), 129.93 (CH), 129.86 (CH), 129.47 (CH), 129.37
(2 x CH), 125.41 (CH), 122.55 (C), 113.95 (2 x CH), 95.67 (CH2), 76.84 (CH),
76.01 (CH), 71.93 (CH2), 71.41 (CH2), 69.61 (CH2), 66.88 (CH2), 59.17 (CH),
55.42 (CH3), 41.90 (C), 40.80 (CH2), 39.18 (CH), 38.12 (CH2), 27.91 (CH2),
25.26 (CH3), 25.22 (CH2), 24.21 (CH3), 17.87 (CH3), 11.81 (CH3), 9.40 (CH3)
IR (HATR): 3504, 2961, 2929, 2877, 1735, 1718, 1612, 1513, 1462, 1366, 1301,
1246, 1176, 851, 822, 786, 700 cm-1
Preparation of SmI2(JOC 2012 3049)
Metallic samarium (601 mg, 4 mmol, 2 eq.) was first activated by stirring dry in a
flask fitted with a rubber septum for 2 days under Ar atmosphere. After activation,
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THF (16,5 ml) was added to the metal, followed by a red solution of I2 (508 mg, 2
mmol, 1 eq.) in THF (3,5 ml). The septum was then replaced by a glass stopper
and the brown reaction mixture was heated to 60◦C. Stirring was continued for 24
h at 60◦C, after which the solution turned dark blue. The mixture was cooled down
to RT and the flask was fitted with a septum again and flushed with argon. This
procedure yielded a solution of SmI2 in THF with a concentration of approximately
0.1M. Upon stirring, the solution could be maintained for a couple of days. Two
hours before using it, stirring was stopped.
5.9.5 Synthesis of diol 3.33
Me3SnOH,
 1,2-Cl2C2H4, 90°C
92%
OMEM
OMPM OH
Br
O O
OMEM
OMPM OH
Br
OH
3.25 3.33
To a solution of 3.25 (52 mg, 74 µmol, 1 eq.) in 1,2-dichloroethane (0.74 ml)in
a pressure tube was added Me3SnOH (130 mg, 0.74 mmol, 10 eq.). The solution
was stirred at 90◦C for 9 days, after which the reaction mixture was poured in a
mixture of a saturated aqueous solution of NH4Cl (5 ml) and water (5 ml) and
extracted with EtOAc (4 x 10 ml). After drying on MgSO4 and concentrating, the
product was purified using flash column chromatography (hexane/ EtOAC 6/4),
yielding diol 3.33 (43 mg, 92%).
Name: (3S,5S,7S,10R,8Z )-2-(3’-bromophenyl)-7-((4”-methoxybenzyl)oxy)-10-
(((2”’-methoxyethoxy)methoxy)methyl)-2,8-dimethyldodec-8-ene-3,5-diol
Formula: C33H49BrO7
Molecular weight: 637.6 g/mol
Rf: 0.31 (hexane/EtOAC 6/4)
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HR-MS: calculated for (M+OAc– ) 695.2795, found 695.2804 (∆ 0.6 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.51 (app. t, J = 1.9 Hz, 1H), 7.33
(app. d, J = 1.8 Hz, 1H), 7.31 (app. d, J = 1.9 Hz, 1H), 7.23-7.19 (m, 2H),
7.16 (app. dd, J = 8.4, 7.4 Hz, 1H), 6.87-6.83 (m, 2H), 5.17 (app. dd, J=
10.5, 1.6 Hz, 1H), 4.68 (d, J = 6.7 Hz, 1H, A part of AB-spinsystem), 4.67
(d, J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.51 (dd, J = 11.0, 2.8 Hz,
1H), 4.41 (d, J = 11.1 Hz, 1H), 4.18 (d, 11.0 Hz, 1H), 4.09-4.03 (m, 1H),
3.98 (dd, J = 10.5, 1.7 Hz, 1H), 3.79 (s, 3H), 3.67-3.64 (m, 2H), 3.55-3.52
(m, 2H), 3.48 (dd, J = 9.4, 5.8 Hz, 1H), 3.40-3.36 (m, 1H), 3.36 (s, 3H), 2.74
(bs, 1H), 2.54 -2.45 (m, 1H), 2.00 (ddd, J = 14.6, 10.7, 10.2 Hz, 1H), 1.73
(d, J = 1.5 Hz, 3H), 1.54-1.45 (m, 1H), 1.40 (ddd, J = 14.2, 10.5, 3.7 Hz,
1H), 1.35-1.27 (m, 2H), 1.30 (s, 3H), 1.29 (s, 3H), 1.20-1.10 (m, 1H), 0.78
(app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 159.43 (C), 150.15 (C), 135.57 (C), 131.94
(CH), 130.22 (C), 130.01 (CH), 129.75 (CH), 129.54 (2 x CH), 129.18 (CH),
125.53 (CH), 122.65 (C), 114.08 (2 x CH), 95.68 (CH2), 78.40 (CH), 75.37
(CH), 71.92 (CH2), 71.53 (CH2), 70.19 (CH), 69.88 (CH2), 66.90 (CH2),
59.18 (CH3), 55.42 (CH3), 42.51 (C), 39.98 (CH2), 39.44 (CH), 37.97 (CH2),
25.15 (CH2), 24.47 (CH3), 23.77 (CH3), 18.02 (CH3), 11.88 (CH3)
5.9.6 Synthesis of acetonide 3.34
CH3CH(OMe)CH2,
PPTS, CH2Cl2, RT
99%
OMEM
OMPM OH
Br
OH
OMEM
OMPM O
Br
O
3.33 3.34
To a solution of 3.33 (38 mg, 59 µmol, 1 eq.) in CH2Cl2 (4 ml) were added
2-methoxypropene (34 µlg, 0.35 mmol, 6 eq.) and pyridinium p-toluenesulfonic
acid. The solution was stirred at RT for 1h20’, after which TLC-analysis indi-
cated complete consumption of the starting material. The reaction mixture was
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quenched by adding a saturated aqueous solution of NaHCO3 (5 ml) and extracted
with CH2Cl2 (2 x 5 ml). After drying on MgSO4 and concentrating, the product
was purified using flash column chromatography (hexane/ EtOAC 8/2), yielding
3.33 (39 mg, 99%).
Name: (4S,6R)-4-(2’-(3”-bromophenyl)propan-2’-yl)-6-((2”’S,5”’R,3”’Z )-2”’-
((4””-methoxybenzyl)oxy)-5”’-(((2””’-methoxyethoxy)methoxy)methyl)- 3”’-
methylhept-3”’-en-1”’-yl)-2,2-dimethyl-1,3-dioxane
Formula: C36H53BrO7
Molecular weight: 677.7 g/mol
Rf: 0.30 (hexane/EtOAC 8/2)
HR-MS: calculated for (M+Na+) 699.2867, found 699.2865 (∆ 0.3 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.48 (app. t, J = 1.8 Hz, 1H), 7.30
(ddd, J = 7.9, 1.9, 1.0 Hz, 1H), 7.27 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 7.23-7.19
(m, 2H), 7.13 (app. t, J = 7.9 Hz, 1H), 6.90-6.87 (m, 2H), 5.12 (app. dd,
J = 10.4, 1.6 Hz, 1H), 4.70 (d, J = 6.7 Hz, 1H, A part of AB-spinsystem),
4.69 (d, J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.36 (d, J = 11.3 Hz,
1H), 4.11 (dd, J = 10.1, 2.9 Hz, 1H), 4.06 (dd, J = 11.5 Hz, 1H), 3.83 (s,
3H), 3.82-3.76 (m, 1H), 3.74 (app. dd, J = 10.2, 6.0 Hz, 1H), 3.69-3.66 (m,
2H), 3.56-3.53 (m, 2H), 3.48 (dd, J = 9.4, 5.7 Hz, 1H), 3.39 (dd, J = 9.4, 7.0
Hz, 1H), 3.38 (s, 3H), 2.43-2.35 (m, 1H), 2.05 (ddd, J = 13.7, 10.2, 4.7 Hz,
1H), 1.67 (d, J = 1.4 Hz, 3H), 1.47-1.38 (m, 1H), 1.36-1.24 (m, 2H), 1.30 (s,
3H), 1.26 (s, 3H), 1.25 (s, 3H), 1.19 (s, 3H), 1.14-1.05 (m, 1H), 1.04 (ddd, J
= 12.6, 9.4, 6.2 Hz, 1H), 0.66 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 159.25 (C), 149.62 (C), 136.40 (C), 131.26
(CH), 131.07 (C), 130.27 (CH), 129.81 (2 x CH), 129.43 (CH), 129.04 (CH),
125.60 (CH), 122.30 (C), 113.91 (2 x CH), 100.48 (C), 95.68 (CH2), 73.27
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(CH), 71.94 (CH2), 71.92 (CH), 71.58 (CH2), 69.36 (CH2), 66.89 (CH2),
64.65 (CH), 59.19 (CH3), 55.41 (CH3), 41.05 (C), 40.80 (CH2), 39.33 (CH),
33.36 (CH2), 25.20 (CH2 + CH3), 25.04 (CH3), 24.40 (CH3), 22.91 (CH3),
18.04 (CH3), 11.95 (CH3)
5.9.7 Synthesis of MPM-acetal 3.35
Molecular sieves 4Â, 
DDQ, CH2Cl2, RT
57%
OMEM
OMPM OH
Br
O O
OMEM
O O
Br
O O
PMP
3.25 3.35
A suspension of 4A˚ molecular sieves in a solution of 3.25 (51 mg, 72 µmol, 1
eq.) in CH2Cl2 was cooled to 0
◦C. Then, DDQ (6 ml, 108 µmol, 1.5 eq, 0.018 M in
CH2Cl2) was added and the reaction mixture was stirred at RT for 3h, after which
TLC-analysis (hexane/acetone 9/1) showed complete consumption of the starting
material. The reaction mixture was filtered over a P4 filter and rinsed with CH2Cl2.
After concentration, the product was purified by flash column chromatography
(hexane/acetone 9/1, then hexane/Et2O 6/4), providing 3.35 (28 mg, 57%).
Name: (2S )-3’-(3”-bromophenyl)-1-((4R,6S )-6-((4”’R,2”’Z )-4”’-(((2””-methoxy-
ethoxy)methoxy)methyl)hex-2”’-en-2”’-yl)-2-(4””’-methoxyphenyl)-1,3-di-
oxan-4-yl)-3’-methyl- butan-2’-yl propionate
Formula: C36H51BrO8
Molecular weight: 691.7 g/mol
Rf: 0.10 (hexane/acetone 9/1)
HR-MS: calculated for (M+NH4
+) 708.3106, found 708.3092 (∆ 2.0 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.51 (app. t, J = 1.9 Hz, 1H), 7.45-7.41
(m, 2H), 7.34 (ddd, J = 5.2, 1.9, 1.0 Hz, 1H), 7.32 (ddd, J = 5.4, 1.9, 0.9 Hz,
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1H), 7.16 (app. t, J = 7.9 Hz, 1H), 6.90-6.86 (m, 2H), 5.55 (dd, J = 10.3,
1.6 Hz, 1H), 5.34 (s, 1H), 5.01 (app. dd, J = 10.5, 1.5 Hz, 1H), 4.67 (s, 2H),
4.64 (dd, J = 11.4, 2.5 Hz, 1H), 3.80 (s, 3H), 3.70-3.63 (m, 3H), 3.52-3.49
(m, 2H), 3.42 (app. dd, J = 6.4, 1.1 Hz, 2H), 3.35 (s, 3H), 2.56-2.48 (m,
1H), 2.35 (app. qd, J = 7.6, 0.9 Hz, 2H), 1.76 (d, J = 1.5 Hz, 3H), 1.67-1.52
(m, 3H), 1.44 (ddd, J = 14.6, 10.4, 3.0 Hz, 1H), 1.31 (s, 3H), 1.29 (s, 3H),
1.26-1.17 (m, 2H), 1.14 (app. t, J = 7.6 Hz, 3H), 0.82 (app. t, J = 7.5 Hz,
3H)
APT (125 MHz; CDCl3): δ (ppm) = 173.87 (C), 159.76 (C), 148.70 (C), 136.66
(C), 131.51 (C), 130.01 (CH), 129.86 (CH), 129.49 (CH), 129.23 (CH), 127.53
(2 x CH), 125.55 (CH), 122.55 (C), 113.52 (2 x CH), 100.24 (CH), 95.70
(CH2), 75.68 (CH), 75.53 (CH), 73.42 (CH), 71.91 (CH2), 71.38 (CH2), 66.87
(CH2), 59.12 (CH3), 55.41 (CH3), 42.11 (C), 39.57 (CH), 36.97 (CH2), 35.00
(CH2), 27.99 (CH2), 25.84 (CH3), 25.25 (CH2), 23.80 (CH3), 19.14 (CH3),
11.83 (CH3), 9.52 (CH3)
5.9.8 Synthesis of methyl ether 3.26
Molecular sieves 4Â, Me3OBF4,
1,8-bis(dimethylamino)-naphtalene,
CH2Cl2, RT
97%
OMEM
OMPM OH
Br
O O
OMEM
OMPM O
Br
O O
3.25 3.26
To a solution of alcohol 3.25 (811 mg, 1.17 mmol, 1 eq.) in CH2Cl2 (29 ml) were
added molecular sieves (4A˚) (470 mg), and the suspension was stirred at RT. After
30’ 1,8-bis(dimethylamino)naphtalene (652 mg, 3.04 mmol, 2.6 eq.) and trimethy-
loxonium tetrafluoroborate (433 mg, 2.92 mmol, 2.5 eq.) were added, respectively.
The mixture was stirred for 24h, after which TLC-analysis (hexane/acetone 8/2)
showed complete conversion of the starting material. The reaction mixture was
filtered, rinsed with 100 ml EtOAc and washed with a solution of CuSO4 in water
(2 x 80 ml, 1M). The aqueous phases were combined and extracted with EtOAc (3
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x 150 ml). All organic phases were collected, dried over MgSO4 and concentrated
in vacuo. Flash column chromatography (hexane/EtOAc 7/3) delivered 3.26 (805
mg, 1.14 mmol, 97%) as a clear oil.
Name: (3S,5R,7S,10R,8Z )-2-(3’-bromophenyl)-5-methoxy-7-((4”-methoxybenzyl)-
oxy)-10-(((2”’-methoxyethoxy)methoxy)methyl)-2,8-dimethyldodec-8-en-3-yl
propionate
Formula: C37H55BrO8
Molecular weight: 707.7 g/mol
Rf: 0.31 (hexane/acetone 8/2)
HR-MS: calculated for (M+NH4
+) 724.3419, found 724.3415 (∆ 0.5 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.50 (app. t, J = 1.9 Hz, 1H) 7.32
(app. dd, J = 7.9, 1.9 Hz, 2H) 7.18-7.13 (m, 3H) 6.85 (app. d, J = 8.7 Hz,
2H) 5.42 (dd, J = 9.8, 2.3 Hz, 1H) 5.12 (dd, J = 10.5, 1.0 Hz, 1H) 4.69 (d,
J = 6.7 Hz, 1H, A part of AB-spinsystem) 4.68 (d, J = 6.7 Hz, 1H, B part
of AB-spinsystem) 4.31 (d, J = 11.2 Hz, 1H) 4.19 (dd, J = 10.1, 2.6 Hz,
1H) 4.04 (d, J = 11.3 Hz, 1H) 3.81 (s, 3H) 6.68-3.65 (m, 2H) 3.56-3.53 (m,
2H) 3.47 (dd, J = 9.2, 5.9 Hz, 1H) 3.41-3.36 (m, 1H) 3.38 (s, 3H) 3.23 (s,
3H) 3.18-3.12 (m, 1H) 2.50-2.42 (m, 1H) 2.24 (app. q, J = 7.6 Hz, 2H) 2.04
(ddd, J = 14.1, 10.3, 3.7 Hz, 1H) 1.67 (d, J = 1.3 Hz, 3H) 1.53-1.38 (m, 3H)
1.33-1.27 (m, 1H) 1.275 (s, 3H) 1.266 (s, 3H) 1.18-1.10 (m, 1H) 1.06 (app. t,
J= 7.6 Hz, 3H) 0.77 (app. t, J = 7.4 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 173.88 (C), 159.11 (C), 149.03 (C), 136.46
(C), 131.20 (C), 130.00 (CH), 129.76 (CH), 129.36 (CH), 129.22 (2 x CH),
125.55 (CH), 122.45 (C), 113.86 (2 x CH), 95.66 (CH2), 76.36 (CH),74.93
(CH), 73.23 (CH), 71.93 (CH2), 71.54 (CH2), 69.69 (CH2), 66.88 (CH2),
59.18 (CH3), 56.58 (CH3), 55.44 (CH3), 42.04 (C), 39.33 (CH), 37.49 (CH2),
35.20 (CH2), 27.90 (CH2), 25.56 (CH3), 25.22 (CH2), 24.04 (CH3), 18.04
(CH3), 11.95 (CH3), 9.50 (CH3)
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5.9.9 Synthesis of stannane 3.9
Me3SnSnMe3, PPh3,
Pd(PPh3)4, PhMe, 70°C
89%
OMEM
OMPM O
Br
O O
OMEM
OMPM O
SnMe3
O O
3.26 3.9
In a pressure tube, 3.26 (805 mg, 1.14 mmol, 1 eq.) was dissolved in toluene
(11 ml), and hexamethylditin (745 mg, 2.27 mmol, 2 eq.) and PPh3 (119 mg, 0.46
mmol, 0.4 eq.) are added. After the addition of tetrakis(triphenylphosphine)palla-
dium (60 mg, 0.052 mmol, 4.6 mol%), the solution turned yellow, and it was heated
to 70◦C, upon which the color disappeared. The reaction was followed using TLC-
analysis (hexane/acetone 9/1). After 20h of refluxing, the formation of Pd black is
clearly visible, and thus a fresh portion of catalyst was added (40 mg, 0.035 mmol,
3.0 mol%). Stirring was continued at 70◦C, and after 44h (in total), a third portion
of catalyst (30 mg, 0.027 mmol, 2.4 mol%, 10 mol% in total) was added, after
which the reaction mixture was stirred for another 22h (65h in total) at 70◦C. The
reaction mixture was then poured into a mixture of a saturated aqueous NaHCO3
solution (15 ml) and water (15 ml) and diluted with EtOAc (30 ml). The phases
were separated and the aqueous solution was extracted with EtOAc (2 x 30 ml).
The organic phases were combined, dried over MgSO4 and concentrated. Flash
column chromatography (pentane/Et2O 6/4) yielded stannane 3.9 (801 mg, 1.01
mmol, 89%).
Name: (3’S,5’R,7’S,10’R,8’Z )-5’-methoxy-7’-((4”-methoxybenzyl)oxy)-10’-(((2”’-
methoxyethoxy)methoxy)methyl)-2’,8’-dimethyl-2’-(3””-(trimethylstannyl)-
phenyl)dodec-8’-en-3’-yl propionate
Formula: C40H64O8Sn
Molecular weight: 791.7 g/mol
Rf: 0.29 (pentane/Et2O 6/4)
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1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.48 (app. d, J = 2.2 Hz, 1H), 7.35-
7.23 (m, 3H), 7.16 (app. d, J = 8.7 Hz, 2H), 6.84 (app. d, J = 8.7 Hz, 2H),
5.51 (dd, J = 9.8, 2.1 Hz, 1H), 5.12 (dd, J = 10.3, 1.4 Hz, 1H), 4.69 (d, J
= 6.7 Hz, 1H, A part of AB-spinsystem), 4.68 (d, J = 6.7 Hz, 1H, B part of
AB-spinsystem), 4.31 (d, J = 11.1 Hz, 1H), 4.20 (dd, J = 9.9, 2.9 Hz, 1H),
4.04 (d, J = 11.2 Hz, 1H), 3.80 (s, 3H), 3.68-3.65 (m, 2H), 3.56-3.53 (m, 2H),
3.46 (dd, J = 9.5, 5.7 Hz, 1H), 3.39 (dd, J = 9.6, 6.7 Hz, 1H), 3.37 (s, 3H),
3.22 (s, 3H), 3.18-3.13 (m, 1H), 2.51-2.42 (m, 1H), 2.22 (app. q, J = 7.6
Hz, 2H), 2.03 (ddd, J = 14.1, 10.0, 4.0 Hz, 1H), 1.66 (d, J = 1.4 Hz, 3H),
1.52-1.40 (m, 3H), 1.32-1.26 (m, 1H), 1.31 (s, 3H), 1.29 (s, 3H), 1.19-1.09
(m, 1H), 1.04 (app. t, J = 7.6 Hz, 3H), 0.76 (app. t, J = 7.5 Hz, 3H), 0.27
(s, 9H)
APT (125 MHz; CDCl3): δ (ppm) = 174.00 (C), 159.12 (C), 145.86 (C), 141.76
(C), 136.44 (C), 133.84 (CH), 133.71 (CH), 131.23 (C), 131.12 (CH), 129.19
(2 x CH), 127.81 (CH), 126.72 (CH), 113.84 (2 x CH), 95.66 (CH2), 76.79
(CH), 75.05 (CH), 73.36 (CH), 71.93 (CH2), 71.51 (CH2), 69.70 (CH2), 66.87
(CH2), 59.18 (CH3), 56.46 (CH3), 55.42 (CH3), 41.95 (C), 39.26 (CH), 37.67
(CH2), 35.18 (CH2), 27.93 (CH2), 26.03 (CH3), 25.21 (CH2), 23.66 (CH3),
18.04 (CH3), 11.91 (CH3), 9.52 (CH3), -9.41 (3 x CH3)
5.10 Completion of the synthesis of pelofen
5.10.1 Synthesis of ester 3.47
Pd2dba3.CHCl3, 
THF, 70°C
92%
OMEM
OMPM O
SnMe3
O O
OMEM
OMPM OMe
MeO
O
O
O
Et
O
O
Br
3.9
3.6
3.47
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In a pressure tube were added respectively methyl-E-4-bromo-2-butenoate (3.6)
(229 µl, 1.91 mmol, 2 eq.) and Pd2(dba)3 ·CHCl3 (15 mg, 14 mol, 1.5 mol%) to
a solution of stannane 3.9 (757 mg, 0.96 mmol, 1 eq.) in THF (4.8 ml). The red
reaction mixture turned brightly yellow upon heating to 70◦C. After 3h of stirring
at 70◦C, TLC-analysis (pentane/Et2O 1/1) showed complete conversion of the
starting material, upon which the mixture was poured into a saturated aqueous
solution of NaHCO3 (30 ml), diluted with CH2Cl2 (30 ml) and the phases were
separated. The aqueous phase was extracted with CH2Cl2 (2 x 30 ml), the organic
phases were combined, dried over MgSO4, and concentrated. Flash column chro-
matography purification delivered the trans-ester 3.47 (639 mg, 0.88 mmol, 92%),
together with a minor amount of the cis-ester.
Name: methyl (E )-4-(3’-((3”S,5”R,7”S,10”R,8”Z )-5”-methoxy-7”-((4”’-methoxy-
benzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-dimethyl-3”-
(propionyloxy)dodec-8”-en-2”-yl)phenyl)but-2-enoate
Formula: C42H62O10
Molecular weight: 726.9 g/mol
Rf: 0.31 (pentane/Et2O 4/6)
ESI-MS (m/z): 744.3 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 744.4681, found 744.4674 (∆ 1.0 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.26-7.15 (m, 5H), 7.08 (app. dt, J =
15.6, 6.8 Hz, 1H), 6.98 (app. dt, J = 6.9, 1.7 Hz, 1H), 6.85 (app. d, J =
8.7 Hz, 2H), 5.80 (app. dt, J = 15.6, 1.6 Hz, 1H), 5.47 (dd, J = 10.1, 1.9
Hz, 1H), 5.12 (dd, J = 10.4, 1.5 Hz, 1H), 4.68(d, J = 6.7 Hz, 1H, A part of
AB-spinsystem), 4.67 (d, J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.32
(d, J = 11.3 Hz, 1H), 4.20 (dd, J = 10.0, 3.0 Hz, 1H), 4.05 (d, J = 11.3 Hz,
1H), 3.80 (s, 3H), 3.70 (s, 3H), 3.68-3.65 (m, 2H), 3.56-3.53 (m, 2H), 3.48
(app. dd, J = 6.7, 1.8 Hz, 2H), 3.46 (dd, J = 9.2, 5.9 Hz, 1H), 3.39 (dd, J =
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9.4, 6.7 Hz, 1H), 3.37 (s, 3H), 3.21 (s, 3H), 3.18-3.12 (m, 1H), 2.51-2.42 (m,
1H), 2.21 (app. q, J = 7.6 Hz, 2H), 2.03 (ddd, J = 14.2, 10.2, 3.9 Hz, 1H),
1.67 (d, J = 1.4 Hz, 3H), 1.52-1.38 (m, 3H), 1.33-1.26 (m, 1H), 1.29 (s, 3H),
1.27 (s, 3H), 1.19-1.09 (m, 1H), 1.04 (app. t, J = 7.6 Hz, 3H), 0.77 (app. t,
J = 7.4 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 173.94 (C), 167.13 (C), 159.12 (C), 147.92
(CH), 147.07 (C), 137.33 (C), 136.46 (C), 131.23 (C), 131.11 (CH), 129.15 (2
x CH), 128.50 (CH), 127.20 (CH), 126.63 (CH), 125.14 (CH), 121.95 (CH),
113.84 (2 x CH), 95.66 (CH2), 76.65 (CH), 74.97 (CH), 73.29 (CH), 71.93
(CH2), 71.50 (CH2), 69.65 (CH2), 66.88 (CH2), 59.18 (CH3), 56.44 (CH3),
55.42 (CH3), 51.57 (CH3), 41.87 (C), 39.28 (CH), 38.87 (CH2), 37.61 (CH2),
35.12 (CH2), 27.91 (CH2), 25.74 (CH3), 25.22 (CH2), 23.84 (CH3), 18.03
(CH3), 11.90 (CH3), 9.49 (CH3)
5.10.2 Synthesis of diol 3.48
AD-mix β, MeSO2NH2, 
NaHCO3, tBuOH:H2O 
1:1, RT
88%
OMEM
OMPM OMe
MeO
O
O
O
Et
OMEM
OMPM OMe
MeO
O
O
O
Et OH
OH
3.47 3.48
To a solution of unsaturated ester 3.47 (500 mg, 0.69 mmol, 1 eq.) in t-
BuOH (6.8 ml) and water (6.8 ml) were added NaHCO3 (555 mg, 6.61 mmol, 9.6
eq.), methanesulfonamide (131 mg, 1.38 mmol, 2 eq.) and AD-mix β (2.48 g),
and the orange-brown biphasic mixture was stirred vigorously. As the reaction
proceeded, the color of the mixture changed to yellow-brown. After 45h, TLC-
analysis (pentane/ Et2O 4/6) indicated full conversion of the starting material,
and the reaction was quenched by addition of a saturated aqueous solution of
Na2S2O3 (24 ml). After stirring for 2h at RT, the color of the aqueous phase had
switched from dark brown to clear yellow to beige brown. The reaction mixture was
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transferred to a separation funnel containing water (50 ml) using CHCl3 (70 ml).
After extraction, the phases were separated and the aqueous phase was further
extracted with CHCl3 (4 x 70 ml). The combined organic phases were dried over
MgSO4 and concentrated. Flash column chromatography (hexane/ EtOAc 4/6)
provided diol 3.48 (460 mg, 0.60 mmol, 88%) as a clear oil.
Name: methyl (2S,3R)-2,3-dihydroxy-4-(3’-((3”S,5”R,7”S,10”R,8”Z )-5”-methoxy-
7”-((4”’-methoxybenzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-
2”,8”-dimethyl-3”-(propionyloxy)dodec-8”-en-2”-yl)phenyl)butanoate
Formula: C42H64O12
Molecular weight: 761.0 g/mol
Rf: 0.16 (hexane/EtOAc 1/1)
ESI-MS (m/z): 778.3 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 778.4736, found 778.4731 (∆ 0.7 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.32 (app. t, J = 1.8 Hz, 1H), 7.24-7.15
(m, 4H), 7.06 (app. dt, J = 6.9, 1.7 Hz, 1H), 6.85 (app. d, J = 8.7 Hz, 2H),
5.4 (dd, J = 10.6, 1.3 Hz, 1H), 5.11 (app. dd, J = 10.4, 1.5 Hz, 1H), 4.69 (d,
J = 6.7 Hz, 1H, A part of AB-spinsystem), 4.68 (d, J = 6.7 Hz, 1H, B part
of AB-spinsystem), 4.31 (d, J = 11.2 Hz, 1H), 4.18 (app. dd, J = 10.2, 2.6
Hz, 1H), 4.15 (app. ddd, J = 8.2, 6.0, 2.0 Hz, 1H), 4.05 (app. bs, 1H), 4.03
(d, J = 11.2 Hz, 1H), 3.80 (s, 3H), 3.77 (s, 3H), 3.69-3.65 (m, 2H), 3.56-3.53
(m, 2H), 3.46 (dd, J = 9.5, 6.3 Hz, 1H), 3.38 (dd, J = 9.4, 6.6 Hz, 1H), 3.37
(s, 3H), 3.24 (s, 3H), 3.15 (dddd, J = 10.3, 8.2, 3.4, 2.1 Hz, 1H), 2.96 (dd, J
= 13.6, 8.5 Hz, 1H), 2.89 (dd, J = 13.6, 5.9 Hz, 1H), 2.69 (bs, 1H), 2.51-2.42
(m, 1H), 2.17 (app. dq, J = 7.5, 0.7 Hz, 2H), 2.03 (ddd, J = 14.1, 10.4, 3.6
Hz, 1H), 1.66 (d, J = 1.4 Hz, 3H), 1.60-1.45 (m, 3H), 1.38 (ddd, J = 14.7,
10.4, 1.3 Hz, 1H), 1.30 (s, 3H), 1.27 (s, 3H), 1.13 (ddd, J = 13.5, 8.6, 7.5 Hz,
1H), 1.00 (app. t, J = 7.6 Hz, 3H), 0.76 (app. t, J = 7.5 Hz, 3H)
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APT (125 MHz; CDCl3): δ (ppm) = 174.20 (C), 173.89 (C), 159.14 (C), 147.07
(C), 137.57 (C), 133.45 (C), 131.13 (C), 131.09 (CH), 129.21 (2 x CH), 128.44
(CH), 127.99 (CH), 127.34 (CH), 124.58 (CH), 113.85 (2 x CH), 95.65 (CH2),
76.73 (CH), 75.31 (CH), 73.32 (CH), 73.09 (CH), 72.66 (CH), 71.93 (CH2),
71.49 (CH2), 69.62 (CH2), 66.89 (CH2), 59.18 (CH3), 56.82 (CH3), 55.43
(CH3), 52.69 (CH3), 41.81 (C), 40.42 (CH2), 39.27 (CH), 37.57 (CH2), 35.05
(CH2), 27.83 (CH2), 25.48 (CH3), 25.19 (CH2), 23.42 (CH3), 18.01 (CH3),
11.92 (CH3), 9.45 (CH3)
5.10.3 Synthesis of bis-MOM-ether 3.8
MOM-Cl, DIPEA,
CH2Cl2, 40°C
97%
OMEM
OMPM OMe
MeO
O
O
O
Et
OMEM
OMPM OMe
MeO
O
O
O
Et OMOM
OMOM
OH
OH
3.48 3.8
In a pressure tube, fitted with a rubber septum, were added diisopropylethy-
lamine (91 µl, 0.52 mmol, 5.5 eq.) and methoxymethylchloride (210 µl, 0.47 mmol,
5.0 eq., 2.25 M solution in MeOAc), respectively, to a solution of diol 3.48 (72 mg,
0.095 mmol, 1 eq.) in CH2Cl2 (473 µl) at 0
◦C. The pressure tube was sealed with
a cap and the reaction mixture was refluxed for 27h, after which TLC-analysis
(hexane/acetone 8/2) indicated complete conversion of the starting material. The
reaction was quenched by pouring the mixture in a separation funnel containing
water (40 ml), and diluted with CH2Cl2 (40 ml). The aqueous phase was further
extracted with CH2Cl2 (3 x 40 ml). The organic phases were combined, dried over
MgSO4, and concentrated. After flash column chromatography (hexane/acetone
8/2), ester 3.8 was obtained (78 mg, 0.091 mmol, 97%) as a yellow oil.
Name: Methyl (2S,3R)-4-(3’-((3”S,5”R,7”S,10”R,8”Z )-5”-methoxy-7”-((4”’-me-
thoxybenzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-di-me-
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thyl-3”-(propionyloxy)dodec-8”-en-2”-yl)phenyl)-2,3-bis(methoxymethoxy)
butanoate
Formula: C46H72O14
Molecular weight: 849.1 g/mol
Rf: 0.36 (hexane/acetone 7/3)
ESI-MS (m/z): 866.4 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 866.5260, found 866.5255 (∆ 0.6 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.26-7.16 (m, 5H), 7.08 (app. dt, J =
6.6, 1.9 Hz, 1H), 6.85 (app. d, J = 8.7 Hz, 2H), 5.49 (dd, J = 10.5, 1.4 Hz,
1H), 5.12 (dd, J = 10.4, 1.4 Hz, 1H), 4.77 (d, J = 7.0 Hz, 1H, A part of
AB-spinsystem 1), 4.72 (d, J = 7.0 Hz, 1H, B part of AB-spinsystem 1), 4.69
(d, J = 6.7 Hz, 1H, A part of AB-spinsystem 2), 4.67 (d, J = 6.7 Hz, 1H,
B part of AB-spinsystem 2), 4.48 (d, J = 7.1 Hz, 1H), 4.39 (d, J = 7.1 Hz,
1H), 4.32 (d, J = 11.3 Hz, 1H), 4.22-4.15 (m, 3H), 4.05 (d, J = 11.3 Hz, 1H),
3.80 (s, 3H), 3.74 (s, 3H), 3.68-3.65 (m, 2H), 3.56-3.52 (m, 2H), 3.49-3.45
(m, 1H), 3.47 (s, 3H), 3.41-3.35 (m, 1H), 3.37 (s, 3H), 3.21 (s, 3H), 3.16-3.11
(m, 1H), 3.16 (s, 3H), 2.97 (dd, J = 13.8, 7.6 Hz, 1H), 2.93 (dd, J = 13.8,
6.3 Hz, 1H), 2.51-2.43 (m, 1H), 2.22 (app. q, J = 7.6 Hz, 2H), 2.02 (ddd, J
= 14.1, 10.1, 3.9 Hz, 1H), 1.66 (d, J = 1.4 Hz, 3H), 1.52-1.45 (m, 2H), 1.39
(ddd, J = 14.7, 10.1, 1.5 Hz, 1H), 1.31-1.24 (m, 1H), 1.28 (s, 3H), 1.26 (s,
3H), 1.18-1.10 (m, 1H), 1.05 (app. t, J = 7.6 Hz, 3H), 0.77 (app. t, J = 7.4
Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 173.93 (C), 171.25 (C), 159.12 (C), 146.93
(C), 137.57 (C), 136.43 (C), 131.23 (C), 131.12 (CH), 129.15(2 x CH), 128.29
(CH), 127.87 (CH), 127.37 (CH), 124.92 (CH), 113.84 (2 x CH), 97.22 (CH2),
96.85 (CH2), 95.66 (CH2), 79.74 (CH), 77.26 (CH), 76.66 (CH), 74.96 (CH),
73.28 (CH), 71.93 (CH2), 71.49 (CH2), 69.63 (CH2), 66.88 (CH2), 59.18
(CH3), 56.67 (CH3), 56.40 (CH3), 55.94 (CH3), 55.42 (CH3), 52.05 (CH3),
226
CHAPTER 5. EXPERIMENTAL PROCEDURES
41.86 (C), 39.27 (CH), 38.05 (CH2), 37.63 (CH2), 35.18 (CH2), 27.90 (CH2),
25.95 (CH3), 25.21 (CH2), 23.55 (CH3), 18.04 (CH3), 11.89 (CH3), 9.51 (CH3)
5.10.4 Synthesis of alcohol 3.49
DDQ, pH7 buffer, 
CH2Cl2, 0°C
95%
OMEM
OH OMe
MeO
O
O
O
Et
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OMPM OMe
MeO
O
O
O
Et OMOM
OMOM
OMOM
OMOM
3.8 3.49
To a solution of 3.8 (71 mg, 0.084 µmol, 1 eq.) in CH2Cl2 (4.2 ml) and pH 7
phosphate buffer (0.42 ml) at 0◦C was added 2,3-dichloro-5,6-dicyanobenzoquinone
(190 mg, 836 mmol, 10 eq.) in one portion. The reaction mixture was stirred
at 0◦C for 1h, after which TLC-analysis (hexane/acetone 6/4) showed complete
conversion of the starting material. The reaction was quenched using a saturated
aqueous solution of NaHCO3 (4.4 ml) and water (5 ml), transferred to a separation
funnel with CH2Cl2 (6 ml) and the phases were separated. The aqueous phase was
extracted with CH2Cl2 (3 x 10 ml), the combined organic phases were dried over
MgSO4 and concentrated. Gradual flash column chromatography (hexane/EtOAc
4/6 to hexane/ acetone 8/2) provided alcohol 3.49 as a colorless oil (58 mg, 0.080
µmol, 95%).
Name: methyl (2S,3R)-4-(3’-((3”S,5”R,7”S,10”R,8”Z )-7”-hydroxy-5”-methoxy-
10”-(((2”’-methoxyethoxy)methoxy)methyl)-2”,8”-dimethyl-3”-(propionyl-
oxy)dodec-8”-en-2”-yl)phenyl)-2,3-bis(methoxymethoxy)butanoate
Formula: C38H64O13
Molecular weight: 728.9 g/mol
Rf: 0.1 (hexane/acetone 8/2)
ESI-MS (m/z): 746.4 (M+NH4
+)
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HR-MS: calculated for (M+OAc– ) 787.4480, found 787.4454 (∆ 4.3 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.28-7.21 (m, 3H), 7.10 (app. dt, J
= 6.9, 1.7 Hz, 1H), 5.46 (dd, J = 8.8, 3.0 Hz, 1H), 4.94 (dd, J = 10.2, 1.5
Hz, 1H), 4.77 (d, J = 7.0 Hz, 1H, A part of AB-spinsystem 1), 4.72 (d, J =
7.0 Hz, 1H, B part of AB-spinsystem 1), 4.68 (d, J = 7.0 Hz, 1H, A part of
AB-spinsystem 2), 4.66 (d, J = 7.0 Hz, 1H, B part of AB-spinsystem 2), 4.49
(d, J = 7.2 Hz, 1H), 4.48 (dd, J = 8.6, 5.0 Hz, 1H), 4.38 (d, J = 7.2 Hz, 1H),
4.20 (ddd, J = 7.6, 6.4, 2.9 Hz, 1H), 4.17 (d, J = 2.9 Hz, 1H), 3.75 (s, 3H),
3.65-3.62 (m, 2H), 3.55-3.52 (m, 2H), 3.51-3.47 (m, 1H), 3.47 (s, 3H), 3.38
(s, 3H), 3.26 (app. t, J = 8.9 Hz, 1H), 3.21 (s, 3H), 3.16 (s, 3H), 3.14-3.07
(m, 1H), 2.99 (dd, J = 13.7, 7.6 Hz, 1H, part of AB2 system?), 2.94 (dd, J
= 13.8, 6.2 Hz, 1H, part of AB2 system?), 2.80 (bs, 1H), 2.60-2.51 (m, 1H),
2.30 (app. q, J = 7.7 Hz, 2H), 1.84 (ddd, J = 14.2, 8.5, 6.4 Hz, 1H), 1.66 (d,
J = 1.4 Hz, 3H), 1.49-1.39 (m, 2H), 1.37-1.30 (m, 1H), 1.32 (s, 3H), 1.28 (s,
3H), 1.20-1.14 (m, 1H), 1.12 (app. t, J = 7.6 Hz, 3H), 0.82 (app. T, J = 7.3
Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 174.02 (C), 171.23 (C), 146.70 (C), 139.60
(C), 137.68 (C), 130.37 (CH), 128.40 (CH), 127.85 (CH), 127.48 (CH), 125.01
(CH), 97.19 (CH2), 96.84 (CH2), 95.53 (CH2), 79.70 (CH), 77.26 (CH), 76.83
(CH), 76.65 (CH), 71.90 (CH2), 71.28 (CH2), 67.00 (CH2), 66.22 (CH), 59.15
(CH3), 56.79 (CH3), 56.68 (CH3), 55.95 (CH3), 52.09 (CH3), 42.07 (C), 39.27
(CH), 38.46 (CH2), 38.08 (CH2), 35.50 (CH2), 28.03 (CH2), 26.37 (CH3),
25.05 (CH2), 23.09 (CH3), 18.25 (CH3), 11.91 (CH3), 9.52 (CH3)
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5.10.5 Synthesis of carboxylic acid 3.50
LiOH.H2O, THF:H2O 
3:1, RT
83%
OMEM
OH OMe
HO
O
OH
OMEM
OH OMe
MeO
O
O
O
Et OMOM
OMOM
OMOM
OMOM
3.49 3.50
To a solution of 3.49 (20 mg, 27 µmol, 1 eq.) in a mixture of THF (0.5
ml) and water (0.5 ml) was added LiOH ·H2O (12 mg, 0.27 mmol, 10 eq.) at
RT. TLC-analysis (CH2Cl2/ MeOH/AcOH 95/5/0.5) indicated hydrolysis of the
methyl ester after 16h, but the reaction was stirred further for 7 days in order to
complete the hydrolysis of the propionate ester. After 7 days, the reaction mixture
was poured into a saturated aqueous solution of NH4Cl (10 ml), and acidified with
HCl (2ml, 0.1 M) until the pH reached 5-6. The reaction mixture was transferred
to a separation flask using CH2Cl2 (10 ml) and the phases were separated. The
aqueous phase was extracted with CH2Cl2 (4 x 10 ml), the organic phases were
combined, dried over MgSO4, and concentrated. The seco-acid was purified using
flash column chromatography (CH2Cl2/ MeOH/ AcOH 96/4/0.5), the fractions
containing target material were combined, washed with water (3 x 25 ml), dried
over MgSO4, and concentrated, delivering 3.50 (15 mg, 23 µmol, 83%) as an
amorphous solid.
Name: (2S,3R)-4-(3’-((3”S,5”R,7”S,10”R,8”Z )-3”,7”-dihydroxy-5”-methoxy-10”-
(((2”’-methoxyethoxy)methoxy)methyl)-2”,8”-dimethyl-dodec-8”-en-2”-yl)-
phenyl)-2,3-bis(methoxymethoxy)butanoic acid
Formula: C34H58O12
Molecular weight: 658.8 g/mol
Rf: 0.1 (CH2Cl2/ MeOH/AcOH 95/5/0.5)
ESI-MS (m/z): 657.3 (M-H+)
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1H-NMR (500 MHz; C6D6): δ (ppm) = 7.26 (app. s, 1H), 7.23-7.19 (m, 1H),
7.16-7.13 (m, 2H), 4.88 (dd, J = 10.1, 1.4 Hz, 1H), 4.77 (dd, J = 9.4, 3.6 Hz,
1H), 4.75 (d, J = 6.8 Hz, 1H), 4.63 (d, J = 6.9 Hz, 1H), 4.61 (d, J = 6.8 Hz,
1H), 4.56 (d, J = 6.6 Hz, 1H, A part of AB-spinsystem), 4.53 (d, J = 6.6
Hz, 1H, B part of AB-spinsystem), 4.52 (d, J = 6.9 Hz, 1H), 4.41 (app. td,
J = 6.6, 4.1 Hz, 1H), 4.29 (d, J = 4.1 Hz, 1H), 4.01 (dd, J = 10.0, 2.2 Hz,
1H), 3.61-3.50 (m, 3H), 3.38 (dd, J = 9.3, 5.0 Hz, 1H), 3.33-3.29 (m, 2H),
3.25 (s, 3H), 3.25-3.21 (m, 1H), 3.18-3.06 (m, 2H), 3.13 (2 x s, 6H), 3.11(s,
3H), 2.65-2.56 (m, 1H), 2.24 (ddd, J = 14.4, 9.4, 5.1 Hz, 1H), 1.79 (d, J =
1.4 Hz, 3H), 1.70-1.59 (m, 3H), 1.46 (s, 3H), 1.39 (s, 3H), 1.39-1.30 (m, 1H),
1.12-1.03 (m, 1H), 0.82 (app. t, J = 7.4 Hz, 3H)
APT (125 MHz; C6D6): δ (ppm) = 172.69 (C), 147.83 (C), 140.41 (C), 138.21
(C), 129.68 (CH), 128.88 (CH), 128.50 (CH), 127.59 (CH), 125.01 (CH), 97.26
(CH2), 96.54 (CH2), 95.34 (CH2), 80.07 (CH), 78.71 (CH), 78.08 (CH), 76.55
(CH), 72.10 (CH2), 71.58 (CH2), 67.24 (CH2), 65.96 (CH), 58.61 (CH3), 56.36
(CH3), 56.16 (CH3), 55.57 (CH3), 42.83 (C), 39.26 (CH), 38.32 (CH2), 37.60
(CH2), 35.37 (CH2), 26.21 (CH3), 25.39 (CH2), 23.64 (CH3), 18.33 (CH3),
12.01 (CH3)
5.10.6 Synthesis of primary alcohol 3.53
LiALH4, 
Et2O, 0°C
89%
OMEM
OMPM OMe
OH
OH
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MeO
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3.8 3.53
To a flask, containing a suspension of LiAlH4 (24 mg, 0.64 mmol, 3 eq.) in
dithylether (5 ml) was added at 0◦C a solution of 3.8 (180 mg, 0.21 mmol, 1 eq.)
in dithylether (5 ml) via a double-ended needle. The reaction was stirred at RT,
and extra LiAlH4 was added until TLC-analysis (hexane/acetone 7/3) indicated
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complete conversion of the starting material. The excess LiAlH4 was destroyed by
adding EtOAc (5 ml) at 0◦C, after which a saturated aqueous solution of Rochelle’s
salt (10 ml) was added and the suspension was stirred for 45’ at RT. The phases
were separated, and the aqueous phase was extracted with EtOAc (5 x 10 ml),
the organic phases were combined, dried over MgSO4, and concentrated. Flash
column chromatography (hexane/EtOAc 2/8) delivered diol 3.53 (144 mg, 0.19
mmol, 89%) as a clear oil.
Name: (3S,5S,7S,10R,8Z )-2’-(3”-((2’R,3’R)-4’-hydroxy-2’,3’-bis(methoxymethox-
y) butyl)phenyl)-5-methoxy-7-((4”’-methoxybenzyl)oxy)-10-(((2””-methoxy-
ethoxy)methoxy)methyl)-2,8-dimethyldodec-8-en-3-ol
Formula: C42H68O12
Molecular weight: 765.0 g/mol
Rf: 0.18 (hexane/acetone 7/3)
ESI-MS (m/z): 609.2 (M+OAc– )
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.23-7.17 (m, 5H), 7.04 (app. dt, J =
6.6, 1.8 Hz, 1H), 6.86 (app. d, 8.7 Hz, 2H), 5.17 (app. dd, 10.4, 1.6 Hz, 1H),
4.81 (d, 6.9 Hz, 1H), 4.69 (d, 6.7 Hz, 1H, A part of AB-spinsystem), 4.68 (d,
J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.67 (d, J = 7.0 Hz, 1H), 4.51 (d,
J = 6.9 Hz, 1H), 4.35 (d, J = 11.1 Hz, 1H), 4.34 (d, J = 7.1 Hz, 1H), 4.29
(dd, J = 9.7, 3.5 Hz, 1H), 4.07 (d, J = 11.2 HZ, 1H), 3.94 (ddd, J = 8.4, 5.4,
3.1 Hz, 1H), 3.85-3.80 (m, 1H), 3.80 (s, 3H), 3.79-3.70 (m, 2H), 3.69-3.65 (m,
2H), 3.57 (ddd, J = 6., 4.7, 3.2 Hz, 1H), 3.56-3.50 (m, 3H), 3.49 (dd, J =
9.5, 6.0 Hz, 1H), 3.46 (s, 3H), 3.41 (dd, J = 9.6, 6.9 Hz, 1H), 3.37 (s, 3H),
3.24 (s, 3H), 3.21 (s, 3H), 2.91 (dd, J = 13.6, 5.4 Hz, 1H), 2.84 (dd, J = 13.6,
8.4 Hz, 1H), 2.70 (d, J = 3.5 Hz, 1H), 2.59-2.51 (m, H), 2.15 (dd, J = 14.3,
9.8, 4.5 Hz, 1H), 1.70 (d, J = 1.4 Hz, 3H), 1.55-1.35 (m, 4H), 1.25 (s, 3H),
1.24-1.17 (m, 1H), 1.22 (s, 3H), 0.83 (app. t, J = 7.5 Hz, 3H)
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APT (125 MHz; CDCl3): δ (ppm) = 159.28 (C), 147.83 (C), 138.11 (C), 136.26
(C), 131.46 (CH), 130.98 (C), 129.63 (2 x CH), 128.30 (CH), 128.00 (CH),
127.06 (CH), 124.82 (CH), 113.90 (2 x CH), 98.11 (CH2), 97.06 (CH2), 95.68
(CH2), 82.48 (CH), 79.67 (CH), 77.23 (CH), 76.00 (CH), 73.22 (CH), 71.93
(CH2), 71.43 (CH2), 69.66 (CH2), 66.88 (CH2), 62.99 (CH2), 59.18 (CH3)
56.48 (CH3), 56.13 (CH3), 55.99 (CH3), 55.43 (CH3), 42.43 (C), 39.24 (CH),
37.60 (CH2), 36.62 (CH2), 34.11 (CH2), 25.29 (CH2), 24.40 (CH3), 23.92
(CH3), 18.11 (CH3), 11.84 (CH3)
5.10.7 Synthesis of aldehyde 3.54
BAIB, TEMPO,
CH2Cl2, RT
OMEM
OMPM OMe
O
OH
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OMPM OMe
OH
OH
OMOM
OMOM
OMOM
OMOM
3.53 3.54
To a solution of 3.53 (90 mg, 118 µmol, 1 eq.) in CH2Cl2 (2.35 ml) were
added bisacetoxyiodobenzene (BAIB) (49 mg, 153 µmol, 1.3 eq.) and (2,2,6,6-
Tetramethylpiperidin-1-yl)oxyl (TEMPO) (3.7 mg, 24 µmol, 0.2 eq.) at 0◦C. The
mixture was then stirred at RT for 19h, after which TLC-analysis (hexane/ ace-
tone 7/3) showed complete conversion of the starting material. The reaction was
quenched by adding a saturated aqueous solution of Na2S2O3 (7.5 ml), and trans-
ferred to a separation funnel, containing a pH 4 buffer solution (7.5 ml) with
CH2Cl2 (12 ml). The phases were separated, the aqueous phase was extracted
with CH2Cl2 (4 x 15 ml), dried over MgSO4 and concentrated. It was used with-
out further purification for the next reaction.
Name: (2S,3R)-4-(3’-((3”S,5”S,7”S,10”R,8Z )-3”-hydroxy-5”-methoxy-7”-((4”’-
methoxybenzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-di-
methyldodec-8”-en-2”-yl)phenyl)-2,3-bis(methoxymethoxy)butanal
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Formula: C42H66O12
Molecular weight: 763.0 g/mol
Rf: 0.40 (hexane/acetone 7/3)
5.10.8 Synthesis of carboxylic acid 3.55
NaH2PO4, NaClO2,
2-Me-2-butene,
tBuOH:H2O 1:1
OMEM
OMPM OMe
O
OH
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O
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OMOM
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3.54 3.55
Compound 3.54 (90 mg, 118 µmol, 1 eq.) was dissolved in tBuOH (17.6 ml)
and 2-methyl-2-butene (2.3 ml) was added. Next, a solution of NaH2PO4 (197
mg, 1.65 mmol, 14 eq.) and NaClO2 (226 mg, 2 mmol, 80%, 17 eq.) in water
(17.6 ml) was added at room temperature and the mixture was stirred for 1h40’,
after which TLC-analysis (hexane/acetone 7/3) showed complete conversion of the
starting material. The reaction mixture was poured in a pH 4 buffer solution (40
ml), extracted with CH2Cl2 (5 x 40 ml), dried over MgSO4, and concentrated. The
reaction mixture was not further purified, and used as such in the next reaction.
Name: (2S,3R)-4-(3’-((3”S,5”S,7”S,10”R,8Z )-3”-hydroxy-5”-methoxy-7”-((4”’-
methoxybenzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-di-
methyldodec-8”-en-2”-yl)phenyl)-2,3-bis(methoxymethoxy)butanoic acid
Formula: C42H66O13
Molecular weight: 779.0 g/mol
Rf: 0.22 (CH2Cl2/MeOH/AcOH 95/5/1)
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5.10.9 Alternative synthesis for carboxylic acid 3.50
DDQ, pH 7 buffer, 
CH2Cl2, RT
OMEM
OH OMe
O
OH
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OMPM OMe
O
OH
OMOM
OMOM
OMOM
OMOM
HOHO
90%
3 steps
3.55 3.50
To a solution of 3.55 (92 mg, 118 µmol, 1 eq.) in CH2Cl2 (23.5 ml) and pH
7 phosphate buffer (3.8 ml) was added DDQ (134 mg, 0.59 mmol, 5 eq.) in one
portion at room temperature. The solution was stirred at that temperature for
4h, after which TLC-analysis (CH2Cl2/MeOH/AcOH 95/5/1) showed complete
conversion of the starting material. The reaction was quenched using a saturated
aqueous solution of NaHCO3 (5 ml) and water (10 ml) and acidified using 0.1M
HCl until pH paper indicated pH 4 (50 ml). The mixture was then transferred to
a separation funnel with CH2Cl2 (20 ml) and extracted with CH2Cl2 (4 x 40 ml).
The combined organic phases were dried over MgSO4 and concentrated. Flash
column chromatography (CH2Cl2/MeOH/AcOH 96/4/1) provided seco-acid 3.50
as a white solid (70 mg, 90% over three steps).
The spectral data were in perfect agreement with the previously reported ones.
5.10.10 Synthesis of macrolactone 3.51
i) 2,4,6-trichlorobenzoylchloride, 
DIPEA, THF, RT
ii) DMAP, PhMe, RT
31%
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3.50 3.51
To a solution of seco-acid 3.50 (14 mg, 21 µmol, 1 eq.) in THF (0.65 ml) was
added diisopropylethylamine (28 µl, 160 µmol, 7.5 eq.) and 2,4,6-trichlorobenzoyl-
chloride (17 µl, 106 µmol, 5 eq.) at RT. The reaction mixture was stirred for 4h,
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after which the solvent was evaporated in vacuo. The remnants were dissolved
in toluene (4 ml) and added to a solution of 4-dimethylaminopyridine (65 mg,
531 µmol, 25 eq.) in toluene (32 ml) over 12h, using a syringe pump. After
the addition, the syringe was rinsed with toluene (3 x 0.3 ml). The reaction
was followed using TLC-analysis (CH2Cl2/ MeOH/ AcOH 95/5/0.5), and as it
progressed, a white precipitation was formed. After 25h, the reaction was quenched
using diluted HCl (30 ml, 0.1 M), the phases were separated, and the aqueous phase
was extracted with EtOAc (3 x 40 ml). The organic phases were combined, dried
over MgSO4, and concentrated. Flash column chromatography (hexane/acetone
8/2) delivered the macrolide 3.51 (5mg, 8 µmol, 36%) as a clear oil.
Name: (1’Z,3R,3’R,4S,7R,9S,11S )-11-hydroxy-3,4-bis(Methoxymethoxy)-7-[3’-
(2”-methoxyethoxymethoxymethyl)-1’-methylpent-1’-enyl]-9-methoxy-12,12-
dimethyl-6-oxabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-one
Formula: C34H56O11
Molecular weight: 640.8 g/mol
Rf: 0.17 (hexane/acetone 8/2)
ESI-MS (m/z): 658.3 (M+Na+)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.44 (app. d, J = 7.9 Hz, 1H), 7.29
(app. t, J = 7.7 Hz, 1H), 7.21 (app. t, J = 1.8 Hz, 1H), 7.17 (app. d, J
= 7.5 Hz, 1H), 5.50 (dd, J = 10.8, 2.0 Hz, 1H), 5.01 (dd, J = 10.4, 1.4 Hz,
1H), 4.88 (d, J = 7.0 Hz, 1H, A part of AB-spinsystem 1), 4.83 (d, J = 7.0
Hz, 1H, B part of AB-spinsystem 1), 4.70 (d, J = 6.7 Hz, 1H, A part of
AB-spinsystem 2), 4.69 (d, J = 6.8 Hz, 1H, B part of AB-spinsystem 2), 4.63
(d, J = 6.8 Hz, 1H, A part of AB-spinsystem 3), 4.59 (d, J = 6.8 Hz, 1H,
B part of AB-spinsystem 3), 4.06 (ddd, J = 9.4, 5.6, 2.4 Hz, 1H), 4.03 (d,
J = 5.7 Hz, 1H), 3.72-3.64 (m, 3H), 3.58-3.54 (m, 2H), 3.50-3.45 (m, 1H),
3.47 (s, 3H), 3.41-3.36 (m, 1H), 3.41 (s, 3H), 3.40 (s, 3H), 3.14 (dd, J =
14.1, 2.1 Hz, 1H), 2.97 (s, 3H), 2.94 (dd, J = 14.1, 9.3 Hz, 1H), 2.77-2.71 (m,
235
5.10. Completion of the synthesis of pelofen
1H), 2.65-2.57 (m, 1H), 1.96 (ddd, J = 14.7, 10.6, 1.0 Hz, 1H), 1.65-1.50 (m,
2H), 1.63 (d, J = 1.4 Hz, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.30-1.24 (m, 1H),
1.19-1.10 (m, 1H), 0.82 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 169.41 (C), 146.36 (C), 137.65 (C), 134.09
(C), 130.86 (CH), 128.71 (CH), 128.04 (CH), 127.63 (CH), 126.03 (CH), 96.90
(CH2), 96.09 (CH2), 95.68 (CH2), 80.06 (CH), 78.17 (CH), 77.85 (CH), 75.51
(CH), 71.97 (CH2), 70.89 (CH2), 70.48 (CH), 66.77 (CH2), 59.15 (CH3), 56.20
(CH3), 55.95 (CH3), 55.90 (CH3), 42.44 (C), 39.91 (CH), 38.87 (CH2), 36.58
(CH2), 36.25 (CH2), 26.22 (CH3), 25.69 (CH3), 25.07 (CH2), 18.29 (CH3),
12.15 (CH3)
5.10.11 Synthesis of pelofen B (3.1)
4N HCl, THF:H2O 
1:1, RT
77% O
O
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3.51 3.1
To a solution of macrolide 3.51 (5 mg, 8 µmol, 1 eq.) in THF (1ml) was added
HCl (1ml, 4M) and the solution was stirred overnight at RT. The solution was
then cooled to 0◦C and neutralized using solid NaHCO3. After the addition of a
saturated aqueous solution of NaHCO3 (5 ml), the mixture was transferred to a
separation funnel using EtOAc (5 ml). The phases were separated and the aqueous
phase is extracted with EtOAc (4 x 5 ml). The combined organic phases were dried
over MgSO4, and concentrated. Flash column chromatography (hexane/acetone
6/4) delivered pelofen 3.1 (3 mg, 6 µmol, 77%) as a white solid.
Name: (1’Z,3R,3’R,4S,7R,9S,11S )-3,4,11-trihydroxy-7-[3’-(hydroxymethylene)-1’-
methylpent-1’-enyl]-9-methoxy-12,12-dimethyl-6-oxabicyclo[11.3.1]heptadeca-
1(17),13,15-trien-5-one
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Formula: C26H40O7
Molecular weight: 464.6 g/mol
Rf: 0.26 (pentane/acetone 6/4)
[α]D: -17.0
◦ (c = 1 mg/ml in CDCl3)
ESI-MS (m/z): 465.2 (M+H+)
HR-MS: calculated for (M+H+) 465.2847, found 465.2851 (∆ 0.9 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.38 (app. bs, 1H), 7.28-7.21 (m, 2H),
7.03 (app. dt, J = 6.9, 1.6 Hz, 1H), 5.44 (dd, J = 10.8, 3.4 Hz, 1H), 4.96
(app. d, J = 10.5 Hz, 1H), 4.32 (app. dd, J = 12.1, 5.0 Hz, 1H), 3.70-3.65
(m, 1H), 3.57 (dd, J = 10.6, 3.8 Hz, 1H), 3.50 (dd, J = 11.2, 2.3 Hz, 1H),
3.43 (app. s, 1H), 3.32-3.25 (m, 1H), 3.27 (s, 3H), 3.20 (dd, J = 12.7, 4.7
Hz, 1H), 2.92 (bs, 2H), 2.70 (app. t, J = 12.3 Hz, 1H), 2.48-2.38 (m, 1H),
1.93 (ddd, J = 15.3, 7.1, 3.4 Hz, 1H), 1.86 (app. dd, J = 15.3, 10.8 Hz, 1H),
1.68 (d, J = 1.4 Hz, 3H), 1.59-1.52 (m, 1H), 1.49 (s, 3H), 1.42-1.34 (m, 1H),
1.36 (s, 3H), 1.30 (app. ddd, J = 14.3, 11.4, 2.8 Hz, 1H), 1.16-1.07 (m, 1H),
0.84 (app. t, J = 7.4 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 174.23 (C), 146.83 (C), 137.03 (C), 136.99
(C), 130.40 (CH), 129.25 (CH), 128.55 (CH), 127.87 (CH), 124.86 (CH),
76.66 (CH), 74.93 (CH), 74.24 (CH), 73.90 (CH), 68.93 (CH), 67.16 (CH2),
57.42 (CH3), 43.44 (CH), 42.59 (C), 40.97 (CH2), 38.69 (CH2), 35.05 (CH2),
26.47 (CH3), 24.66 (CH2), 21.17 (CH3), 18.07 (CH3), 12.33 (CH3)
IR (HATR): 3450, 2955, 2926, 2871, 1735 (s), 1449, 1384, 1218, 1161, 1119, 1088,
1069, 962, 907, 797, 712 cm-1
237
5.11. Synthesis of the 2,3-dideoxy analog
5.11 Synthesis of the 2,3-dideoxy analog
5.11.1 Synthesis of alcohol 3.68
LiAlH4, Et2O, 0°C
100%
OMEM
OMPM O
Br
O O
OMEM
OMPM O
Br
OH
3.26 3.68
To a cooled (0◦C) suspension of LiAlH4 (152 mg, 4.01 mmol, 3 eq.) in Et2O
(32 ml) was added a solution of ester 3.26 (946 mg, 1.34 mmol, 1 eq.) in Et2O
(32 ml) using a double-ended needle. The solution was stirred for 1h at 0◦C,
upon which TLC-analysis (hexane/EtOAc 7/3) indicated full conversion of the
starting material. The excess LiAlH4 was quenched by adding EtOAc (10 ml).
Then, a saturated aqueous solution of Rochelle’s salt (25 ml) was added, and
the resulting mixture was stirred for 1h at RT. The mixture was transferred to
a separation funnel containing another portion of a saturated aqueous solution
of Rochelle?s salt (25 ml), extracted with EtOAc (3 x 50 ml), dried over MgSO4
and concentrated. Flash column chromatography (hexane/ acetone 8/2) delivered
alcohol 3.68 (871 mg, 1.34 mmol, 100%) as a colorless oil.
Name: (3S,5S,7S,10R,8Z )-2-(3’-bromophenyl)-5-methoxy-7-((4”-methoxybenzyl)
oxy)-10-(((2”’-methoxyethoxy)methoxy)methyl)-2,8-dimethyldodec-8-en-3-ol
Formula: C34H51BrO7
Molecular weight: 651.7 g/mol
Rf: 0.40 (hexane/acetone 7/3)
ESI-MS (m/z): 673.3 (M+Na+)
HR-MS: calculated for (M+Na+) 673.2710, found 673.2705 (∆ 0.8 ppm)
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1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.49 (app. t, J = 1.9 Hz, 1H), 7.32
(ddd, J = 7.9, 2.0, 1.0 Hz, 1H), 7.29 (ddd, J = 7.9, 1.8, 1.0 Hz, 1H), 7.21
(app. d, J = 8.8 Hz, 2H), 7.16 (app. t, J = 7.9 Hz, 1H), 6.86 (app. d, J =
8.7 Hz, 2H), 5.17 (dd, J = 10.4, 1.6 Hz, 1H), 4.70 (d, J = 6.7 Hz, 1H, A part
of AB-spinsystem), 4.69 (d, J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.35
(d, J = 11.3 Hz, 1H), 4.24 (dd, J = 10.0, 3.3 Hz, 1H), 4.04 (d, J = 11.3 Hz,
1H), 3.81 (s, 3H), 3.81-3.78 (m, 1H), 3.69-3.66 (m, 2H), 3.56-3.50 (m, 3H),
3.50 (dd, J = 9.4, 5.9 Hz, 1H), 3.42 (dd, J = 9.5, 6.9 Hz, 1H), 3.37 (s, 3H),
3.25 (s, 3H), 2.97 (bs, 1H), 2.57-2.48 (m, 1H), 2.17 (ddd, J = 14.3, 10.1, 4.2
Hz, 1H), 1.71 (d, J = 1.5 Hz, 3H), 1.58-1.50 (m, 1H), 1.49 (ddd, J = 14.3,
7.8, 3.3 Hz, 1H), 1.43 (ddd, J = 14.8, 10.3, 4.6 Hz, 1H), 1.34 (ddd, J = 14.7,
5.9, 2.0 Hz, 1H), 1.24-1.17 (m, 1H), 1.23 (s, 3H), 1.22 (s, 3H), 0.83 (app. t,
J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 159.31 (C), 150.10 (C), 136.19 (C), 131.54
(CH), 130.87 (C), 130.07 (CH), 129.72 (CH), 129.64 (2 x CH), 129.12 (CH),
125.63 (CH), 122.56 (C), 113.93 (2 x CH), 95.69 (CH2), 77.33 (CH), 75.88
(CH), 73.08 (CH), 71.93 (CH2), 71.47 (CH2), 69.63 (CH2), 66.89 (CH2), 59.18
(CH3), 56.55 (CH3), 55.46 (CH3), 42.64 (C), 39.31 (CH), 36.26 (CH2), 33.53
(CH2), 25.28 (CH2), 24.53 (CH3), 23.98 (CH3), 18.12 (CH3), 11.87 (CH3)
5.11.2 Synthesis of stannane 3.79
Me3SnSnMe3, PPh3,
Pd(PPh3)4, PhMe, 70°C
81%
OMEM
OMPM O
Br
OH
OMEM
OMPM O
SnMe3
OH
3.68 3.79
In a pressure tube was added to a solution of alcohol 3.68 (873 mg, 1.34 mmol,
1 eq.) in toluene (13 ml), respectively hexamethylditin (555 µl, 2.68 mmol, 2 eq.),
AsPh3 (164 mg, 0.54 mmol, 0.4 eq.) and tetrakis(triphenylphosphine)palladium(0)
(50 mg, 34 µmol, 3.3 mol%). The solution was heated to 70◦C and stirred for 94h,
239
5.11. Synthesis of the 2,3-dideoxy analog
after which there was clear formation of Pd-black. Although TLC-analysis (hex-
ane/acetone 8/2) did not show complete conversion, the reaction was quenched
using a saturated aqueous solution of NaHCO3 (15 ml) and water (15 ml). The
aqueous phase was extracted with EtOAc (3 x 30 ml), dried over MgSO4 and con-
centrated. Starting and target material were isolated together using flash column
chromatography (hexane/ acetone 8/2). This mixture was then put back into re-
action, using the same conditions as before. Every 20h fresh catalyst (50 mg, 34
µmol, 3.3 mol%) was added for 3 times. Quenching and workup was accomplished
as described. After performing flash column chromatography, the mixture of start-
ing and target material was put into reaction for a 3rd time, but now using 4 eq.
of hexamethylditin, to prevent homo-coupling. Quenching and workup proceeded
exactly as described earlier. Flash column chromatography (hexane/ acetone 9/1)
now provided the stannane 3.79 (804 mg, 1.09 mmol, 81%) as a sticky oil.
Name: (3S,5S,7S,10R,8Z )-5-methoxy-7-((4’-methoxybenzyl)oxy)-10-(((2”-meth-
oxyethoxy)methoxy)methyl)-2,8-dimethyl-2-(3”’-(trimethylstannyl)phenyl)-
dodec-8-en-3-ol
Formula: C37H60O7Sn
Molecular weight: 735.6 g/mol
Rf: 0.28 (hexane/acetone 8/2)
ESI-MS (m/z): 759.3 (M+Na+)
HR-MS: calculated for (M+Na+) 759.3253, found 759.3251 (∆ 0.3 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.49-7.47 (m, 1H), 7.33-7.27 (m, 3H),
7.21 (app. d, J = 8.7 Hz, 2H) 6.85 (app. d, J = 8.7 Hz, 2H), 5.17 (dd, J =
10.5, 1.7 Hz, 1H), 4.70 (d, J = 6.7 Hz, 1H, A part of AB-spinsystem), 4.69
(d, J = 6.7 Hz, 1H, B part of AB-spinsystem), 4.34 (d, J = 11.3 Hz, 1H),
4.28 (dd, J = 9.6, 3.5 Hz, 1H), 4.06 (d, J = 11.3 Hz, 1H), 3.87 (dd, J = 10.1,
3.4 Hz, 1H), 3.80 (s, 3H), 3.68-3.65 (m, 2H), 3.56-3.50 (m, 3H), 3.49 (dd, J
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= 9.3, 5.8 Hz, 1H), 3.42 (dd, J = 9.3, 6.8 Hz, 1H), 3.37 (s, 3H), 3.24 (s, 3H),
2.66 (d, J = 3.4 Hz, 1H), 2.60-2.51 (m, 1H), 2.15 (ddd, J = 14.4, 9.7, 4.5 Hz,
1H), 1.70 (d, J = 1.4 HZ, 3H), 1.56-1.46 (m, 3H), 1.41 (ddd, J = 14.4, 6.4,
2.1 Hz, 1H), 1.28 (s, 3H), 1.25 (s, 3H), 1.24-1.16 (m, 1H), 0.83 (app. t, J =
7.5 Hz, 3H), 0.27 (s, 9H, satellitepeaks: J = 27.5, 26.2 Hz)
APT (125 MHz; CDCl3): δ (ppm) = 159.24 (C), 146.93 (C), 141.96 (C), 136.28
(C), 133.85 (CH), 133.60 (CH), 131.44 (CH), 131.00 (C), 129.62 (2 x CH),
127.84 (CH), 126.79 (CH), 113.90 (2 x CH), 95.69 (CH2), 77.21 (CH), 76.05
(CH), 73.35 (CH), 71.93 (CH2), 71.44 (CH2), 69.71 (CH2), 66.88 (CH2), 59.18
(CH3), 56.43 (CH3), 55.43 (CH3), 42.54 (C), 39.23 (CH), 36.75 (CH2), 34.04
(CH2), 25.29 (CH2), 24.43 (CH3), 23.73 (CH3), 18.33 (CH3), 11.85 (CH3),
-9.34 (3 x CH3)
5.11.3 Synthesis of unsaturated ester 3.69
Pd2dba3.CHCl3, 
THF, 70°C
100%
OMEM
OMPM O
SnMe3
OH
OMEM
OMPM OMe
MeO
O
OH
O
O
Br
3.79
3.6
3.69
To a solution of stannane 3.79 (250 mg, 0.34 mmol, 1 eq.) in THF (1.7
ml) were added methyl-E -4-bromobutenoate (3.6) (81 µl, 0.68 mmol, 2 eq.) and
Pd2(dba)3 ·CHCl3 (5 mg, 5.1 µmol, 1.5 mol%) in a pressure tube and the resulting
red-brown mixture was heated to 70◦C, upon which it colored yellow. TLC-analysis
(hexane/acetone 7/3) after 4h showed complete conversion of the starting material.
The reaction was then quenched with a saturated aqueous solution of NaHCO3 (15
ml), extracted with CH2Cl2 (4 x 15 ml), dried over MgSO4 and concentrated. Flash
column chromatography (hexane/acetone 8/2) yielded the unsaturated ester 3.69
(228 mg, 0.34 mmol, 100%) as a yellow oil.
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Name: (3S,5S,7S,10R,8Z )-5-methoxy-7-((4’-methoxybenzyl)oxy)-10-(((2”-meth-
oxyethoxy)methoxy)methyl)-2,8-dimethyl-2-(3”’-(trimethylstannyl)phenyl)-
dodec-8-en-3-ol
Formula: C39H58O9
Molecular weight: 670.9 g/mol
Rf: 0.14 (hexane/acetone 8/2)
ESI-MS (m/z): 688.4 (M+NH4
+)
HR-MS: calculated for (M+Na+) 693.3973, found 693.3968 (∆ 0.7 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.25-7.19 (m, 4H), 7.16-7.14 (m, 1H),
7.09 (app. dt, J = 15.6, 6.9 Hz, 1H), 7.00-6.97 (m, 1H), 6.85 (app. d, J =
8.9 Hz, 2H), 5.81 (app. dt, J = 15.4, 1.7 Hz, 1H), 5.17 (app. dd, J = 10.4,
1.5 Hz, 1H), 4.70 (d, J = 6.7 Hz, 1H, A part of AB-spinsystem), 4.69 (d, J =
6.7 Hz, 1H, B part of AB-spinsystem), 4.35 (d, J = 11.4 Hz, 1H), 4.27 (dd,
J = 9.8, 3.4 Hz, 1H), 4.05 (d, J = 11.3 Hz, 1H), 3.83 (ddd, J = 10.3, 3.4,
2.0 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 3.68-3.65 (m, 2H), 3.56-3.46 (m, 6H),
3.42 (dd, J = 9.4, 6.8 Hz, 1H), 3.37 (s, 3H), 3.23 (s, 3H), 2.80 (d, J = 3.4
Hz, 1H), 2.59-2.50 (m, 1H), 2.16 (ddd, J = 14.1, 9.6, 4.6 Hz, 1H), 1.70 (d,
J = 1.6 Hz, 3H), 1.57-1.46 (m, 2H), 1.44 (ddd, J = 14.7, 10.2, 4.6 Hz, 1H),
1.36 (ddd, J = 14.5, 6.2, 2.0 Hz, 1H), 1.27-1.19 (m, 1H), 1.24 (s, 3H), 1.23
(s, 3H), 0.83 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 167.06 (C), 159.26 (C), 148.08 (C), 148.00
(CH), 137.36 (C), 136.25 (C), 131.46 (CH), 130.95 (C), 129.64 (2 x CH),
128.48 (CH), 127.29 (CH), 126.42 (CH), 125.21 (CH), 121.92 (CH), 113.90
(2 x CH), 95.68 (CH2), 77.26 (CH), 76.01 (CH), 73.20 (CH), 71.92 (CH2),
71.42 (CH2), 69.64 (CH2), 66.88 (CH2), 59.17 (CH3), 56.45 (CH3), 55.42
(CH3), 51.59 (CH3), 42.44 (C), 39.24 (CH), 38.92 (CH2), 36.53 (CH2), 33.72
(CH2), 25.28 (CH2), 24.45 (CH3), 23.97 (CH3), 18.11 (CH3), 11.83 (CH3)
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5.11.4 Synthesis of saturated ester 3.70
NiCl2.6H2O, NaBH4,
MeOH, 0°C
96%
OMEM
OMPM OMe
MeO
O
OH
OMEM
OMPM OMe
MeO
O
OH
3.69 3.70
To a solution of unsaturated ester 3.69 (111 mg, 0.18 mmol, 1 eq.) in MeOH
(3.6 ml), was added NiCl2 · 6 H2O (1 mg, 0.7 mol, 4 mol%) and the red solution
was cooled to 0◦C. Then, NaBH4 (14 mg, 0.36 mmol, 2 eq.) was added, gas started
to evolve and the solution turned first brown, then black. After 10’, TLC-analysis
(hexane/acetone 8/2) showed complete conversion of the starting material, upon
which the reaction mixture was filtered over Celite and concentrated. Flash column
chromatography (hexane/acetone 8/2) yielded saturated ester 3.70 (116 mg, 0.17
mmol, 96%) as a colorless oil.
Name: Methyl 4-(3’-((3”S,5”S,7”S,10”R,8”Z )-3”-hydroxy-5”-methoxy-7”-((4”’-
methoxybenzyl)oxy)-10”-(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-di-
methyldodec-8”-en-2”-yl)phenyl) butanoate
Formula: C39H60O9
Molecular weight: 672.9 g/mol
Rf: 0.3 (hexane/acetone 8/2)
[α]D: -48.2
◦ (c: 7.3 mg/ml in CHCl3)
HR-MS: calculated for (M+Na+) 695.4130, found 695.4115 (∆ 2.2 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = (7.23-7.16 (m, 5H), 7.00 (app. dt, J =
6.7, 1.8 Hz, 1H), 6.85 (app. d, J = 8.7 Hz, 2H), 5.17 (dd, J = 10.5, 1.6 Hz,
1H), 4.69 (d, J = 6.6 Hz, 1H, A part of AB-spinsystem), 4.68 (d, J = 6.6
Hz, 1H, B part of AB-spinsystem), 4.34 (d, J = 11.3 Hz, 1H), 4.28 (dd, J =
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9.6, 3.5 Hz, 1H), 4.07 (d, J = 11.3 Hz, 1H), 3.85 (dd, J = 9.5, 2.8 Hz, 1H),
3.80 (s, 3H), 3.69-3.65 (m, 2H), 3.66 (s, 3H), 3.56-3.48 (m, 3H), 3.49 (dd, J
= 9.5, 5.9 Hz, 1H), 3.42 (dd, J = 9.4, 6.7 Hz, 1H), 3.37 (s, 3H), 3.24 (s, 3H),
2.65-2.52 (m, 3H), 2.32 (app. t, J = 7.4 Hz), 2H), 2.15 (ddd, J = 14.4, 9.8,
4.5 Hz, 1H), 1.98-1.91 (m, 2H), 1.70 (d, J = 1.4 Hz, 3H), 1.56-1.37 (m, 4H),
1.27 (s, 3H), 1.25 (s, 3H), 1.24-1.18 (m, 1H), 0.84 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 174.05 (C), 159.34 (C), 147.70 (C), 141.14
(C), 136.38 (C), 131.41 (CH), 131.18 (C), 129.56 (2 x CH), 128.22 (CH),
127.08 (CH), 126.11 (CH), 124.52 (CH), 113.98 (2 x CH), 95.77 (CH2), 77.26
(CH), 76.10 (CH), 73.49 (CH), 72.01 (CH2), 71.54 (CH2), 69.76 (CH2), 66.98
(CH2), 59.13 (CH3), 56.41 (CH3), 55.45 (CH3), 51.56 (CH3), 42.48 (C), 39.29
(CH), 36.95 (CH2), 35.62 (CH2), 34.23 (CH2), 33.67 (CH2), 26.79 (CH2),
25.35 (CH2), 24.54 (CH3), 23.94 (CH3), 18.10 (CH3), 11.78 (CH3)
5.11.5 Synthesis of alcohol 3.71
DDQ, pH7 buffer, 
CH2Cl2, 0°C
96%
OMEM
OH OMe
MeO
O
OH
OMEM
OMPM OMe
MeO
O
OH
3.70 3.71
To a solution of ester 3.70 (68 mg, 102 µmol, 1 eq.) in CH2Cl2 (5 ml) and pH 7
phosphate buffer (0.5 ml) at 0◦C was added 2,3-dichloro-5,6-dicyanobenzoquinone
(115 mg, 508 µmol, 5 eq.) in one portion. The reaction mixture was stirred
at 0◦C for 2 h, after which TLC-analysis (hexane/acetone 8/2) showed complete
conversion of the starting material. The reaction was quenched using a saturated
aqueous solution of NaHCO3 (5 ml) and water (5ml), diluted with CH2Cl2 (5 ml)
and the phases were separated. The aqueous phase was extracted with CH2Cl2 (3
x 10 ml), the combined organic phases are dried over MgSO4 and concentrated.
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Flash column chromatography (hexane/acetone 8/2) provides 3.71 as a colorless
oil (53 mg, 96 µmol, 96%).
Name: Methyl 4-(3’-((3”S,5”S,7”S,10”R,8”Z )-3”,7”-dihydroxy-5”-methoxy-10”-
(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-dimethyldodec-8”-en-2”-yl)-
phenyl)butanoate
Formula: C31H52O8
Molecular weight: 552.7 g/mol
Rf: 0.07 (hexane/acetone 8/2)
[α]D: -15.8
◦ (c: 7.3 mg/ml in CHCl3)
HR-MS: calculated for (M+Na+) 575.3554, found 575.3550 (∆ 0.8 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.25-7.18 (m, 3H), 7.04-6.99 (m, 1H),
4.97 (dd, J = 10.1, 1.6 Hz, 1H), 4.68 (d, J = 6.8 Hz, 1H, A part of AB-
spinsystem), 4.66 (d, J = 6.8 Hz, 1H, B part of AB-spinsystem), 4.57 (dd, J
= 8.7, 4.6 Hz, 1H), 3.90 (dd, J = 10.2, 1.4 Hz, 1H), 3.67-3.61 (m, 2H), 3.65
(s, 3H), 3.56-3.44 (m, 4H), 3.38 (s, 3H), 3.29-3.23 (m, 1H), 3.28 (s, 3H), 3.00
(bs, 1H), 2.84 bs, 1H), 2.64-2.54 (m, 3H), 2.33 (app. t, J = 15.2 Hz, 2H),
2.03 (ddd, J = 14.4, 8.5, 6.9 Hz, 1H), 1.99-1.91 (m, 2H), 1.70 (d, J = 1.3 Hz,
3H), 1.62-1.38 (m, 4H), 1.33 (s, 3H), 1.32 (s, 3H), 1.23-1.12 (m, 1H), 0.84
(app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 174.11 (C), 147.49 (C), 141.19 (C), 139.60
(C), 130.67 (CH), 128.27 (CH), 127.02 (CH), 126.23 (CH), 124.42 (CH), 95.50
(CH2), 78.66 (CH), 76.24 (CH), 71.90 (CH2), 71.26 (CH2), 67.02 (CH2), 66.49
(CH), 59.15 (CH3), 56.80 (CH3), 51.66 (CH3), 42.46 (C), 39.30 (CH), 37.27
(CH2), 35.57 (CH2), 34.25 (CH2), 33.61 (CH2), 26.78 (CH2), 25.04 (CH2),
24.51 (CH3), 23.82 (CH3), 18.30 (CH3), 11.95 (CH3)
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5.11.6 Synthesis of carboxylic acid 3.72
LiOH.H2O, THF:H2O 
1:1, RT
OMEM
OH OMe
HO
O
OH
OMEM
OH OMe
MeO
O
OH
3.71 3.72
To a solution of 3.71 (10 mg, 18 µmol, 1 eq.) in a mixture of THF (360
µl) and water (360 µl) is added LiOH ·H2O (7 mg, 180 µmol, 10 eq.) at RT.
The reaction mixture was stirred overnight. TLC-analysis (hexane/ acetone 6/4)
indicated complete conversion of the starting material. The reaction mixture was
then poured into a saturated aqueous NH4Cl solution (5 ml), extracted with EtOAc
(5 x 5 ml), dried over MgSO4 and concentrated. Dry toluene (1 ml) is added to
the crude product and evaporated, yielding crude carboxylic acid 3.72 (10 mg, 18
µmol, 100%) as a clear oil, which is used without further purification.
Name: Methyl 4-(3’-((3”S,5”S,7”S,10”R,8”Z )-3”,7”-dihydroxy-5”-methoxy-10”-
(((2””-methoxyethoxy)methoxy)methyl)-2”,8”-dimethyldodec-8”-en-2”-yl)-
phenyl) butanoic acid
Formula: C30H50O8
Molecular weight: 538.7 g/mol
Rf: 0.55 (CH2Cl2/MeOH/AcOH 95/5/1)
ESI-MS (m/z): 537.2 (M-H+)
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5.11.7 Synthesis of macrolactone 3.73
i) 2,4,6-trichlorobenzoylchloride, 
DIPEA, PhMe, RT
ii) DMAP, PhMe, RT
OMEM
OH OMe
HO
O
OH
O
O
O
OHMEMO
H
88%
2 steps
3.72 3.73
To a solution of the crude carboxylic acid 3.72 (10 mg, 18 µmol, 1 eq.) in
PhMe (540 µl) were added consecutive DIPEA (24 µl, 135 µmol, 7.5 eq.) and
2,4,6-trichlorobenzoylchloride (14 µl, 90 µmol, 5 eq.) at RT. After 45’ of anhydride
formation, the reaction mixture was diluted with PhMe (5 ml), and sucked into
a syringe. The flask was rinsed with PhMe (4.4 ml in 3 times) and everything
was added to the same syringe. The solution containing the anhydride (10 ml
total volume) was then added at RT over 12h (0.8 ml/h) to a solution of DMAP
(55 mg, 450 mmol, 25 eq.) in PhMe (18 ml) using a syringe pump. 22h after
the start of the addition, TLC-analyis (CH2Cl2/MeOH/AcOH 95/5/1) showed
complete conversion of the starting material. The reaction was poured into diluted
HCl (20 ml, 0.1 M) and the phases were separated. The aqueous phase was
extracted with EtOAc (2 x 30 ml), the combined organic phases were washed with a
saturated aqueous NaHCO3 solution (25 ml), dried over MgSO4 and concentrated.
Purification using flash column chromatography (hexane/acetone 88/12) delivered
the macrocyclic ester 3.73 as a sticky oil (8 mg, 15 µmol, 88% over 2 steps).
Name: (3’R, 7S, 9R, 11S, 1’Z)-11-hydroxy-9-methoxy-7-(3’-(2”-methoxyethoxy-
methoxymethyl)-1’-methylpent-1’-enyl)-12,12-dimethyl-6-oxabicyclo-[11.3.1]-
heptadeca-1(17)-13,15-trien-5-one
Formula: C30H48O7
Molecular weight: 520.7 g/mol
Rf: 0.39 (hexane/acetone 9/1)
247
5.11. Synthesis of the 2,3-dideoxy analog
[α]D: -72.7
◦ (c:7.3 mg/ml in CHCl3)
ESI-MS (m/z): 538.3 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 538.3738, found 538.3753 (∆ 2.8 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.28-7.23 (m, 2H), 7.06-7.01 (m, 2H),
5.52 (dd, J = 10.4, 1.3 Hz, 1H), 4.97 (dd, J = 10.4, 1.4 Hz, 1H), 4.704 (d, J
= 6.9 Hz, 1H, A part of AB-spinsystem), 4.695 (d, J = 6.9 Hz, 1H, B part
of AB-spinsystem), 3.79-3.74 (m, 1H), 3.74-3.64 (m, 2H), 3.61-3.54 (m, 2H),
3.50 (dd, J = 9.4, 5.0 Hz, 1H) 3.40 (s, 3H), 3.40-3.33 (m, 2H), 3.36 (dd, J =
9.4, 6.7 Hz, 1H), 3.23 (s, 3H), 2.88 (ddd, J = 13.5, 8.6, 4.7 Hz, 1H), 2.69-2.61
(m, 2H), 2.29-2.16 (m, 3H), 1.93 (ddd, J = 17.6, 10.3, 2.9 Hz, 1H), 1.89-1.79
(m, 2H), 1.66-1.50 (m, 3H), 1.57 (d, J = 1.5 Hz), 1.40 (s, 3H), 1.37 (s, 3H),
1.21-1.14 (m, 1H), 1.05 (ddd, J = 14.8, 8.5, 2.4 Hz, 1H), 0.81 (app. t, J =
7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 171.70 (C), 145.84 (C), 139.91 (C), 135.04
(C), 129.67 (CH), 128.60 (CH), 127.90 (CH), 126.57 (CH), 124.84 (CH), 95.68
(CH2), 77.03 (CH), 75.95 (CH), 72.00 (CH2), 70.91 (CH2), 68.37 (CH), 66.75
(CH2), 59.15 (CH3), 56.59 (CH3), 42.38 (C), 39.36 (CH), 36.79 (CH2), 35.55
(CH2), 34.53 (CH2), 31.49 (CH2), 27.54 (CH3), 25.16 (CH2), 23.47 (CH3),
23.22 (CH2), 18.67 (CH3), 11.84 (CH3)
5.11.8 Synthesis of 2,3-dideoxy analog 3.74
n-BuSH, ZnBr2, 
CH2Cl2, RT
96% O
O
O
OHHO
H
O
O
O
OHMEMO
H
3.73 3.74
To a solution of the MEM-ether 3.73 (7 mg, 13 µmol, 1 eq.) in CH2Cl2 (540
µl) was added n-BuSH (2 µl, 20 µmol, 1.5 eq.) and ZnBr2 (5 mg, 20 µmol, 1.5
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eq.) at RT. The reaction was followed using TLC-analysis (hexane/acetone 8/2)
and stirred for 25’, after which the mixture was poured into a saturated aque-
ous NaHCO3 solution (5 ml). The mixture was extracted with CH2Cl2 (4 x 5
ml), dried over MgSO4 and concentrated. Flash column chromatography (hex-
ane/acetone 8/2) delivered the 3.74 as a white solid (5.5 mg, 12.5 µmol, 96%).
Before submitting the sample to biological testing, it was extra purified using
preparative HPLC (Luna C18 column, 50% MeCN to 100% MeCN in 30 minutes).
Name: (3’R, 7S, 9R, 11S, 1’Z)-11-hydroxy-9-methoxy-7-(3’-hydroxymethyl-1’-
methylpent-1’-enyl)-12,12-dimethyl-6-oxabicyclo-[11.3.1]-heptadeca-1(17)-
13,15-trien-5-one
Formula: C26H40O5
Molecular weight: 432.6 g/mol
Rf: 0.19 (hexane/acetone 8/2)
[α]D: -53.7
◦ (c: 5.6 mg/ml in CHCl3)
ESI-MS (m/z): 450.3 (M+NH4
+)
HR-MS: calculated for (M+NH4
+) 433.2949, found 433.2958 (∆ 2.2 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.30-7.22 (m, 2H), 7.06-7.02 (m, 2H),
5.46 (dd, J = 10.5, 1.2 Hz, 1H), 4.91 (dd, J = 10.8, 1.5 Hz, 1H), 3.76 (dd,
J = 8.9, 2.4 Hz, 1H), 3.63 (dd, J = 10.3, 4.1 Hz, 1H), 3.46-3.40 (m, 1H),
3.27 (s, 3H), 3.24 (app. t, J = 10.1 Hz, 1H), 2.83 (ddd, J = 13.7, 8.8, 4.6
Hz, 1H), 2.67-2.58 (m, 2H), 2.27 (ddd, J = 17.2, 6.8, 3.4, 1H), 2.24-2.15 (m,
1H), 1.96 (ddd, J = 17.2, 10.2, 3.3 Hz, 1H), 1.89 (ddd, J = 15.1, 10.4, 2.7
Hz, 1H), 1.88-1.80 (m, 1H), 1.65 (ddd, J = 15.1, 5.8, 1.5 Hz, 1H), 1.57 (d, J
= 1.4 Hz, 3H), 1.50 (ddd, J = 14.8, 11.0, 2.4 Hz, 1H), 1.41 (s, 3H), 1.41-1.34
(m, 1H), 1.38 (s, 3H), 1.11-1.04 (m, 1H), 1.01 (ddd, J = 14.9, 8.9, 2.4 Hz,
1H), 0.82 (app. t, J = 7.4 Hz, 3H)
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APT (125 MHz; CDCl3): δ (ppm) = 173.27 (C), 145.74 (C), 139.84 (C), 136.10
(C), 131.24 (CH), 128.73 (CH), 128.10 (CH), 126.56 (CH), 124.79 (CH),
76.80 (CH), 75.80 (CH), 69.58 (CH), 66.85 (CH2), 56.84 (CH3), 42.71 (CH),
42.39 (C), 37.04 (CH2), 35.34 (CH2), 34.44 (CH2), 31.55 (CH2), 27.56 (CH3),
24.80 (CH2), 23.47 (CH2), 23.07 (CH3), 18.10 (CH3), 12.05 (CH3)
5.12 Ring-closing metathesis approach
5.12.1 Synthesis of ketone 3.84
4Â Molecular sieves,
TPAP, NMO, CH2Cl2, RT
95%
OMEM
OMPM O
SnMe3
OH
OMEM
OMPM O
SnMe3
O
3.79 3.84
To a flask, containing molecular sieves 4A˚ (408 mg) and N -methylmorpholine-
N -oxide (60 mg, 0.49 mmol, 3 eq.), was added a solution of 3.79 (120 mg, 0.16
mmol, 1 eq.) in CH2Cl2 (8.16 ml). Next, tetrapropylammonium perruthenate (4.5
mg, 0.013 mmol, 0.075 eq.) was added in one portion and the reaction mixture
was stirred at RT for 24h, after which TLC-analysis (hexane/acetone 9/1) showed
complete conversion of the starting material. The reaction mixture was filtered
over a P4 filter and to the filtrate a saturated aqueous solution of NH4Cl (8 ml) and
water (8ml) were added. The isolated organic phase was dried over MgSO4, con-
centrated and purified using flash column chromatography (hexane/EtOAc 8/2),
yielding 3.84 (113 mg, 95 %).
Name: (5R,7S,10R,8Z )-5-methoxy-7-((4’-methoxybenzyl)oxy)-10-(((2”-methoxy-
ethoxy)methoxy)methyl)-2,8-dimethyl-2-(3”’-(trimethylstannyl)phenyl)do-
dec-8-en-3-one
Formula: C37H58O7Sn
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Molecular weight: 733.6 g/mol
Rf: 0.28 (hexane/acetone 9/1)
HR-MS: calculated for (M+NH4
+) 752.3543, found 752.3539 (∆ 0.5 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.35 (app. dt, J = 7.1, 1.1 Hz, 1H),
7.33-7.25 (m, 2H), 7.17 (app. d, J = 8.7 Hz, 2H), 7.12 (ddd, J = 7.8, 2.2, 1.2
Hz, 1H), 6.84 (app. d, J = 8.7 Hz, 2H), 5.17 (app.dd, J = 10.4, 1.5 Hz, 1H),
4.68 (d, J = 6.7 Hz, 1H, A part of AB-spinsystem), 4.67 (d, J = 6.7 Hz, 1H,
B part of AB-spinsystem), 4.32 (d, J = 11.1 Hz, 1H), 4.22 (dd, J = 8.7, 4.3
Hz, 1H), 4.08 (d, J = 11.2, 1H), 3.83-3.77 (m, 1H), 3.80 (s, 3H), 3.68-3.64
(m, 2H), 3.55-3.52 (m, 2H), 3.46 (dd, J = 9.4, 5.8 Hz, 1H), 3.39 (dd, J =
9.4, 6.6 Hz, 1H), 3.37 (s, 3H), 2.53 (dd, J = 17.3, 7.5 HZ, 1H), 2.50-2.42 (m,
1H), 2.20 (dd, J = 17.3, 4.8 Hz, 1H), 1.87 (ddd, J = 14.2, 8.8, 5.3 Hz, 1H),
1.68 (d, J = 1.4 Hz, 3H), 1.49-1.40 (m, 2H), 1.46 (s, 3H), 1.42 (s, 3H), 1.16
(ddt, J = 15.2, 13.5, 7.6 Hz, 1H), 0.74 (app. t, J = 7.5 Hz, 3H), 0.26 (s, 9H,
satellitepeaks: d, J(1H-119Sn) = 55.2 Hz, d, J(1H-117Sn) = 52.7 Hz)
APT (125 MHz; CDCl3): δ (ppm) = 211.70 (C), 159.12 (C), 143.46 (C), 142.90
(C), 136.08 (C), 134.42 (CH), 133.41 (CH), 131.59 (CH), 131.25 (C), 129.49
(2 x CH), 128.30 (CH), 126.28 (CH), 113.84 (2 x CH), 95.67 (CH2), 74.70
(CH), 73.23 (CH), 71.92 (CH2), 71.38 (CH2), 69.54 (CH2), 66.85 (CH2), 59.17
(CH3), 56.72 (CH3), 55.42 (CH3), 52.54 (C), 42.35 (CH2), 39.05 (CH), 37.82
(CH2), 25.38 (CH3), 25.30 (CH3), 25.23 (CH2), 18.03 (CH3), 11.74 (CH3),
-9.37 (3 x CH3)
5.12.2 Synthesis of stannane 3.85
DDQ, pH7 buffer,
CH2Cl2, 0°C
94%
OMEM
OMPM O
SnMe3
O
OMEM
OH O
SnMe3
O
3.84 3.85
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To a solution of 3.84 (96 mg, 0.13 mmol, 1 eq.) in CH2Cl2 (6.5 ml) were added
a pH 7 phosphate buffer (0.65 ml) and DDQ (149 mg, 0.65 mmol, 5 eq.) at 0◦C.
The reaction mixture was stirred for 1h at that temperature, after which TLC-
analysis (hexane/EtOAc) showed complete conversion of the starting material.
The reaction mixture was transferred to a separation funnel containing water (10
ml) and a saturated aqueous solution of NaHCO3 (10 ml), and extracted with
CH2Cl2 (4 x 20 ml). After drying over MgSO4, the product was purified using
gradual flash column chromatography (hexane/acetone 9/1 to 8/2), providing 3.85
(75 mg, 94%).
Name: (5R,7S,10R,8Z )-5-methoxy-7-hydroxy-10-(((2”-methoxyethoxy)methoxy)-
methyl)-2,8-dimethyl-2-(3”’-(trimethylstannyl)phenyl)dodec-8-en-3-one
Formula: C29H50O6Sn
Molecular weight: 613.4 g/mol
Rf: 0.32 (hexane/acetone 8/2)
HR-MS: calculated for (M+Na+) 637.2522, found 637.2523 (∆ 0.2 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.38 (app. dt, J = 7.1, 1.1 Hz, 1H),
7.35-7.33 (m, 1H), 7.31 (app. t, J = 7.4 Hz, 1H), 7.19 (ddd, J = 7.8, 2.2, 1.3
Hz), 4.98 (app. dd, J = 10.1, 1.5 Hz, 1H), 4.68 (d, J = 6.8 Hz, 1H, A part
of AB-spinsystem), 4.67 (d, J = 6.8 Hz, 1H, B part of AB-spinsystem), 4.60
(app. t, J = 6.6 Hz, 1H), 3.71-3.63 (m, 3H), 3.56-3.53 (m, 2H), 3.50 (dd, J =
9.3, 5.0 Hz, 1H), 3.38 (s, 3H), 3.28 (dd, J = 9.0, 8.6 Hz, 1H), 2.96 (d, J = 1.5
Hz, 1H), 2.64-2.55 (m, 1H), 2.61 (dd, J = 17.2, 5.2 Hz, 1H), 2.30 (dd, J =
17.2, 7.1 Hz, 1H), 1.71 (d, J = 1.5 Hz, 3H), 1.68-1.59 (m, 1H), 1.54-1.40 (m,
2H), 1.50 (s, 3H), 1.48 (s, 3H), 1.23-1.13 (m, 2H), 0.84 (app. t, J = 7.5 Hz,
3H), 0.28 (s, 9H, satellitepeaks: d, J(1H-119Sn) = 55.2 Hz, d, J(1H-117Sn) =
52.8 Hz)
APT (125 MHz; CDCl3): δ (ppm) = 211.68 (C), 143.16 (C), 143.03 (C), 139.40
(C), 134.62 (CH), 133.37 (CH), 130.56 (CH), 128.42 (CH), 126.24 (CH), 95.54
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(CH2), 76.59 (CH), 71.91 (CH2), 71.34 (CH2), 67.17 (CH), 66.96 (CH2), 59.15
(CH3), 56.96 (CH3), 52.71 (C), 42.28 (CH2), 39.24 (CH), 39.03 (CH2), 25.20
(CH3), 25.16 (CH3), 25.10 (CH2), 18.15 (CH3), 11.96 (CH3), -9.33 (3 x CH3)
5.12.3 Synthesis of ester 3.86
CH2CHCOCl, 
DIPEA, CH2Cl2, RT
71%
OMEM
OH O
SnMe3
O
OMEM
O OMe
SnMe3
O
O
3.85 3.86
To a solution of 3.85 (35.6 mg, 58 µmol, 1 eq.) in CH2Cl2 (0.58 ml) was
added DIPEA (0.15 ml, 0.87 mmol, 15 eq.) and the mixture was cooled to 0◦C.
Then, acryloyl chloride (5.8 ml, 0.58 mmol, 10 eq., 0.1 M solution in CH2Cl2) was
added and the reaction mixture was stirred for 1h at 0◦C, then warmed to RT and
stirred further for 2h. TLC-analysis (hexane/ acetone 8/2) did not show complete
conversion of the starting material, but the reaction was quenched anyway by
addition of a saturated aqueous solution of NH4Cl (10 ml). The reaction was
extracted with CH2Cl2 (4 x 10 ml), dried over MgSO4 and concentrated. Flash
column chromatography deliverd 3.86 (27.4 mg, 71%) as a clear oil. Also the
non-reacted starting material could be recuperated (6 mg, 84% yield based on
recovered starting material).
Name: (5R,7S,10R,8Z )-2’-(3”-(trimethylstannyl)phenyl)-3’-oxo-2’,8’-dimethyl-
10’-(((2”’-methoxyethoxy)methoxy)methyl)-dodec-8’-en-7’-yl butenoate
Formula: C32H52O7Sn
Molecular weight: 667.5 g/mol
Rf: 0.48 (hexane/acetone 8/2)
HR-MS: calculated for (M+NH4
+) 686.3073, found 686.3069 (∆ 0.6 ppm)
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1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.36 (app. dt, J = 7.1, 1.1 Hz, 1H),
7.32-7.28 (m, 2H), 7.18 (ddd, J = 7.8, 2.1, 1.3 Hz, 1H), 6.29 (dd, J = 17.3,
1.5 Hz, 1H), 6.01 (dd, J = 17.3, 10.4 Hz, 1H), 5.76 (dd, J = 7.8, 6.1 Hz, 1H),
5.74 (dd, J = 10.4, 1.5 Hz, 1H), 5.14 (dq, J = 10.2, 1.5 Hz, 1H), 4.65 (app.
s, 2H), 3.69-3.61 (m, 3H), 3.55-3.52 (m, 2H), 3.44 (dd, J = 9.5, 5.6 Hz, 1H),
3.40 (dd, J = 9.5, 6.1 Hz, 1H), 3.38 (s, 3H), 3.13 (s, 3H), 2.69-2.61 (m, 1H),
2.58 (dd, J = 17.3, 6.1 Hz, 1H), 2.25 (dd, J = 17.3, 6.3 Hz, 1H), 1.83 (app.
dt, J = 14.4, 7.3 Hz, 1H), 1.71 (d, J = 1.5 Hz, 3H), 1.63 (ddd, J = 14.3, 6.1,
4.8 Hz, 1H), 1.56-1.50 (m, 1H), 1.48 (s, 3H), 1.46 (s, 3H), 1.27-1.17 (m, 1H),
0.82 (app. t, J = 7.5 Hz, 3H), 0.28 (s, 9H, satellitepeaks: d, J(1H-119Sn) =
55.5 Hz, d, J(1H-117Sn) = 52.8 Hz)
APT (125 MHz; CDCl3): δ (ppm) = 211.42 (C), 165.01 (C), 143.12 (C), 143.07
(C), 134.57 (CH), 133.77 (C), 133.39 (CH), 132.07 (CH), 130.34 (CH2),
129.02 (CH), 128.44 (CH), 126.17 (CH), 95.62 (CH2), 74.44 (CH), 71.97
(CH2), 70.67 (CH2), 70.15 (CH), 66.70 (CH2), 59.12 (CH3), 56.46 (CH3),
52.64 (C), 41.75 (CH2), 39.32 (CH), 37.09 (CH2), 25.43 (CH3), 25.09 (CH2),
25.03 (CH3), 18.62 (CH3), 11.76 (CH3), -9.35 (3 x CH3)
5.12.4 Synthesis of diene 3.87
CH2CHCH2Br,
Pd2(dba)3.CHCl3,60°C
95%
OMEM
O OMe O
O
OMEM
O OMe
SnMe3
O
O
3.86 3.87
In a pressure tube containing 3.86 (27.4 mg, 41 µmol, 1 eq.) in pure allyl-
bromide (0.41 ml) was added Pd2(dba)3 ·CHCl3 (2mg, 2 µmol, 0.05 eq.) and the
reaction mixture was heated to 60◦C. After 45’, TLC analysis (Hexane/EtOAc
8/2) showed complete conversion of the starting material, and the reaction mix-
ture was poured in water (10 ml), extracted with Et2O (4 x 10 ml), dried over
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MgSO4 and concentrated. Purification by means of flash column chromatography
(hexane/EtOAc 8/2) provided diene 3.87 (21 mg, 95%) as a colorless oil.
Name: (5R,7S,10R,8Z )-2’-(3”-(prop-2”’-ene)phenyl)-3’-oxo-2’,8’-dimethyl-10’-
(((2””-methoxyethoxy)methoxy)methyl)-dodec-8’-en-7’-yl butenoate
Formula: C32H48O7
Molecular weight: 544.7 g/mol
Rf: 0.15 (hexane/EtOAc 8/2)
HR-MS: calculated for (M+NH4
+) 562.3738, found 562.3728 (∆ 1.9 ppm)
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.26 (app. t, J = 7.7 Hz, 1H), 7.10-7.06
(m, 2H), 7.03 (app. t, J = 2.0 Hz, 1H), 6.30 (dd, J = 17.3, 1.5 Hz, 1H), 6.01
(dd, J = 17.3, 10.4 Hz, 1H), 5.93 (dddd, J = 13.3, 10.9, 9.4, 6.6 Hz, 1H),
5.75 (dd, J = 10.4, 1.6 Hz, 1H), 5.75 (dd, J = 7.8, 5.9 Hz, 1H), 5.13 (app.
dd, J = 10.2, 1.5 Hz, 1H), 5.09-5.03 (m, 2H), 4.65 (app. s, 2H), 3.69-3.60
(m, 3H), 3.55-3.52 (m, 2H), 3.45 (dd, J = 9.5, 5.6 Hz, 1H), 3.40 (dd, J = 9.5,
6.1 Hz, 1H), 3.38 (s, 3H), 3.38-3.35 (m, 2H), 3.13 (s, 3H), 2.68-2.60 (m, 1H),
2.55 (dd, J = 17.2, 6.1 Hz, 1H), 2.23 (dd, J = 17.2, 6.2 Hz, 1H), 1.82 (ddd,
J = 14.4, 7.6, 7.0 Hz, 1H), 1.70 (d, J = 1.5 Hz, 3H), 1.61 (ddd, J = 14.4,
5.9, 4.8 Hz, 1H), 1.57-1.50 (m, 1H), 1.47 (s, 3H), 1.45 (s, 3H), 1.27-1.17 (m,
1H), 0.82 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 211.31 (C), 165.01 (C), 143.82 (C), 140.64
(C), 137.32 (CH), 133.81 (C), 131.99 (CH), 130.35 (CH2), 129.00 (CH),
128.95 (CH), 127.38 (CH), 126.65 (CH), 124.03 (CH), 116.17 (CH2), 95.62
(CH2), 74.47 (CH), 71.97 (CH2), 70.68 (CH2), 70.16 (CH), 66.71 (CH2), 59.12
(CH3), 56.46 (CH3), 52.53 (C), 41.75 (CH2), 40.41 (CH2), 39.33 (CH), 37.09
(CH2), 25.39 (CH3), 25.10 (CH2), 24.87 (CH3), 18.60 (CH3), 11.76 (CH3)
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5.12.5 Synthesis of macrolactone 3.98
OMEM
O OMe O
O
O
O
O
OMEMO
H
18% (E):
O
O
O
OMEMO
H
Grubbs II
PhMe, 120°C
28% (Z):
22%
3.87
3.97
3.98
3.99
In a flask fitted with a reflux condenser, containing 3.87 (17.2 mg, 32 µmol,
1 eq.) in toluene (31.6 ml ml) was added Grubbs 2nd generation catalyst (2.7
mg, 3.2 µmol, 0.1 eq.) at 110◦C. After 15 min, the reaction mixture was poured
in water (20 ml), the phases were separated and the aqueous phase was extracted
with Et2O (3 x 30 ml), dried over MgSO4 and concentrated. Purification by means
of consecutive flash column chromatography (hexane/acetone 8/2, CH2Cl2/Et2O
98/2) provided 3.98 (3 mg, 18%) as a colorless oil, together with 3.99 (4.5 mg,
28%) and 3.97 (3.5 mg, 22%).
Formula: C30H44O7
Molecular weight: 516.7 g/mol
HR-MS: calculated for (M+NH4
+) 534.3425, found 534.3412 (∆ 2.6 ppm)
Most apolar compound 3.99
Name: (1’Z,3Z,3’R,4S,7R,9S )-11-oxo-7-[3’-(2”-methoxyethoxymethoxymethyl)-
1’-methylpent-1’-enyl]-9-methoxy-12,12-dimethyl-6-oxabicyclo[11.3.1]hepta-
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deca-1(17),3,13,15-quadruplen-5-one
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.24 (app.t, J = 7.7 Hz, 1H), 7.21
(app.t, J = 1.8 Hz, 1H), 7.15 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.06 (app. d,
J = 7.6 Hz, 1H), 6.51 (ddd, J = 11.6, 8.9, 7.8 Hz, 1H), 5.87 (dd, J = 11.5,
1.9 Hz, 1H), 5.78 (dd, J = 9.9, 2.1 Hz, 1H), 5.99 (dq, J = 10.3, 1.5 Hz, 1H),
4.69 (app. s, 2H), 4.25 (ddd, J = 14.2, 7.7, 2.0 Hz, 1H), 3.73-3.64 (m, 2H),
3.58-3.55 (m, 2H), 3.49-3.35 (m, 4H), 3.40 (s, 3H), 3.18 (s, 3H), 2.73-2.65 (m,
1H), 2.65 (dd, J = 16.8, 8.8 Hz, 1H), 2.14 (dd, J = 16.8, 4.1 Hz, 1H), 1.97
(ddd, J = 15.1, 9.9, 3.0 Hz, 1H), 1.67 (d, J = 1.5 Hz, 3H), 1.66 (ddd, J =
15.1, 6.5, 2.1 Hz, 1H), 1.61-1.55 (m, 1H), 1.58 (s, 3H), 1.45 (s, 3H), 1.23-1.13
(m, 1H), 0.82 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 210.98 (C), 165.11 (C), 144.02 (CH), 143.73
(C), 140.23 (C), 135.13 (C), 130.26 (CH), 128.87 (CH), 127.54 (CH), 127.29
(CH), 123.81 (CH), 123.28 (CH), 95.66 (CH2), 74.41 (CH), 72.00 (CH2),
71.02 (CH2), 67.91 (CH), 66.74 (CH2), 59.15 (CH3), 56.87 (CH3), 52.23
(C), 41.16 (CH2), 39.46 (CH), 35.67 (CH2), 33.26 (CH2), 25.21 (CH2), 25.13
(CH3), 24.72 (CH3), 18.52 (CH3), 11.83 (CH3)
Middle compound 3.97
Name: (1’Z,2Z,3’R,4S,7R,9S )-11-oxo-7-[3’-(2”-methoxyethoxymethoxymethyl)-
1’-methylpent-1’-enyl]-9-methoxy-12,12-dimethyl-6-oxabicyclo[11.3.1]hepta-
deca-1(17),2,13,15-quadruplen-5-one
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.30 (app. t, J = 7.7 Hz, 1H), 7.26-7.21
(m, 2H), 7.01 (ddd, J = 7.4, 2.2, 1.2 Hz, 1H), 6.88 (d, J = 11.0 Hz, 1H),
5.88 (app. dt, J = 10.9, 8.1 Hz, 1H), 5.84 (dd, J = 9.8, 1.3 Hz, 1H), 5.03
(app. dd, J = 10.3, 1.4 Hz, 1H), 4.712 (d, J = 6.8 Hz, 1H, Apart of AB-
spinsystem), 4.706 (d, J = 6.8 Hz, 1H, B part of AB-spinsystem), 3.77-3.67
(m, 3H), 3.59-3.55 (m, 2H), 3.54 (dd, J = 9.4, 4.8 Hz, 1H), 3.43-3.38 (m,
1H), 3.40 (s, 3H), 3.23 (s, 3H), 2.92-2.88 (m, 2H), 2.84 (dd, J = 17.1, 9.3 Hz,
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1H), 2.78-2.69 (m, 1H), 1.92 (dd, J = 17.2, 4.1 Hz, 1H), 1.89 (ddd, J = 15.3,
5.3, 2.2 Hz, 1H), 1.81 (ddd, J = 15.4, 5.1, 1.5 Hz, 1H), 1.65-1.55 (m, 1H),
1.61 (d, J = 1.5 Hz, 3H), 1.54 (s, 3H), 1.49 (s, 3H), 1.25-1.15 (m, 1H), 0.83
(app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 211.57 (C), 170.44 (C), 144.00 (C), 138.06
(C), 134.93 (CH), 134.82 (C), 130.10 (CH), 128.81 (CH), 127.76 (CH), 126.67
(CH), 125.27 (CH), 124.28 (CH), 95.74 (CH2), 74.55 (CH), 72.01 (CH2),
70.86 (CH2), 68.72 (CH), 66.79 (CH2), 59.16 (CH3), 57.25 (CH3), 52.22
(C), 41.64 (CH2), 39.40 (CH), 34.75 (CH2), 34.01 (CH2), 25.22 (CH3), 25.18
(CH2), 24.58 (CH3), 18.42 (CH3), 11.83 (CH3)
Most polar compound 3.98
Name: (1’Z,3E,3’R,4S,7R,9S )-11-oxo-7-[3’-(2”-meth-oxyethoxymethoxymethyl)-
1’-methylpent-1’-enyl]-9-methoxy-12,12-dimethyl-6-oxabicyclo[11.3.1]hepta-
deca-1(17),3,13,15-quadruplen-5-one
1H-NMR (500 MHz; CDCl3): δ (ppm) = 7.27-7.23 (m, 2H), 7.17 (ddd, J = 8.0,
2.0, 1.2 Hz, 1H), 7.11 (app. dt, J = 7.4, 1.3 Hz, 1H), 6.85 (ddd, J = 15.9,
9.4, 4.8 Hz, 1H), 5.69 (ddd, J = 15.9, 1.9, 0.8 Hz, 1H), 5.68 (dd, J = 10.7,
1.8 Hz, 1H), 5.05 (app. dd, J = 10.5, 1.6 Hz, 1H), 4.72 (d, J = 6.6 Hz, 1H, A
part of AB-spinsystem), 4.71 (d, J = 6.6 Hz, 1H, B part of AB-spinsystem),
3.89 (s, 3H), 3.26 (s, 3H), 2.83 (dd, J = 18.0, 9.5 Hz, 1H), 2.76-2.68 (m, 1H),
1.91 (ddd, J = 15.3, 6.2, 2.1 Hz, 1H), 1.80 (ddd, J = 15.4, 10.5, 1.6 Hz, 1H),
1.80 (dd, J = 18.0, 2.4 Hz, 1H), 1.64 (d, J = 1.5 Hz, 3H), 1.64-1.57 (m, 1H),
1.53 (s, 3H), 1.50 (s, 3H), 1.25-1.16 (m, 1H), 0.84 (app. t, J = 7.5 Hz, 3H)
APT (125 MHz; CDCl3): δ (ppm) = 210.89 (C), 165.04 (C), 148.65 (CH), 143.83
(C), 139.62 (C), 134.91 (C), 131.08 (CH), 129.86 (CH), 129.11 (CH), 127.54
(CH), 124.45 (CH), 123.76 (CH), 95.83 (CH2), 73.97 (CH), 72.06 (CH2),
70.92 (CH2), 69.71 (CH), 66.89 (CH2), 59.10 (CH3), 57.45 (CH3), 53.32
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(C), 43.88 (CH2), 39.70 (CH), 37.85 (CH2), 35.38 (CH2), 25.27 (CH2), 25.13
(CH3), 24.32 (CH3), 18.84 (CH3), 11.89 (CH3)
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(+)-Peloruside A (6.1, figuur 6.1) is een natuurproduct dat cytotoxische ac-
tiviteit vertoont bij nanomolaire concentratie.52,75 Belangrijker echter, is dat het
werkt als microtubuli-stabiliserend middel op dezelfde manier als paclitaxel, e´e´n
van de belangrijkste hedendaagse chemotherapeutica.82 Peloruside werd enkel gevon-
den op enkele specifieke plaatsen in Nieuw-Zeeland, en kan niet geoogst worden uit
het gecultiveerd producerend organisme. Dit lage natuurlijk voorkomen gecom-
bineerd met de complexitieit zorgt er voor dat het niet als dusdanig als medicijn
kan dienen. Analyse van de structuur-activiteitsrelatie kan in dat geval gebruikt
worden om vereenvoudigde analogen te ontwerpen die niet inboeten aan activiteit,
en op die manier het volle potentieel van het natuurproduct uit te buiten.
Daarom werden in deze thesis enerzijds inspanningen geleverd om het belang
van de substituenten op de pyranosering van peloruside na te gaan. Dit werd
gedaan aan de hand van synthese van tetrahydropyranyl-analogen 6.2, via de
relatief onbekende Mukaiyama aldol - Prins reactie.99
Anderzijds werd een nieuwe synthese ontwikkeld voor een in ons lab eerder
gesynthetiseerd analoog, pelofen (6.3, figuur 6.1) waarin de pyranosering van
peloruside vervangen is door een fenylring.149,150 Deze nieuwe synthese moest ons
in staat stellen op een laat stadium kleine veranderingen toe te passen, en zo meer
te weten te komen over de SAR van dit vereenvoudigd analoog en bij uitbreiding
peloruside.
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Figure 6.1
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6.1 Tetrahydropyranyl analogen
The synthese van de tetrahydropyranyl-analogen (6.4, schema 6.1) is gebaseerd
op de aldolkoppeling van twee geavanceerde intermediairen: een methylketon 6.5,
dat twee stereocentra en de dubbele binding van de zijketen bevat en een aldehyde
6.6, dat de THP-ring en twee bijkomende stereocentra bevat. Voor de synthese
van laatstgenoemd fragment werd beroept op de Mukaiyama aldol-Prins (MAP)
reactie, een cascadereactie tussen een aldehyde 6.7 en een dubbel nucleofiel 6.8,
in aanwezigheid van een Lewiszuur.
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Scheme 6.1: Retrosynthese van de beoogde THP-analogen
De synthese van het C12 –C20 fragment 6.5 (schema 6.2) startte met de car-
bomagnesatie van dihydrofuran (6.9) met ethylmagnesium chloride (6.10), in een
reactie die gekatalyseerd wordt door zirconium, en doorgaat met excellente cont-
role over de enantioselectiviteit (>98:2).101 Het resulterende homoallylisch alcohol
werd beschermd als MEM-acetaal en de dubbele binding werd ge-ozonolyseerd, wat
het aldehyde 6.12 opleverde. De Z -dubbele binding werd gevormd door middel
van fosfonaat 6.18 in een modificatie van de Horner-Wadsworth-Emmons reactie,
ontwikkeld door Still en Gennari.104 De geometrie van de dubbele binding werd
bevestigd door middel van NOE NMR spectroscopie. Een reductie tot het alco-
hol, gevolgd door oxidatie resulteerde in aldehyde 6.15 hetwelke diastereoselectief
geallyleerd werd volgens Brown, met behulp van di-isopinocamfeylboraan.206 Dit
gebeurde zowel met een redelijk goed rendement (79%) als diastereomere overmaat
(90%). De stereochemie van het gevormde carbinol werd aangetoond aan de hand
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a) [(S,S)-ethylene-bis(4,5,6,7-tetrahydro-1-indenyl)]Zr(IV)BINOL , THF, 40h, RT; b) DIPEA, MEM-Cl, 
CH2Cl2, reflux; c) i) O3, CH2Cl2, -78°C; ii) Ph3P, CH2Cl2; d) 18-crown-6, KHMDS, THF, -78°C, 
(CF3CH2O)2POCH(CH3)CO2CH3; e) DIBAL-H, CH2Cl2, -78°C, 1h; f) DMP, pyridine, CH2Cl2, 1h, rt; g) 
i) (-)-Ipc2BOMe, allylMgBr, Et2O, -78°C; ii) NaOH, H2O2, RT; h) i) NaH, THF, 0°C; ii) MPM-Cl, TBAI, 
DMF, RT; i) PdCl2, Cu(OAc)2.H2O, DMF:H2O 9:1, O2, RT
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100% 95% 79%
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Scheme 6.2: Synthese van het C12-C20 fragment
van Mosher-ester analyse.207 Na bescherming van het homoallylisch alcohol 6.16
als MPM-ether, werd het eindstandig alkeen selectief omgezet tot methylketon 6.5
door gebruik te maken van een palladium-gekatalyseerde Wacker oxidatie.
Deze bouwsteen werd gesynthetiseerd in een lineaire sequentie van negen stap-
pen met een totaalrendement van 21%. Dit rendement is vooral te wijten aan
de eerste stap (carbomagnesatie) (40%) die werd geoptimaliseerd in termen van
katalysator turnover nummer.
Het tweede fragment 6.6 is zelf opgebouwd uit twee bouwstenen (schema 6.1).
De eerste hiervan, aldehyde 6.7, werd gesynthetiseerd, startend van D-mannitol,
waarvan vier hydroxyls beschermd werden met benzaldehyde als bis-1,3-4,6 ben-
zylideen acetaal (6.20) met 30% rendement (schema 6.3). De overblijvende al-
coholen werden gebenzyleerd, waarna de benzylideen acetalen opnieuw afgesplitst
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a) PhCHO, H2SO4, DMF, RT; b) KOH, DMSO, BnBr, RT c) HCl, MeOH/C6H14 5/3, RT; d) TBSCl, 
imidazole, CH2Cl2, RT; e) NaIO4, THF/H2O 4/1, RT
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Scheme 6.3: Synthese van aldehyde 6.7
werden, om te komen tot tetra-alcohol 6.22. Hiervan werden de primaire alco-
holen beschermd als silylethers, resulterend in bis-silyl ether 6.23. Oxidatieve
splitsing van het overblijvend diol gebeurde met natriumperiodaat in water en
leverde aldehyde 6.7 op in 19% rendement over 5 stappen.
OH OH MPMO OH MPMO O
MPMO OH MPMO O
a c d
e
a) 4-MeO-PhCH(OMe)2, CSA, CH2Cl2, RT; b) LiAlH4, AlCl3, Et2O, -10°C; c) i) (COCl)2, DMSO, -78°C 
ii) Et3N, CH2Cl2, -78°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, 
THF, allylOAc, 2-PrOH, 120°C;  e) Hg(CF3COO)2, EtOCHCH2, RT
92% 98% 96%
96% e.e.
73%
O O
b
99%
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6.28 6.29
Scheme 6.4: Synthese van bisnucleofiel 6.29
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De tweede bouwsteen voor de opbouw van het C1 –C11-fragment startte met
de acetalisering van 2,2-dimethyl-1,3-propaandiol met 4-methoxybenzyl dimethy-
lacetaal, gevolgd door reductieve splitsing tot alcohol 6.26 (schema 6.4). Dit werd
geoxideerd onder invloed van Swern condities, resulterend in aldehyde 6.27, het-
welke stereoselectief geallyleerd werd met behulp van een chirale iridium-katalysator
bij hoge temperaturen.132 Het resulterend homoallylisch alcohol 6.28 werd omgevormd
tot de vinylether door middel van een kwik-gekatalyseerde reactie, resulterend in
de vorming van het bisnucleofiel 6.29136 Het totaalrendement voor deze bouwsteen
bedroeg 62% over 5 stappen en de enantiomere overmaat bedroeg 96%.
MPMO O TBSO O
OBn
O O
OH
OBn
TBSO
TiBr4
2,6-DBMP
CH2Cl2
-78°C
6.29 6.7 6.30
Scheme 6.5: Eerste poging tot de Mukaiyama aldol - Prins reactie
Uit een eerste poging om de Mukaiyma aldol-Prins reactie tussen aldehyde 6.7
en enol ether 6.29 te bewerkstelligen, bleek dat de 4-methoxyfenylmethyl ether
(MPM) niet bestand was tegen de Lewis-zure condities die gebruikt werden voor
de cyclizatie (schema 6.5). Bijgevolg kon enkel acetaal 6.30 ge¨ısoleerd worden, en
werd het bisnucleofiel opnieuw gesynthetiseerd, ditmaal gebruik makend van een
minder electronenduwende beschermende groep, namelijk een naftoyl ester.
De synthese van de naftoyl-beschermde enol ether 6.35 startte met de enkelvou-
dige bescherming van diol 6.24 met naftoylchloride (schema 6.6). Swern oxidation
van het resulterende alcohol in 6.32 leverde aldehyde 6.33 op, dat dan opnieuw
geallyleerd werd, gebruik makend van de eerder toegepaste Krische-condities. Het
resulterende homoallylic alcohol 6.34 werd gevormd met een geisoleerd rendement
van 68% en een enantiomere overmaat van 98%. De laatste kwik-gekatalyseerde
vinylvorming gebeurde met een rendement van 82%. Globaal gezien, werd deze
tweede generatie enol ether gesynthetiseerd in 4 stappen met een totaalrendement
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BIPHEP, Cs2CO3, 4-Cl-3-NO2-benzoic acid, THF, allylOAc, 120°C; d) [Ir(cod)Cl]2, (S)-(-)-Cl, MeO-BIPHEP, Cs2CO3, 4-
Cl-3-NO2-benzoic acid, THF, allylOAc, 2-PrOH, 120°C;  e) Hg(CF3COO)2, EtOCHCH2, RT
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Scheme 6.6: Synthese van de ester beschermde C4-C11 enol ether 6.35
van 50% en met een excellente optische zuiverheid.
De tweede poging tot de Mukaiyama aldol - Prins reactie was succesvol in die
zin dat het volledige koolstofskelet gevormd werd in een behoorlijk rendement van
78% (schema 6.7). Helaas was de reactie minder succesvol in termen van diastere-
oselectiviteit: de beoogde bromo-tetrahydropyran ether 6.36 werd gevormd als
mengsel van diastereomere alcoholen op de C3 positie en als mengsel van axiaal en
equatoriaal bromide op de C7 positie, in equimolaire hoeveelheden.
O O TBSO O
OBn
TiBr4
2,6-DBMP
CH2Cl2, -78°C
78%
O
O O
O
Br
H
H
OHTBSO
OBn
1:1:1:1
3
5
79
6.37 6.38 6.36
Scheme 6.7: Mukaiyama aldol - Prins reactie met bisnucleofiel 6.39
Verschillende pogingen werden ondernomen om de diastereoselectiviteit op te
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krikken: andere Lewiszuren werden gebruikt, de volgorde van toevoegen werd
aangepast, de temperatuur werd beter gecontroleerd, ... Helaas resulteerden deze
pogingen niet in een verbetering van de diastereomere overmaat. Het opdrijven van
de omvang van het aldehyde door de TBDMS-ether te vervangen door een minder
zuurgevoelige TBDPS-ether, resulteerde niet in een verbetering in diastereomere
selectiviteit, maar verhoogde het rendement tot 84%.
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Scheme 6.8: Verdere synthese van het MAP-product 2.89
Omdat de analytische methoden niet toereikend waren, werd het complexe
mengsel van diastereomeren geanalyseerd aan de hand van chemische modificatie
(schema 6.8). Reductieve verwijdering van het bromide leverde een scheidbaar
mengsel van diastereomere C3-alcoholen (6.40 en 6.41) op, terwijl oxidatie van de
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C3-alcoholen een scheidbaar mengsel van equatoriaal 6.42 en axiaal 6.43 bromide
opleverden. De stereochemie van de C5-substituent was altijd cis in vergelijking
met de substituent op C9, waarvan de stereochemie eerder werd aangetoond na de
allylering.
Na de chromatografische scheiding werd keton 6.42 stereoselectief gereduceerd
met lithium selectride met vorming van alcohol 6.44 in 85% rendement, nu aan-
gerijkt in e´e´n diastereomeer. De configuratie van dit alcohol werd aangetoond door
de TBS-ether te ontschermen en een acetaal te vormen (6.45) tussen de alcoholen
op C1 en C3. Uit de Karplus vergelijking kon afgeleid worden dat het nieuw gevor-
mde carbinol centrum cis staat ten opzichte van de benzyloxy groep, waarvan de
stereochemie vaststaat, aangezien deze voortkomt uit de chiral pool.
Op dit ogenblik werd de focus van dit doctoraat bijgesteld naar de synthese van
fenyl-analogen. Verdere belangrijke stappen voor het vervolg van dit eerste deel
zijn (schema 6.9): de methylering van het C3-alcohol van 6.46, en transformatie
van het bromide 6.47 naar bijvoorbeeld methylether 6.48. Na ontscherming van
de naftoyl ester, moet het primaire alcohol geoxideerd worden naar aldehyde 6.49,
wat dan gekoppeld kan worden met het C12 –C20 fragment 6.5 tot 6.50. Daarna is
er nog een stereoselectieve reductie nodig om het koolstofskelet met de juiste stere-
ochemie te vervolledigen. Na selectieve methylering,57 oxidatie en ontscherming
zou dan het ω-hydroxyzuur gevormd worden, wat nodig is voor de macrolacton-
isatie. Eindontscherming zou dan resulteren in het 8,9-dehydroxy analoog 6.51
van peloruside.
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Scheme 6.9: Toekomstige stappen ter vervollediging van de synthese van het 8,9-
dehydroxy analoog van (+)-Peloruside A (6.54).
6.2 Fenyl analogen
6.2.1 Pelofen B via macrolactonisering
Voor pelofen B 6.3 (figuur 6.1) werd een verbeterde synthese ontwikkeld, startend
van het commercieel beschikbare 3-bromofenyl acetonitrile 6.55, hetwelke eerst
gealkyleerd werd tot 6.56 (scheme 6.10). Dit werd gereduceerd tot het imine,
wat na zure hydrolyse aldehyde 6.57 opleverde, met 89% rendement over 2 stap-
pen. Het C12 –C20 methylketone dat eerder gesynthetiseerd was (6.5) kon dan
gebruikt worden in een stereoselectieve aldolreactie onder invloed van dicyclo-
hexylboor chloride, resulterend in β-hydroxyketon 6.58 in 88% rendement, als een
enkel diastereomeer.153
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Scheme 6.10: Synthese van het C5 –C20 fragment in de vernieuwde synthese van
pelofen.
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Op dit stadium werd de absolute stereochemie toegewezen via Mosher-ester
synthese en analyse. In een volgende stap werd gebruik gemaakt van propionalde-
hyde en samarium dijodide in een Evans-Tishchenko reductie.165 Dit zorgde voor
differentiatie ten opzichte van een diol, waarbij een alcohol nu ester beschermd
is (6.59). Op dit stadium, werd ook de relatieve stereochemie tussen het alcohol
dat gegenereerd werd tijdens de aldolreactie (C11) en het alcohol dat gegenereerd
werd in de Evans-Tishchenko reductie (C13) aangetoond, door de synthese van een
acetonide (6.61, figuur 6.2), gevolgd door NMR-analyse. Ook werd de relatieve
stereochemie tussen het MPM-beschermd alcohol (C15) en het alcohol dat gevormd
werd tijdens de reductie aangetoond door de synthese van het corresponderende
PMP-acetaal (6.62, figuur 6.2) en opnieuw NMR-analyse. Na methylering van
het nieuw gevormde alcohol in 6.59, werd het arylisch bromide omgezet in het
trimethyltin derivaat 3.9 door middel van een palladium(0)-gekatalyseerde Stille
koppeling.
Voor de vervollediging van het koolstofskelet van het fenylanaloog 6.63 werd
het geavanceerd stannaan 6.60 gekoppeld met het commercieel beschikbare methyl
4-bromocrotonaat in een tweede Stille koppeling (scheme 6.11). Gebruik makend
van AD-mix β, werd de dihydroxylering van het olefine voltooid met een diastere-
omere overmaat van 97% en een rendement van 88%. Vervolgens werden beide
alcoholen beschermd als MOM-ethers met een rendement van 97%, en werd het
MPM beschermd alcohol selectief vrijgesteld met DDQ (95%).
De bedoeling was dan om beide resterende esters tegelijk te hydrolyseren onder
basische omstandigheden. Hierbij gaf het gebruik van LiOH de minste nevenpro-
ducten, maar de reactie duurde lang (meerdere dagen). Uiteindelijk werd het
γ-hydroxyzuur (6.64) gevormd met 83% rendement na 7 dagen zonder volledige
conversie bereikt te hebben.
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Scheme 6.11: Vervollediging van de synthese van pelofen.
Om de lange reactietijd te omzeilen, werd een andere tactiek toegepast: beide
esters werden reduceerd met LiALH4, terwijl de MPM ether nog intact was (scheme
6.12). Het resulterende primaire alcohol werd dan selectief geoxideerd tot het
carbonzuur, via het aldehyde. Daarna werd de MPM-ether afgesplitst in bijzijn
van het carbonzuur, met een rendement van 80% over vier stappen.
Voor de macrolactonisering werden verschillende condities getest, maar het oor-
spronkelijke rendement van 36%, onder Yamaguchi-Yonemitsu condities. Zowel
variatie in condities als activatiereagens, vertoonden geen verbetering in rende-
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Scheme 6.12: Alternatieve synthese van het ω-hydroxyzuur 6.64.
ment. De eindontscherming onder zure omstandigheden resulteerde in het feny-
lanaloog 6.63 met 77% rendement.
Globaal gezien werd de synthese van het fenylanaloog vervolledigd in 22 stap-
pen, in een langste lineaire sequentie van 20 stappen, startend van ethylmagne-
siumchloride, met een totaalrendement van 2.7%. Dit is lineair 1 stap minder dan
de oorspronkelijke synthese, 4 stappen minder wat betreft het totaal aantal stappen
en een verbetering in totaalrendement met ongeveer 400% (0.7% totaalrendement
in de originele route).
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6.2.2 Synthese van 2,3-dideoxy pelofen (6.73)
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a) LiAlH4, Et2O, 0°C; b) (E)-4-Br-CH2CHCHCOOMe, Pd2dba3.CHCl3, THF, 70°C; c) NiCl2.6H2O, 
NaBH4, MeOH, 0°C; d) DDQ, pH7 buffer, CH2Cl2, RT; e) LiOH.H2O THF:H2O 1:1 RT; f) i) 2,4,6-
trichlorobenzoylchloride, DIPEA, PhMe, RT; ii) DMAP, PhMe, RT; g) n-BuSH, ZnBr2, CH2Cl2, RT
6.60 6.69
6.70 6.71
6.72 6.73
Scheme 6.13: Synthese van het 2,3-dideoxy analoog van pelofen (6.73).
Een analoog van pelofen, waarin de substituenten op de C2 en C3 positie ont-
breken, kan informatie verschaffen over het belang van deze hydroxylgroepen voor
de activiteit. Dit 2,3-dideoxy analoog was relatief eenvoudig toegankelijk via de
hierboven beschreven route. (schema 6.13).
Startend van stannaan 6.60 werd het probleem van de moeilijke ontscherming
van de propionaatester ontweken door deze eerst te reduceren. Het resulterend
alcohol 6.69 vereiste geen beschermende groep voor de volgende stappen. De
Stille-koppeling met het voorheen gebruikte 4-bromocrotonaat, resulteerde in on-
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verzadigd ester 6.70. Hiervan werd de dubbele binding van het onverzadigd es-
ter uitgereduceerd door middel van nikkel-katalyse, zonder de dubbele binding
in de zijketen aan te tasten, wat ester 6.71 opleverde met 96% rendement over
drie stappen. Na ontscherming van de MPM-ether en basische hydrolyse van de
methylester, was het resulterende hydroxycarbonzuur klaar voor macrolactonis-
ering. Deze ging in dit geval uitzonderlijk goed: toepassen van de standaard
Yamaguchi condities, resulteerde in het macrolacton 6.72 met een rendement van
84% over drie stappen. The eindontscherming, gebruik makend van een thiol als
scavenger in combinatie met een Lewiszuur, resulteerde in het 2,3-dideoxy analoog
6.73 in 96% rendement.
Globaal gezien werd dit analoog bekomen na 20 stappen, startend van ethyl-
magnesiumchloride, met een totaal aantal stappen van 22 en een totaalrendement
van 12%. Helaas zijn er nog geen significante resultaten betreffende de activiteit
beschikbaar.
6.2.3 Nieuwe route naar pelofen B en toegang tot analogen
op de C2–C3-positie
OMEM
OH OMe OH
O
O
O
HO
O
HO
6.74 6.75 6.76
Scheme 6.14: Geobserveerde isomerisatie tijdens de verzeping van 6.74.
Aangezien de macrolactonisering van het ongesubstitueerd analoog zeer vlot
doorging, werden pogingen ondernomen om de ringsluiting te vervolledigen terwijl
de dubbele binding op de C2 –C3-positie nog aanwezig was. Deze aanpak zou ons
in staat gesteld hebben om substituenten in te voeren op een zeer laat stadium
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in de synthese, wat ideaal zou zijn, aangezien van een gemeenschappelijke pre-
cursor snel analogen te ontwikkelen zijn. Helaas werd tijdens de verzeping van de
geconjugeerde methylester 6.74 slechts een kleine hoeveelheid van het beoogde car-
bonzuur 6.75 gevormd, en er was duidelijk vorming van de styreen-derivaten 6.76,
door isomerisatie van de dubbele binding. Een mogelijke oplossing van dit prob-
leem, koppeling van het 4-bromocrotonzuur bleek ineffectief aangezien dezelfde
isomerisatie werd geobserveerd onder de basische omstandigheden die gebruikt
werden bij de macrolactonisering. Omwille van de complexiteit van de gevormde
reactiemengsels werd deze route niet verdergezet.
6.2.4 Pelofen B via ringsluitingsmetathese
De laatste manier om tot pelofen B te komen die in deze thesis gevalideerd werd,
was gebaseerd op de ringsluitingsmetathese. Naast de macrolactonisering, is dit
een veel voorkomende manier om macrolactonen van grotere omvang te synthetis-
eren.198
Aangezien de selectieve acrylering van het alcohol op de C15 positie voor prob-
lemen zorgde, werd besloten om het concurrerende alcohol op de C11 positie
te oxideren naar het keton, alvorens het allylisch alcohol op C15 vrij te stellen
(schema 6.15). Deze manier van bescherming zou ons in staat gesteld hebben
om later zowel het vereiste als het geinverteerde alcohol te vormen, terwijl ook
andere substituenten nog steeds tot de mogelijkheden zouden behoren. De oxi-
datie gebeurde door gebruik te maken van Ley’s condities en leverde keton 6.77
in 95%. Vervolgens werd de MPM-ether verwijderd, waardoor het allylisch alcohol
6.78 vrijgesteld werd. De geoptimaliseerde condities voor de acryloylering maak-
ten gebruik van een 0.1M oplossing van acryloylchloride in CH2Cl2 en DIPEA en
resulteerden in acryloylester 6.79 in 71%, met nog 10% uitgangsproduct resterend.
The laatste stap in de synthese van het precursor dieen 6.80 was de allylering
van de aromaat onder Stille condities, die nu uitgevoerd werd in puur allylbromide,
met een rendement van 95%, zonder observatie van isomerisatie van de dubbele
binding.
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Scheme 6.15: Synthese van het onverzadigd macrolacton 6.81 door ringsluit-
ingsmetathese
De ringsluitingsmetathese zelf werd geoptimaliseerd in termen van monomeer-
versus oligomeervorming, in functie van verdunningsgraad, solvent, katalysator,
reactietijd en temperatuur. Door gebruik te maken van Grubbs’ tweede generatie
katalysator bij 110◦C in tolueen, werd een geoptimaliseerde ratio van 70:30 ten vo-
ordele van het monomeer, bekomen na enkele minuten. Zoals verwacht werd een
mengsel van E en Z -olefine gevormd. Tijdens de opschaling van deze reactie daar-
entegen, werd waargenomen dat de 66% ge¨ısoleerd ringproduct was samengesteld
uit drie fracties: de E -en Z -isomeren van de ringgesloten geconjugeerde ester (18%
6.81 vs. 28% 6.82, respectievelijk) maar ook het Z -styreenproduct (22% 6.83).
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6.2.5 Besluit en toekomstperspectieven
Tijdens dit onderzoek werd de synthese van het fenylanaloog van peloruside (pelofen
B) geoptimaliseerd voor alle stappen behalve de macrolactonisering. Een factor
die niet onderzocht werd bij deze reactie, is de invloed van de temperatuur. Af-
gaande op de goede resultaten die behaald werden bij de ringsluitingsreactie bij
hogere temperaturen, zou dit een mogelijkheid kunnen bieden voor de verdere
optimalisatie.
O
O
O
OMEMO
H
OH
11
11
OH
OH
OH
OH OH
OH
OH
OH
2
3 2
3
2
3
2
3
2
3
24
HO
24
H2N
24
F
24
NH2
11
A
B
C
6.84
Scheme 6.16: Snelle toegang tot analogen van pelofen door diversificatie van 6.85
Voor de snelle introductie van modificatie op een later stadium in de synthese,
lijkt de ringsluitingsmethode de betere aanpak. Startend van de onverzadigde
macroring 6.84, zijn verscheidene analogen toegangelijk door eenvoudige synthe-
sestappen (schema 6.16). Op de C2 –C3-positie kan dhydroxylering van de E -
dubbele binding toegang geven tot de syn-alcoholen, terwijl dihydroxylering van
de Z -dubbele binding kan resulteren in de anti -diolen (stap A). Reductie van het
keton op de C11-positie kan resulteren in beide epimere alcoholen, waar reductieve
aminering de epimere amines oplevert (stap B). Het primair alcohol op positie C24
kan eenvoudig ontschermd worden onder zure omstandigheden, zodat het substi-
tuties kan ondergaan (stap C).
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List of Abbreviations
A˚: A˚ngstro¨m
Ac: acetyl
AD: asymmetric dihydroxylation
AIBN: azobisbutyronitrile
APC: anaphase promoting complex
APT: attached proton test
BAIB: bisacetoxy iodobenzene
BINOL: 1,1’-bi-2-naphtolate
BIOS: biology oriented synthesis
Bn: benzyl
Boc: tert-butyl oxycarbonyl
BPS: tert-butyl diphenylsilyl
Bz: benzoyl
CBS: Corey Bakshi Shibata
CDK: cyclin dependent protein kinase
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COSY: correlation spectroscopy
d: doublet
DBMP: di-tert-butyl 4-methylpyridine
DDQ: 2,3-dichloro-5,6-dicyanobenzoquinone
d.e.: diastereomeric excess
DHQD: dihydroquinidine
DIBAH: diisobutylaluminiumhydride
DIPEA: N,N-diisopropylethylamine
DMF: N,N-dimethylformamide
DMAP: 4-dimethylaminopyridine
DMP: Dess-Martin periodinane
DMSO: dimethylsulfoxide
DNA: deoxyribo nucleic acid
DOS: diversity oriented synthesis
DTBP: di-tert-butylpyridine
EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
e.e.: enantiomeric excess
EI-MS: electron impact ionization-mass spectrometry
EMA: European Medicine Agency
ESI: electrospray ionization
Et: ethyl
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FDA: United States Food and Drug Administration
FOS: function oriented synthesis
GC: gas chromatography
GDP: guanosine 5’-diphosphate
GTP: guanosine 5’-triphosphate
HATR: horizontal attenuated total reflection
HDX: hydrogen/deuterium exchange
HMBC: heteronuclear multiple bond correlation spectroscopy
HMDS: hexamethyldisilazane
HSQC: heteronuclear single quantum correlation spectroscopy
HTS: high-throuhput screening
HWE: Horner-Wadsworth-Emmons
Hz: hertz
Ipc: isopinocampheyl
iPr: iso-propyl
IR: infrared
KHMDS: potassium hexamethyldisilazide
LC: liquid chromatography
LLS: longest linear sequence
m: multiplet (NMR); medium (IR)
MAP: Mukaiyama aldol - Prins
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MDA: microtubule destabilizing agent
MDR: multi drug resistence
Me: methyl
MEM: (2’-methoxyethoxy)-methyl
MHz: megahertz
M.M.: molar mass
MOM: methoxymethyl
MPM: 4-(methoxyphenyl)-methyl
MS: mass spectrometry
MSA: microtubule stabilizing agent
MT: microtubule
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MTPA: α-methoxy-α-trifluoromethylphenylacetyl
NCE: new chemical entity
nM: nanomolar
NMR: nuclear magnetic resonance
NOE: nuclear Overhauser effect
NOESY: nuclear Overhauser effect spectroscopy
Pgp: permeability glycoprotein
PKC: protein kinase C
Ph: phenyl
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PHAL: phtalazine
PMB: para-methoxybenzyl
PMP: para-methoxyphenyl
Pr: propyl
PTK-2: protein tyrosine kinase 2
q: quadruplet
R&D: Research and Development
Rf: ratio to front
RCM: ring closing metathesis
s: singlet (NMR); strong (IR)
SEM: trimethylsilyl ethoxymethyl
SRB: sulforhodamine B
t: triplet
T: Tesla
TBAI: tetrabutylammonium iodide
TBDPS: tert-butyl diphenylsilyl
TBS: tert-butyl trimethylsilyl
Tf: triflate (trifluoromethyl sulphonate)
TFA: trifluoroacetic acid
THF: tetrahydrofuran
THP: tetrahydropyran
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TLC: thin layer chromatography
tert : tertiary
TES: triethylsilyl
TIPS: triisopropylsilyl
TMS: trimethylsilyl
TOCSY: total correlation spectroscopy
TTS: transition state
w: weak (IR)
WHO: World Health Organization
Xc: chiral auxiliary
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